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 I 
Abstract 
 
Stroke is a devastating neurological disease with high mortality rate and has profound 
implications for health economics and resources globally. There is a sense of urgency for scientists 
to discover a pharmacological target in stroke that could modulate multiple molecular cell injury 
mechanisms since many therapeutic agents that targeted only a single injury mechanism result in 
disappointing outcomes in human clinical trials. During stroke, cerebral ischemia triggers a number 
of membrane bound receptor-mediated signaling cascades that can activate many downstream 
kinases and transcription factors known to induce neuronal apoptosis. The activation of the 
membrane receptor Notch1 and its signaling pathway is seen in the infarcted brain, which is shown 
to deteriorate the outcome of ischemic stroke.  
 
Notch1 is a transmembrane receptor that regulates cell fate decisions in the developing 
nervous system and adult brain.   Binding   of   Notch’s   ligands   leads   to   the   proteolytic   cleavage   of  
Notch1 by γ-secretase and the generation of Notch1 intracellular domain (NICD1), which is able to 
translocate to the nucleus and regulate transcription of its downstream genes. Although Notch1 has 
been demonstrated to worsen stroke outcome by stimulating the infiltration of pro-inflammatory 
leukocytes and microglia-induced inflammatory responses, the molecular mechanisms of Notch1 in 
neurons following ischemic stroke in the induction of pro-apoptotic cascades are still not yet fully 
established. 
 
The present studies aim to investigate the role of γ-secretase-mediated Notch signaling 
pathway in the induction of neuronal cell death through its modulation with the nuclear factor-κB 
(NF-κB) pathway, the collaboration with hypoxia-inducible factor-1α   (HIF-1α)   pathway, and its 
contribution to the mitogen activated protein kinase (MAPK) pathway, which are all crucial in the 
induction of neuronal apoptosis. It also aims to observe the modulation of the pro-apoptotic proteins 
that are activated as a result of Notch1 activation in neurons following ischemic stroke.  
 
The present studies demonstrate that the inhibition of Notch1 activation using γ-secretase 
inhibitors protect neuronal cells against ischemia-induced cell death by targeting an apoptotic 
marker, cleaved caspase-3, NF-κB subunits p65, p50 and pro-apoptotic BH3-only protein, Bcl-2 
interacting mediator of cell death (Bim). In addition, treatment of mice with the γ-secretase 
inhibitor reduces NICD1, phosphorylated-p65 and Bim expression levels, with reduced infarct size 
and improved functional outcome in a mouse model of focal ischemic stroke. These findings 
 II 
suggest that γ-secretase-mediated Notch signaling endangers neurons after ischemic stroke by 
modulating the NF-κB-Bim pathway. 
 
Additional findings suggest that the HIF-1α  pathway, a global regulation pathway of cellular 
response to hypoxia, is able to interact with Notch1 and modulate its signaling during ischemic 
stroke. Treatment with either a HIF-1α  inhibitor or a γ-secretase inhibitor protects neurons against 
ischemic stress and a combined inhibition of Notch1 and HIF-1α  further decreases neuronal death. 
HIF-1α   and NICD1 are co-expressed in the neuronal nucleus, and co-immunoprecipitated in 
cultured neurons and brain tissue from mice subjected to focal ischemic stroke. RNA interference-
mediated endogenous Notch1 and HIF-1α  depletion also decreases neuronal cell death in ischemic 
conditions. Finally, mice treated with HIF-1α  and γ-secretase inhibitors exhibit improved outcome 
against stroke-induced injury, with combined treatment being superior to individual treatments. 
Evidence suggest that HIF-1α   and NICD1 collaboration engage the apoptotic pathways via 
modulating the expression of cleaved caspase-3, phosphorylated-p65 and JNK MAP kinase, hence 
exacerbate the outcome in mice subjected to focal ischemic stroke.  
 
Lastly, the role of γ-secretase-mediated Notch signaling in activating MAPK following 
ischemic stroke was investigated in a model of human neuronal death using human neuroblastoma 
cells (SH-SY5Y) subjected to stroke-like conditions. The γ-secretase inhibitor treated cells express 
decreased levels of phosphorylated JNK MAP kinase and downstream transcription factor c-Jun 
under ischemic conditions. Moreover, human embryonic kidney (HEK) cells overexpressing 
NICD1 express higher levels of phosphorylated JNK and c-Jun compared to wild type cells in 
response to ischemic conditions. Ischemic-induced cell death is significantly higher in NICD1 
overexpressed cells and is reduced by JNK inhibition. These results suggest that Notch signaling 
induces cell death by modulating the JNK-c-Jun pathway following ischemic stroke. 
 
In summary, these studies verify that γ-secretase-mediated Notch signaling regulates 
multiple molecular cell injury mechanisms during ischemic stroke and demonstrate for the first time 
that activation of Notch signaling pathway following ischemic stroke endangers neurons by 
activating the NF-κB, HIF-1α,   and JNK pathways. Therefore, these studies will enhance the 
existing knowledge of the protective therapeutic effects of γ-secretase inhibitors in cerebral 
ischemia and indicate that γ-secretase inhibition as a potential pharmacological intervention in 
stroke therapy. 
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Chapter 1 Ischemic stroke 
  
Introduction 
 
Stroke is a major neurological disease that ranks as the second leading cause of mortality 
worldwide. It strikes around 16 million people globally, causing a total of 5.7 million deaths each 
year; among whom, a vast majority of people are left disabled, thus contributing to 2-4% of global 
health care costs (Carlo 2009; Strong et al. 2007). According to the World Health Organization 
(WHO), stroke is defined as a rapidly developing condition where clinical signs of focal or global 
disturbance of cerebral function is evident, with symptoms lasting for more than 24 hours or leading 
to death caused by either transient or permanent impairment of cerebral blood flow (Anon 1988). 
Other than the familiar risk factors of stroke such as obesity, diabetes, hypertension and smoking, 
the current aging population may contribute to the increasing rate of stroke incidence each year. It is 
projected that stroke will overtake heart disease as the most common cause of death worldwide, 
especially amongst the older population (Donnan et al. 2008). 
 
Improvement in stroke mortality attributed to enhanced management of stroke risk factors 
such as blood pressure control and diets, alongside with the emergence of new therapies have 
resulted in an increased number of stroke survivors with residual impairments and disabilities in 
western countries (Sarti et al. 2000). This is likely to increase the burden in the health and social 
care system and economy in the future. Over the past decades, many neuroprotectants that aimed to 
prevent salvageable neurons from dying have been developed and shown to be effective in 
experimental animal stroke studies. Unfortunately, human clinical trials of these agents have shown 
many disappointing outcomes (Minnerup et al. 2012). As a result, more comprehensive research, 
deeper understanding of the complex pathophysiology of stroke, and improved animal models in 
the stroke research field are required in order to develop better and more effective therapies.   
 
Pathologically, stroke is broadly classified into either ischemic or hemorrhagic according to 
the cause of cerebral blood flow disruption. Around 80-85% of stroke cases account for ischemic 
stroke, which occurs due to the occlusion of blood vessels in the brain. On the other hand, 15-20% 
of the remaining stroke cases are hemorrhagic stroke, which occurs due to the rupture of blood 
vessels within the cerebral vasculature (Flynn et al. 2008).  
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Hemorrhagic stroke 
 
Hemorrhagic stroke occurs due to a ruptured blood vessel that causes bleeding into the brain 
or the area surrounding the brain, which compresses the surrounding brain tissue (Amarenco et al. 
2009). Hemorrhagic stroke can be further divided into two types: intracerebral hemorrhage that is 
caused by bleeding of a cerebral blood vessel within the brain, and subarachnoid hemorrhage that is 
caused by bleeding into the subarachnoid space. Hemorrhagic stroke is primarily associated with 
hypertension, and less common causes of intracerebral hemorrhage include trauma, infections, 
tumor, intracranial vascular malformations, or existing infarcts that experience secondary 
hemorrhage (Auer & Sutherland 2005).  The deaths in hemorrhagic stroke is mainly cause by 
edema and increased pressure in the brain tissue (Mayer et al. 1994). In addition, the reduced blood 
flow to the brain tissue caused by hemorrhage also induces excitotoxicity, necrosis, apoptosis, and 
inflammation in the affected region that lead to neuronal death (Lo et al. 2003). Since the focus of 
this doctorial research is on ischemic stroke, further details of hemorrhagic stroke will not be 
discussed in this thesis.  
 
Ischemic stroke 
 
 Ischemic stroke occurs when the blood supply to the brain is interrupted. Similar to other 
types of stroke, the brain cells begin to die within minutes due to a lack of oxygen and glucose, 
producing an area of dead tissue called an infarct (Dirnagl et al. 1999). Cerebral ischemic stroke can 
be further divided into global and focal ischemia depending on the size of the affected brain area 
and the pathophysiological mechanisms (Nagahiro et al. 1998).  
 
Global ischemic stroke 
 
Global cerebral ischemia occurs due to a transient reduction of blood flow to the entire brain. 
A complete cessation of blood supply is commonly seen during a cardiac arrest, open heart surgery, 
prolonged hypoxia or hypoglycemia, and pathologically elevated cerebral metabolic rate (Zheng et 
al. 2001; Sehba et al. 2013). Reduced blood supply to the entire brain results in oxygen and glucose 
deprivation and the formation of lesions in the most vulnerable regions of the brain such as the 
hippocampus, the striatum and the neocortex (Crain et al. 1988). The initial global ischemic event 
causes an increase in intracellular calcium levels and initiates excitotoxic mechanisms that are 
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deleterious to brain cells (Taoufik & Probert 2008). Continued cell loss can be observed from days 
to weeks post-ischemia as the pyramidal cell layer in the cornu ammonis-1 (CA1) region of the 
hippocampus is almost completely destroyed from four to seven days following ischemia (Kirino 
1982). 
 
Focal ischemic stroke 
Focal cerebral ischemia is a common manifestation of ischemic stroke. It is characterised by 
an occlusion in a cerebral blood vessel by a blood clot or fatty deposits, resulting in the reduction of 
cerebral blood flow (CBF) in the brain region irrigated by that vessel, leading to brain cell loss in a 
localized area in the brain (Traystman 2003). Depending on the origin of the occlusion in the 
cerebral artery, focal ischemic stroke is further divided into thrombotic and embolic stroke 
(Amarenco et al. 2009). 
 
Thrombotic stroke is caused by a thrombus (blood clot) that forms in the cerebral blood 
vessels (Stam 2005). The most common cause is the repeated build-up of fatty deposits, calcium 
and clotting factors such as fibrinogen and cholesterol carried in the blood. The body perceives the 
build-up as an injury to the vessel wall and thus forms a blood clot. The blood clot gets caught on 
the plaque on the vessel wall, and eventually occludes blood flow. This type of stroke is often seen 
in the elderly, especially those with high cholesterol levels, atherosclerosis or diabetes (Andrade-
Machado et al. 2001).  
 
In an embolic stroke, an embolus is formed elsewhere in the body (usually the heart) and 
reaches the brain by travelling through the bloodstream. The embolus is lodged into a narrow 
cerebral blood vessel, hence blocking blood flow into the brain region it supplies (Donnan 2009). 
Embolic stroke usually results from  heart disease (in particular atrial fibrillation) or heart surgery, 
but may also occur from elsewhere in the arterial tree (Ferro 2004). Furthermore, the embolus can 
also be a number of other substances such as fat, air, metastic tumor cells, and bacterial lumps that 
contribute to cerebral vasculature occlusion (Jovićević  et  al.  2010;;  Dudney  &  Elliott  1994).  
 
The middle cerebral artery (MCA) is the most common site of occlusion in human ischemic 
stroke (del Zoppo et al. 1992), since the MCA is the largest cerebral artery that supplies blood to 
most of the outer convex brain surface, basal ganglia, and the posterior and anterior internal 
capsules (Marinkovic et al. 2001). It is for this reason that a great amount of research effort is 
focused on this blood vessel and MCA is also the most commonly occluded blood vessel in animal 
models of ischemic stroke. 
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Pathophysiology of focal cerebral ischemia 
Under normal physiological conditions, a continuous regional cerebral blood flow (rCBF) at 
a rate of 50-60 mL/100g of brain tissue/minute and a cerebral perfusion pressure (CPP) of 60-130 
mm Hg are required for adequate supply of oxygen and glucose to maintain normal brain functions 
(Astrup et al. 1981). When the occlusion of a cerebral artery ensues, the brain tissues affected by 
focal ischemia can be differentiated into four regions according to the different rCBF and CPP 
profiles: the unaffected tissue, the mildly hypoperfused tissue, the ischemic penumbra, and the 
ischemic core (Figure 1.1).  
 
The unaffected region does not experience any reduction of blood flow or perfusion 
abnormality and the tissue structure remains intact. This region maintains normal physiological 
rCBF and CPP (Powers 1991). The mildly hypoperfused tissue region experiences a moderate 
decrease of rCBF and CPP. However, a decrease of CPP to 45-130 mm Hg induces an 
autoregulatory mechanism from the brain tissue to maintain its normal physiological perfusion rate 
by dilating the blood vessels and thus increasing cerebral blood flow into that particular region. As a 
result this region survives the ischemic insult and maintains its physiological functions and 
morphological structure (Fieschi et al. 1998).  
 
The brain tissue within the penumbra region experiences a further reduction of rCBF and 
CPP causing failure of the autoregulatory mechanisms. The rCBF rate further falls below 18-20 
mL/100g of brain tissue/minute, which is regarded as the penumbra threshold (Astrup et al. 1981). 
The collateral blood supply maintains the integrity of the penumbra region however the physiology 
of this region is severely impaired due to the reduction in blood flow. The transient zone lying in-
between the core and penumbra is likely to evolve with the core and ultimately increases the infarct 
size if blood flow is not immediately restored (Baron 2001). Nevertheless, this region can be 
rescued by restoring blood flow or by interfering with the onset of cell death mechanisms in the 
brain (Brouns & De Deyn 2009). As a result, the penumbra area is the most clinically relevant target 
and is the focus of current research to improve the outcome of stroke patients (Ramos-Cabrer et al. 
2011).  
 
The ischemic core is the region which suffers a complete energy deficit where the rCBF 
falls below 10-12 mL/100g of brain tissue/minute (Durukan & Tatlisumak 2007; Jones et al. 1981). 
The core suffers severely from impaired blood supply due to the fast decline in perfusion rate, 
therefore the damage is rapid and irreversible. The cells undergo uncontrolled cell death involving 
cell swelling and lysis and the tissue soon becomes necrotic.  
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Figure 1.1 Schematic diagram demonstrating the regions defined in the ischemic stroke brain. 
During an ischemic stroke insult, different regions form according to the cerebral blood flow 
thresholds. This figure is adapted and modified from Molecular targets in cerebral ischemia for 
developing novel therapeutics. Mehta et al.; Brain Research Reviews, 2007. 54 (1):34-66 
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The ischemic cascade 
 
When a focal ischemic stroke occurs, a reduction in oxygen and glucose supply triggers a 
complex series of biochemical processes that determines the fate of brain cells in the affected brain 
tissue known as the ischemic cascade (Figure 1.2) (Brouns & De Deyn 2009). In general, it is 
characterized by the following events: ionic imbalance and bioenergy failure, excitotoxicity, 
oxidative stress and inflammation. The outcome of the ischemic cascade is highly dependent on the 
duration of the occlusion, the severity of ischemia and also blood reperfusion, which contributes to 
the ischemic cascade processes.   
 
Ionic imbalance and bioenergy failure 
 
Brain cells have a high demand for oxygen and glucose, especially neurons, due to their 
exclusive dependency on glycolysis and oxidative phosphorylation for energy production in the 
form of adenosine triphosphate (ATP) to maintain their physiological functions (Hertz & Dienel 
2002; Hertz 2008). The primary insult caused by cerebral ischemia is focal hypoperfusion. The 
interrupted cerebral blood flow impedes oxygen and glucose supply, leading to the failure of ATP 
production and dysfunction of energy-dependent ion transport pumps such as Na+/K+ ATPase 
pumps. Hence, the ionic gradients across the cell membrane are lost, resulting in unregulated influx 
of sodium (Na+) and efflux of potassium (K+) and subsequently depolarisation of neurons and glial 
cells in a short period of time (Martin et al. 1994; Katsura et al. 1994). Depolarisation of neuronal 
cells results in the opening of voltage-gated calcium (Ca2+) channels at the pre-synaptic terminal 
which allows an influx of Ca2+, inducing uncontrolled release of the major excitatory 
neurotransmitter glutamate into the synaptic cleft (Arundine & Tymianski 2003). Furthermore, 
energy failure also impairs of glutamate re-uptake by glutamate transporters located on pre-synaptic 
neurons and surrounding astrocytes, contributing to excessive accumulation of glutamate in the 
extracellular matrix (Camacho & Massieu 2006; Rossi et al. 2000).  
 
Excitotoxicity 
 
During ischemia, depolarisation and voltage-gated channel failure result in the release of the 
excitotoxic neurotransmitter glutamate (Dirnagl et al. 1999; Kauppinen et al. 1988). The 
extracellularly accumulated glutamate cause an over-stimulation of α-amino-3-hydroxy-5-methyl-4-
isoxasole propionic acid (AMPA), kainate and N-methyl-D-aspartic acid (NMDA) subtype of 
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glutamate receptors on surrounding neurons that promote a further influx of Ca2+ and Na+ through 
these receptors (Dirnagl et al. 1999; Suzuki et al. 2012). As a result, neuronal depolarization occurs, 
leading to more influx of Ca2+ and release of glutamate, augmenting the initial ischemic injury. In 
addition, the increased Na+ influx drives an osmotic movement of water into the neurons, and 
causes cell swelling and cytotoxic brain edema (Ayata & Ropper 2002; Simard et al. 2007). At the 
same time, the increased Ca2+ influx leads to both nuclear and cytoplasmic damage resulting in fatal 
outcomes to neurons known as excitotoxicity (Bano et al. 2005; Jeffs et al. 2007). The disrupted 
calcium homeostasis activates multiple damage mechanisms including the activation of catabolic 
enzymes (calpains and endonucleases) that cause the proteolysis of cytoskeletal and extracellular 
matrix proteins, and increased generation of reactive oxygen species from the electron transport 
chain, NADPH oxidase, phospholipase A2, cyclooxygenase and nitric oxide synthase (NOS) type 1 
(Kontos 2001; Lee et al. 2005; Neumar et al. 2001). These events ultimately lead to extensive 
cellular damage and neuronal death through necrosis as well as apoptosis in the ischemic area 
(Lipton 1999; Iadecola & Anrather 2011). 
 
Oxidative stress 
 
 Under physiological conditions, the mitochondria utilise oxygen to generate ATP via 
oxidative phosphorylation at the mitochondrial respiratory chain (MRC) (Newmeyer & Ferguson-
Miller 2003). However, during ischemia the depletion of oxygen leaves anaerobic glycolysis as the 
favoured pathway for the mitochondria to produce ATP (Hertz 2008). The consequence is an 
accumulation of lactic acid leading to intracellular acidosis, which promotes the production of pro-
oxidants, antioxidant inactivation, the release of oxidant iron from proteins (Ying et al. 1999), and 
increased glutamate toxicity (Lewerenz et al. 2010). In addition, excitotoxicity stimulation of Ca2+ 
influx also triggers the generation of free radical species, which builds up oxidative stress in 
neurons (Manzanero et al. 2013). Other contributors of ROS production during ischemia include 
mitochondrial depolarisation and xanthine oxidase (XO) activation (Abramov et al. 2007). These 
excessively produced ROS build up oxidative stress and have potential to cause damage in 
mitochondria and in the cytoplasm. Recently, one of the ROS generating enzymes, NADPH 
oxidases (NOX) has been described to induce oxidative stress during ischemic stroke (Vallet et al. 
2005). The abundantly expressed vascular isoform NADPH oxidase type 4 (NOX4) is identified as 
the major source of oxidative stress that leads to the blood brain barrier (BBB) leakage and 
neuronal apoptosis in cerebral ischemia (Kleinschnitz et al. 2010). Another subtype of the NOX 
family, NOX2 was also reported to promote ROS generation that results in BBB disruption and 
neuronal cell death in ischemic stroke (Kahles & Brandes 2012).    
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In acute stroke, blood reperfusion is currently the only accepted intervention used to reduce 
extensive brain injury caused by the lack of blood supply. However, many brain cells continue to 
die even after blood flow has been restored due to secondary damage in the affected area, which is 
known as ischemia/reperfusion (I/R) injury (Wong & Crack 2008). Oxygen availability after 
reperfusion restores the MRC inadequately and leads to a substantial increase of mitochondrial ROS 
production, thus further enhancing the injury (Peters et al. 1998). Increased ROS production and 
intracellular Ca2+ causes opening of the mitochondrial permeability transition pores (MPTP), which 
allow water entry from the cytoplasm leading to mitochondrial swelling and damage, triggering 
necrotic cell death (Yamato et al. 2003). Increased levels of superoxide O- can also lead to the 
conversion of other detrimental ROS that impair the mitochondrial functions, causing the leakage of 
cytochrome c into the cytoplasm, which triggers apoptosis in neurons (Ferrer & Planas 2003). 
Furthermore, oxidative stress is able to stimulate signal transduction through the mitogen activated 
protein kinases (MAPK) pathway (in particular p38, JNK, and the downstream transcription factor 
activator protein-1 (AP-1)), as well as the nuclear factor kappa B (NF-κB) pathway, leading to 
caspase-mediated apoptosis in neurons and glial cells (Chen et al. 2011; Kratsovnik et al. 2005) 
(Figure 1.2).  
 
Ischemic inflammation  
 
 Inflammation can occur within minutes after ischemic insult, and last for days to weeks 
following ischemic stroke (Dirnagl et al. 2003). Inflammation following ischemic stroke involves 
the activation of several cell types and acts as a double-edged sword that is responsible for both 
repairing and promoting tissue damage (Wang & Feuerstein 2004). There are several factors that 
contribute to post-ischemic inflammation including signaling molecules, inflammatory cells, 
adhesion molecules, and transcriptional regulators (Brouns & De Deyn 2009). At the early onset of 
ischemia, the cellular contents released from necrotic cells including damage-associated molecular 
patterns (DAMPs), cytokines, and ROS can induce a local inflammatory response to the 
surrounding cells (Majno & Joris 1995). Astrocytes activated by ROS following ischemic stroke 
can secrete pro-inflammatory cytokines, chemokines, and inducible nitric oxide synthase (iNOS) 
that exacerbate the injury (Yamagami et al. 1999; Hewett et al. 1996). In addition, activated 
astrocytes can also express major histocompatibility complex (MHC) molecules I and II, 
erythropoietin, and transforming growth factor-β   (TGF-β)   which are associated with anti-
inflammatory responses (Stoll et al. 1998; Ruscher et al. 2002; Kunz et al. 2010). Once activated by 
ROS, microglia is able to clear up cellular debris and harmful substances via phagocytosis along 
with anti-inflammatory cytokine secretion (Neumann et al. 2009; Jin et al. 2010). On the other hand, 
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microglia is also able to release a number of neurotoxic mediators such as excitatory amino acids, 
proteases, pro-inflammatory cytokines and nitric oxides (Wood 1995).  
 
Moreover, after reperfusion occurs, the full extent of peripheral inflammation can take part 
in the ischemic cascade. Although blood reperfusion may reduce the infarct size by salvaging the 
penumbra, leukocytes that are carried through in the blood are able to propagate inflammation 
resulting in enhanced brain injury (Brouns & De Deyn 2009). Studies indicate that reperfusion 
injury is caused by components in the inflammatory response, including cytokine release by 
activated glial cells and infiltration of leukocytes through adhesion to activated cerebral endothelial 
cells (Pan et al. 2007). Cytokines secreted by immune cells such as tumour necrosis factor (TNF), 
interleukin-1β   (IL-1β), interleukin-6 (IL-6), interleukin-18 (IL-18), interleukin-10 (IL-10) and 
interferon-γ   play key roles in exacerbating reperfusion injury (Pan et al. 2007; Iadecola & 
Alexander 2001; Wang et al. 2007; Fann et al. 2013). Furthermore, cytokines also modulate the 
expression of adhesion molecules on endothelial cells in order to regulate the recruitment of 
leukocytes to the ischemic brain area (Iadecola & Alexander 2001; Wang et al. 2007). The 
overexpression of endothelial and leukocyte adhesion molecules such as intracellular adhesion 
molecule-1 (ICAM-1), vascular adhesion molecules (VCAM), P-selectin and E-selectin allow the 
recruitment and infiltration of leukocytes into the brain parenchyma and subsequently release more 
pro-inflammatory mediators that lead to further destruction of brain tissue (Lucas et al. 2006; 
Yilmaz & Granger 2008; Lakhan et al. 2009). Neutrophils are the earliest leukocyte subtype to 
infiltrate into the ischemic area (Buck et al. 2008) followed by lymphocytes, monocytes, and 
macrophages (Campanella et al. 2002). In addition, T lymphocytes have also been reported to play 
vital roles in response to ischemic conditions, of which CD4+ and CD8+ T lymphocytes contribute 
to ischemic injury (Yilmaz et al. 2006), whereas the role of regulatory T lymphocytes (Treg) in 
ischemic stroke still remains ambiguous. Tregs have been reported to exert both deleterious 
(Kleinschnitz et al. 2013) and neuroprotective effects (Liesz et al. 2009; Li et al. 2013), and others 
reported them to be neutral (Ren et al. 2011; Stubbe et al. 2013) in brain ischemia. 
 
The complement system as part of innate immune system has been shown to play a role in 
post-ischemic inflammation through the production of several inflammatory mediators including C1, 
C3a and C5a anaphylatoxins. These anaphylatoxins are involved in T-lymphocyte and leukocyte 
infiltration, and the formation of the membrane attack complex (MAC) in neurons and glial cells, 
which causes cell lysis and hence exacerbates tissue damage (Arumugam et al. 2004; Ducruet et al. 
2012; Kim et al. 2008).  
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Figure 1.2 Simplified overview of the ischemic cascade and cell death mechanisms following 
ischemic stroke. During an ischemic stroke, energy failure leads to ATP-dependent ion channel 
failure and thus increased intracellular Ca2+, Na+ and extracellular K+. Excessive levels of 
intracellular Na+ results in depolarization and edema. Increased intracellular Ca2+ triggers synaptic 
release of glutamate and this activates glutamate receptors from extracellular space. The activation 
of glutamate receptors further increases intracellular Ca2+, Na+ and extracellular K+ levels. 
Diffusion of glutamate and K+ in the extracellular space propagates a series of depolarization waves 
to surrounding cells (peri-infarct depolarization). Increased intracellular Ca2+ overstimulates a 
number of enzyme systems and free radical production, which leads to activation of microglia and 
leukocyte infiltration, as well as several signal transduction pathways including NF-κB  and  MAPK.  
This figure is adapted and modified from Pathobiology of ischemic stroke: an integrated view. 
Dirnagl et al.; Trends in Neurosciences, 1999. 22(9):393 
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The cell death mechanisms in ischemic stroke 
 
Cerebral focal ischemia occurs when blood supply to the brain is interrupted, leading to 
reduced CBF in a certain part of the brain region. Insufficient CBF thereby causes a cellular energy 
crisis that initiates a complex series of pathophysiological mechanisms, leading to irreversible 
cellular damage and eventually cell death, especially of neurons, if the blood flow is not restored 
(Mitsios et al. 2006). The mechanisms of cell death during ischemic stroke arise from all events in 
the ischemic cascade, and ultimately lead to necrotic or apoptotic cell death.  
 
Necrosis 
 
 Necrosis is an unregulated pathological process of cell injury that results in cell death. 
Necrotic cell death can be seen early following acute ischemic stroke and usually occurs in areas 
that are most severely affected by abrupt biochemical collapse in the ischemic core region. The 
major cause of necrotic cell death is ischemia itself, acute depletion of energy is an instant event 
that initiates the lethal necrotic response (Leist et al. 1997; Lee et al. 1999). The brain cells in the 
affected region experience depolarisation and edema due to ionic imbalance, mitochondrial and 
nuclear swelling, uncontrolled vesicle formation and plasma membrane degradation resulting in 
irreversible necrotic death seen in the ischemic core region (Lipton 1999). As mentioned above, 
ROS production and inflammatory responses activated following ischemic stroke can also cause 
necrotic cell death. The necrotic cells release their cellular contents into the extracellular space. 
These cellular contents include damage-associated molecular patterns (DAMPs), cytokines, and 
ROS that can induce a local inflammatory response in the surrounding area (Majno & Joris 1995). 
One study used a genetic engineered Drosophila model of necrosis in neurons showed evidence of 
necrosis mediated by Rho-associated kinase (Yang et al. 2013). Nevertheless, overall the molecular 
mechanisms of neuronal necrosis are still poorly understood due to limited tools for necrosis in 
neurons. 
 
Apoptosis 
 
Apoptosis is a form of programmed cell death that plays a major part in delayed damage in 
the penumbra which is initiated within minutes and can persist for days (Dirnagl et al. 2003). 
Following the ischemic cascade, activation of glutamate receptors (Choi 1995), early mitochondrial 
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production of ROS (Shin et al. 2008), reduced cytoplasmic K+ (Cole et al. 1990), and enhancement 
of toxic Zn2+ (Leonardi-Bee et al. 2002) may all trigger apoptosis. The apoptotic mechanism can be 
divided into the extrinsic (death receptors) and intrinsic (mitochondrial) pathways (Rossi & 
Gaidano 2003). 
 
The extrinsic apoptotic pathway involves the activation of death receptors including death 
receptors 3, 4, 5, Fas receptor (FasR), and tumor necrosis factor receptor1 (TNFR1) (Nakka et al. 
2008). Fas mediated apoptosis is regarded as the canonical extrinsic apoptotic pathway and 
contributes to cell death during an ischemic insult (Nakka et al. 2008). The binding of Fas ligand to 
FasR leads to homo-trimerization and the recruitment of Fas-associated death domain (FADD) 
signaling adaptor molecule, consequently forming the death inducing signaling complex (DISC) 
(Danial & Korsmeyer 2004). DISC formation leads to the recruitment and activation of caspase-8 
protein, which is liberated into cytoplasm and triggers the caspase cascade. The activated caspase 
cascade ultimately cleaves pro-caspase 3 into its cleaved form, which executes apoptosis by 
cleaving cellular substrates that induce the morphological and biochemical features of apoptosis 
(Algeciras-Schimnich et al. 2002). In addition to caspase-3 activation, activated caspase-8 also 
mediates the cleavage and activation of a mitochondrial pro-apoptotic Bcl-2 protein, Bid, to 
integrate with the intrinsic apoptotic pathway (Broughton et al. 2009). Extrinsic apoptosis has been 
shown in experimental brain ischemia as FasR, Fas ligand, and TNF-related apoptosis inducing 
ligand expression are increased in the post-ischemic rat brain, and mice expressing dysfunctional 
Fas ligand have significantly smaller cerebral infarct after an experimental ischemic stroke (Martin-
Villalba et al. 1999; Rosenbaum et al. 2000).  
 
 Mitochondrial proteins of the Bcl-2 family play major roles in the intrinsic apoptotic 
pathway during ischemic stroke. Increased intracellular Ca2+ following cerebral ischemia activates 
calpains and the cleavage of Bid into truncated Bid (tBid), and leads to the release of cytochrome c 
and caspase-dependent apoptosis (Broughton et al. 2009). Released cytochrome c binds to apoptotic 
protease activating factor-1 (Apaf-1) and procaspase-9 to form an apoptosome, which regulates the 
caspase activation cascade (Fujimura et al. 1998). Procaspase-9 is auto-cleaved upon apoptosome 
formation, and activated caspase-9 in turn activates further caspase signaling cascade from caspase-
6, followed by caspase-7 and caspase-3 (Nakka et al. 2008). Activated caspase-3 triggers the 
breakdown of DNA and cellular integrity via activation, cleavage, and degrading molecules 
including lamin, specrin, huntingtin, gelsolin, and poly (ADP-ribose) polymerase (PARP), leading 
to compromised nucleus and cell viability (Mehta et al. 2007).  
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 Apoptosis can also occur independently of the cytochrome c/caspase-3 mediated apoptotic 
cascade. The second group of pro-apoptotic proteins released from the mitochondria including 
apoptosis inducing factor (AIF), endonucleases G, and Bcl-2/adenovirus E1B 19kDa-interacting 
protein3 (BNIP3) (Elmore 2007). AIF, being the most studied protein among them, induces 
caspase-independent apoptosis through chromatin condensation and DNA fragmentation (Cregan et 
al. 2002; Plesnila et al. 2004). This caspase-independent apoptosis has been shown to occur 
following cerebral ischemia by translocation of AIF and endonuclease G to the nucleus of ischemic 
neurons (Culmsee et al. 2005; Lee et al. 2005).  
 
Experimental animal models of ischemic stroke 
 
Modeling cerebral ischemia with animals is an essential tool to elucidate the 
pathophysiological and molecular mechanisms of ischemic stroke, and to evaluate novel 
recanalization and neuroprotective therapies in pre-clinical settings. From the late 1970s, animal 
models of cerebral ischemia have been developed to mimic the human ischemic stroke conditions to 
enhance the study and understanding of this disease (Bacigaluppi et al. 2010). Several animal 
models of stroke have been developed in various species including primates, pigs, sheep, dogs, cats, 
mongolian gerbils, rabbits, rats, and mice (Traystman 2003). Although using primates or larger 
mammal stroke models achieves the important goal of better resembling of human stroke conditions, 
small animals especially rodents can provide sufficient numbers for statistical analysis without 
excessive cost, which makes small animals more favorable than large animals in laboratories. In 
addition, it is also easier to achieve a more consistent and smaller infarct volume with higher 
reproducibility in small animals in terms of experiments (Bacigaluppi et al. 2010). Moreover, since 
mouse is the most popular species to generate transgenic animals and the easy availability of 
knockouts, there has been an increased number of stroke studies performed using mice since the 
1990s (Durukan & Tatlisumak 2007). However, although rodents have similar cerebral vasculature 
to humans, there is a great difference in the morphological and functional resemblance between 
smaller   rodent’s   brains   and   human   brains. Smaller rodents such as rats and mice have smooth-
surfaced or unconvoluted brains called lissencephalics while larger mammals have folded or 
convoluted brains called gyrencephalics (Hofman 1985). Therefore these variations must be taken 
into account when interpreting experimental data from animal stroke models and translating them 
into human stroke conditions. 
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 The experimental stroke models can be divided into two types: global ischemic stroke 
models and focal ischemic stroke models. 
 
Global ischemic stroke models 
 
 Global ischemic stroke models are developed to represent the brain damage resulting from 
interrupted blood flow to most parts of the brain that can occur during cardiovascular events 
(McBean & Kelly 1998). Global ischemic stroke can be induced by different approaches in animals. 
The four-vessel occlusion (4-VO) model involves a reversible occlusion on both common carotid 
arteries (CCA) with permanent interruption of vertebral arteries through cauterization. This method 
is commonly used in rats and it is the most successful global ischemia model since it induces a 
highly predictable ischemic damage in the bilateral forebrain and brainstem (Pulsinelli & Brierley 
1979). Alternatively, the two-vessel occlusion (2-VO) model induces global ischemia by the 
occlusion of both CCAs together with systemic hypotension for a limited time period. In this model 
selective injury from the CA1 pyramidal neurons in the hippocampus, the caudoputamen, and the 
neocortex is observed as fast as 2 minutes (Smith et al. 1984). Another technique for inducing 
global ischemia is through inducing cardiac arrest followed by resuscitation which is very close to 
what occurs in humans. This method involves first cardiac arrest induced by ventricular fibrillation 
and shortly thereafter the defibrillation combined with chest compression and administration of 
adrenaline for resuscitation (Berkowitz et al. 1991). This later model induces selective injury of 
neurons in the hippocampus and striatum and is in fact more clinically relevant to human global 
ischemic stroke (Kofler et al. 2004). 
 
Focal ischemic stroke models 
 
 Focal ischemic stroke caused by an acute occlusion in the cerebral vessel can be introduced 
in animals by many techniques. There are two main strategies to induce animal focal ischemic 
stroke: mechanical occlusion of the middle cerebral artery (MCA) at the proximal or distal site of 
the MCA, and thrombotic occlusion either through blood clots or thrombin injection into the MCA, 
or photo-thrombosis via Rose Bengal injection (Bacigaluppi et al. 2010). 
 
 The proximal middle cerebral artery occlusion (MCAO) models are the most frequently 
used method in focal ischemic stroke research and are used in this thesis. This procedure is 
conducted by direct mechanical occlusion via the insertion of a nylon intraluminal monofilament 
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into the internal carotid artery (ICA) and subsequently to the circle of Willis to occlude the origin of 
MCA (Hermann et al. 2001). In detail, a midline incision is made in the neck to expose and ligate 
the common carotid artery (CCA), external carotid artery (ECA), internal carotid artery (ICA), and 
pterygopalatine artery. A monofilament with a blunted tip is inserted into a small incision made on 
the ECA, and then advanced pass the ICA and into the MCA until a light resistance is felt 
(Woodruff et al. 2011). The severity of ischemic injury is relevant to the duration of time that the 
MCA is occluded, usually range between 30 to 120 minutes. MCAO can be performed transiently 
or permanently depending on whether or not the reperfusion is desired following the occlusion. For 
permanent MCAO, the MCA is occluded throughout the experiments without any reperfusion. To 
reperfuse the ischemic brain, the filament is removed and blood flow is allowed back to the brain 
from the ICA.   
 
In distal MCAO, the superficial MCA branches such as lenticulostriate branches are directly 
exposed and occluded by a clip or electrocoagulation through a craniotomy (Tamura et al. 1981).  
As a result, the damage is more restricted to the surface of the brain comparing to proximal MCAO 
as the occluded vessel is superficial, thus sparing deep structures of the brain such as the 
hippocampus, thalamus hypothalamus and midbrain (Carmichael 2005). 
 
As human focal ischemic stroke is of either thrombotic or embolic origin, a number of 
animal models that mimic the cerebral thromboembolism have been developed. Embolic stroke can 
be induced via the injection of artificial spheres (ranging from large-sized macrospheres, 300-400 
μm diameter, to small-sized microspheres, less than 50μm) into the animal’s   ICA. The infarcts 
produced in macrospheres injection are similar to those induced by MCA occlusion, while smaller, 
multifocal infarcts are produced in microspheres injection (Gerriets et al. 2003; Miyake et al. 1993). 
Another model using autologous blood clots injection into the internal carotid artery can be used to 
study thrombolytic therapies (Kilic et al. 1998). A better model of thromboembolic stroke by local 
injection of purified thrombin results in autologous thrombus generation in the MCA, which 
produced highly reproducible ischemic injury volumes (Orset et al. 2007).  
 
Another novel technique to induce localized stroke is through the delivery of a 
photosensitive dye (Rose Bengal) to create a photothrombotic stroke. It is induced by a systemic 
injection of this photosensitive dye followed by illumination by a cold light source. After this dye 
becomes activated and induces endothelial damage with platelet activation and thrombin formation, 
local blood flow will eventually be interrupted. The light source can be applied on the intact skull 
without craniotomy, and it is able to target any cortical area of interest, therefore creating an 
 16 
ischemic injury within a given cortical area in a reproducible and non-invasive way (Labat-gest & 
Tomasi 2013). However, this procedure creates a lesion from endothelial damage and a small 
penumbra is formed compared to other models, which becomes a limitation of this method 
(Carmichael 2005).  
 
Overall, these experimental animal models of ischemic stroke provide a basic apparatus that 
has allowed us to manipulate, explore, and treat this devastating disease over the past decades. The 
reliable models for ischemic stroke research should have a sufficient number of features that are 
similar to those in humans as well as higher consistency and reproducibility so that the outcomes 
can be investigated with minimal divergence from human strokes. The studies in this thesis use the 
transient MCAO model with reperfusion as the in vivo setting of ischemic stroke for its high 
reproducibility and no requirement for craniotomy.  
 
Current treatments in ischemic stroke 
 
 Following ischemic stroke, around 10% of stroke patients die within 30 days (Rathore et al. 
2011). When patients reach the hospital with ischemic stroke symptoms, the first priority is to 
restore   the   patient’s   breathing,   heart   rate,   blood   pressure,   and   temperature   to   normal.   Currently, 
there are two main strategies in the development of ischemic stroke therapy: intravenous 
thrombolysis and neuroprotection. Thrombolysis aims to restore blood flow to the brain by 
dissolving the clots using thrombolytic (fibrinolytic) agents. Intravenous thrombolysis with 
recombinant tissue plasminogen activator (rt-PA) is the only pharmacological treatment for patients 
with acute ischemic stroke approved by the Food and Drug Administration (FDA) since 1996 
(Adams et al. 2003). However, there are some limitations towards the use of rt-PA in the treatment 
of stroke such as the relatively short therapeutic window of 4.5 hours, the risk of haemorrhage when 
administered beyond the therapeutic window and its inability to convey any neuroprotection (Anon 
1995). Moreover, at present only around 15% of patients are eligible to receive thrombolysis 
treatment when selected according to the guidelines from the American Heart Association/ 
American Stroke Association (AHA/ASA) (Adams et al. 2007). 
 
 Neuroprotective agents have been developed in an attempt to save neurons from irreversible 
injury by either limiting acute injury to neurons in the penumbra region or preventing reperfusion 
injuries (Green 2004). The strategy of neuroprotection is to antagonize, interrupt, or slow down the 
detrimental biochemical processes of ischemic injury that lead to irreversible neuronal death 
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(Ginsberg 2008). To date, the neuroprotective agents that have undergone clinical trials include ion 
channel modulators such as K+ channel modulator (BMS-204352) (Jensen 2002), Ca2+ channel and 
Na+ channel blockers (Lubeluzole and Fosphenytoin, respectively) (Sareen 2002; Taylor & 
Meldrum 1995), which work to restore ion balance and cellular integrity in injured neurons. There 
are also glutamate receptor modulators such as NMDA (Dyker et al. 1999), AMPA (Langer et al. 
2011) and GABA receptor antagonists (Chi et al. 2011) that target excitotoxicity through the 
activation and release of glutamate. Moreover, antioxidants, free radical scavengers and anti-
inflammatory therapies are other approaches in reducing ischemia/reperfusion injury to neurons 
(Jain 2000). Overall, more than 1000 potential neuroprotective agents/therapies that targeted the 
mentioned molecular events and shown protection in pre-clinical studies have been taken into Phase 
II and Phase III human clinical trials for ischemic stroke therapy (O’Collins  et  al.  2006). However, 
none of the neuroprotective agents have proven beneficial in clinical trials due to certain side effects 
or low efficacy (Cheng et al. 2004; Minnerup et al. 2012). It is believed that these drugs failed to 
deliver due to the fact that they only target a single stroke injury mechanism in a single cell type or 
a single injury mechanism in multiple cell types (Ginsberg 2008). Therefore, agents that target 
diverse pathogenic events in multiple cell types are of importance in order to convey 
neuroprotection against ischemic stroke-induced cell death. 
 
One such candidate with the potential to target multiple mechanisms in multiple cell types is 
the Notch1 signaling pathway. The pleiotropic nature of Notch1 signalling allows it to regulate cell 
fate decisions in almost all developing tissues and organs (Guruharsha et al. 2012; Fortini 2012). 
Evidence has shown that Notch1 signaling can integrate with other signaling pathways to fulfil its 
pleiotropic roles under different situations (Guruharsha et al. 2012). Furthermore, perturbations in 
Notch1 signaling pathway have been linked to several neurological diseases including ischemic 
stroke (Alberi et al. 2013). In order to establish the network of Notch1 signaling in ischemic stroke, 
this thesis focused on unravelling the molecular mechanisms of Notch1 signaling mediated 
neuronal death. In depth discussion of Notch1 signaling and its role in ischemic stroke will be 
reviewed in the next chapter. 
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Chapter 2 Notch signaling in stroke 
 
Introduction 
 
Cell-cell interaction is crucial for signal transduction during development in all animals 
from metazoan to vertebrates (Gerhart 1999). The Notch signaling pathway is one of the 
predominant pathways that plays such a role in early embryonic development together with four 
other pathways: the Wingless (Wnt), Hedgehog (Hh), Transforming Growth Factor-β  (TGF-β)  and 
Receptor Tyrosine Kinase/Phosphatase (RTK/P) (Gerhart 1999). These signaling pathways control 
cell-cell communication during embryonic development and adult life, and they serve as key 
regulators for cell fate decision, proliferation, differentiation and migration in several cell types and 
tissues (Gerhart 1999). 
 
Notch signaling belongs to one of the novel signaling paradigms called Regulated 
Intramembrane Proteolysis (RIP). RIP is a highly regulated proteolytic event that requires two 
consecutive proteolysis steps in initiating the activation of a transmembrane receptor and 
downstream genes expression: the extracytosolic shedding followed by an intramembrane cleavage 
(Lal & Caplan 2011). RIP functions through two separate subcellular locations. The first site is at 
the transmembrane where in response to stimulus/ligand binding, the full-length receptor undergoes 
a two step proteolysis to release an intracellular domain that translocates to the second site of action 
which is usually the nucleus, as is the case with Notch (Brown et al. 2000).  
 
Notch was discovered in 1914, when John S. Dexter described the appearance of a notch in 
the wing blades of the fruit fly Drosophila melanogaster, and the allele of the mutant gene that 
causes this phenotype was identified by Thomas Hunt Morgan in 1917 (Morgan 1917). Since then 
Notch has been investigated in numerous studies at the genetic, embryological, and molecular levels 
(Mohr 1924). There are four homolog Notch genes discovered in mammals, which are referred to as 
Notch1, Notch2, Notch3, and Notch4 (Fortini et al. 1993). In the nervous system, Notch1 is 
abundantly expressed in neural stem/progenitor cells (NSCs), neurons and astrocytes, and it is 
important in the regulation of neuronal differentiation and adult neurogenesis (Xiao et al. 2009). 
Notch2 is transiently expressed in granule neuron precursors in developing cerebellar cortex 
(Solecki et al. 2001) and expressed mainly by glial cells in the postnatal brain (Tanaka et al. 1999). 
In adult tissues, Notch3 expression is restricted to vascular smooth muscle cells (VSMCs) and is 
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involved in ischemic cerebral small-vessel disease pathology (Louvi et al. 2006). Notch4 is 
specifically expressed in endothelial cells and its activation is involved in brain arteriovenous 
malformations (BAVMs) pathogenesis in mice (Uyttendaele et al. 2000; Murphy et al. 2008). 
Among the four Notch homologs, Notch1 is the most abundantly expressed in neurons and its 
function has been extensively studied in both invertebrates and mammals, therefore this thesis 
research focused on Notch1 in neurons. 
 
Notch signaling is a highly conserved pathway that is essential for various functions in the 
central nervous system throughout the life span of a mammal from neurogenesis and specification 
during embryonic development (de la Pompa et al. 1997) to synaptic plasticity and 
learning/memory in adulthood (Wang et al. 2004). Notch signaling activation is highly regulated by 
the binding of its ligand to the receptors and the subsequent proteolysis, hence understanding the 
structures of the receptors and ligands is crucial for learning the activation of this signaling pathway 
and especially for studying the molecular mechanisms of Notch signaling. 
 
Structures of Notch receptors and ligands 
 
Although this core pathway is evolutionarily conserved, the numbers of paralogues for each 
component in Notch signaling differ between species (Table 2.1). For example, there is one Notch 
receptor (Notch) in Drosophila, two (LIN-2 and GLP-1) in C.elegans, and four (Notch1-4) in 
mammals. However, the basic paradigm is common throughout (Artavanis-Tsakonas et al. 1999; 
Bray 2006). The Notch gene encodes a large extracellular domain containing 29-36 tandem 
epidermal growth factor-like repeats (EGF-LR) and followed by 3 cysteine-rich LIN12/Notch 
repeats (LNR) that prevent signaling without the presence of the ligand (Fehon et al. 1990; Rebay et 
al. 1991). The extracellular domain is connected to the intracellular domain with a single pass 
transmembrane domain. The Notch intracellular domain (NICD) contains a 938 amino acid RAM 
(RBP-Jκ-associated module) domain and 7 ankyrin/cdc10 (ANK) repeats. Notch1-3 contain two 
nuclear localization signals (NLS) whereas Notch4 contains only one NLS. Notch1 and 2 contain a 
transactivation domain (TAD) consisted of one NLS and a polyglutamine repeat-containing region 
(OPA), compared to none in Notch3 and 4. All four intracellular domains contain a proline, 
glutamic acid, serine, and threonine-rich (PEST) domain (Blank et al. 1992) (Figure 2.1). Among 
the domains in NICD, both RAM and ANK domains are known to interact with a DNA-binding 
protein called CSL (C-promoter-binding factor-1/recombination signal-sequence binding protein Jκ),  
and the ANK domain is also known to interact with the co-activator Mastermind-like-1 (MAML1) 
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(Del Bianco et al. 2008). The NLS assists in targeting the intracellular domain to the nucleus where 
the TAD can activate downstream events (Jarriault et al. 1995). The PEST domain is found to be 
important to signal for NICD degradation (McGill & McGlade 2003). 
 
The Notch ligands are expressed on the membrane of adjacent signaling cells and contain a 
DSL-motif that is essential for binding to Notch receptors and the activation of Notch signaling 
(Artavanis-Tsakonas et al. 1999). In mammals, the classical Notch ligands are evolutionally 
conserved and include the Delta orthologs Delta-like 1, 3, and 4 and Serrate orthologs Jagged1 and 
2 (Chiba 2006). These five structurally similar Notch ligands have been identified to be single pass 
transmembrane polypeptides. A signal peptide is followed by a conserved DSL domain of 
approximately 45 amino acids and multiple EGF-like repeats from 2 to as many as 16 (Fleming 
1998). The Serrate-related group Jagged1 and 2 contain an additional cysteine-rich domain (CRD) 
consisting of 70-215 amino acids that lacks homological significance to other sequenced proteins 
(Figure 2.2) (Fleming 1998). 
 
 
 
Table 2.1 Core components of Notch signaling in different species. This table is adapted and 
modified from Notch signaling: a simple pathway becomes complex. Sarah J. Bray; Nature reviews, 
molecular cell biology, 2006. 7(9): 678-689 
 
 C. elegans Drosophila Mammals 
Notch receptor LIN-12, GLP-1 Notch Notch1-4 
Ligand LAG-2, APX-1, ARG-1, 
DSL-1 
Delta, Serrate Delta1, 3, 4, 
Jagged1-2 
CSL  
DNA-binding protein 
LAG-1 Su(H) CBF-1/RBP-Jκ 
Co-activator LAG-3 Mastermind Mastermind1-3 
γ-secretase complex Presenilin, nicastrin,  
APH-1, PEN-2 
Presenilin, nicastrin,  
APH-1, PEN-2 
Presenilin1-2, nicastrin,  
APH-1, PEN-2 
Metalloprotease SUP-17/Kuzbanian, 
ADM-4/TACE 
Kuzbanian ADAM10, 
TACE/ADAM17 
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Figure 2.1 Schematic diagram of Notch receptor structures in mammals. The Notch receptors 
are expressed on the cell surface as heterodimers composed of an extracellular domain, a single 
pass transmembrane and an intracellular domain. The extracellular domain of each Notch receptor 
contains a short signal peptide, 29-36 tandem epidermal growth factor-like repeats (EGF-LR) and 
three LIN/Notch repeats (LNR). The intracellular domain contains the RAM (RBP-Jκ-associated 
module) domain and 7 ankyrin/cdc10 (ANK) repeats, which are necessary for protein-protein 
interactions. Moreover, Notch 1-3 contain two NLS (nuclear localization signals) domains around 
ANK domain while there is only one NLS in Notch 4. The NLS is necessary to translocate the 
intracellular domain to the nucleus where the TAD (transcriptional activation domain) can activate 
downstream events. There is no TAD domain in Notch 3 and Notch4, but all four Notch receptors 
contain a PEST (proline, glutamic acid, serine, and threonine-rich region) domain for degradation. 
This figure is adapted and modified from The molecular logic of Notch signaling- a structural and 
biochemical perspective. Gordon et al.; Journal of Cell Science, 2008. 121(19): 3109-3119 
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Figure 2.2 Schematic diagram of Notch ligand structures in mammals. Notch ligands are 
transmembrane proteins of which the extracellular domain contains a short signal peptide followed 
by a conserved DSL domain, which are necessary for their interaction with the Notch receptor. The 
EGF-like repeats comprise most of the extracellular domain in all ligands. Unlike Delta-like, Jagged 
1 and Jagged 2 contain an additional cysteine-rich domain (CRD) in the extracellular segment 
between the EGF-like domain and the transmembrane domain. This figure is adapted and modified 
from The molecular logic of Notch signaling- a structural and biochemical perspective. Gordon et 
al.; Journal of Cell Science, 2008. 121(19): 3109-3119 
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Overview of the Notch signaling pathway 
 
Cell-cell communication mediated by Notch receptors is crucial for cells to respond to 
Notch signaling and then translate to distinct cell fate decisions according to the overall cell context. 
Ligand binding to the extracellular domain of Notch receptor leads to a conformational change that 
allows for metalloproteinase domain-containing protein (ADAM10 and 17 in mammals, Kuzbanian 
in Drosophila, and Kuzbanian and TACE in C. elegans, see Table 2.1) shedding at the extracellular 
domain. This is followed by a second γ-secretase cleavage at the transmembrane domain of Notch. 
The cleavage of Notch by γ-secretase generates the release of the Notch intracellular domain 
(NICD). The liberated NICD then translocates to the nucleus and interacts with a DNA-binding 
protein CSL (CBF-1, RBP-Jκ in mammals, Suppressor of Haireless (Su(H)) in Drosophila, and 
LAG-1 in C. elegans, see Table 2.1). The binding of NICD to CSL and the recruitment of the co-
activator protein (Mastermind-like, MAML) convert CSL from a transcriptional repressor to an 
activator, which promotes the transcription of Notch1 target genes (Mumm & Kopan 2000; Fortini 
2002; Fryer et al. 2002) (Figure 2.3).  
 
There are many reported binding sites for the CSL to carry out transcription throughout the 
whole genome. The best characterized Notch target genes are Hes (Hairy and Enhancer of split) and 
Herp (Hes-related protein), which encode basic helix-loop-helix (bHLH) transcriptional repressors 
that antagonize proneuronal genes such as Mash1 and neurogenins (Yoon & Gaiano 2005). Other 
recently identified targets include proliferation and survival related genes such as interleukin-6 (IL-
6), nuclear factor-κB (NF-κB) and cyclin D1; and apoptosis related genes such as Bcl-2, Bcl-xl, 
survivin (anti-apoptosis) and p53, Bim (pro-apoptosis) (Figure 2.3) (Borggrefe & Oswald 2009).  
 
Activation through γ-secretase and NICD/CSL (RBP-Jκ) is referred to as canonical Notch 
signaling. There have been several non-canonical modes of Notch signaling reported, which could 
be mediated by cytoplasmically localized NICD and independent of γ-secretase cleavage and RBP-
Jκ. RBP-Jκ independent Notch signaling has been described in vertebrates and invertebrates and is 
speculated to involve Notch-mediated transcription via other DNA-binding proteins (Martinez Arias 
et al. 2002). NICD is also able to interact with other downstream effectors in the cytosol through the 
non-canonical pathway described in many studies. It was found that cytoplasmic NICD is able to 
regulate β-Catenin protein post-transcriptionally in the cytosol and does not require ligand binding 
mediated membrane cleavage of Notch receptor (Kwon et al. 2011). In addition, Notch signaling 
pathway can act as an endogenous signal that modulates cytokine production in dendritic cells 
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independently of γ-secretase activity (Gentle et al. 2012). The cytoplasmic NICD has been reported 
to activate expression of the pro-inflammatory cytokine IL-6 independently of the DNA binding 
protein CSL, which is controlled by NF-κB and p53 in breast tumor cells (Jin et al. 2013). Recently, 
our laboratory has shown that the peptidyl-prolyl cis/trans isomerase (Pin1) stabilizes NICD 
through their binding in the cytosol and facilitates its pro-apoptotic function in neurons following 
stroke. Overexpression of Pin1 increased NICD expression and further potentiated Notch-mediated 
neuronal cell death in simulated ischemia. Furthermore, binding of Pin1 to NICD augmented NICD 
accumulation and increased NICD stability by blocking the ubiquitin-mediated proteolysis of NICD 
(Baik et al. 2014). 
 
After Notch activation and translocation of NICD to the nucleus, the NICD, CSL and co-
activator MAML assemble around the DNA binding site and result in the transcription of Notch 
target genes. MAML is not only essential in organising this activator complex and recruiting other 
proteins for the transcription of target genes, but it is also important in recruiting the complex of 
cyclin C and cyclin C-dependent kinase 8 (CycC: CDK8) that directly phosphorylates NICD and 
targets it to the Fbw7/Sel 10 ubiquitin ligase for the consequent proteasomal degradation (Fryer et 
al. 2002; Fryer et al. 2004). Thus, MAML plays an essential role in the tight control of Notch 
signaling by bringing both transcriptional proteins and the means for termination in a short time. 
 
Several other studies have provided evidence supporting that the ubiquitin/proteasome 
degradation pathway is involved in regulating Notch signaling. A number of distinct classes of E3 
ubiquitin appear to directly regulate Notch receptors. In Drosophila melanogaster, the homologous 
to E6-AP Carboxyl Terminus (HECT) domain containing E3 ubiquitin ligase targets Notch 
receptors to late endosomes for subsequent degradation in the lysosome, thus negatively regulating 
Notch signaling (Cornell et al. 1999). In mammalian cells, the E3 ubiquitin ligase Itch has been 
shown to ubiquitinate membrane bound Notch1 receptor (Qiu et al. 2000). It has also been 
suggested that the cell fate determinant Numb influences developmental decisions by antagonizing 
the Notch signaling pathway. It was found that the mammalian Numb protein promotes 
ubiquitination of membrane bound Notch1 receptor and degradation of the NICD (McGill & 
McGlade 2003). The membrane-associated protein Numb recruits components of the ubiquitination 
machinery to the Notch receptors and facilitates ubiquitination of Notch receptors at the membrane, 
which in turn induces the degradation of the intracellular domain in the cytosol. Overall, these 
ubiquitin modifications of the Notch receptors control the availability of Notch receptors at the cell 
surface and, therefore regulate the strength and duration of the signal.  
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It is important to properly terminate Notch activity in a rapid turnover rate to prevent NICD 
from being reused for target genes transcription. NICD is a short-lived transcription co-factor, its 
target genes which belong to the Hes family are also regulated in a tight temporal fashion 
(Kageyama et al. 2007). The Hes family of proteins not only have short half-lives (~20 minutes), 
they are also able to repress the transcription of their own genes, thus ensuring that their activity is 
limited in time (Hirata et al. 2004). This autoregulation of the Hes genes and the short lives of Hes 
mRNAs and Hes proteins are evidence of the very transient character of the Notch response. 
 
In addition to negative feedback mechanisms of Notch signaling, several mechanisms have 
been described to up-regulate Notch signaling, including increased DSL ligands transcription, 
selective recycling of Notch receptors and ligands to the cell membrane, and post-translational 
modifications of ligands and receptors to increase their mutual affinity (Bray 2006; Le Borgne 2006; 
Schweisguth 2004). Altogether, the Notch signaling pathway produces an effective but highly 
transient response in interacting cells that requires a precise control of balanced feedback 
mechanisms. These regulatory mechanisms are all very crucial in regulating the timing, duration, 
strength, and downstream genes in response to different environmental stimuli and allow it to 
regulate cell fate decisions in several histogenic processes. 
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Figure 2.3 Notch signaling pathway in mammals. Interaction of the ligand with the Notch 
receptor results in the 2 step proteolytic cleavage accomplished by metalloproteinase domain-
containing protein (ADAM) and then the γ-secretase complex, leading to a subsequent release of 
the intracellular domain (NICD). The NICD then translocates to the nucleus and interacts with the 
transcription factor RBP-Jκ  and nuclear protein MAML. This complex is essential to activate the 
expression of downstream target genes in the nucleus. Cytoplasmic NICD is reported to affect 
several signaling pathways through the non-canonical pathway (dashed line). This figure is adapted 
and modified from Not(ch) just development: Notch signaling in the adult brain. Ables et al.; 
Nature review, Neuroscience, 2011. 12: 269-283 
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Structure and role of Gamma (γ)-secretase 
 γ-Secretase plays a chief role in Notch1 signaling activation and γ-secretase inhibitors 
treatment is able to reduce brain damage caused by Notch1 activation (Arumugam et al. 2006). γ-
Secretase is a membrane-embedded proteolytic complex belonging to a diverse family of 
intramembrane-cleaving proteases and is composed of four integral membrane proteins: presenilin 
(PS), nicastrin (NCT), anterior pharynx-defective 1 (Aph1), and presenilin enhancer 2 (Pen2), with 
presenilin being the catalytic subunit (Krishnaswamy et al. 2009). Presenilins are nine-pass 
transmembrane proteins containing two conserved aspartate residues in adjacent transmembrane 
domains and considered to have catalytic activity (Wolfe et al. 1999). Nicastrin is a single-pass 
transmembrane protein with a large ectodomain that is heavily glycosylated and plays a vital role in 
presenilin-mediated cleavage. Aph1 is a seven-pass transmembrane protein playing a role in 
forming a stable complex with nicastrin. It also shares essential roles with Pen2, a two-pass 
transmembrane protein, in γ-secretase activity and presenilin accumulation (Francis et al. 2002; Luo 
et al. 2003) (Figure 2.4A). 
 
The γ-secretase complex is assembled within early compartments of the endoplasmic 
reticulum (ER) and transported to late compartments and the cell surface where it encounters 
substrates and subsequently process the substrates within respective transmembrane segments (Kim 
et al. 2004). γ-Secretase mediates intramembrane cleavage of various transmembrane substrates 
including amyloid precursor protein (APP), Notch receptors, ErbB4, E- and N-cadherins, p75 and 
EphB2 (Koo & Kopan 2004). The PS-dependent γ-secretase cleavage is involved in the essential 
maturation of its two major substrates APP and Notch receptors, leading to the production of 
amyloid β   (Aβ)   peptides and the Notch intracellular domain (NICD), respectively (Takami & 
Funamoto 2012; De Strooper et al. 1999) (Figure 2.4B and C). Many other substrates of γ-secretase 
have recently been identified and thoroughly reviewed (Haapasalo & Kovacs 2011).  
 
Several lines of evidence have indicated a possible role for γ-secretase in post-mitotic 
neurons. Loss of presenilin function in C. elegans results in aberrant neurite growth and 
connectivity (Wittenburg et al. 2000). In addition, activation of Notch1 signaling in primary 
hippocampal neurons inhibits neurite development, and it is attenuated in PS1-deficient neurons and 
γ-secretase inhibitors treated neurons (Redmond & Ghosh 2001). Therefore, the role of presenilin is 
not only crucial in γ-secretase cleavage, but also obligatory to Notch1 signaling activation. Previous 
studies have shown that PS deficient mice exhibit a complete Notch deficiency and result in early 
embryonic deficits (Donoviel et al. 1999), and similar deficiency in Notch1 function is also noted in 
presenilin-deficient cells (De Strooper et al. 1999; Herreman et al. 2000).   
 28 
 
 
 
 
 
 
Figure 2.4 Structure of the γ-secretase complex and its cleavage of two main substrates, APP 
and Notch. (A) Schematic diagram of the four components of the γ-secretase complex. Presenilin, 
the catalytic center, is activated by endoproteolysis in between domain 6 and 7. (B) Illustration of 
APP processing by α-,  β-, and γ-secretases and the corresponding products. (C) Illustration of Notch 
receptor cleavage by ADAM followed by γ-secretase and the production of NICD. This figure is 
adapted and modified from Development and mechanism of γ-secretase  modulators  for  Alzheimer’s  
disease. Crump et al.; Biochemistry, 2013. 52(19): 3197-3216 
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Notch signaling in physiological brain functions  
 
Notch signaling plays crucial roles in cell fate determination and differentiation in 
embryonic and adult brains in the mammalian central nervous system, including NSC maintenance 
and differentiation (Pierfelice et al. 2011; Louvi & Artavanis-Tsakonas 2006), neuronal maturation 
(Redmond et al. 2000), glial determination (Wang et al. 2009; Nelson et al. 2011), and even learning 
and memory (Costa et al. 2003). During neurogenesis, the Notch signaling pathway acts as a 
regulator   of   a   process   known   as   “lateral   inhibition”,   which   ensures   that a subset of cells 
differentiates into distinct cell types and the others remain as the initial cell type. For example, in 
developing mammalian brains the NSCs initially only proliferate, and then some NSCs start 
undergoing neuronal differentiation. In those differentiating cells, Notch ligands such as Delta-like1 
(Dll1) are upregulated, which in turn activates Notch signaling in neighboring cells. Neuronal 
differentiation in neighboring cells is then inhibited as a result of Notch activation, hence 
maintaining the neighboring cells as NSCs (Ross et al. 2003; Miller & Gauthier 2007).  
 
Notch activity is crucial for maintaining embryonic NSCs in an undifferentiated state. 
Activation of Notch signaling induces the expression of transcriptional repression genes such as 
Hes1 and Hes5, leading to repression of proneural gene expression and thereby maintains NSCs by 
inhibition of neuronal differentiation (Lütolf et al. 2002). When Notch downstream transcription 
factor RBP-Jκ   is deleted from the embryonic brain, NSCs differentiate into neurons prematurely 
and are diminished, indicating that Notch signaling is essential for the maintenance of neural stem 
cells and it is a proper control of neurogenesis in embryonic brains (Imayoshi et al. 2010).  
 
Besides development, Notch signaling seems to be crucial in regulating the balance between 
stem cell maintenance and differentiation in the adult brains. The Notch receptor is found to be 
expressed in the progenitor cells in the neurogenic regions of the adult zebrafish (de Oliveira-Carlos 
et al. 2013). In the adult mouse brain, NSCs exist and neurogenesis continuously occurs in the 
subventricular zone (SVZ) of the ventricle and the subgranular zone of the hippocampal dentate 
gyrus (Alvarez-Buylla et al. 2001; Doetsch 2003). It was found that the Notch-RBP-Jκ  pathway is 
highly active in NSCs of the adult mouse hippocampus and is essential for long-term maintenance 
of NSCs (Ehm et al. 2010; Ables et al. 2010). By deletion of RBP-Jκ  in the adult brain, NSCs are all 
differentiated into neurons in the adult brain at the telencephalon region. Similarly, Notch1 
overexpression induces progenitor cell proliferation, whereas genetic deletion of Notch1 or γ-
secretase inhibition promotes cell cycle exit in the postnatal dentate gyrus (Breunig et al. 2007).  
 30 
More evidence of the divergent role of Notch signaling in physiological conditions can be 
seen during adult brain neurogenesis. The generation of neurons in the adult brain is thought to 
undergo several stages, beginning with radical glial-like NSCs to horizontal NSCs, progenitor cells, 
neuroblasts, immature neurons, and ending in mature neurons (Rakic et al. 2009). Early in the 
development of adult-born neurons, Notch signaling activation occurs during several divisions 
(from radial glial-like NSC to neuroblast). Notch activation also occurs in post-mitotic or quiescent 
cells in the absence of division (from neuroblast to mature neuron). In radial glial-like NSCs, Notch 
promotes a radial glial fate. While in both radial glial-like NSCs and horizontal NSCs, Notch 
activation promotes self-renewing divisions, depending on the cellular conditions and the stages the 
cells are at (James et al. 2003). Notch has also been implicated in regulating quiescence of NSCs 
according to varying levels of Notch activity (Chapouton et al. 2010). In progenitor cells, Notch 
activation is important for proliferation as its most well-known role is to inhibit neural 
stem/progenitor cells differentiation. 
 
 A number of studies suggested that Notch signaling influences synaptic plasticity and 
behaviour in the adult brain. Notch has also been implicated in regulating synaptic strength 
including long term potentiation and long term depression, and increases in the density of filopodia 
and spines in neurons (Wang et al. 2004). Furthermore, forebrain-specific conditional knockout of 
either Notch1 (Costa et al. 2003), or γ-secretase components nicastrin (Tabuchi et al. 2009) and 
presenilin-1 (Yu et al. 2001; Saura et al. 2004) results in learning and memory impairment, and even 
age-related neurodegeneration in adult mice. The cognitive deficits in both Notch1 and presenilin 
conditional knockout mice are restricted to both spatial leaning and long-term memory, indicating 
that Notch signaling is crucial for spatial learning and long-term memories in animals. 
 
Taken together, these studies highlight that Notch signaling is essential for neurogenesis in 
the embryonic and the mature brain, and it is also crucial for neuronal function and memory 
formation in animals. 
 
Notch signaling in pathological conditions  
 
As mentioned earlier, components of Notch signaling are continuously expressed and 
activated throughout the adult brain in fully differentiated cells (Berezovska et al. 1998; Sestan et al. 
1999). Recent findings have suggested that Notch signaling is also involved in adult neurological 
diseases. It is suggested that Notch signaling in neurons, glia, and NCSs may also play a role in 
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pathological changes that occur in neurological disorders such as Alzheimer’s   disease  
(Veeraraghavalu et al. 2010), CNS tumors (Dang et al. 2006; Pierfelice et al. 2011), CADASIL 
(cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) 
(Joutel et al. 1996), and stroke (Arumugam et al. 2006).  
 
Notch signaling in Alzheimer’s  disease 
 
There is a considerable amount of research indicating that Notch1 signaling influences the 
disease process in Alzheimer's disease (AD). The pathogenesis of AD involves the accumulation of 
amyloid β  peptide (Aβ)  leading to the formation of senile plaques, neurofibrillary tangles and then 
death of neurons in brain regions associated with learning and memory (Mattson 2004). Given the 
fact that γ-secretase cleavage is responsible for the production of Aβ and NICD by cleavage of 
amyloid precursor protein (APP) and Notch receptor, respectively, it has raised substantial interests 
to elucidate the roles of Notch1 signaling in AD.  
  
  It was found that Notch1 expression and activity are increased in sporadic  Alzheimer’s  
disease (Berezovska et al. 1998; Nagarsheth et al. 2006). In addition, increased Notch1 expression 
and amyloid plaques formation were observed in other neurodegenerative diseases such as Down 
syndrome (Fischer et al. 2005),  Pick’s  disease  (Nagarsheth et al. 2006) and  Pion’s  disease  (Ishikura 
et al. 2005). Other evidence further demonstrates that Notch1 and Notch2 directly bind to APP in rat 
E18 neurons and human embryonic kidney (HEK) 293 cells (Chen et al. 2006; Oh et al. 2005; Oh et 
al. 2010). Furthermore, APP intracellular domain and Notch intracellular domain (AICD and NICD) 
physically interact with adaptor proteins of NICD and APP, Numb and Fe65, respectively; and the 
crosstalk of NICD and AICD influences the transcription of Notch and APP-regulated genes, either 
positively (Fischer et al. 2005), or negatively (Roncarati et al. 2002). It is clear that Notch signaling 
and components in Notch signaling are involved in AD, however, at present the molecular 
mechanisms involving Notch signaling in progressive neurodegeneration still remain elusive.  
  
Notch signaling in CNS cancers 
 
 Substantial evidence has indicated that Notch signaling is activated in a variety of human 
cancers (Miele et al. 2006; Roy et al. 2007), and there are also several lines of evidence suggesting 
that Notch also plays a role in brain tumor progression. Analysis of human glioma brain tumors has 
shown that the Notch ligand Delta 3 can serve as a good clinical marker for gliomas (Phillips et al. 
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2006). In addition, expression of Notch receptors (Notch1-3) and their downstream targets (Hes 1, 2, 
4) are increased in cancer stem cells in glioblastomas (Shiras et al. 2007) and Notch signaling 
activation is associated with the growth and the feature of cancer stem cells in glioblastoma 
(Kristoffersen et al. 2013). Furthermore, γ-secretase inhibition decreases the total number of cancer 
stem cells and hamper tumor progression in medulloblastomas, suggesting a critical role of Notch 
signaling in CNS tumors (Fan et al. 2006). It was found that Notch1 expression induces 
tumorigenesis in the mouse brain and these mice eventually develop spontaneous medulloblastomas 
(Natarajan et al. 2013). Overall, these studies confirm that Notch signaling is involved in brain 
cancers and modifying Notch signaling activity could be a potential strategy for brain cancer 
therapy.  
  
Notch signaling in CADASIL 
 
 Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy, CADASIL, is a most common form of hereditary cerebral angiopathy that 
causes stroke and other impairments (Chabriat 2014). It is characterised by cerebral microvascular 
pathology with multiple infarcts and white matter damage and is highly associated with Notch3 
mutation (Joutel et al. 1996; Ringelstein & Nabavi 2005; Louvi et al. 2006). Notch3 is primarily 
expressed in vascular smooth muscle cells (Williams et al. 1995; Prakash et al. 2002). More than 
130 different mutations in Notch3 have been identified (Joutel et al. 1996). The mutated Notch3 
impairs the function and survival of vascular smooth muscle cells and leads to blood vessel damage, 
particularly the cerebral vessels within the brain, that cause the signs and symptoms of CADASIL 
(Domenga et al. 2004; Joutel 2011). Therefore, Notch3 plays a vital role in cerebral vascular 
formation and function, and impairment of Notch3 results in cerebral infarcts and associated 
functional deficits. 
 
Notch signaling in ischemic stroke 
 
Several studies have reported that Notch signaling plays a vital role in ischemic brain injury. 
Notch1 signaling was first shown to be involved in ischemic brain injury in the transient MCAO 
model in 2006 (Arumugam et al. 2006). In this study, γ-secretase activity and NICD1 expression in 
cortical brain tissue samples were found to increase in response to ischemia/reperfusion (I/R) injury. 
Mice transgenic for antisense Notch1 (NAS) and wild type mice treated with γ-secretase inhibitors 
showed reduced NICD1 expression in comparison to wild type vehicle treated mice after I/R. 
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Furthermore, the infarct volume and neurological deficits were significantly less in NAS mice and 
in mice treated with γ-secretase inhibitors in comparison to wild type mice and vehicle treated mice, 
respectively. In primary cortical neurons, hypoxia-induced cell death was increased in Jagged 
peptide treated group and decreased in γ-secretase treated group when compared with control 
groups. Increased level of cleaved caspase-3, an indicator of apoptosis, was seen in primary neurons 
and human neuroblastoma cells (SH-SY5Y) overexpressing NICD1 under glucose deprived (GD) 
conditions in comparison to vehicle treated cells, suggesting increased vulnerability of neurons to 
ischemic-induced apoptosis by Notch signaling. Mouse primary cortical neurons treated with γ-
secretase inhibitors showed decreased NICD1 and cleaved caspase-3 expression compared to 
vehicle control when subjected to ischemic conditions. Finally, the numbers of adherent leukocytes 
and platelets in the cerebral vasculature were significantly increased in vehicle treated mice 
following I/R injury, and γ-secretase inhibitors treated mice showed attenuated recruitment of 
leukocytes and platelets in brain microvessels. I/R injury also promoted microglial activation and 
lymphocyte infiltration, which was reduced in NAS and γ-secretase inhibitors treated mice. These 
results suggest that Notch signaling is involved in ischemic brain injury by regulating multiple cell 
types including neurons, microglia, and lymphocytes, which contributes to pathological outcomes 
in ischemic stroke (Arumugam et al. 2006).  
 
There are more studies supporting that Notch signaling is involved in neuronal apoptosis 
following ischemic stroke. Up-regulation of Notch2 contributes to prolonged apoptosis in brain 
injury induced by a neonatal stroke mouse model. In vitro oxygen and glucose deprivation (OGD) 
treatment showed an increase of Notch2 expression in apoptotic neurons, suggesting that Notch2 
activation following neonatal ischemia is detrimental to neuronal survival (Albéri et al. 2010). 
Notch1 is also involved in chronic mild stress (CMS) induced neuronal apoptosis and synaptic 
density reduction following ischemia. The mice exposed to a CMS paradigm after ischemic stroke 
induction showed increased apoptotic markers and reduced synaptic vesicle formation in the dentate 
gyrus, which can be reversed with γ-secretase inhibitor treatment. These results indicate that Notch1 
signaling is involved in neuronal susceptibility to apoptosis and synaptic deficit during post-stroke 
stresses (Wang et al. 2012). Additional evidence has shown that Notch signaling pathway induces 
ischemic brain injury via modulation of inflammatory responses. It was found that Notch1 signaling 
regulates reactive astrocyte proliferation, resulting in immune cell invasion following stroke 
(Shimada et al. 2011). Notch1 signaling also activates microglia and promotes pro-inflammatory 
cytokine production such as TNF-α  and IL-1β through an upregulation and a nuclear translocation 
of NF-κB transcription factor in the ischemic hemisphere of mice, which underwent transient 
MCAO. γ-Secretase inhibitor treatment significantly reduces NF-κB activation and production of 
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pro-inflammatory cytokines, and attenuates neurotoxicity of microglia under OGD conditions in 
neuron and microglia co-cultures (Wei et al. 2011). These studies suggested Notch signaling plays a 
critical role in post-ischemic inflammation and contributes to neuronal death in ischemic stroke. 
 
Notch signaling also plays a role in processes that contributes to the risk of ischemic stroke 
onset. For example, Notch1 is continuously activated during the event of large vessel vasculitis, 
which is a risk factor of ischemic stroke. Notch1 signaling activation increases T cells activity, in 
particular the Th1 and Th17, and leads to increased vascular infiltration of T cells and vascular 
inflammation (Piggott et al. 2011). In pulmonary arterial hypertension, another risk factor of stroke, 
Notch1, Notch 3 and Jagged1 expression were highly elevated in the lungs of both mice and rat 
models. Soluble Jagged1 inhibition of Notch signaling significantly reduced the proliferation and 
enhanced the apoptosis of pulmonary arterial smooth muscle cells, thus attenuating pulmonary 
arterial hypertension (Xiao et al. 2013). These   lines   of   evidence   stress   the   relevance   of   Notch’s  
effects on susceptibility to ischemic stroke. 
 
Although Notch1 receptor has been demonstrated to worsen stroke outcome by inducing 
neuronal apoptosis, the molecular mechanisms of Notch-mediated neuronal death in ischemic 
stroke still remains unclear. Hence, more research is required to dissect the mechanisms of Notch- 
mediated neuronal death following ischemic stroke. 
 
Gamma secretase in Notch-mediated cell injury in ischemic stroke 
 
γ-Secretase is crucial in Notch signaling activation, and there is also increasing evidence 
suggesting that γ-secretase or subunits of γ-secretase play an important role in ischemic stroke. 
During ischemic stroke, gene expression of presenilin and γ-secretase activity has been found to 
increase in the brain (Pennypacker et al. 1999; Tanimukai et al. 1998; Arumugam et al. 2006). In 
addition, PS1 and nicastrin expression were increased significantly in activated microglia and 
astrocytes following traumatic brain damage, including closed-head injuries, brain stabbing, and 
inflammatory insults, indicating enhanced γ-secretase activity in microglia and astrocytes after 
traumatic brain injury (Nadler et al. 2008). Numbers of studies have used γ-secretase inhibitors to 
interfere with Notch signaling activation in order to investigate the role of Notch signaling in 
ischemic stroke. The γ-secretase inhibitor treated mice in the transient MCAO model has been 
shown to improve ischemic stroke outcome by reducing leukocytes infiltration and microglial 
activation (Arumugam et al. 2006). γ-Secretase-mediated Notch signaling activation has been 
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shown to contribute to post-ischemic inflammation by modulating the microglia innate response in 
stroke. The microglia-mediated inflammatory response associated with focal ischemic stroke was 
attenuated in Notch1 antisense mice and γ-secretase inhibitor treated mice (Wei et al. 2011). The 
number of activated microglia and expression of pro-inflammatory cytokines such as IL-1β   and 
TNF-α   was reduced by γ-secretase treatment and in Notch1 antisense mice (Wei et al. 2011). 
Moreover, γ-secretase inhibitor treatment has been found to reduce the proliferation and 
differentiation of reactive astrocytes following stroke as well as ischemic brain injury (Marumo et 
al. 2013). 
 
A large number of structurally diverse γ-secretase inhibitors have been developed and tested 
in clinical trials for  Alzheimer’s  disease   and  various cancers such as breast cancer, colon cancer, 
and glioma (Tolcher et al. 2012; Schott et al. 2013; Doody et al. 2013). The first reported in vivo 
testing of a γ-secretase inhibitor was a dipeptidic compound N-[N-(3,5-difluorophenacetyl-L-
alanyl)]-S-phenylglycine t-butyl ester (DAPT), developed by Elan and Eli Lilly for treating 
Alzheimer’s   disease   (Lanz et al. 2003). DAPT is a cell permeable non-transition state analog 
inhibitor of γ-secretase. It reduces total Aβ  production with an IC50 of 115 nM in human primary 
neuronal cultures and with an IC50 of 100 mg/kg in mice. Another cell permeable non-transition 
state analog inhibitor of γ-secretase, (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-
oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (compound E) is able to 
inhibit γ-secretase activity at 7nM in vitro (Morohashi et al. 2006). Benzodiazepine analogues LY-
411575 (DBZ) and LY-450139 (semagacestat), developed at Eli Lilly, are also highly potent γ-
secretase inhibitors that have been tested extensively in an in vivo APP transgenic mouse model in 
Alzheimer's disease (Milano et al. 2004; Siemers et al. 2005). DAPT, compound E, DBZ, and 
semagacestat are a group of inhibitors with similar structures and functional properties. DAPT is 
found to directly bind to the C-terminal fragment of presenilin1, whereas compound E and DBZ 
bind to N-terminal fragment of presenilin1 (Fuwa et al. 2007; Tomita 2009). However the 
mechanism of action is still poorly understood (Burton et al. 2008; Lanz et al. 2006; Mitani et al. 
2012; Morohashi et al. 2006). 
 
Amongst the first generation γ-secretase inhibitors, semagacestat is the first γ-secretase 
inhibitor that has been taken into phase III clinical trials for  Alzheimer’s  disease (Doody et al. 2013). 
Notably, although pre-clinical studies have shown some of these potent γ-secretase inhibitors to be 
effective in animal models of Alzheimer's disease, clinical trials of semagacestat were shown to 
worsen cognition and functionality in patients in comparison to those on placebo (Doody et al. 
2013). In addition, semagacestat causes greater adverse effects such as increased risk of skin cancer 
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and infections in patients (Hsu et al. 2013). One possible  explanation  for  semagacestat’s  failure  is 
the non-specific inhibition of the cleavage of all γ-secretase’s   substrates,   particularly   Notch.   γ-
Secretase inhibitors have been shown to cause abnormalities in the gastrointestinal tract, thymus 
and spleen in rodents and these toxic effects are primarily related to the impairment of Notch 
signaling, which is known to regulate cell fate decisions in various cell types (Imbimbo 2008). 
Evidence from AD studies has shown that partial reduction γ-secretase activity has beneficial 
effects in the CNS that outweigh the toxicity associated with reduced γ-secretase activity (Li et al. 
2007). This evidence suggested that partial pharmacological inhibition of γ-secretase may provide a 
more effective strategy in reducing Aβ   production with lesser side effects in AD, and similar 
scenario may occur in stroke cases as well. Moreover, studies using γ-secretase inhibitors in mouse 
models of stroke showed that only one dose is required to inhibit Notch1 signaling and improve 
stroke outcome, suggesting a potential new treatment by using γ-secretase inhibitors.  
 
Notch signaling crosstalk with other signaling pathways- NF-κB, HIF-1α,   and 
MAPK pathways 
 
The framework of the Notch signaling pathway is simple but it functions in an enormous 
diversity of biological processes in different cell types under different conditions. The pleiotropic 
function of Notch signaling is thought to be the result of intensive crosstalk with other regulatory 
pathways (Ables et al. 2011). Several studies have shown that Notch receptor and the activated 
NICD exhibit signaling capacity through the interaction with other signaling pathways in different 
cell types (Andersen et al. 2012; Sanalkumar et al. 2010). In neurons, although γ-secretase-mediated 
Notch1 activation has been found to be detrimental to neuronal survival in ischemic stroke 
(Arumugam et al. 2006), there is still limited knowledge regarding the molecular mechanisms of 
Notch1-mediated neuronal death following ischemic stroke and whether there is Notch1 signaling 
crosstalk with other regulatory pathways in neurons following ischemic injury is not yet fully 
understood. Hence it is the goal of this thesis project to investigate Notch1 signaling crosstalk with 
potential pathways in neurons under ischemic conditions.  
 
One remarkable interaction is the crosstalk between Notch1 and NF-κB  pathways.  Notch1 
signaling has been found to activate NF-κB  activity  by  direct binding of NICD to NF-κB  subunits  
p50 and p65, leading to prolonged nuclear retention of NF-κB in T cells (Shin et al. 2006). Another 
regulatory pathway that has been linked to Notch signaling is the hypoxic response pathway 
mediated by hypoxia inducible factor-1α  (HIF-1α). Interaction of HIF-1α and NICD is required in 
 37 
maintaining neuronal stem cell in undifferentiated state (Gustafsson et al. 2005), and is important in 
regulating medulloblastoma precursor proliferation (Pistollato et al. 2010). Furthermore, Notch 
signaling has been found to regulate macrophage polarization through the MAPK pathway (Xu et al. 
2012), and seems to inhibit endothelial proliferation by repressing the MAPK pathway (Liu et al. 
2006). However, little is known about the crosstalk between Notch signaling and these pathways in 
neurons and how these interactions affect neuronal survival during ischemic stroke. Therefore, the 
primary focus of this thesis is to investigate the molecular mechanisms of how γ-secretase mediated 
Notch signaling results in neuronal cell death during ischemic stroke, specifically, the modulation 
or interactions with NF-κB,  HIF-1α, and MAPK pathways. The first project aimed to determine γ-
secretase-mediated Notch signaling in inducing neuronal cell death through the NF-κB pathway 
following ischemic stroke. It was hypothesised that γ-secretase mediated Notch signaling is 
activated during ischemic stroke and induces neuronal cell death via modulating the NF-κB 
induction of pro-apoptotic protein expression. The second project aimed to investigate the 
collaborations between Notch and HIF-1α  in ischemic stroke-induced neuronal cell death. With the 
knowledge that Notch and HIF-1α  interact with each other to regulate neuronal cell fate decisions, it 
was hypothesised that Notch and HIF-1α   collaborate in promoting neuronal cell death via 
modulating pro-apoptotic protein expression during ischemic stroke. The last project aimed to 
investigate the contribution of Notch signaling to MAPK activation-induced neuronal cell death 
following ischemic stroke. It was hypothesised that activation of Notch signaling following 
ischemic stroke induces neuronal cell death via the activation of MAPK pathways (Figure 2.5). 
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Figure 2.5 Simplified diagram of the projects undertaken in this thesis. The aim of this thesis 
project is to investigate whether NF-κB,  HIF-1α, and MAPK signaling pathways are affected by γ-
secretase-mediated Notch signaling in the induction of neuronal cell death following ischemic 
stroke.  
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Chapter 3  The Notch1-NF-κB-Bim axis mediates cell death following 
ischemic stroke  
 
Introduction 
 
The Notch1 receptor is part of a well-conserved signaling pathway that regulates various 
cell-fate decisions at multiple stages of the developing nervous system, and it also plays significant 
roles in the adult brain from regulating synaptic plasticity to influencing pathological events in 
neurological disorders (Wang et al. 2004; Lathia et al. 2008). Binding of Notch1 ligands, such as 
Delta and Jagged, results in proteolytic cleavage of the Notch1 receptor at its transmembrane 
domain. This cleavage is facilitated by the γ-secretase complex, leading to the release of a Notch1 
intracellular domain (NICD) that translocates to the nucleus where it regulates gene expression 
(Kopan 2002; Krämer 2000). γ-Secretase is a multi-subunit protease complex comprised of four 
integral membrane proteins: presenilin, nicastrin, Aph1, and Pen2 (Krishnaswamy et al. 2009), with 
presenilin as the catalytic subunit that is responsible for the transmembrane cleavage of its 
substrates (De Strooper et al. 1998). γ-Secretase plays a vital role in the generation of amyloid β-
peptide (Aβ)  in Alzheimer's disease, as well as in Notch1 receptor-mediated signaling under normal 
physiological conditions. It has been previously shown that the activity of γ-secretase, and 
subsequent Notch1 activation, are elevated in mouse brain following ischemic stroke and in 
cultured cortical neurons subjected to ischemic conditions (Arumugam et al. 2006). γ-Secretase-
mediated Notch1 signaling modulates pathways that increase neuronal vulnerability to apoptosis 
and also activates microglial cells and stimulates the infiltration of pro-inflammatory leukocytes, 
which jeopardize neuronal survival following ischemic stroke (Arumugam et al. 2006). The 
treatment of γ-secretase inhibitors, DAPT and DBZ significantly reduced neuronal death and brain 
damage, thus improving functional outcome in mice following an ischemic stroke. These findings 
suggest that γ-secretase-mediated Notch1 activation is detrimental to brain cells in ischemic stroke 
(Arumugam et al. 2006). 
 
 NF-κB is a multi-subunit complex that when activated, induces the expression of genes that 
are involved in cell survival, apoptosis, and inflammation (Mattson & Camandola 2001). The 
transcription factor NF-κB consists of preformed dimers composed of five members which in the 
mammalian NF-κB family are: p-50, p-53, p-65 (RelA), RelB and c-Rel, forming homo- or 
heterodimer in various combinations among which p-50 and p-65 are the most widely studied NF-
κB subunits (Nabel & Verma 1993). Transcription factor NF-κB has been shown to be activated in 
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neurons, glial, and endothelial cells after ischemic stroke/ reperfusion by several studies (Gabriel et 
al. 1999; Stephenson et al. 2000; Nurmi et al. 2004; Tang et al. 2007). NF-κB activation in neurons 
was shown to contribute to cell death following ischemic stroke (Zhang et al. 2005), and p-50 
knockout mice are protected from ischemic brain injury in the transient MCAO model (Schneider et 
al. 1999). These studies provided evidence of a detrimental role of NF-κB activation following 
ischemic stroke. Some evidence of Notch signaling modulating the function and activity of NF-κB 
signaling pathway has been observed. NF-κB was found to be the target gene of γ-secretase-
mediated Notch signaling, that Notch1 signaling induces NF-κB promoter activity and thus 
increasing the expression of NF-κB components (Oswald et al. 1998). It has also been found that γ-
secretase-mediated Notch1 signaling is required to sustain NF-κB activity and IFN-γ production in 
peripheral T cells. Inhibition of Notch1 activity with γ-secretase inhibitors attenuates sustained NF-
κB activity by affecting its nuclear distribution, resulting in reduced transcriptional activity (Shin et 
al. 2006). Whether Notch signaling activation induced by cerebral ischemia is associated with the 
induction of NF-κB expression or its transcriptional activity still remains elusive.  
 
The intrinsic (mitochondrial) apoptotic pathway is tightly regulated by the Bcl-2 family of 
proteins that are involved in either pro-apoptotic or anti-apoptotic pathways (Adams 2003). The 
pro-apoptotic pathway begins with the activation of members of the BH3-only protein subgroup, 
such as Bim and Bid, leading to the pro-apoptotic proteins Bax and/or Bak activation. Bax/Bak 
activation leads to the release of cytochrome c from mitochondria to the cytosol, where it induces 
the activation of the caspase cascade and induces apoptosis. The anti-apoptotic pathway is involved 
with anti-apoptotic Bcl-2 proteins including Bcl-2 and Bcl-XL, which interfere with the BH3-only 
protein-mediated Bax/Bak activation and thus neutralize the pro-apoptotic pathway (Puthalakath & 
Strasser 2002; Green & Kroemer 2004). Evidence suggests that the BH3-only protein Bim is 
essential for pro-apoptotic Bax and Bak activation. Bim induces apoptosis through direct binding to 
Bax/Bak and transmit stress signaling to Bax/Bak, leading to neuronal apoptosis following transient 
focal cerebral ischemia (Okuno et al. 2004). However little is known whether Notch1 signaling 
promotes neuronal apoptosis through Bim. Therefore this study aims to explore the molecular 
mechanism of γ-secretase-mediated Notch signaling in inducing neuronal cell death through NF-κB 
following ischemic stroke. The apoptotic protease cleaved caspase-3 and pro-apoptotic BH3-only 
protein, Bcl-2-interacting mediator of cell death (Bim) are also examined to elucidate whether their 
expression are modulated by NF-κB induction after ischemic stroke. This present study provides 
evidence that γ-secretase mediated Notch1 activation induced by ischemia promotes neuronal cell 
death and brain injury through modulating the NF-κB-Bim, and caspase pathways. 
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Materials and Methods 
 
Animals 
 
The embryos of wild type female mice (C57BL/6J) at embryonic day 16 (E16) were used as 
the source of cortical neurons for primary cell culture. Three to six month old male wild type mice 
(C57BL/6J) were used for the animal stroke model. All mice were purchased from the University of 
Queensland Biological Resources (UQBR) animal facilities and all animal experimental procedures 
were reviewed and approved by the University of Queensland Animal Ethics Committee. 
Primary mouse cortical neuronal culture 
 
The primary cortical neuronal cultures were established from 16-day C57BL/6 mouse 
embryos according to the procedure described by Okun et al (Okun et al. 2007). Mouse embryos 
were removed from anaesthetised pregnant mice, the heads of the embryos were removed and 
cortical tissue were collected in a petri dish with cold Ca2+/Mg2+-free Hanks balanced saline 
solution (HBSS) (Life Technologies, Australia). The dissected cortical tissue was then incubated 
with 5ml of HBSS containing 0.2% trypsin (Sigma Aldrich, USA) for enzymatic dissociation 
purposes. Following 15-20 minutes incubation, the digested tissue was rinsed with fresh HBSS and 
incubated with 5ml of HBSS containing 0.1% soybean trypsin inhibitor (Sigma Aldrich, USA) to 
prevent toxic effects of trypsin to the cells. The cortical neurons were separated by triturating the 
tissue in a 50ml falcon tube using a Pasteur pipette until no visible tissue chunks are visible. Cells 
were cultured on 100-mm diameter petri dishes in Neurobasal medium containing 25 mM glucose 
(Life Technologies, Australia) and B-27 supplements (Life Technologies, Australia), 2 mM L-
glutamine (Sigma Aldrich, USA), 0.001% gentamicin (Life Technologies, Australia), and 1 mM 
HEPES, pH 7.2, and maintained in 37°C incubator for 7 days to mature. Approximately 95% of the 
cells in the cultures were neurons, and the remaining 5% of the cells were astrocytes.  
 
Pharmaceutical treatments 
 
γ-Secretase inhibitor XXI (compound E) was purchased from Merck Calbiochem, Germany. 
NF-κB   inhibitor, 7-methoxy-5, 11, 12-trihydroxycoumestan, was purchased from Sigma Aldrich, 
USA. Primary neuronal cultures were subjected to glucose deprivation at 7 days post seeding, 
together with pharmacological treatment at stated concentrations (100 nM for compound E and 1 
μM   for  NF-κB   inhibitor). Compound E was administered to cortical neurons 3 hours before GD 
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treatment or on the onset of GD. Mice subjected to middle cerebral artery occlusion (MCAO) were 
treated with 1 mg/kg Compound E or vehicle (dimethyl sulfoxide, DMSO) by intravenous infusion 
from femoral  vein  (20  μl) 30 minutes before or immediately after the occlusion. 
 
Glucose deprivation  
For glucose deprivation (GD), the medium of cultured neurons was replaced with glucose-
free Locke's buffer containing 154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 1 mM MgCl2, 3.6 mM 
NaHCO3, 5 mM HEPES, pH 7.2, supplemented with 5 mg/L of gentamicin for stated time points. 
The GD model was selected in favor of oxygen and glucose deprivation (OGD) in order to induce 
slower cell death through apoptotic mechanisms. 
 
Cell viability assay 
 
Cell viability was determined using trypan blue exclusion assay. 50  μl  of  0.4%  trypan  blue  
(Sigma Aldrich, USA) were added into all treatment culture plates for 10 minutes at room 
temperature. The cells were washed and fixed using phosphate buffered saline (PBS) and 4% 
paraformaldehyde (PFA) respectively before they were incubated in PBS for light microscope 
observation. Dead or dying cells were stained blue and the staining is excluded from viable cells 
with intact membranes. 
 
Immunoblot analysis 
 
Protein samples were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using a Tris-glycine running buffer (Bio-Rad, USA) at 80V. The 
proteins were then transferred into nitrocellulose membranes (Bio-Rad, USA) in transfer buffer 
(Bio-Rad, USA) for 1.5 h at 350 mA. The membranes were then incubated in blocking buffer (5% 
BSA; Sigma Aldrich, USA) in 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, and 0.2% Tween 20 (TBS-
T) for 1 hour at room temperature. The membrane was then incubated overnight at 4°C with 
primary antibodies against cleaved caspase-3, phosphorylated-p50 and p65, Bim (Cell Signaling 
Technology, USA), activated Notch1 (Abcam, UK) and beta actin (Sigma Aldrich, USA). The 
polyclonal anti-activated Notch1 antibody does not cross-react with mouse Notch2, 3, or 4. This 
antibody only recognizes the cleaved intracellular form of Notch1 (NICD). After washing with 
TBS-T, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody 
for 1 hour at room temperature. After washing again with TBS-T, the membrane was incubated 
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with substrate for enhanced chemiluminescence (Pierce Endogen, USA), and chemiluminescent 
signals were visualized using X-ray films in a dark room (Fujifilm Corporation, Japan). 
 
Middle cerebral artery occlusion and reperfusion (MCAO/R) stroke model 
 
Male C57BL/6 mice aged three to six months were used for in vivo experiments. The focal 
cerebral ischemia/reperfusion model was similar to that described previously (Arumugam et al. 
2004). In brief, the mice were anesthetized with isoflurane, an incision was made in the neck to 
isolate and ligate the left external carotid (ECA), common carotid artery (CCA) and pterygopalatine 
arteries with 5–0 silk threads. The left internal carotid artery (ICA) was occluded at the peripheral 
site of the bifurcation of the ICA. A small incision was then made on the ECA, and a 6–0 nylon 
monofilament with a blunted tip (0.2–0.22 mm) was inserted into the ECA. After the silk thread at 
the ICA was removed, the nylon monofilament was advanced into the middle cerebral artery until 
light resistance was felt. For reperfusion, the nylon thread and the common carotid artery ligature 
were removed after 1 hour after occlusion. In the sham group, these arteries were visualized but not 
disturbed. The MCA occlusion was considered successful when cerebral blood flow in the affected 
side fell below 20% from the baseline measured via Laser Doppler flowmeter (Moor LAB, UK). A 
craniotomy was performed to access the left middle cerebral artery to allow positioning of a 0.5-
mm Doppler probe over the underlying parietal cortex approximately 1 mm posterior to bregma and 
1 mm lateral to the midline.  
 
Neurological assessment 
 
The animals were subjected to a neurological assessment every 24 hours in all the groups in 
a blinded manner. The neurological impairments following focal cerebral ischemia and reperfusion 
injury were evaluated according to the five-point neurological deficit scoring scale (0, no deficit; 1, 
failure to extend right paw; 2, circling to the right; 3, falling to the right; and 4, unable to walk 
spontaneously) (Longa et al. 1989). 
 
Quantification of cerebral infarction 
 
At 72 hours of reperfusion, the mice were euthanized with a lethal dose of isoflurane. The 
brains were collected immediately into cold PBS (4°C) for 15 min and sectioned into five 2-mm 
thick coronal slices. The brain sections were then stained with 2% 2,3,5-triphenyltetrazolium 
chloride (TTC) (Sigma Aldrich, USA) in phosphate buffer at 37°C for 15 minutes. The stained 
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brain sections were photographed, and the images were used for analysis. The areas of the 
infarction in each brain slice were quantified using NIH Image 6.1 software. To compensate for 
brain edema, the infarct area was determined as follows: the corrected infarct area = area of intact 
contralateral hemisphere – (area of ipsilateral hemisphere – area of infarct). Infarct volume was 
calculated by integration of infarct areas for all five slices to calculate total infarct volume and was 
expressed as a percentage of the ipsilateral hemisphere. 
 
Data analysis 
 
All the results are reported as means ± standard deviation (SD). The overall significance of 
the data was examined by one-way analysis of variance (ANOVA). The differences between the 
groups were considered significant at p < 0.05 with the appropriate Bonferroni correction made for 
multiple comparisons. Neurological behavior scores were analyzed using a nonparametric Kruskal-
Wallis test and Dunn's multiple comparison test. 
 
Results 
Involvement of γ-secretase in cell death induced by ischemic conditions 
 
To investigate the  effect  of  a  γ-secretase inhibitor against ischemic stroke-like cell death in 
vitro, primary neuronal cells were used. Previously, it  has  been  shown  that  one  of   the  γ-secretase 
inhibitors, DAPT, reduced GD-induced primary neuronal cell death (Arumugam et al. 2006), 
therefore in this study the effect of another  γ-secretase inhibitor compound E was studied. Similar 
to the effect of DAPT, 100 nM of compound E also significantly reduced GD-induced cell death in 
primary cortical neurons (Figure 3.1). Next, how γ-secretase inhibitor protects against neuronal cell 
death under GD conditions was investigated. Primary cortical neurons subjected to 12 hours GD 
conditions resulted in increased levels of the cleaved form of the apoptotic protease caspase-3, NF-
κB  phosphorylated subunits p65 (p-p65) and p50 (p-p50), and the pro-death BH3-only protein, Bim 
(Figure 3.2A). Treatment of compound E (100 nM) reduced expression levels of cleaved caspase-3, 
p-p65, p-p50, and Bim (Figure 3.2A-C). Furthermore, to determine whether NF-κB   activation   is  
directly linked to GD-mediated apoptosis via Bim, neurons were treated with an NF-κB  inhibitor  (1  
μM) when subjected to GD conditions. The NF-κB   inhibitor   reduced   expression   levels   of   both  
cleaved caspase-3 and Bim after 12 and 24 hours of GD conditions. In addition, it was observed that 
the level of apoptosis-inducing factor (AIF) was attenuated in the NF-κB   inhibitor treated neurons 
at 24 hours of GD (Figure 3.2D). 
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Figure 3.1 γ-Secretase inhibitor compound E protects against ischemic neuronal cell death.
Compound E treatment significantly reduced GD-induced cell death in primary cortical neurons. **, 
P < 0.01 compared with the GD group. n=3 different cultures.  
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Figure 3.2 γ-Secretase inhibition reduces cleaved caspase-3, NF-κB,  and Bim expression and 
Bim is downstream of NF-κB. (A-C) Treatment with compound E (100 nM) significantly reduced 
levels of cleaved caspase-3, p-p65, p-p50, and Bim in primary neurons after 12 hours of GD 
conditions. (D) Primary cortical neurons treated with a NF-κB  inhibitor showed reduced expression 
of both cleaved caspase-3 and Bim after 12 and 24 hour of GD conditions. The expression of 
apoptosis-inducing factor (AIF) was attenuated with NF-κB  inhibitor  treatment at 24 hours of GD. 
***, P < 0.05 compared with the GD group. n=3 different cultures. 
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In vivo γ-secretase inhibitor treatment protects against ischemic-induced brain injury through 
NF-κB-Bim pathway 
 
It has been previously shown that γ-secretase inhibitors DAPT and DBZ reduce brain 
damage and neurological deficits after cerebral ischemia reperfusion (Arumugam et al. 2006). To 
test whether the   γ-secretase inhibitor compound E protects against ischemic-induced brain injury 
with similar mechanisms as those observed in vitro (Figure 3.1- 3.2), compound E was tested for 
the first time in a stroke model. Intravenous infusion of compound E (1mg/kg) 30 minutes before or 
immediately after ischemia resulted in reduced infarct volume (Figure 3.3A) and improved 
functional outcome (Figure 3.3B). The infarct volume was increased in vehicle-treated mice and 
pre- and post-treatment of compound E significantly decreased the infarct volume. Nonparametric 
Kruskal-Wallis test and Dunn's multiple comparison test showed that the neurological deficit score 
from vehicle-treated group was significantly increased compared to the sham group. On the other 
hand, the neurological score of mice treated with compound E 30 minutes before or immediately 
after ischemia were significantly reduced in comparison to the vehicle treated mice. Next, the 
protein levels of NICD and Bim in the ipsilateral brain region after 1, 3, or 24 hours of reperfusion 
were tested. As expected, both NICD and Bim levels were increased in the brain after ischemic 
stroke (Figure 3.4A). The expression levels of NICD, p-p65 and Bim were then assessed to verify 
whether compound E protect against ischemic stroke-induced brain injury by affecting these 
proteins (Fig. 3.4B-E). The data confirmed that NICD, p-p65 and Bim levels were all significantly 
reduced in compound E treated group in comparison to the vehicle-treated group (Figure 4.4C-E). 
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Figure 3.3 Treatment of compound E reduces brain damage in vivo. (A) Infarct volumes in 
mice treated with compound E 30 minutes before and immediately after ischemia were significantly 
decreased compared to those in vehicle treated mice. (B) Mice treated with compound E 30 minutes 
before and immediately after ischemia showed reduced neurological deficit compared to vehicle 
treated mice. ***, P < 0.05; n = 6 to 14 in each group.  
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Figure 3.4 Treatment with a γ-secretase inhibitor compound E immediately after ischemia 
reduces the levels of NICD, p-p65, and Bim. (A) The NICD and Bim expression levels in the 
ipsilateral hemisphere were increased after 1, 3 and 24 hours of reperfusion. (B-E) The expression 
levels of NICD, p-p65 and Bim were significantly reduced in compound E treated group compared 
with the vehicle-treated (control) group. * p< 0.05, ** p< 0.01, *** p< 0.001; n = 6 to 8 in each 
group. 
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Discussion 
 
A major finding of this study is that inhibition of Notch1 signaling using a γ-secretase 
inhibitor attenuates neuronal damage and ischemic stroke outcome through modulating the NF-κB, 
pro-apoptotic protein Bim, and caspase pathways. It has been previously shown that γ-secretase 
activity and subsequent NICD production are elevated in the brain after ischemic stroke 
(Arumugam et al. 2006). NICD and pro-apoptotic protein cleaved caspase-3 levels were increased 
in primary cortical neurons under GD conditions, whereas treatment of a γ-secretase inhibitor 
reduced the levels of NICD and cleaved caspase-3 (Arumugam et al. 2006). Furthermore, 
preventing Notch1 signaling activation using intravenous treatment with γ-secretase inhibitors 
DAPT or DBZ improved functional outcome and reduced brain damage in an experimental 
ischemic stroke mouse model (Arumugam et al. 2006). However, it is still not clear how Notch1 
signaling promotes neuronal death and worsens the ischemic outcome. Thus the aim of this study is 
to further investigate the molecular mechanisms by which Notch mediates neuronal cell death 
following ischemic stroke. 
 
In this study, Notch1 signaling activation was determined by increased level of NICD in the 
ipsilateral hemisphere of mice following transient focal ischemic stroke. A potent γ-secretase 
inhibitor, compound E, was used in this study since it is more potent than DAPT and its protective 
effect on ischemic neurons and brains has never been tested before. Compound E successfully 
reduced neuronal cell death as well as the apoptotic marker, cleaved caspase-3 expression in 
neurons under ischemic conditions. These results are expected as similar results using DAPT and 
DBZ had been shown previously by Arumugam et al., suggesting all these γ-secretase inhibitors are 
able to prevent neuronal death in cerebral ischemia. 
 
Next, the apoptotic pathway that might be mediated by Notch1 signaling and leads to cell 
death was investigated. Phosphorylated NF-κB subunits p50 and p65 expression levels increase in 
primary cortical neurons under GD conditions. Phosphorylated p65 level is also increased in mice 
under ischemia/reperfusion when compared to sham mice.  Ample evidence has shown that NF-κB 
is activated and promotes cell death during ischemic stroke. Most studies have found the activation 
of NF-κB in neurons (Stephenson et al. 2000; Huang et al. 2001; Nurmi et al. 2004; Tang et al. 
2007), other studies showed NF-κB activation in astrocytes, microglia, and endothelial cells (Terai 
et al. 1996; Howard et al. 1998; Gabriel et al. 1999; Kaushal & Schlichter 2008). NF-κB activation 
has been detected in the ipsilateral hemisphere in a transient MCAO model, and ischemic brain 
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damage was significantly reduced in p50 knockout mice, indicating a cell death-promoting role of 
NF-κB in ischemic stroke (Schneider et al. 1999). The results in this study confirmed the activation 
of NF-κB in neurons and in the brain under ischemic conditions as shown in previous studies. 
 
Next, to investigate whether NF-κB activation following ischemic stroke is involved in 
Notch1 mediated cell death, the expression level of NF-κB under the treatment of the γ-secretase 
inhibitor compound E was investigated. It is found that compound E treatment reduces GD-induced 
p-p65 and p-p50 levels in primary cortical neurons. Compound E treated mice also show reduced p-
p65 levels in the ipsilateral hemisphere in comparison to control mice after transient MCAO. This 
result suggests that NF-κB protein complex expression is the target of Notch signaling activation 
following ischemia, and it is likely to assist Notch1 signaling to induce cell death via the activation 
of pro-apoptotic pathways. It has been shown that γ-secretase-mediated Notch signaling is required 
to sustain NF-κB activity and cytokine production in peripheral T cells. The intracellular domain of 
Notch1 (NICD) directly binds to NF-κB and competes with IκB, therefore increases the 
translocation of NF-κB to the nucleus and its activity (Shin et al. 2006). A study in Jurkat T cells 
showed that γ-Secretase-mediated Notch signaling also enhances NF-κB subunits expression by 
binding to NF-κB promoters (Oswald et al. 1998). Numbers of studies have suggested the interplay 
of Notch signaling to the NF-κB pathway in the brain (Y. Wang et al. 2004; Fujita et al. 2011; X. 
Zhang et al. 2012). A recent study supports the finding in this study by showing down-regulated 
expression of Notch1 and NF-κB p65 with DAPT treatment in rats under MCAO (Li et al. 2012). 
Another study in microglia under hypoxic injury showed that Notch1 inhibition with DAPT reduced 
the expression and translocation of NF-κB p65, as well as most inflammatory mediators induced by 
hypoxia. Hypoxia-induced up-regulation of NF-κB immunoreactivity in microglia was prevented in 
DAPT treated rats, suggesting Notch1 signaling regulates the NF-κB pathway in microglia 
activation under hypoxic conditions (Yao et al. 2013).  
  
The data in this study shows that expression of the pro-apoptotic protein Bim is increased in 
the ipsilateral hemisphere following MCAO/reperfusion. Furthermore, compound E not only 
reduces phosphorylated NF-κB subunits p65 and p50 but also Bim expression, both in vitro and in 
vivo after conditions of ischemic stroke. Studies have suggested that Bim promotes apoptosis 
through two pathways: binding to Bax with its BH3 domain causes a conformational change of Bax, 
which leads to oligomerization and insertion of Bax into the outer mitochondrial membrane and 
ultimately apoptosis through release of cytochrome c together with other mitochondrial apoptogenic 
factors; and binding to Bcl-2, which neutralizes its ability to sequester Bax in an inactive state 
(Desagher et al. 1999; Marani et al. 2002). The finding in this study also suggests that increased 
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Bim expression could contribute to neuronal apoptosis following ischemic stroke. 
 
To further confirm that Bim and cleaved caspase-3 are downstream of NF-κB activation and 
leading to apoptotic cell death, a NF-κB inhibitor was administered into neurons under ischemic 
conditions and both expression levels of Bim and cleaved caspase-3 are reduced significantly when 
compared with non-treated groups. The expression of apoptosis-inducing factor (AIF), which is 
involved in the caspase-independent pathway of apoptosis, is also reduced in NF-κB inhibitor 
treated neurons at 24 hours of GD conditions. This result further supports the conclusion that γ-
secretase-mediated Notch signaling induces neuronal cell death via the NF-κB pathway. In the 
canonical activation pathway, NF-κB dimers are mainly retained in the cytoplasm by interacting 
with the inhibitory IκB proteins. Activating stimuli (e.g., tumor necrosis factor (TNF)) triggers the 
activation of the IKK (inhibitor of κB kinase) complex that phosphorylates the inhibitory IκB 
protein, and the phosphorylated IκB is then ubiquitinylated and degraded by the proteasome 
(Wallach et al. 2002). The degradation of IκB results in the liberation and translocation of the NF-
κB complex into the nucleus, where it initiates gene transcription by binding to regulatory DNA 
sequences. Recent studies show evidence that NF-κB modulates apoptosis through the regulation of 
Bim. One of the NF-κB regulator IκB family proteins, Bcl-3, prevents NF-κB induced apoptosis via 
the inhibition of BH3-only protein Bim in activated T cells. Blocking of Bcl-3 leads to the 
activation of NF-κB and thus Bim activation and apoptosis (Bauer et al. 2006). Furthermore, BH3-
only protein Bim and Noxa are the targets of NF-κB p65 in neurons under ischemic conditions. p65 
induces Bim and Noxa gene transcription by binding to their promoters in primary cortical neurons 
under ischemic conditions. It was suggested in the study that the deleterious function of NF-κB in 
cerebral ischemia may be mediated by Bim and Noxa (Inta et al. 2006).  Therefore the findings in 
this project support these previous studies that Bim is downstream of NF-κB activation, and show 
for the first time that NF-κB-Bim mediates neuronal cell apoptosis following ischemic stroke. 
 
Previously it has been shown that 3 days after ischemia/reperfusion, the degree of brain 
damage and neurological deficit is significantly reduced in mice treated with γ-secretase inhibitors 
compared with vehicle treated mice and in mice transgenic for antisense Notch compared with 
nontransgenic mice (Arumugm et al. 2006). Here in this study, similar results using another potent 
γ-secretase inhibitor, compound E was obtained. Notably, compound E effectively reduced the 
infarct volume and improved functional outcome when administered 30 min before the onset of 
ischemia or immediately after the ischemic period. Using the recombinant substrate ex vivo, it was 
shown previously that compound E crosses the blood-brain barrier and inhibits cortical γ-secretase 
activity, resulting in decreased amount of cleaved substrates in plasma, cerebrospinal fluid (CSF) 
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and cortical tissues (Grimwood et al. 2005). These results again confirmed the detrimental role of γ-
secretase-mediated Notch signaling activation during ischemic stroke, and γ-secretase inhibitors are 
able to reduced brain damage and neurological deficit caused by ischemia effectively. 
 
The in vivo data also confirmed the neuroprotective mechanisms of compound E observed in 
the in vitro settings. The levels of NICD and Bim were increased throughout the time course of 
ischemic/reperfusion, confirming the activation of Notch signaling and pro-apoptotic protein 
expression in the ischemic brain. Moreover, levels of NICD, p65, and Bim were significantly 
reduced in compound E treated mice compared with vehicle control treated mice. A recent study 
using permanent focal ischemia model in rats supported that γ-secretase inhibitor protects against 
ischemic brain injury through Notch1-NF-κB pathway with very similar results to this study. In that 
study, rats under permanent MCAO showed increased expression of NICD throughout the time 
course of 72 hours, and DAPT administration significantly reduced NICD and NF-κB in the 
ischemic brain. Moreover, DAPT also significantly reduced brain damage caused by MCAO (Li et 
al. 2012). Overall this study confirmed Notch1-NF-κB-Bim pathway as a novel mechanism that is 
involved in brain damage following ischemic stroke and administration of γ-secretase inhibitors 
protects against ischemic brain injury.  
 
One major drawback of this study is that γ-secretase inhibition is the only strategy utilized to 
investigate Notch-mediated cell death in ischemic stroke. γ-Secretase inhibitors are known to inhibit 
the processing numbers of γ-secretase substrates at the same time (Selkoe & Wolfe 2007). Therefore 
γ-secretase inhibitors are not the best ways to identify the involvement of Notch1 signaling during 
ischemic stroke although the majority of studies have used γ-secretase inhibitors to block Notch 
signaling activation in their studies. Hence, in the future more specific modulation of Notch1 
signaling using molecular technologies such as endogenous knockdown of Notch1 gene using 
siRNA or overexpression of NICD1 protein, and Notch1 antisense mice would be better choices to 
support the findings of Notch1-mediated cell death in neurons and in mice following ischemic 
stroke.  
 
A noteworthy aspect from the results in this study is that NF-κB and Bim are modulated by 
γ-secretase-mediated Notch signaling during ischemic stroke-induced injury, and this Notch1-NF-
κB-Bim axis contributes to cell death in neurons as well as in the brain tissues following ischemic 
stroke. The present study provides the first evidence that γ-secretase-mediated Notch activation 
induces the pro-apoptotic pathway through NF-κB and Bim leading to neuronal cell death following 
ischemic stroke. As currently hundreds of neuroprotective agents have all failed in clinical trials, 
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there is an urgent need in the search for agents that can effectively protect neurons in ischemic 
stroke. γ-Secretase inhibitors may provide this promising effect and act as a potential therapeutic 
candidate in ischemic stroke intervention. 
 
Conclusion 
 
 Both Notch1 and NF-κB signaling pathways play crucial roles in regulating cell fate 
decisions including proliferation, differentiation and apoptosis. During ischemic stroke, Notch1 and 
NF-κB signaling pathways are activated and are detrimental to stroke outcome. γ-Secretase- 
mediated Notch1 signaling has been shown to sustain NF-κB activity by direct binding of NICD to 
NF-κB in the nucleus of T cells. This study explores a molecular mechanism of Notch1-mediated 
neuronal cell death through NF-κB and the downstream pro-apoptotic protein Bim. A major finding 
of this study is that γ-secretase-mediated Notch1 signaling endangers neurons under ischemic stress 
and worsens ischemic stroke outcome through the NF-κB-Bim pathway. Treatment of γ-secretase 
inhibitors successfully attenuates ischemic-induced neuronal death and brain damage. Moreover, γ-
secretase inhibitor treatment significantly reduces the expression of NF-κB and Bim under ischemic 
conditions in vitro and in vivo. In summary, this study demonstrates a novel molecular mechanism 
of Notch1-mediated neuronal death following ischemic stroke, and provides evidence of γ-
secretase-mediated Notch1 signaling as a potential therapeutic target for ischemic stroke therapy. 
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Chapter 4  Notch1 collaborates with HIF-1α  to mediate neuronal cell 
death following stroke 
 
Introduction 
 
Stroke has evolved to be one of the leading causes of mortality and disability worldwide 
over the past decades, despite the various surveillance systems and therapeutic agents against stroke 
induced injury that have been developed and trialed around the world (Mukherjee & Patil 2011). 
The cellular and molecular mechanisms responsible for the degeneration and death of neurons 
affected in stroke are poorly understood, but involve excitotoxicity, oxidative stress, cellular energy 
deficit, inflammation and a form of programmed cell death called apoptosis (Broughton et al. 2009; 
Hou & MacManus 2002; Sims & Muyderman 2010 for review). Notch1 signaling plays a crucial 
role in all phases of brain development; it regulates the proliferation and differentiation of neural 
stem cells, and influences cell survival and synaptic plasticity. In addition, there is increasing 
evidence that Notch pathways are important in neuropathological events including inflammatory 
central nervous system (CNS) disease, brain and spinal cord trauma, and ischemic stroke 
(Arumugam et al. 2006; Arumugam et al. 2011; Dias et al. 2012; Park et al. 2013; Wei et al. 2011; 
Yuan & Yu 2010).  
 
It has been previously reported by Arumugam et al. that activity of γ-secretase and resulting 
Notch1 activation, are elevated in cultured primary cortical neurons subjected to ischemic 
conditions and ischemic brain tissue in a mouse model of focal ischemic stroke (Arumugam et al. 
2006). Furthermore, γ-secretase inhibitor treatment protects the brain from ischemic stroke injury 
via preventing the neurons from undergoing apoptosis, reducing microglia activation and 
infiltration of pro-inflammatory leukocytes (Arumugam et al. 2006). The results reported in the 
previous chapter revealed that inhibition of Notch1 signaling with a γ-secretase inhibitor protected 
neurons and brain tissues from NF-κB-Bim-mediated apoptosis in ischemic stroke. To further 
elucidate the molecular mechanisms of Notch1-mediated cell death of neurons, a new candidate, the 
hypoxia inducible factor-1 (HIF-1), is investigated. This hypothesis is based on the emerging 
evidence suggesting that a mode of cross-coupling between Notch and hypoxia signaling pathways 
through the interaction between Notch1 and hypoxia inducible factor-1 (HIF-1) contributes to 
injury outcome following hypoxic conditions (Zheng et al. 2008) 
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Hypoxia inducible factor-1 (HIF-1) is a global regulator of oxygen homeostasis that is 
responsible for cellular and tissue adaptation to low oxygen tension (Bruick 2003). HIF-1 is a 
heterodimer consisting of  a  constitutively  expressed  β-subunit and an oxygen-regulated  α-subunit, 
which primarily determines HIF-1 activation, and regulates the transcription of a series of genes 
that participate in angiogenesis, iron and glucose metabolism and cell proliferation and survival 
(Shi 2009; Singh et al. 2012). HIF-1 responds to reduced oxygen levels in the brain after cerebral 
ischemia. Systemic hypoxia rapidly increases the nuclear content of HIF-1α   in   mouse   brains  
(Bernaudin et al. 2002; Stroka et al. 2001). Furthermore, HIF-1α  expression is induced in the brain 
following focal ischemia (Bergeron et al. 1999), with HIF-1α  levels  diminishing  gradually  from  the  
ischemic core to more distant regions (Demougeot et al. 2004). Both neuroprotective and 
detrimental effects of HIF-1 have been reported in experimental models of ischemic stroke 
(Baranova et al. 2007; Chen et al. 2007, p.2; Helton et al. 2005; Shi 2009; Xin et al. 2011), 
including in neuron-specific HIF-1α   deficient   mice.   One   study   reported   that   neuron-specific 
knockdown of HIF-1α   resulted   in   increased   tissue   damage   and   reduced   survival   rate following 
transient middle cerebral artery occlusion (MCAO), suggesting a neuroprotective effect of HIF-1α. 
In the same study however, it was also found that HIF-1α  activation  with pharmacologic HIF-1α  
stabilizer protected cultured neurons and mice from MCAO induced injury (Baranova et al. 2007). 
In contrast, inhibition or deletion of HIF-1α  reduced damage following ischemic stroke or hypoxic 
conditions, indicating a detrimental effect of HIF-1α  (Chen et al. 2009; Helton et al. 2005). Other 
studies have shown HIF-1α  to  play  a  role  in  hypoxic  preconditioning,  a  process  in  which  mild  stress  
prior to a stroke is neuroprotective (Liu et al. 2005). Taken together, these observations might 
suggest the possibility that HIF-1α   can   induce   cell   death   in   severe   and   protracted   ischemia,   but  
promote cell survival when activated prior to stroke and during mild ischemic stress. Another recent 
study provided a mechanistic paradigm for HIF-1α  and  Notch   interaction   in  Drosophila that may 
also be present in mammals, involving a ligand-independent mechanism for hemocyte survival 
during both normal development and hypoxic stress (Mukherjee et al. 2011). Furthermore, recent 
evidence showed that HIF-1α-induced activation of the Notch pathway is essential for hypoxia-
mediated maintenance of glioblastoma stem cells (Qiang et al. 2012). Whether the interaction 
between Notch1 and HIF-1α  by   ischemia   leads   to  neuronal   cell death or survival and the related 
transcriptional activity is unknown. Therefore the study in this chapter investigates the crosstalk 
between Notch1 and HIF-1α   during   ischemia   and   provides evidence that Notch and HIF-1α  
collaborate in the activation of apoptotic, pro-inflammatory, and neurodegenerative pathways 
during brain injury following ischemia–reperfusion. 
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Materials and methods 
 
Animals 
 
The embryos of wild type female mice (C57BL/6J) at embryonic day 16 (E16) were used as 
the source of cortical neurons for primary cell culture. Three to six month old male wild type mice 
(C57BL/6J) were used for the animal stroke model. All mice were purchased from the University of 
Queensland Biological Resources (UQBR) animal facilities and all animal experimental procedures 
were reviewed and approved by the University of Queensland Animal Ethics Committee. 
 
Primary mouse cortical neuronal culture 
 
Dissociated cell cultures of mouse cortex were established from day 16 C57BL/6J mouse 
embryos, as described in chapter 3. Cells were plated in 100-mm diameter polyethylenimine-coated 
plastic dishes and maintained at 37 °C in Neurobasal medium containing 25 mM of glucose and B-
27 supplement (Life Technologies, Australia), 2 mM l-glutamine, 0.001% gentamycin sulfate and 
1 mM HEPES (pH 7.2). Approximately 95% of the cells in such cultures were neurons and the 
remaining cells were astrocytes. 
 
Pharmaceutical treatments 
 
γ-Secretase inhibitor XXI (Compound E) was purchased from Merck Calbiochem 
(Germany), HIF-1α   inhibitor 2-methoxyestradiol (2ME2) and HIF-1α   stabilizer  
dimethyloxaloylglycine (DMOG) were purchased from Sigma-Aldrich (USA). 1μM  of  CE,  5μM  of 
2ME2,  and  500μM  of  DMOG  was  used  according  to  the  EC50 of each pharmaceutical and tested in 
primary cortical neurons. Primary neuronal cultures were subjected to glucose deprivation (GD) or 
oxygen and glucose deprivation (OGD) at 7 days after plating, together with pharmaceutical 
treatment at the stated concentrations.  
 
siRNA transfection  
 
Five days old primary cortical neurons were transfected with siRNA using Lipofectamine 
2000 (Life Technologies, Australia) according to the manufacturer's instruction and then incubated 
for 48 hours. Control siRNA, Notch-1 siRNA and HIF-1α  siRNA were purchased from Santa Cruz 
(USA).  
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Glucose/Oxygen-Glucose deprivation  
 
For glucose deprivation (GD), glucose-free Locke's buffer containing (in mM) 154 NaCl, 
5.6 KCl, 2.3 CaCl2, 1 MgCl2, 3.6 NaHCO3, 5 HEPES (pH 7.2) and 5 mg/L gentamycin was used. 
For GD, cultured neurons were incubated with glucose-free Locke's buffer for 6, 12 or 24 hours. 
For combined oxygen and glucose deprivation (OGD), neurons were incubated in GD medium in an 
oxygen-free chamber for 1, 3 and 8 hours. 
 
Cell viability assay 
 
Cell viability was determined by the trypan blue exclusion assay as described in Chapter 3.  
 
Immunoblot analysis 
 
Protein samples were subjected to sodium dodecyl sulfate-polyacrylamide (10%) gel 
electrophoresis using a Tris-glycine running buffer. Gels were then electro-blotted using a transfer 
apparatus (Bio-Rad, USA) in transfer buffer containing 0.025 mol/L Tris base, 0.15 mol/L glycine, 
and 10% (v/v) methanol for 1.5 hours at 350 mA onto a nitrocellulose membrane (Bio-Rad, USA). 
The membrane was then incubated in blocking buffer (5% non-fat milk in 20 mmol/L Tris–HCl, 
pH 7.5, 137 mmol/L NaCl, 0.2% Tween-20) for 1 hour at room temperature. The membrane was 
then incubated overnight at 4 °C with primary antibodies including those that selectively bind 
cleaved caspase-3 (Cell Signaling Technology, USA), Activated Notch1 (Abcam, UK), HIF-1α  
(Novus Biologicals, USA), phosphorylated p65 (Ser536; Cell Signaling, USA), phosphorylated 
JNK (Cell Signaling, USA), total JNK (Cell Signaling, USA), and actin (Sigma Aldrich, USA). 
After washing three times (5 minutes per wash) with Tris-buffered saline-T (20 mmol/L Tris–HCl, 
pH 7.5, 137 mmol/L NaCl, 0.2% Tween-20), the membrane was incubated with a horseradish 
peroxidase-conjugated secondary antibody. After washing five times (5 minutes per wash) with 
Tris-buffered saline, the membrane was incubated with chemiluminescent substrate for enhanced 
chemiluminescence (Pierce Endogen, USA) for 5 minutes, and chemiluminescent signals were 
visualized by exposing the membrane to an X-ray film (Fujifilm Corporation, Japan). 
 
Co-immunoprecipitation 
 
 300μg of cell lysates were precleared with the addition of 20μl of bead slurry (Merck 
Millipore, USA) and incubated at 4°C for 1 hour. After incubation, the beads were removed and 
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antibody specific to activated Notch1 (Abcam, UK) or HIF-1α   (Novus   Biologicals, USA) were 
added to cell lysates and incubated overnight at 4°C. On the next day, the immunocomplex were 
captured by adding 100μl washed bead slurry and incubated at 4°C for 3 hours. The beads were 
then collected and resuspended in 10μl loading buffer (Bio-Rad, USA). The immunocomplex were 
detected using immunoblot.  
 
Immunocytochemistry and immunohistochemistry 
 
Coverslips containing cortical neurons subjected either to normal Neurobasal medium or 
GD medium were fixed in 4% buffered paraformaldehyde in phosphate-buffered saline (PBS; 
Sigma-Aldrich, USA). Fixed cells were permeabilized and incubated in blocking solution (0.2% 
BSA, 1% FBS, and 0.1% Triton-X in PBS) at room temperature for 1 hour before incubation with 
microtubule-associated protein 2 antibody (MAP2, mouse monoclonal; Millipore, Germany) along 
with either HIF-1α   (rabbit polyclonal; Santa Cruz, USA), or activated Notch1 (rabbit polyclonal; 
Abcam, UK) diluted in blocking solution at room temperature for 1 hour. Following incubation with 
the primary antibody, the cells were incubated in the appropriate Alexa Fluor-conjugated secondary 
antibodies (Life Technologies, Australia) for 1 hour at room temperature. Following secondary 
antibody incubation, coverslips were mounted with Vectashield mounting medium (Vector 
Laboratories, USA) on glass slides. For immunohistochemistry, frozen cryostat brain sections were 
obtained from sham surgery and stroke mice, following trans-cardiac perfusion with 4% 
paraformaldehyde and were immunostained with antibodies against HIF-1α   (mouse monoclonal, 
Novus Biologicals, USA), Activated Notch1 (rabbit polyclonal, Abcam, UK) and MAP2 (chicken 
monoclonal, Abcam, UK). Imaging was performed using confocal microscopy (Olympus LV1000, 
Japan) with a 100 × oil immersion objective. Single confocal images were converted to 512 × 512 
pixel 12 bit TIFF images.
 
Middle cerebral artery occlusion and reperfusion (MCAO/R) stroke model 
 
Three-month-old C57BL/6J male mice were used for in vivo experiments. The focal cerebral 
ischemia/reperfusion model was similar to that described previously (Arumugam et al. 2004). 
Briefly, the mice were anesthetized with isoflurane, a midline incision was made in the neck, and 
the left external carotid and pterygopalatine arteries were isolated and ligated with 5–0 silk thread. 
The internal carotid artery (ICA) was occluded at the peripheral site of the bifurcation of the ICA 
and the pterygopalatine artery with a small clip, and the common carotid artery (CCA) was ligated 
with 6–0 silk thread. The external carotid artery (ECA) was cut, and a 6–0 nylon monofilament with 
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a tip that was blunted (0.2–0.22 mm) using a coagulator was inserted into the ECA. After the clip at 
the ICA was removed, the nylon thread was advanced into the middle cerebral artery (MCA) until 
light resistance was felt. The nylon thread and the CCA ligature were removed after 1 hour of 
occlusion to initiate reperfusion. In the sham group, these arteries were visualized but not disturbed. 
Mice were administered either 1 mg/kg compound E (Merck Calbiochem, Germany), 20 mg/kg 
2ME2 (Sigma-Aldrich, USA) or vehicle (DMSO) by infusion into the femoral vein (20 μL)  
immediately after the ischemic period. Cerebral blood flow was measured to confirm the occlusion 
by placing the animal's head in a fixed frame after it had been anesthetized and prepared for surgery. 
A craniotomy was performed to access the left middle cerebral artery and was extended to allow 
positioning of a 0.5-mm Doppler probe (Moor LAB, UK) over the underlying parietal cortex 
approximately 1 mm posterior to bregma and 1 mm lateral to the midline. The University of 
Queensland Animal Care and Use Committee approved these procedures. 
 
Neurological assessment 
 
The functional consequences of focal cerebral ischemia and reperfusion (I/R) injury were 
evaluated using a 5-point neurological deficit score (0, no deficit; 1, failure to extend right paw; 2, 
circling to the right; 3, falling to the right; and 4, unable to walk spontaneously) and were assessed 
in a blinded fashion. 
 
Quantification of cerebral infarction 
 
Following 72 hours of reperfusion, the mice were euthanized with a lethal dose of isoflurane. 
The brains were immediately removed and placed into PBS (4 °C) for 15 min, and 2-mm coronal 
sections were cut with a brain slicer matrix. The brain sections were stained with 2% 2,3,5-
triphenyltetrazolium chloride (TTC) in phosphate buffer at 37 °C for 15 min. The stained sections 
were photographed, and the digitized images were used for analysis. The borders of the infarct in 
each brain slice were outlined and the area quantified using NIH image 6.1 software (National 
Institutes of Health, USA). To correct for brain swelling, the infarct area was determined by 
subtracting the area of undamaged tissue in the left hemisphere from that of the intact contralateral 
hemisphere. Infarct volume was calculated by integration of infarct areas for all slices of each brain 
in a blinded manner, and was expressed as a % of the ipsilateral hemisphere. 
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Data analysis 
 
All the results are reported as the means ± SEM, except for cell viability assay results which 
are presented in the box and whiskers form. The overall significance of the data was examined by 
one-way analysis of variance (ANOVA). The differences between the groups were considered 
significant at p < 0.05 with the appropriate Bonferroni correction made for multiple comparisons. 
Neurological behavior scores were analyzed by using a nonparametric Kruskal–Wallis test and 
Dunn's Multiple Comparison Test. 
 
Results 
Inhibition of HIF-1α  and γ-secretase reduces neuronal death during ischemia-like conditions 
 
The effects of the cell-permeable HIF-1α   inhibitor  2-methoxyestradiol (2ME2) which is a 
competitive inhibitor of HIF-1α  prolyl  hydroxylase   (HIF-PH) (Chen et al. 2008), and the HIF-1α  
inducer DMOG (Zhou et al. 2006) against ischemic stroke-like cell death in mouse primary cortical 
neurons were first investigated. Primary cortical neurons were subjected to glucose deprivation (GD) 
in the presence of 2ME2 or DMOG. GD-induced cell death was attenuated by 2ME2 (5 μM)  and  
increased by DMOG (500 μM)   (Figure 4.1A). It was previously shown that   the   γ-secretase 
inhibitors N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) and 
(S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H 
benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E; CE), decreased primary neuronal cell 
death during GD, or combined oxygen and glucose deprivation (OGD) (Arumugam et al. 2006; 
Arumugam et al. 2011). Here, 1 μM of CE also decreased death of primary cortical neurons under 
both GD and OGD conditions (Figure 4.1B, C). Moreover, combined HIF-1α   and   γ-secretase 
inhibition with 2ME2 and CE, respectively, provided enhanced protection against cell death 
compared to either CE or 2ME2 alone following GD (Figure 4.1B). Next, levels of cleaved caspase-
3, the active form of an apoptotic protease, were analyzed following GD or OGD. Treatment with 
either 2ME2 or CE reduced cleaved caspase-3 levels compared to vehicle treatment under either 
GD or OGD conditions (Figure 4.2A-D). Furthermore, combined 2ME2/CE treatment was more 
effective than either single treatment in reducing cleaved caspase-3 during GD and OGD 
(Figure 4.2A-D). Both NICD and HIF-1α  were  elevated  following  OGD  conditions and reduced by 
treatment with CE and 2ME2 (Figure 4.2 E). 
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Figure 4.1 Inhibition of NICD and HIF-1α  protects   cultured  cortical  neurons  against  death  
under ischemia-like conditions. (A) Treatment with 2ME2 significantly reduced cell death, and 
treatment with DMOG increased cell death, under GD conditions. n = 6 different cultures, *** 
p < 0.005 compared with the vehicle-treated group under normal culture conditions; +++, ### 
p < 0.005 compared with the vehicle treated group under GD condition. (B) Compound E and 
2ME2 each significantly reduced GD-induced cell death, and combined treatment further reduced 
cell death during GD. n = 6 different cultures, *** p < 0.005 compared with the untreated group 
under normal conditions; +++ p < 0.005 compared with the vehicle treated group under GD 
conditions; ** p < 0.01 2ME2 compared with compound E + 2ME2 treated group; * p < 0.05 
compound E compared with compound E + 2ME2 treated groups. (C) Neuronal cell death was 
quantified in cultures that had been subjected to OGD. n = 6 different cultures, *** p < 0.005 
compared with the untreated group under normal condition; +++ p < 0.005 compared with the 
vehicle treated group under OGD conditions. 
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Figure 4.2 Inhibition of NICD and HIF-1α  reduces cleaved caspase-3 expression in cultured 
cortical neurons under ischemia-like conditions. Treatment with either compound E or 2ME2 
reduced the level of cleaved caspase-3, and combined treatment further reduced cleaved caspase-3 
levels under GD (A, B) and OGD (C, D) conditions. (E) NICD and HIF-1α  expression  in  2ME2  and  
CE treated cultures under OGD conditions. n = 4 different cultures, * p < 0.05 compared with 
vehicle-treated group; ** p < 0.01 compared with vehicle treated group. 
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HIF-1α  and Notch-1 co-localize in the nucleus of neurons in response to ischemia-like 
conditions 
 
In order to investigate whether Notch-1 and HIF-1α  cooperate  in  promoting  neuronal  death 
in stroke, the expression profiles of NICD and HIF-1α  in  primary  cortical  neurons  under  ischemia-
like conditions were first analyzed. Levels of both NICD and HIF-1α  increased  after  6–24 hours of 
GD and 1–8 hours of OGD (Figure 4.3A, B). NICD is believed to migrate into the nucleus and 
associate with a transcription factor, RBP-jκ, which up-regulates the expression of various Notch 
effector target genes (Guruharsha et al. 2012). Confocal imaging confirmed NICD accumulation in 
the nucleus following OGD in primary cortical neurons (Figure 4.3C). In normoxic conditions, 
hydroxylation of two proline residues and acetylation of a lysine residue at the oxygen-dependent 
degradation domain (ODDD) of HIF-1α  trigger  its  association  with  the  pVHL  E3  ligase  complex,  
leading to HIF-1α  degradation   via   the  ubiquitin–proteasome pathway (Ke & Costa 2006). Under 
hypoxic conditions, HIF-1α   becomes   stable   and   translocates   from   the   cytoplasm   to   the nucleus, 
where it dimerizes with HIF-1β  forming  a  HIF-1 complex that becomes transcriptionally active and 
regulates the expression of target genes (Ke & Costa 2006). Confocal imaging analysis of cortical 
neurons immunostained with HIF-1α  antibody  confirmed  increased  levels  of  HIF-1α  in  the  nucleus 
in response to OGD (Figure 4.3D). Using confocal imaging, it was observed that NICD and HIF-1α  
both accumulate in and around the nucleus of cortical neurons during ischemia-like conditions 
(Figure 4.4A). 
 
Next, Notch and HIF-1α  expression after stroke in vivo was examined. In the cerebral cortex 
of sham-operated control mice, little immunoreactivity with HIF-1α  antibodies  was  observed  and  
NICD appeared restricted to the neuronal cytoplasm (Figure 4.4 B). At 24 hours after 
ischemia/reperfusion (I/R), neurons in the ischemic cortex exhibited robust NICD immunoreactivity 
in both nucleus and cytoplasm, while the expression of HIF-1α  around  the nucleus was increased 
(Figure 4.4 B). Immunoblots of tissue samples taken from the ischemic cortex further demonstrated 
increased levels of NICD and HIF-1α  proteins  within 1–24 hours of ischemia/reperfusion (Figure 
4.4 C). Immunoprecipitation analysis of cortical neurons following OGD and of brain samples from 
the ischemic hemisphere showed that NICD and HIF-1α  do  indeed  interact  in  cortical  neurons.  The 
direct binding of NICD and HIF-1α  was  also  observed  in  cortical  tissues  from sham and I/R mice 
(Figure 4.4 D) Co-immunoprecipitation data further supported the notion that Notch and HIF-1α  
bind directly to each other and/or are part of a multi-protein complex. 
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Figure 4.3 NICD and HIF-1α  levels in primary cortical neurons under normal, GD and OGD 
conditions. (A, B) Immunoblots showing NICD and HIF-1α  protein levels at different time points 
during GD (A) and OGD (B) conditions. NICD levels were increased with GD and OGD treatment. 
HIF-1α  levels increased from 6-12 hours of GD and from 1-3 hours of OGD, and then decreased at 
later time points. (C, D) Immunofluorescence images showing staining of NICD (C, green), HIF-1α  
(D,  green),  the  neuronal  marker  MAP2  (red)  and  the  nuclear  marker  4′,6-diamidino-2-phenylindol 
(DAPI) (blue). Both NICD and HIF-1α  staining showed a slight increase at 8 h of OGD. Scale bar: 
10 μm. 
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Figure 4.4 NICD and HIF-1α  interaction  in  cortical  neurons  and  mouse  brain  under  ischemic  
conditions. (A) Immunofluorescence staining of NICD and HIF-1α  in  mouse  cortical  neurons  and  
neurons under GD conditions. NICD (red), HIF-1α   (green)   and   DAPI (blue) staining showing 
translocation of NICD and HIF-1α  from  the cytoplasm to the nucleus at 24 hours of GD. Scale bar: 
20 μm.  (B)  Immunofluorescence  staining  of  NICD  and  HIF-1α  in  the  ipsilateral  peri-infarct tissue 
section showing NICD (red), HIF-1α   (green),   MAP2 (magenta) and DAPI (blue) staining. The 
immunoreactivity of NICD and HIF-1α  was  more  robust  at  24 hours after ischemia/reperfusion (I/R) 
compared to the sham control. Scale bar: 40 μm.  (C)  The  expression  level of NICD and HIF-1α  was  
increased in the ipsilateral hemisphere after 1, 12 and 24 hours of I/R compared to sham. (D) Co-
immunoprecipitation of NICD and HIF-1α  in  neurons  under  OGD  8 hours and in brain tissue from 
the ipsilateral cerebral cortex following 24 hours of I/R showing increased binding of NICD and 
HIF-1α  compared  to  controls.  
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siRNA knockdown of Notch1 and HIF-1α  decrease neuronal death during ischemic conditions 
 
In order to evaluate the roles of endogenous Notch1 and HIF-1α  in  neuronal  cell  death  under 
ischemic conditions, RNA interference was used to specifically knockdown endogenous Notch1 
and HIF-1α  (Figure 4.5 A, B, C, D). Cell death under both GD and OGD conditions was reduced in 
primary cortical cultures transfected with Notch1 siRNA and HIF-1α   siRNA   compared  with   the  
control siRNA group (Figure 4.5 E, F). However, combined Notch1 and HIF-1α  siRNA  treatment  
did not achieve any further reduction in cell death. (Figure 4.5 A, B, C, D) 
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Figure 4.5 Effect of siRNA knockdown of NICD and HIF-1α   in   neuronal   cell   death under 
ischemia-like conditions. Notch1 and HIF-1α  siRNA  were  transfected  to  primary  cortical  neurons  
to inhibit endogenous NICD and HIF-1α   expression.   (A,   B) Knockdown of endogenous Notch1 
using Notch1 siRNA transfection. (C, D) Knockdown of endogenous HIF-1α  using  HIF-1α  siRNA  
transfection. (E, F) Cell death in neurons transfected with Notch1 and HIF-1α   siRNA   was  
significantly reduced at 9 hours of GD (E) and 8 hours of OGD (F). n = 3 different cultures. * 
p < 0.05, ** p < 0.01, *** p < 0.005 compared with the vehicle treated group. 
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Inhibition of HIF-1α  and γ-secretase protects against ischemic stroke-induced brain injury 
 
To determine whether blockade  of  both  γ-secretase-mediated Notch activation and HIF-1α  
protect against stroke-induced brain injury by reducing the interaction between NICD and HIF1-α,  
γ-secretase inhibitor CE and the HIF1-α   inhibitor   2ME2 were used in mice underwent 
ischemia/reperfusion. Treatment with either CE or 2ME2 by intravenous infusion immediately after 
I/R resulted in reduced infarct volume and neurological deficits (Figure 4.6A, B, C). In addition, 
combined CE and 2ME2 treatment further reduced brain damage (Figure 4.6A, B). Next, the effect 
of CE and 2ME2 treatment on the levels of NICD and HIF-1α  were analyzed in the ischemic 
hemisphere of mice underwent 1 hour MCAO and 24 hours of reperfusion (Figure 4.7A). It was 
found that both NICD and HIF-1α   were   elevated   in   the   ischemic hemisphere after 
ischemia/reperfusion for 24 hours and reduced by treatment with CE and 2ME2 (Figure 4.7A). The 
levels of NF-κB  p65  and  JNK  were  next  measured  to assess whether inhibition of Notch and HIF-
1α  might  protect  against  ischemic  stroke-induced brain injury by affecting these proteins. The data 
showed no significant difference in total and phosphorylated p65 (p-p65) and total and 
phosphorylated JNK (p-JNK) levels between treatment groups (CE, 2ME2, or combination 
treatment) and the vehicle-treatment group after 6 hours of reperfusion (n = 5 in each group) 
(Figure 4.7B). However, the levels of cleaved caspase-3 (Figure 4.7C, D), p-p65 (Figure 4.7C, E), 
p-JNK1, 2/3 (Figure 4.7C, F, G) and total JNK1, 2/3 (Figure 4.7C, H, I) were all significantly 
reduced in the CE, 2ME2 and combined treatment groups compared with the vehicle-treatment 
group at 24 hours of reperfusion. Furthermore, combined CE and 2ME2 treatment further reduced 
cleaved caspase-3 and JNK levels (total JNK1 and phosphorylated JNK1) compared to either CE or 
2ME2 treatments alone. 
 
 
 70 
           
 
Figure 4.6 Inhibition of NICD and HIF-1α  reduces  focal  ischemic  brain  injury  in vivo. (A, B) 
Mice underwent 1 hour MCAO and 24–72 hours of reperfusion. Mice treated with CE (n = 11) and 
2ME2 (n = 10), alone or in combination (n = 13), exhibited improved neurological function and 
reduced brain injury after stroke, compared to vehicle-treated (n = 11) mice. Neurological score was 
measured at 24, 48, and 72 hours following reperfusion; infarct volume was measured at 72 hours 
following reperfusion. Mice treated with both 2ME2 and CE treated showed significant reduction in 
infarct size compared to mice treated with either CE or 2ME2 alone. Data are represented as 
mean ± SEM. (C) Representative images of brains from each treatment group following 1 hour 
MCAO and 72 hours of reperfusion. 
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Figure 4.7 Inhibition of NICD and HIF-1α   reduces   cleaved caspase-3, NF-κB  p65  and  JNK  
expression in vivo. (A) NICD and HIF-1α  expression in 2ME2 and CE treated mice brains after 1 
hour MCAO and 24 hours of reperfusion. n = 5 in each group. (B) total/phosphorylated NF-κB  p65, 
total/phosphorylated JNK expression in the ipsilateral brain hemisphere at 6 hours I/R from mice 
treated with either 2ME2, CE, or both 2ME2 and CE. (C) Cleaved caspase-3, total/phosphorylated 
NF-κB  p65, total/phosphorylated JNK expression in the ipsilateral brain hemisphere at 24 hours I/R 
from mice treated with 2ME2, CE, and both 2ME2 and CE. (D-I) Quantification graphs of cleaved 
caspase-3, p-p65 and total- and p-JNK expression from mice underwent 24 hours of I/R. n = 5 in 
each group, * p < 0.05, ** p < 0.01, *** p < 0.005 compared with the vehicle treated group. 
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Discussion 
 
Notch1 and HIF-1α  have been shown to play important roles under both physiological and 
pathological conditions. During stroke, Notch1 activation is associated with neuronal apoptosis, 
microglia activation and pro-inflammatory leukocytes infiltration, and lead to detrimental outcomes 
(Arumugam et al. 2006). The evidence provided by the previous study showed that Notch1 
inhibition with γ-secretase inhibitors DAPT and DBZ reduced stroke-induced brain damage and 
neurological deficits in mice after experimental cerebral ischemia/reperfusion model (Arumugam et 
al. 2006). Also in the study described in Chapter 3, Notch1 signaling is found to mediate apoptosis 
via the NF-κB-Bim axis and results in ischemia-induced neuronal cell death and brain damage. 
HIF-1α   plays an essential role in the response to cellular and systemic oxygen homeostasis by 
regulating the transcription of genes related to angiogenesis, erythropoiesis, and glucose 
metabolism (Salceda & Caro 1997; Kallio et al. 1998). As shown in a previous study, brain specific 
HIF-1α  knock  out  mice  are protected from hypoxia-induced injury (Helton et al. 2005). Moreover, 
HIF-1α  interacts with NICD in order to maintain neural stem cells in an undifferentiated state under 
low oxygen conditions (Gustafsson et al. 2005). Therefore, this study explores the hypothesis that 
Notch and HIF-1α   collaboration plays a detrimental role in neuronal survival during ischemic 
stroke. It also demonstrates that Notch and HIF-1α  collaborate in promoting neuronal cell death via 
modulating pro-apoptotic protein expression in both in vitro and in vivo models of ischemia. 
 
In order to investigate the effect of Notch and HIF-1α  inhibition on ischemic neuronal cell 
death, γ-secretase inhibitor CE and HIF-1α  inhibitor 2ME2 were administered in cultured neurons 
either individually or simultaneously under ischemic conditions. The results showed that cell death 
and cleaved caspase-3 expression were decreased in neurons treated with either CE or 2ME2, and 
were further decreased in neurons with combined CE and 2ME2 treatment. HIF-1α  itself is believed 
to be a key regulator of cellular responses to ischemic conditions. HIF-1α   and its target genes 
expression are increased in the brain after focal cerebral ischemia (Bergeron et al. 1999). However, 
the roles of HIF-1α   activation following ischemic stroke have been controversial depending on 
whether a pro-apoptotic or an anti-apoptotic pathway is activated by HIF-1α.  Brain-specific knock 
out of HIF-1α   reduces neuronal damage in the cortex and hippocampus in a mouse model of 
ischemia (Helton et al. 2005).  In addition, HIF-1α  inhibition reduced neuronal injury in a neonatal 
ischemic stroke model (Chen et al. 2008). On the other hand, other studies showed that HIF-1α  
deficient mice have increased brain injury in both neonatal hypoxic ischemia and focal ischemia 
models (Sheldon et al. 2009; Baranova et al. 2007). It was previously shown that the HIF-1α  
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inhibitor 2ME2 worsens outcome after global ischemia in rats (Zhou et al. 2008) but is 
neuroprotective in focal ischemia by preserving blood brain barrier (BBB) integrity, and reducing 
brain edema and neuronal apoptosis (Chen et al. 2007; Chen et al. 2008). The results in this study 
suggest that HIF-1α   activation following ischemic stroke is detrimental to neuronal survival. 
Interestingly, a combined treatment of CE and 2ME2 further decreases cleaved caspase-3 
expression and neuronal cell death, suggesting that neuronal death following ischemic stroke is 
partly influenced by the collaboration of Notch1 and HIF-1α  pathways. 
 
In addition, the results in this study showed that NICD expression is reduced with 2ME2 
treatment and HIF-1α  expression  is  reduced  with  CE  treatment,  both  in vitro and in vivo. The results 
suggest that Notch1 and HIF-1α  pathways   can   regulate   each   other at the transcriptional level. A 
previous study found that overexpression of full length Notch1 or NICD1 increased HIF-1α  protein  
levels in the breast cancer cell line MCF7 (Soares et al. 2004). In addition, NICD modulates HIF-1α  
post-transcriptionally by increasing the recruitment of HIF-1α  to  hypoxia response elements and the 
transcription of its target genes (Zheng et al. 2008). In neuronal stem cells and myogenic progenitor 
cells, HIF-1α up-regulates the expression of Notch1 downstream genes and promotes the 
undifferentiated state of stem/progenitor cells (Gustafsson et al. 2005). The results in this study 
provide evidence for the first time to show that Notch1 signaling modulates the transcription of 
HIF-1α  and conversely, the HIF-1α  pathway  was  able   to  modulate   the   transcription  of  Notch1   in 
mature neurons and in brain tissue under ischemic stroke conditions. 
 
Next, whether NICD1 and HIF-1α   interact during ischemia was investigated. 
Immunofluorescent images show an accumulation of NICD1 and HIF-1α   in   the  neuronal nucleus 
following ischemia. Furthermore, immunoprecipitation analysis of cortical neurons following OGD, 
and of brain samples from the ischemic hemisphere, revealed that an interaction between NICD1 
and HIF-1α   occurs   under   these   conditions   providing   further   evidence   that   NICD1 and HIF-1α  
interact directly following ischemia. HIF-1α  was   first   found   to   interact  with  NICD1   to  maintain  
neuronal stem cells and muscle progenitor cells in an undifferentiated state during hypoxia 
(Gustafsson et al. 2005). It was shown that hypoxia directly enhances Notch1 signaling by 
increasing NICD1 activity and binding of HIF-1α  and NICD1 that lead to stabilization of NICD1. 
Moreover, during hypoxia HIF-1α  is  recruited  to  the Notch-responsive promoter, and consequently 
up-regulates expression of Notch1 downstream genes such as Hes1 and Herp1 (Gustafsson et al. 
2005). A recent study suggested a key role for Notch as a mediator in the crosstalk between HIF-1α  
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and aspartyl-(asparaginyl)-β-hydroxylase (AAH) for the regulation of neuronal migration in 
primitive neuroectodermal tumor cells  (Lawton et al. 2010). Furthermore, the interaction of HIF-1α  
and Notch1 was found to be important in the regulation of medulloblastoma precursor cell 
proliferation and survival (Pistollato et al. 2010). More recently, it was found that echinomycin, a 
compound that inhibits DNA-binding activity of HIF-1α, suppresses leukemia cell growth via 
reducing the expression of Notch1 receptor and NICD1 in leukemia cells (Yonekura et al. 2013). 
The data in this study further supports the existence of a Notch1-HIF-1α  collaboration  as  NICD1 
inhibition affects HIF-1α  levels  and,  likewise,  HIF-1α  inhibition  affects  NICD  levels  under  in vitro 
and in vivo ischemic conditions. However, further research is needed to unravel the precise 
molecular mechanisms of how Notch inhibition affects HIF-1α  levels,  and  how  HIF-1α  inhibition  
affects NICD levels under cerebral ischemic conditions. These lines of evidence are consistent with 
the possibility that HIF-1α   and  Notch   interact   and   additively contribute to neuronal injury under 
conditions of severe metabolic stress such as that which occurs in ischemic stroke. However, how 
and why NICD and HIF-1α  association becomes more damaging in cerebral ischemia is still not 
completely revealed. Further research is required to disclose this question.  
In order to confirm the  results  that  decreased  neuronal  cell  death  by  inhibition  of  γ-secretase 
activity is due to Notch1 down-regulation, a more specific strategy to target Notch1 using siRNA 
was performed. Cell death is reduced in neuronal cultures transfected with Notch1 siRNA and HIF-
1α   siRNA   compared   with   control   siRNA   group   under   GD   and   OGD   conditions.   However,  
combined Notch and HIF-1α  siRNA  treatment  did  not  further  reduce  cell  death  as expected when 
compared to individual siRNA treatment. There are some possible reasons for this observation. Due 
to the transfection efficiency, figure 4.5 A-D showed semi-quantification of the endogenous NICD 
and HIF-1α  expression was reduced for only 40-60%. With combined siRNA treatment, 40-60% 
reduction of both NICD and HIF-1α  might not be enough to observe a further reduction in cell 
death. However, transfecting the neurons with higher siRNA concentration resulted in increased cell 
death even before GD/OGD challenge, hence it was not considered to be a good strategy to achieve 
the aims of this study. Another possible rationale for this observation might be due to the 
transfection efficiency of primary neuronal cultures. The transfection efficiency with primary 
neuronal culture in our hands using lipofectamine is 25-30%. The combined transfection of NICD 
and HIF-1α  siRNA is not guaranteed to have the same or similar efficiency, which could be less in 
this case, and this resulted in a decreased cell death that is difficult to differentiate from individual 
transfection. The same experimental design using a better knockdown strategy such as the use of 
Notch1 antisense transgenic mice (NAS) has been considered for future experiments in order to 
address the question. 
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There are two phases of HIF-1α  up-regulation, early before 24 hours and late from 24 hours 
up to 8 days. The early elevation of HIF-1α  activates  mainly   the  pro-death genes such as Noxa1 
(NADPH oxidase activator 1), Nix (NIP3-like protein X) and bNIP3 (BCL2/adenovirus E1B 
19 kDa interacting protein 3) (Baranova et al. 2007). In the second phase of HIF-1α  activation,  the  
pro-death genes are no longer elevated; instead, the genes involved in angiogenesis and glucose 
metabolism were elevated (Baranova et al. 2007). It was supported by a recent study that selective 
inhibition of early but not late expressed HIF-1α  is  neuroprotective  in  rats  after  focal  ischemia  (Yeh 
et al. 2011). Treating mice with 2ME2 30 minutes after ischemic stress or pre-silencing HIF-1α  in 
neurons with siRNA decreased brain injury, edema and apoptotic cell death (Yeh et al. 2011). 
Conversely, administering 2ME2 to mice 8 hours after ischemic stress, or silencing HIF-1α  with  
siRNA 12 hours after OGD, increased brain and neuronal damage (Yeh et al. 2011). Another study 
showed that treatment with HIF-1α   inhibitors   2ME2 and D609 1 hour after MCAO powerfully 
protected the brain from ischemic injury by inhibiting HIF-1α  expression,  attenuating  expression of 
vascular endothelial growth factor to avoid blood–brain barrier disruption, and neuronal apoptosis 
via the bNIP3 pathway (Chen et al. 2007). These results demonstrate that HIF-1α   induced   early  
after ischemia leads to cellular apoptosis, whereas later induction of HIF-1α  promotes  survival.  The 
results in this study also agree with this the first part of this two-phase effect of HIF-1α  activation.  
This current investigation following in vivo ischemia and reperfusion found that early inhibition of 
HIF-1α  protects  neurons  in vitro and reduces neurological deficits and brain infarct volume in vivo; 
additional protection is obtained with combined inhibition of   γ-secretase and HIF-1α. These data 
suggest that Notch1 signaling plays a role in the pro-death function that HIF-1α  plays  at  the  early  
stage of ischemic stroke.    
 
Next, in order to investigate the  mechanism  of  enhanced  protection  by  combined  γ-secretase 
and HIF-1α  inhibition,  the levels of NF-κB  phospho-p65, JNK and cleaved caspase-3 were analysed 
in vivo. The results showed that the levels of NF-κB   phospho/total-p65, phospho/total-JNK and 
cleaved caspase-3 at ischemia/reperfusion of 24 hours were  all  reduced  by  γ-secretase and HIF-1α  
inhibition alone or in combination when compared with vehicle control. Elevated NF-κB  activation  
has also been demonstrated in various animal models of stroke, suggesting that this could contribute 
to the inflammatory reaction and apoptotic cell death in post-stroke brain   injury.   γ-Secretase-
mediated Notch signaling is required to sustain NF-κB   activity,   and  NICD may increase NF-κB  
activity by binding to and enhancing the nuclear distribution of the active NF-κB  signaling  complex  
(Shin et al. 2006).   The   phosphorylation   at   serine   536   of   p65   by   IκB   kinases   has   been   shown   to  
increase transcriptional activity (Sakurai et al. 1999). It has also been shown that phosphorylation of 
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p65 at serine 536 contributes to various pro-inflammatory responses and neuronal vulnerability in 
ischemic stroke (Crack et al. 2006; Ryu et al. 2011; Shen et al. 2003; Yang et al. 2003). It was 
found in the previous study from chapter 3 that   treatment   with   a   γ-secretase inhibitor reduces 
ischemia-induced levels of phosphorylated NF-κB-p65   in   the   neurons.   In   this   study,   both   γ-
secretase inhibitor and 2ME2 treatment resulted in decreased levels of total and serine 536-
phosphorylated NF-κB-p65 under ischemia/reperfusion for 24 hours, suggesting that NF-κB  
expression and activation are Notch-mediated and also require HIF-1α.   
 
The levels of phospho/total-JNK and cleaved caspase-3 at 24 hours I/R were reduced  by  γ-
secretase and HIF-1α  inhibition  alone  or  in  combination  when  compared  with  vehicle  control. More 
interestingly, total JNK and caspase-3   levels   were   further   reduced   by   combined   γ-secretase and 
HIF-1α   inhibition.   This   indicates   that   combined early intervention could lead to protection 
following stroke by targeting cell death pathways mediated by JNK expression and activation. 
NICD has been shown to physically associate with the JNK binding domain of JNK-interacting 
protein 1 (JIP1), thereby interfering with the binding of JIP1 and JNK and inhibiting JNK activation 
during GD (Kim et al. 2005). Another study showed that loss of Notch in Drosophila embryos 
resulted in high levels of JNK activity, indicating that Notch represses JNK signaling in 
development (Zecchini et al. 1999). However, the data from this study showed that treatment with a 
γ-secretase inhibitor leads to a reduction in ischemic stroke-induced phosphorylation of JNK. 
Furthermore, it was shown that treatment with D-JNKI1, a JNK-inhibiting peptide, rescues adult 
hypoxic neurons from death and contributes to HIF-1α   up-regulation, probably via a direct 
interaction with the HIF-1α   protein   (Antoniou et al. 2010). Activator protein 1 (AP-1) is a 
transcription factor belonging to the leucine zipper family, and it has been demonstrated that 
ischemic or hypoxic conditions lead to an increase in JNK-AP-1 activity (Michiels et al. 2001; Tang 
et al. 2007). HIF-1α  and  AP-1 have been shown to cooperate to increase transcription (Michiels et 
al. 2001). The findings suggest that ischemic stroke-induced elevation of total JNK levels was 
reduced by combined inhibition of Notch and HIF-1α.  This  may  suggest  roles  for  Notch and HIF-
1α   signaling   in   JNK   expression   following   stroke.  However,   the   exact molecular mechanisms by 
which the NICD-HIF-1α   association affects JNK expression and augments neuronal damage in 
cerebral ischemia remain unknown and further research is needed to answer this question. In 
conclusion, the present   findings  suggest   that  agents   that   target   the  γ-secretase-Notch pathway and 
HIF-1α  pathway  may  prove  effective  in  reducing  neuronal  cell  death  and  brain  injury  after  ischemic  
stroke. 
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Conclusion 
 
Both Notch1 and HIF-1α   pathways   play   important   roles   in   regulating   cell   fate   decisions  
under physiological conditions. Under pathological conditions such as ischemic stroke, Notch1 and 
HIF-1α pathways are activated and contribute to neuronal cell death and cerebral injury with 
unclear mechanisms. Notch1 and HIF-1α  pathways also interact to maintain neuronal stem cells in 
an undifferentiated state. This study explores the protective  modulatory  effects  of  γ-secretase and 
2ME2 on neurons in ischemic stroke, and the mechanisms of Notch1 and HIF-1α   interaction   that  
leads to neuronal cell death following ischemic stroke. A major finding of this study is the 
compromising effect that Notch and HIF-1α   signaling  exerts on neuronal viability after ischemic 
stroke, and that this neuronal damage can be inhibited under in vitro and in vivo ischemic conditions 
by treatment with inhibitors of γ-secretase and HIF-1α.  Blockade of both Notch and HIF-1α  using  a  
combination   of   γ-secretase and HIF-1α   inhibitors   resulted   in   enhanced   neuroprotection.  
Furthermore, γ-secretase and HIF-1α  inhibition reduces ischemic-induced brain injury via inhibiting 
the expression of NF-κB  p-65, JNK, and the cleavage of caspase-3. Thus this study demonstrates 
for the first time that Notch1 and HIF-1α   collaborate   in   neurons   and   contribute to neuronal cell 
death following ischemic stroke. It also provides more evidence of the protective pleiotropic effects 
of   targeting   γ-secretase mediated Notch1 signaling during ischemic stroke, strengthening the 
potential  of  γ-secretase inhibitors as a new therapeutic agent in ischemic stroke therapy.  
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 Chapter 5  Notch1-JNK-c-Jun mediate neuronal cell death following 
stroke 
 
Introduction 
 
Notch1 signaling is a highly conserved pathway that regulates cell fate decisions during 
embryonic development, and influences cell survival and synaptic plasticity in the adult brain 
(Lathia et al. 2008). Besides the role of Notch1 in all phases of brain development and in 
physiological events in the adult, increasing evidence has shown that Notch1 also plays an 
important role during pathological events. It was recently reported that activity of γ-secretase and 
the resulting Notch1 activation, may endanger neurons in ischemic stroke by modulating pathways 
to increase vulnerability to apoptosis and by activating microglial cells and stimulating the 
infiltration of pro-inflammatory leukocytes (Arumugam et al. 2006; Li et al. 2012; Wang et al. 
2012).  Furthermore it was shown in previous studies in this thesis and studies from other groups 
that Notch1 signaling endangers neurons after ischemic stroke by modulating nuclear factor-κB 
(NF-κB), pro-death protein Bim, hypoxia inducible factor-1α  (HIF-1α)  and caspase-3 (Arumugam 
et al. 2011; Wei et al. 2011; Cheng et al. 2014). 
 
Notch1 signaling is known to also modulate mitogen-activated protein kinase (MAPK) 
pathways and to regulate cell proliferation and inflammation (Gentle et al. 2012; Pallavi et al. 2012). 
Multiple MAPK pathways exist in all eukaryotic cells, which co-ordinately regulate diverse cellular 
functions such as motility, survival, differentiation and apoptosis (Takeda & Ichijo 2002). Once 
activated, these MAPKs transduce stress-related signals by phosphorylating intracellular enzymes, 
transcription factors and cytosolic proteins involved in apoptosis and inflammatory cytokine 
production which is heavily involved in cell death following ischemic stroke (Barone et al. 2001; 
Maddahi & Edvinsson 2010).  
 
There are four groups of conventional MAPKs characterized in mammalian cells, including 
extracellular signal-regulated kinase (ERK1/2), Jun N-terminal kinase (JNK1, 2 and 3), p-38 kinase 
isozymes (p38α, β, γ   and δ), and ERK5 (Davis 2000; Chen et al. 2001). The JNK signal 
transduction pathway is activated by cytokines, ultraviolet irradiation and to a lesser extent, some 
G-protein-coupled receptors and growth factors. Members of the JNK family are important in 
regulating the responses to various stresses, neuronal function, inflammation and apoptosis 
 79 
(Kyriakis & Avruch 2001). The mammalian p38 isoforms are strongly activated in response to 
environmental stress and inflammatory cytokines but not much by mitogenic stimuli. Similar to the 
JNK family, the p38 MAPKs play pivotal roles in development, differentiation, apoptosis, and 
inflammation especially in asthma and autoimmunity (Kyriakis & Avruch 2001). The ERK1/2 
(p44/42) family is known as the classical mitogen kinase cascade, which can be activated by growth 
factors, mitogenic stimuli and to a lesser extent by cytokines and osmotic stress. They regulate a 
number of responses including proliferation, differentiation and meiosis (Lewis et al. 1998). It was 
discovered that ERK5, similar to the other ERKs, is activated by growth factors, serum and strongly 
by oxidative stress (English et al. 1998). The responses of ERK5 activation are involved in cell 
proliferation and development, and recently it has been found to enhance neurogenesis and long-
term memory in adult mice (Wang et al. 2014). The downstream effector of JNK, transcription 
factor, c-Jun is a member of the Jun family (c-Jun, Jun-D and Jun-B). The Jun family and the Fos 
family members (Fra1, Fra2, c-Fos and Fos-B) form a dimeric transcription factor complex called 
activator protein-1 (AP-1). The AP-1 complex can bind to the TPA response element (TRE), thereby 
regulating gene transcription (Henken et al. 2012). 
 
MAPK pathways contribute significantly in several CNS disorders including ischemic 
stroke. The stress-activated JNK and p38 MAPK pathways are reported to contribute to ischemic-
induced neuronal cell death, which can be induced by oxidative stress and calcium overload 
(Barone et al. 2001; Bogoyevitch et al. 2004). Excitotoxic stimulation of the N-Methyl-D-aspartate 
receptor (NMDAR) triggers the activation of p38, which requires the influx of calcium (Cao et al. 
2004; Cao et al. 2005). Sustained activation of p38 MAPK and JNK have been shown to activate 
downstream transcription factor AP-1 and contribute to neuronal apoptotic cell death following 
stroke (Tang et al. 2007; Tang et al. 2008). The p38 MAPK is also thought to contribute to 
extrasynaptic NMDAR-mediated excitotoxicity in neurons and in a mouse model of Huntington 
disease (Xu et al. 2009; Fan et al. 2012). In addition, it was shown that p38 MAPK activation is 
involved in induction of reactive astrocytes and thus the formation of glial scar following ischemic 
stroke (Choudhury et al. 2014). Studies have indicated that the JNK-c-Jun pathway plays a critical 
role during the injury response in association with stroke, such as persistent induction of c-Jun 
during short term exposure to ischemia (Sommer et al. 1995), inhibition of ischemia-induced c-Jun 
expression with K+-channel openers (Heurteaux et al. 1993) and reduced axon/dendrite damage 
after global cerebral ischemia with JNK inhibitor treatment (Carboni et al. 2008). Recent evidence 
has also shown that Toll-like receptor 8 (TLR8) activation triggered post-stroke inflammation and 
neuronal cell death through the pro-apoptotic JNK signaling pathway (Tang et al. 2013) (Figure 5.1).  
ERK5, on the other hand, appears to confer anti-apoptotic neuroprotection (Wang et al. 2009) while 
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the role of ERK1/2 is presently controversial (Sawe et al. 2008).  
 
Previous studies have shown evidence that Notch1 signaling regulates macrophage 
polarisation through MAPK pathways (Xu et al. 2012), mutant PS1 has been shown to mediate 
ERK pathway activation in human embryonic kidney (HEK) cells (Shin et al. 1999) and treatment 
with γ-secretase inhibitors blocked the activation of p38 MAPK induced by β-amyloid precursor 
protein (APP) in neurons (Song et al. 2002). Notch1 signaling has also been shown to inhibit 
endothelial cell proliferation (Liu et al. 2006) and suppress Toll-like receptor triggered 
inflammatory responses in macrophages by repressing the MAPK pathway (Zhang et al. 2012). In 
addition, Notch1 activity is required for the up-regulation of p38 MAPK since inhibition of Notch1 
signaling reduced the level of p38 MAPK in Müller glia (Ghai et al. 2010). These findings provide 
the foundations for the hypothesis that the regulatory role of Notch1 signaling with the MAPK 
pathways might also play a role in ischemic neuronal injury through the induction of pro-apoptotic 
responses. 
 
To determine the contribution of Notch1 signaling in MAPK-dependant neuronal cell death 
following ischemic stroke, this study investigated the temporal expression and activation of three 
major MAPKs (JNK, ERK, p38) and the AP1 subunit c-Jun in SH-SY5Y neuroblastoma cells in 
response to ischemic conditions as well as the influence of Notch1 signaling in the expression and 
activation of MAPKs following ischemia in both SH-SY5Y and HEK cells. The results showed that 
Notch1 signaling, JNK, p38 and c-Jun are activated under ischemic conditions, while there is 
decreased expression and activity for ERK1/2. Utilising γ-secretase treated SH-SY5Y cells and 
NICD1 overexpressed HEK cells, it is demonstrated for the first time that Notch1 signaling 
promotes the activation of the JNK-c-Jun pathway and contributes to cell death under ischemic 
conditions. 
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Figure 5.1 MAPK signaling in neurons following ischemic stroke. Following ischemic stroke, 
interruption of cerebral blood flow causes ion pump failure, which results in increased calcium 
influx and generation of free radicals. The ischemic stress and cytokines released from neighboring 
cells activate several receptors on the neurons including Toll-like receptors and tumor necrosis 
factor receptors. These events activate downstream signaling cascades such as the MAPK pathway 
and lead to cell death and neuroinflammation. NMDA receptor: N-Methyl-D-aspartate receptor, 
TNFR: tumor necrosis factor receptor, TLR: Toll-like receptor, ROS: reactive oxygen species, AP1: 
activator protein 1.   
 82 
Materials and methods 
 
Human neuroblastoma cell line culture 
 
SH-SY5Y cells (ATCC, USA) were cultured in complete growth medium composed of 
Dulbecco’s   modified   Eagle’s   medium-F12 (DMEM/F12) (Invitrogen, USA) supplemented with 
10% fetal bovine serum and 1% penicillin and 1% streptomycin (Gibco, USA) in a 37°C humidified 
incubator with 5% CO2. To differentiate neuroblast-like cells towards a neuronal-like phenotype 
cells were cultured in complete growth medium with the addition of 10 μM all-trans retinoic acid 
(RA, Sigma, USA) for 1 week. The culture medium was replaced every 3-4 days.  
 
NICD1-overexpressing HEK cell lines 
 
Human embryonic kidney (HEK) 293T cells were kindly provided by Dr. Kah Leong Lim 
(National University of Singapore, Singapore). Myc-tagged NICD1 stably-overexpressing HEK 
293T cells were kindly provided by Dr. Dong-Gyu Jo (Sungkyunkwan University, Republic of 
Korea). Cells were cultured  in  complete  growth  medium  composed  of  Dulbecco’s  modified  Eagle’s  
medium (DMEM) (Invitrogen, USA) supplemented with 10% fetal bovine serum and 1% penicillin 
and 1% streptomycin (Gibco, USA) in a 37°C humidified incubator with 5% CO2. To generate 
stable NICD1-overexpressing cell lines, HEK 293T cells were co-transfected with myc-tagged 
NICD1 and pBABE-puro using Lipofectamine 2000 (Invitrogen, USA).  Cells expressing 
transgenes  were   selected  with  1μg/ml  of  puromycin (Merck Calbiochem, Germany). To maintain 
NICD1 overexpression, 1μg/ml of puromycin was added to the complete growth medium in cell 
cultures. 
 
Pharmaceutical treatments 
 
 The γ-secretase inhibitors IX (DAPT) and XXI (Compound E) were purchased from Merck 
Calbiochem (Germany). DAPT was administered into SY5Y cultures in a final concentration of 
20μM and the final concentration of Compound E was 1μM. The JNK inhibitor SP600125 was 
purchased from Cayman Chemical (USA). SP600125 was dissolved in DMSO and final 
concentration of 20 μM was used. 
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Oxygen-glucose deprivation  
 
 To induce oxygen-glucose deprivation (OGD), the complete growth medium was replaced 
with glucose–free  Locke’s  buffer  containing  154 mM NaCl. 5.6 mM KCl, 2.3 mM CaCl2, 1 mM 
MgCl2, 3.6 mM NaHCO3, 5 mM HEPES and 5 mg/L of gentamycin, pH 7.2. The plates were then 
incubated in an airtight hypoxia chamber by replacing the air with 95% N2/5%CO2 for different 
time points. 
 
Cytotoxicity assay 
 
 A cytotoxicity detection kit purchased from Roche (Germany) was used to detect cell death 
based on measuring the activity of lactate dehydrogenase (LDH) which is released from the cytosol 
of damaged cells into the supernatant. The assay was performed according to the kit instructions 
with some modifications. In brief, the medium of treated cells were collected and cells were lysed 
with 500μl PBS + 0.1% Triton X-100. Samples were mixed with reaction solution and incubated for 
10 minutes at room temperature before stopping the reaction in 1N hydrochloric acid. Absorbance 
of the sample solution was measured at 490 nm with reference wavelength at 700 nm.  
 
Protein lysate preparation and Immunoblot analysis 
 
 To obtain protein lysates for immunoblot analysis, cells were lysed by RIPA buffer (Thermo 
Scientific, USA) containing 1% of protease and phosphatase inhibitors. The supernatants were 
collected after sonication and centrifugation at 13,000 rpm at 4°C for 10 minutes as protein lysate. 
Protein lysates were subjected to sodium dodecyl sulphate-poly-acrylamide gel (10%) 
electrophoresis using a Tris-glycine-SDS running buffer and then transferred onto a nitrocellulose 
membrane (Bio-Rad, USA). The membrane was blocked with 5% bovine serum albumin (BSA) in 
Tris-Buffered Saline and Tween 20 (TBS-T) for 1 hour at room temperature. The membrane was 
then incubated overnight at 4 °C with primary antibodies including those that selectively bind to 
cleaved caspase-3, phosphorylated JNK, phosphorylated c-Jun, phosphorylated p38, phosphorylated 
ERK, total JNK, total c-Jun, total p38, total ERK (Cell Signaling Technology, USA), activated 
Notch1 (Abcam, UK), c-Myc (Roche, Germany), and Actin (Sigma Aldrich, USA). The membrane 
was then washed with TBS-T and incubated with a horseradish peroxidase-conjugated secondary 
antibody for 1 hour at room temperature. After washing, the membrane was incubated in 
chemiluminescent substrate for enhanced chemiluminescence (Bio-Rad, USA). Chemiluminescent 
signals of protein bands were visualised using ChemiDoc imaging system (Bio-Rad, USA). 
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Immunofluorescence 
 
 Coverslips containing SY5Y neuroblastoma cells subjected either to normal medium or 
OGD medium were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS, Sigma, 
USA). Fixed cells were blocked and permeabilised with blocking buffer (0.2% BSA, 1% Fetal 
Bovine Serum (FBS), and 0.1% Triton-X in PBS) at room temperature for 1 hour before 2 hours 
incubation with activated Notch1 (Abcam, USA) and phosphorylated c-Jun (Santa cruz, USA) 
antibodies diluted in blocking buffer. Cells were then incubated with Alexa Fluor-conjugated 
secondary antibodies (Invitrogen, USA) diluted in blocking buffer for 45 minutes at room 
temperature. Following secondary antibody incubation, the nuclei of all cells were stained with 
DAPI (Bio-Rad, USA) for 10 minutes at room temperature and coverslips were mounted with 
Vectashield mounting solution (Vector Laboratories, USA) on microscope slides. The slides were 
observed under a confocal microscope (Olympus LV1000, Japan) 
 
Data analysis 
 
 All results are reported as mean ± standard deviation (SD). Overall significance of the data 
from SH-SY5Y cells was examined by one-way analysis of variance (ANOVA). Overall 
significance of the data from HEK cells was examined by two-way analysis of variance (ANOVA). 
Differences between groups were considered significant at p<0.05 with the appropriate Bonferroni 
correction made for multiple comparisons. 
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Results 
Expression of NICD1 and pro-apoptotic cleaved caspase-3 during ischemic conditions  
 
The expression levels of NICD1 and a pro-apoptotic marker, cleaved caspase-3 were first 
assessed in an in vitro model of ischemic neuronal injury using human SH-SY5Y cells. Over a time 
course of oxygen-and glucose deprivation (OGD) of 0.5-6 hours, NICD1 expression as an indicator 
of Notch signaling activation was significantly increased (Figure 5.2A and B) and it was correlated 
with the increased expression of cleaved caspase-3 (Figure 5.2C and D). This result was consistent 
with previous findings in mouse primary neuronal cultures (Arumugam et al. 2006; Arumugam et al. 
2011; Cheng et al. 2014). 
 
 
 
 
Figure 5.2 NICD1 and pro-apoptotic cleaved caspase-3 in SH-SY5Y cells subjected to OGD 
conditions. (A, B) NICD1 expression was increased over 0.5- 6 hours of OGD. (C, D) Expression 
of cleaved caspase-3 was also increased at 3 hours of OGD treatment. * p< 0.05, ** p< 0.01 
compared with normal group; n=4 different cultures. 
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Expression of MAPKs during ischemic conditions 
 
In order to investigate if Notch1 signaling may be involved in modulating MAPK activity 
under ischemic conditions, the levels of phosphorylated-/total- JNK, c-Jun, p38 and ERK during 
OGD conditions were examined. Expression levels of phosphorylated-JNK (p-JNK) 1 and p-JNK 
2/3 significantly increased within 0.5-6 hours of OGD conditions, with a peak level of expression 
occurred at 3 hours (Fig 5.3A, B, and D). However total expression of JNK remained constant, 
suggesting activation of the JNK pathway through phosphorylation and not synthesis of JNK 
contributing to SH-SY5Y cell death under OGD conditions (Fig 5.3C, E, F, and G). By contrast, 
levels of both phosphorylated- and total- c-Jun were increased after 3-6 hours of OGD (Figure 5.4).  
 
Whereas similar to JNK, phosphorylated p38 was increased while total p38 remained 
constant during OGD treatment (Figure 5.5), consistent with a role for p38-MAPK in OGD-induced 
cell death. ERK, on the other hand, exhibited an opposite trend in response to OGD treatment. 
Phosphorylated-ERK-42/44 expression was reduced in cells subjected to OGD, whilst the total 
ERK-42/44 levels were unchanged (Figure 5.6). These results indicated that MAPKs were affected 
differently in ischemic conditions. 
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Figure 5.3 Increased level of JNK in SH-SY5Y cells subjected to OGD treatment. (A) 
Representative immunoblots showing phosphorylated and total JNK1 and JNK 2/3 under normal 
and OGD conditions. (B-G) Levels of phosphorylated JNK1 and JNK2/3 were increased following 
OGD compared to normal cultures. * p< 0.05, ** p< 0.01, *** p< 0.001; n=4 different cultures.  
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Figure 5.4 Increased level of p-c-Jun in SH-SY5Y cells subjected to OGD treatment. (A) 
Representative immunoblots showing phosphorylated and total c-Jun under normal and OGD 
conditions. (B-D) levels of phosphorylated and total c-Jun were increased following OGD 
compared to normal cultures. * p< 0.05, ** p< 0.01, *** p< 0.001; n=4 different cultures. 
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Figure 5.5 Increased level of p-p38 in SH-SY5Y cells subjected to OGD treatment. (A) 
Representative immunoblots showing phosphorylated and total p38 under normal and OGD 
conditions. (B-D) Levels of phosphorylated and total p38 were increased following OGD compared 
to normal cultures. * p< 0.05, ** p< 0.01, *** p< 0.001; n=4 different cultures. 
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Figure 5.6 Decreased level of p-ERK in SH-SY5Y cells subjected to OGD treatment. (A) 
Representative immunoblots showing phosphorylated and total ERK42 and ERK44 under normal 
and OGD conditions. (B-G) Levels of phosphorylated and total ERK42 and ERK44 were decreased 
following OGD compared to normal cultures. * p< 0.05, ** p< 0.01, *** p< 0.001; n=4 different 
cultures. 
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Effects of a gamma secretase inhibitor on expression of NICD1 and p-c-Jun during ischemic 
conditions  
 
In order to determine whether the Notch1 signaling pathway may directly affect the activity 
of MAP kinases during ischemic conditions, the expression and cellular localisation of NICD1 and 
p-c-Jun were assessed using immunofluorescence. Confocal images confirmed that accumulation of 
NICD1 occurred in the nucleus following OGD, which is inhibited by the γ-secretase inhibitor, 
compound E (1μM, CE). Similar to NICD1, the level of p-c-Jun was also increased by OGD, and 
was reduced with CE treatment. Interestingly, NICD1 and p-c-Jun appeared to co-localise (as seen 
in yellow), suggesting possible interaction under ischemic stress. The robust expression of both 
NICD and p-c-Jun were reduced with CE treatment (Figure 5.7). 
 
 
 
Figure 5.7 NICD and p-c-Jun found to be co-expressed in SH-SY5Y cells under ischemic 
conditions. Immunofluorescence staining of NICD1 (red), p-c-Jun (green) and DAPI (blue) in SH-
SY5Y cells in normal and OGD conditions. The immunofluorescence images show that levels of 
both NICD and p-cJun robustly increased in the nucleus following OGD. Addition of the γ-
secretase inhibitor, compound E (CE), decreased expression of NICD and p-c-Jun. Scale bar: 10 μm. 
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Gamma secretase inhibitors decreased the expression of p-JNK and p-c-Jun but not p-p38 
and p-ERK in ischemic conditions  
 
To determine the concentrations of two γ-secretase inhibitors, compound E (CE) and DAPT, 
that were required to inhibit Notch activation in SH-SY5Y cells, different concentrations of CE and 
DAPT were tested. Based on these data, 1μM of CE and 20 μM of DAPT were chosen to inhibit γ-
secretase activity and thus Notch1 signaling in this study (Figure 5.8). Next, SH-SY5Y cells 
subjected to OGD conditions were treated with or without the addition of CE and DAPT, and 
expression of MAPKs were quantified. Levels of p-JNK were increased in OGD-treated cells when 
compared with cells under normal conditions as previously seen, and expression of p-JNK was 
reduced in cells treated with either CE or DAPT compared to vehicle (DMSO) treated cells (Figure 
5.9A, B, D). The results suggested the integration of Notch1 signaling into JNK pathway in neurons 
following ischemic conditions through the phosphorylation of JNK. Similarly, levels of p-c-Jun 
were reduced in cells treated with CE or DAPT compared to vehicle treatment (Figure 5.10A, B, D), 
consistent with an involvement of c-Jun, a downstream effector of JNK pathway, in Notch1-
mediated cell death during ischemic conditions. By contrast, neither phosphorylated or total p38 
and ERK expression levels were affected by γ-secretase inhibitors (Figure 5.11). 
 
 
 
 
Figure 5.8 NICD1 expression under different concentrations of γ-secretase inhibitors. (A) 
NICD1 levels in SH-SY5Y cells under normal, OGD, and OGD conditions with different 
concentrations of compound E (CE). (B) NICD1 levels in SH-SY5Y cells under normal, OGD, and 
OGD conditions with different concentrations of DAPT. Selected concentrations for subsequent 
experiments were 1μM of CE and 20 μM of DAPT. n=3 different cultures. 
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Figure 5.9 Treatment with a γ-secretase inhibitor downregulates expression of JNK in SH-
SY5Y cells subjected to OGD treatment. (A) Representative immunoblots showing 
phosphorylated and total JNK1 and JNK 2/3 under normal, OGD conditions, and the treatment of γ-
secretase inhibitors CE and DAPT. (B-G) CE and DAPT reduced the levels of phosphorylated 
JNK1 and JNK 2/3 following OGD compared to vehicle-treated cells. * p< 0.05; n=5 different 
cultures.  
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Figure 5.10 Treatment with a γ-secretase inhibitor downregulates expression of c-Jun in SH-
SY5Y cells subjected to OGD treatment. (A) Representative immunoblots showing 
phosphorylated and total c-Jun under normal, OGD conditions, and the treatment of γ-secretase 
inhibitors CE and DAPT. (B-D) CE and DAPT reduced the levels of phosphorylated c-Jun 
following OGD compared to vehicle-treated cells. * p< 0.05, ** p< 0.01, *** p< 0.001; n=5 
different cultures. 
 
                     
Figure 5.11 Levels of phosphorylated/ total p38 and ERK under OGD conditions when treated 
with γ-secretase inhibitors were not affected.  Immunoblots showing the levels of 
phosphorylated/ total p38 and ERK were not changed following γ-secretase inhibitor treatments. 
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NICD1 overexpression potentiates expression levels of JNK and c-Jun following ischemic 
conditions  
 
To further investigate Notch1-mediated JNK/c-Jun activation under ischemic conditions, the 
levels of JNK and c-Jun expression and activation were tested in c-Myc-tagged NICD1 protein-
overexpressing HEK cells. First, immunoblot analysis of c-Myc confirmed the overexpression of 
NICD1 (Figure 5.12). Immunoblot analysis indicated that under normal conditions there tended to 
be increased basal levels of phosphorylated JNK 1 and 2/3 in NICD1-overexpressing cells under 
compared to wild type cells. Furthermore, under OGD conditions, phosphorylation of both JNK 1 
and 2/3 were significantly increased in NICD1-overexpressing cells compared to wild type cells 
(Figure 5.13). Similarly, phosphorylated-c-Jun levels were significantly higher in NICD1-
overexpressing cells compared to wild type cells under both basal and OGD conditions (Figure 
5.14). Finally, immunofluorescent staining showed increased expression of p-c-Jun in both wild 
type and NICD1-overexpressing cells under OGD conditions comparing to normal condition, and 
NICD1-overexpressing cells exhibited higher level of p-c-Jun comparing to wild type cells when 
exposed to OGD conditions (Figure 5.15). 
 
 
       
Figure 5.12 Verification of NICD1 overexpression in HEK cells. HEK cells were transfected 
with myc-tagged NICD1 and selected with 1% Puromycin for few passages. Immunoblot analysis 
shows stable overexpression of c-Myc-NICD1 protein in transfected HEK cells. WT, wild type 
HEK cells. NICD, NICD1 overexpressed HEK cells. 
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Figure 5.13 NICD1 induces JNK expression in HEK cells. (A) Representative immunoblots 
showing phosphorylated and total JNK expression in wild type and NICD1 overexpressing cells 
under normal and OGD conditions. (B-G) Levels of phosphorylated JNK1 and JNK 2/3 were 
increased in NICD1 overexpressed cells following OGD condition compared to wild type cells. * 
p< 0.05, ** p< 0.01; n=6 different cultures. WT, wild type HEK cells. NICD, NICD1 overexpressed 
HEK cells. 
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Figure 5.14 NICD1 induces c-Jun expression in HEK cells. (A) Immunoblots showing 
phosphorylated and total c-Jun expression in wild type and NICD1 overexpressing cells under 
normal and OGD conditions. (B-D) Levels of phosphorylated c-Jun were increased in NICD1 
overexpressing cells under normal and OGD conditions compared to wild type cells. * p< 0.05, ** 
p< 0.01; n=6 different cultures. WT, wild type HEK cells. NICD, NICD1 overexpressed HEK cells. 
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Figure 5.15 Phosphorylated c-Jun expression under OGD conditions in NICD1-
overexpressing cells. Immunofluorescence staining of p-c-Jun (green) and DAPI (blue) in HEK 
cells in normal and OGD conditions. Immunofluorescence images show phosphorylated c-Jun 
increased in the nucleus under OGD conditions, with more intense staining in NICD1 
overexpressing cells. WT, wild type HEK cells. NICD, NICD1 overexpressed HEK cells. Scale bar: 
10  μm. 
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NICD1 overexpression potentiate cell death following ischemic conditions 
  
Cell death in wild type and NICD1-overexpressing cells was assessed by LDH release under 
normal and OGD conditions (Figure 5.16). The experiments confirmed that NICD1- overexpressing 
cells were more susceptible to OGD conditions than wild type cells, and that cell death was 
significantly reduced in NICD1-overexpressing cells treated with the JNK inhibitor, SP600125.  
 
                                
                              
Figure 5.16 JNK inhibitor reduces the increased cytotoxicity in NICD1 overexpressed cells. 
LDH release was measured in cells under normal and OGD conditions. LDH release data shows 
that cell death was significantly higher in NICD1-overexpressing cells compared to wild type cells 
under OGD conditions. NICD1-overexpressing cells treated with a JNK inhibitor display a 
significant decrease of LDH release compared to vehicle-treated cells.  *** p< 0.001; n=5 different 
cultures. WT, wild type HEK cells. NICD, NICD1 overexpressed HEK cells, JNKI, JNK inhibitor 
(SP600125). 
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Discussion 
 
A major finding of this study is Notch1 signaling endangers neurons under ischemic 
conditions by modulating the JNK/c-Jun pathway, and this neuronal damage can be inhibited in 
vitro by treatment with a γ-secretase inhibitor. It has been previously demonstrated that γ-secretase 
activity and subsequent Notch1 signaling are elevated in the brain following ischemic stroke in vivo 
(Arumugam et al. 2006). Furthermore, studies in the previous chapters of this thesis and in 
published literature showed that γ-secretase activity is elevated in cultured primary neurons after 
ischemic conditions, and γ-secretase-mediated Notch signaling contributes to neuronal death in 
ischemic stroke by modulating the NF-κB, pro-death protein Bim, calcium signaling, HIF-1α,  and 
caspase-3 (Arumugam et al. 2011; Cheng et al. 2014). Certain MAPK pathways are known to 
contribute to ischemic stroke injury by promoting apoptosis and neuroinflammation via the 
transcription of inflammatory mediators such as tumor necrosis factor α  (TNFα),  interleukin 1β (IL-
1β)  IL-6 and IL-8 (Figure 5.1) (Jin et al. 2013). Recent evidence indicates that Notch signaling may 
mediate several of its physiological responses through MAPK pathways (Stockhausen et al. 2005; 
Kondoh et al. 2007; Yamashita et al. 2013). Therefore, this research aimed to test the hypothesis 
that Notch1 signaling mediates cell death after ischemic conditions by modulating MAPK signaling. 
 
To investigate the role of Notch1 signaling in the activation of MAPKs during ischemic 
stroke-like conditions, the expression levels of Notch1, cleaved caspase-3, and MAPKs were first 
examined. The results showed that NICD1, cleaved caspase-3, phosphorylated-JNK, p38, and c-Jun 
were elevated in response to OGD conditions. Furthermore, total-c-Jun expression was also 
increased during the time course of OGD conditions. By contrast, phosphorylated-ERK expression 
was reduced under OGD conditions. Increased expression of NICD1 and cleaved caspase-3 
following OGD in SH-SY5Y cells correlates with the previous findings in primary neurons, 
indicating a detrimental role of Notch1 activation in ischemic cell death in SH-SY5Y cells 
(Arumugam et al. 2011).  
 
MAPK pathways are known to contribute to ischemic stroke injury by promoting the 
transcription of pro-inflammatory mediators (Wang et al. 2004; Sawe et al. 2008). An increased 
phosphorylation level of both JNK and p38, indicative of activation of these kinases, was observed 
under OGD conditions in SH-SY5Y cells. In addition, both phosphorylated and total expression 
levels of c-Jun were observed, suggesting that activation of c-Jun might occur through both 
phosphorylation and translation of c-Jun. JNK-MAPK signaling has been implicated in stress-
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induced neuronal apoptosis (Kuan et al. 2003; Pirianov et al. 2007; Coffey 2014). Activation of 
JNK may result in the phosphorylation of many transcription factors, including components of the 
AP-1 family, c-Jun, and activating transcription factor 2 (ATF2) (Coffey 2014). Recent studies have 
indicated that the JNK/c-Jun pathway plays a critical role during the injury responses in association 
with stroke (Simi et al. 2000; Dong et al. 2009). The results in this study showed both 
phosphorylated and total expression levels of c-Jun were elevated during OGD conditions, 
suggesting that activation of c-Jun might occur through both phosphorylation and translation of c-
Jun. It is known that c-Jun transcription can be auto-regulated by its own product, Jun, through the 
binding of AP-1 to the Jun promoter and induces Jun transcription (Angel et al. 1988). This positive 
auto-regulation by stimulating its own transcription may be a mechanism for prolonging the signals 
from extracellular stimuli and has significance for the activity of c-Jun (Angel et al. 1988). In this 
study p38 was activated following OGD conditions, which is also consistent with previous studies 
that showed increased phosphorylated-p38 following ischemic stroke in neurons (Liu et al. 2009; 
Irving et al. 2000).  
 
 On the other hand, the phosphorylated-ERK42/44 were reduced in response to OGD 
conditions, which is opposite to JNK and p38. The ERK pathway is known to modulate cell 
survival and proliferation, even during ischemic stroke (Lai et al. 2014). Several studies have 
indicated that ERK promotes cell survival during ischemic stroke in neurons (Navon et al. 2012; 
Kim et al. 2012), human brain microvessel endothelial cells (hCMEC/D3) (Krupinski et al. 2012), 
and oligodendrocyte precursor cells (Sun et al. 2013). The result in this study showed reduced 
phosphorylation of ERK during ischemic conditions, suggesting that down-regulation of pro-
survival ERK could contribute to neuronal cell death following ischemic stroke. Previous evidence 
has shown that global or extrasynaptic NMDAR stimulation decreases ERK activation in neurons 
(Chandler et al. 2001; Ivanov et al. 2006; Léveillé et al. 2008), strengthening the finding in this 
study that negative regulation of ERK activity is involved in brain injury during stroke. 
 
In order to explore whether Notch1 signaling plays a role in the activation of MAPKs during 
ischemic stroke-like conditions,  γ-secretase inhibitors were administered to SH-SY5Y cells at the 
onset of OGD. The data from this study showed that  inhibition  of  γ-secretase results in decreased 
levels of phosphorylated JNK and c-Jun, suggesting the Notch1 signaling modulates JNK and c-Jun 
activation during ischemic stroke. Evidence has shown that both Notch1 and JNK-c-Jun signaling 
can regulate one another under different physiological circumstances. It was found that JNK 
signaling can mediate expression of Hes-1, immediately downstream of Notch1 signaling, in a 
Notch1-independent manner (Curry et al. 2006). Another recent study found that moderate Notch 
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activation leads to increased AP-1 transcription and DNA binding activity, which contributes to 
increased viability and anchorage-independent growth in HPV-infected cervical cancer cells 
(Henken et al. 2012).  By contrast, there is no effect  of  γ-secretase inhibition on the expression of 
both phosphorylated- and total- p38 and ERK under OGD conditions. Although there are a number 
of studies that show Notch signaling regulates the p38 pathway in different cell types and disease 
conditions (Song et al. 2002; Xu et al. 2012; Mathern et al. 2014), there is no clear evidence of 
Notch activation in the regulation of p38 in neurons following ischemic conditions in this study. 
Likewise, while current literature postulates that ERK has dual roles in ischemic stroke 
(Szydlowska et al. 2010; Gladbach et al. 2014), this study found that ERK activity was decreased 
under ischemic stress. There was also no clear evidence for Notch signaling in the regulation of 
ERK in neurons under ischemic conditions in this study. 
 
Moreover, to further investigate the possibility that Notch1 influences the JNK-c-Jun 
pathway, HEK cells that overexpressed NICD1 was subjected to OGD conditions and levels of JNK 
and c-Jun were assessed. The data indicate higher levels of phosphorylated JNK and c-Jun were 
present in NICD1-overexpressing cells under both normal and OGD conditions compared to wild 
type controls. Immunofluorescent staining of SH-SY5Y cells showed higher phosphorylated c-Jun 
levels in the nucleus during OGD conditions, and the level of phosphorylated c-Jun was reduced 
following treatment with   the   γ-secretase inhibitor CE. Furthermore, higher phosphorylated c-Jun 
was observed in NICD1 overexpressing HEK cells under OGD conditions compared to wild type 
HEK cells. Lastly, the NICD1-overexpressing cells were more susceptible to OGD-induced cell 
death, and inhibition of JNK was able to increase survival. These results further confirmed that 
Notch1 signaling could activate the JNK-c-Jun pathway to promote ischemic cell death. The role of 
the JNK signaling pathway in cell death and survival is controversial, both pro-apoptotic and pro-
survival roles have been attributed to JNK in neurons (Coffey 2014). By showing increased cell 
death in NICD1-overexpressing HEK cells and reduced cell death with a JNK inhibitor, this study 
shows that Notch1-induced JNK pathway activation mediates cell death under ischemic conditions. 
Nonetheless, Notch-MAPK pathway interactions have been reported to occur in the context of 
macrophage polarisation (Xu et al. 2012), and some evidence showed the coupling of Notch1 
signaling and the JNK-c-Jun pathway in regulating eye development (Kockel et al. 2001) and dorsal 
closure (Zecchini et al. 1999) in Drosophila. The current study has shown for the first time that 
Notch1 signaling modulates the JNK-c-Jun pathway under ischemic conditions in the induction of 
cell death. 
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Conclusion 
 
 Notch1 and the JNK pathways play important roles in regulating cell fate decisions in the 
CNS system. The roles of the JNK pathway in cell survival and apoptosis have been controversial, 
and the mechanism that regulates the JNK pathway to pro-survival or pro-apoptotic functions is still 
unclear. When brain injury such as an ischemic stroke occurs, Notch1 signaling is activated and 
contributes to neuronal death by crosstalk with other signaling pathways including the NF-κB and 
HIF-1α pathways. Therefore this study explores the effect of γ-secretase inhibition on the JNK and 
c-Jun pathway in an in vitro model of ischemic stroke. The present study provided evidence that the 
JNK-c-Jun pathway is activated and contributes to ischemic-induced injury in neurons, and 
provides further evidence that Notch signaling activates the JNK-c-Jun pathway following ischemic 
stroke. Furthermore, cell death induced by Notch1 overexpression can be attenuated by JNK 
inhibition. The connection between the Notch1 signaling pathway and the JNK pathway represents 
a mechanism that accounts for the detrimental effect of their activation after ischemic stroke. As it 
is important to find a molecular target that is able to regulate multiple injury mechanisms following 
ischemic stroke, these results increase the attractiveness for the use of γ-secretase inhibitors as 
potential ischemic stroke therapy. This study provides evidence that besides the NF-κB and HIF-1α  
pathways, inhibition of Notch1 signaling is also able to attenuate neuronal death by interfering the 
JNK-c-Jun pathway.  
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Chapter 6  Conclusion and future directions 
 
Notch1 signaling is an important pathway that determines cell fate decisions during 
development and synaptic plasticity in the adult brain. However, Notch1 activation during ischemic 
stroke is known to be detrimental to neuronal survival and stroke outcome by inducing neuronal 
apoptosis, microglial activation, and pro-inflammatory leukocyte infiltration. Having such 
influential role in several cell types in the brain, it becomes highly critical to unravel the roles of 
Notch1 signaling following ischemic stroke in order to reveal the mechanisms underlying neuronal 
cell death in stroke. Understanding the roles that Notch1 signaling plays during ischemic stroke 
may help in developing effective neuroprotective strategies to treat this devastating disease. Thus, 
the focus of this research thesis is to uncover the molecular mechanisms of Notch1 signaling in the 
induction of neuronal cell death following ischemic stroke.  
 
The major outcome from this research study is that γ-secretase-mediated Notch1 signaling 
activation induces the activation of the NF-κB, HIF-1α,   and JNK-c-Jun pathways and ultimately 
leads to neuronal cell death in ischemic stroke conditions. In addition, this thesis study confirmed 
again that γ-secretase inhibition reduces ischemic-induced neuronal cell death and improves 
ischemic stroke outcome. This thesis study demonstrated that γ-secretase-mediated Notch1 
activation induces apoptosis through the expression of NF-κB, and the downstream pro-apoptotic 
protein Bim and cleaved caspase-3 in neurons following ischemic stroke. Furthermore, NICD1 is 
found to interact with HIF-1α,  and collaboration of Notch1 and HIF-1α  pathways leads to neuronal 
apoptosis following ischemic stroke. Moreover, the simultaneous inhibition of both γ-secretase and 
HIF-1α   further reduces neuronal death and ischemic brain injury, with evidence suggesting that 
Notch1 and HIF-1α   collaboration affects NF-κB and JNK expression and leads to increased cell 
death in the ischemic brain. Lastly, the findings indicate that Notch1 signaling induces neuronal 
death following ischemic stroke by modulating the JNK-c-Jun pathway (Figure 6.1). 
 
Thus, the findings of this project expand the existing knowledge of Notch1-mediated 
neuronal death in ischemic stroke and outline the importance of Notch1-mediated mechanisms in 
the pathological progress and outcome of ischemic stroke. In addition, understanding the molecular 
mechanisms of Notch1 signaling in ischemic stroke contributes significantly to further 
understanding the detrimentally and complex network of the ischemic cascade in ischemic stoke.  
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The attempt to discover the full picture of Notch1 mediated neuronal death in ischemic 
stroke is of great interest in this doctoral project, however there are many tasks that were unable to 
be completed in this thesis. Despite the research findings gathered in these studies, there are still 
questions that remain to be answered which will require tremendous research efforts in the future. 
The studies in this thesis have established signaling networks of Notch1-mediated neuronal cell 
death in stroke that are formed by NF-κB, HIF-1α,  and JNK. In the in vitro settings of ischemic 
stroke in this study, primary neurons and SH-SY5Y cells under GD and OGD conditions were used 
to study the molecular mechanisms of Notch1-mediated cell death following ischemic stroke. 
However, Notch1 also has profound roles in other cell types in the brain. Therefore it will be 
unequivocally important to understand the roles that Notch1 plays in astrocytes, microglia, and 
endothelial cells, or a combination of all three with neurons to represent the neurovascular unit. 
Furthermore, in the in vivo settings of ischemic stroke in this study, γ-secretase inhibitors were 
administered to male 3-6 month old C57BL/6J mice to inhibit Notch1 activation. It is known that γ-
secretase inhibitors affect the cleavage of all the substrates of γ-secretase besides Notch1 and the 
fact that age and gender would also affect the outcome of ischemic stroke. Therefore studies using 
specific Notch1 antisense (NAS) mice, and experiments in older aged mice or female mice would 
serve as additional useful models to achieve a more comprehensive understanding of Notch1 
signaling during ischemic stroke. Moreover, to confirm the results from the Notch-JNK-c-Jun 
project, in vivo settings of experiments would be ideal. 
 
Finally, further research should be developed in mapping the molecular pathways modulated 
by Notch1 signaling in inducing neuronal cell death following ischemic stroke. There are still a 
number of proteins that are potentially contributing to neuronal death in association with Notch1 
signaling. For instance, the tumor suppressor protein p53, peptidyl-prolyl cis/trans isomerase Pin1, 
and calcium-mediated cell death are good candidates for future research as various studies have 
reported evidence for these elements in the induction of cytotoxicity by means related to Notch1 
signaling. It is known that Notch1 signaling and NF-κB, HIF-1α,  and JNK pathways individually 
contribute to neuronal death following ischemic stroke, and this thesis provides evidence that 
combined inhibition of Notch1 and HIF-1α provided further protection in neurons. However, it is 
still difficult to conclude that targeting Notch1 together with these pathways would afford much 
better neuroprotection than targeting only the Notch1 signaling pathway or one of these 
mechanisms at a time since this study did not compare the degree of each molecular pathway in 
inducing neuronal death following ischemic stroke. In order to answer the question whether should 
we use dual treatment or should only target Notch1 be sufficient to block detrimental effects from 
other pathways, further researches should be done in the future. Since NF-κB, HIF-1α,  and JNK 
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pathway individually affects neuronal cell death through Notch1 dependent and independent 
mechanisms, it would be crucial to elucidate which one is more important among them. Difficulties 
in the treatment of AD with γ-secretase inhibitors have arisen due to the pleiotropic actions of γ-
secretase. This, and the relevant downstream pathways of Notch1 signaling that have been 
discovered in this thesis, bings up the possibility that targeting the downstream pathways such as 
those mediated by NF-κB and JNK may also be more effective or potentially safer than use of γ-
secretase inhibitors in the treatment of ischemic stroke. However, more work needs to be done with 
stringent guidelines before any conclusion can be drawn since there is not yet any research 
comparing the effect of targeting the NF-κB and JNK pathways to the Notch1 signaling pathway. In 
addition, it is also very important to understand the time point to inhibit each signaling pathway to 
gain the maximum neuroprotective effect and when it would be suitable to inhibit two or more 
pathways at the same time. Furthermore, Notch1, NF-κB, HIF-1α,   and JNK pathways may play 
different roles in glial cells, endothelial cells and leukocytes in the picture of the whole brain, 
therefore it would be necessarily to clarify their roles in these cell types following ischemic stroke 
to ascertain if the concurrent inhibition of these pathways is able to exert a better outcome 
altogether. 
 
This thesis has provided evidence of the molecular pathways associated with γ-secretase- 
mediated Notch1 signaling in inducing neuronal death under ischemic conditions and suggested 
targeting Notch1 using a γ-secretase inhibitor as a multi-targeted approach in stroke therapy. 
However, there is no doubt that further studies in  understanding  Notch1’s  pleotropic  roles  in  other 
cell types in the brain is still required before taking γ-secretase inhibitors into clinical trials for 
ischemic stroke therapy. Although it is yet too early to speculate γ-secretase inhibitors as an 
adequate therapeutic option against ischemic stroke, nevertheless the analysis of the molecular 
mechanisms of Notch1-mediated neuronal death described in this thesis has contributed to the 
current knowledge of the complex ischemic cascades and shed some light for translating scientific 
discoveries from basic research into the development of novel strategies for neuroprotective 
therapeutic intervention in ischemic stroke. 
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Figure 6.1 Summary of the molecular mechanisms of Notch1-mediated neuronal cell death 
following ischemic stroke demonstrated in this thesis. Utilising γ-secretase inhibitor treatment, 
siRNA inhibition and NICD1 overexpression techniques, this thesis demonstrates that γ-secretase 
mediated-Notch1 activation following ischemic stroke leads to neuronal cell death through NF-κB-
Bim, HIF-1α,  JNK-c-Jun, and caspase-3 pathways. Furthermore, HIF-1α  is also able to regulate the 
NF-κB and JNK, and lead to neuronal apoptosis.   
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ABSTRACT
Notch-1 (Notch) is a cell surface receptor that regulates
cell-fate decisions in the developing nervous system, and it
may also have roles in synaptic plasticity in the adult brain.
Binding of its ligands results in the proteolytic cleavage of
Notch by the !-secretase enzyme complex, thereby causing
the release of a Notch intracellular domain (NICD) that trans-
locates to the nucleus, in which it regulates transcription.
Here we show that activation of Notch modulates ischemic
neuronal cell death in vitro and in vivo. Specifically, our findings
from the use of Notch-1 siRNA or the overexpression of NICD
indicate that Notch activation contributes to cell death. Using
modified NICD, we demonstrate an apoptosis-inducing function
of NICD in both the nucleus and the cytosol. NICD transfection-
induced cell death was reduced by blockade of calcium signaling,
caspase activation, and Janus kinase signaling. Inhibition of the
Notch-activating enzyme, !-secretase, protected against isch-
emic neuronal cell death by targeting an apoptotic protease,
cleaved caspase-3, nuclear factor-"B (NF-"B), and the pro-death
BH3-only protein, Bcl-2-interacting mediator of cell death (Bim).
Treatment of mice with a !-secretase inhibitor, compound E,
reduced infarct size and improved functional outcome in a model
of focal ischemic stroke. Furthermore, !-secretase inhibition re-
duced NICD, p-p65, and Bim levels in vivo. These findings sug-
gest that Notch signaling endangers neurons after ischemic stroke
by modulating the NF-"B, pro-death protein Bim, and caspase
pathways.
Introduction
!-Secretase (!-secretase) is a membrane-embedded proteo-
lytic complex, which generates the amyloid #-peptide in Alz-
heimer’s disease, and it plays important roles in physiology,
especially in Notch-1 receptor-mediated signaling. !-Secre-
tase belongs to a diverse family of intramembrane-cleaving
proteases and is composed of four integral membrane pro-
teins: presenilin, nicastrin, Aph-1, and Pen-2 (Krishna-
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swamy et al., 2009), with presenilin being an aspartyl pro-
tease that is the catalytic subunit (De Strooper et al., 1998).
Notch-1 is a single-pass type 1 transmembrane receptor that
regulates cell-fate decisions in the developing nervous sys-
tem, and it may also play a role in regulating synaptic plas-
ticity in the adult brain (Wang et al., 2004; Lathia et al.,
2008). Binding of ligands, such as Delta and Jagged, results
in proteolytic cleavage of Notch. This cleavage is facilitated
through the !-secretase complex, which further leads to the
release of a Notch-1 intracellular domain (NICD) that trans-
locates to the nucleus, in which it regulates transcription
(Kra¨mer, 2000; Kopan, 2002). We have shown that activity of
!-secretase, and subsequent Notch-1 activation, are elevated
after ischemic stroke in vivo (Arumugam et al., 2006). Fur-
thermore, !-secretase activity was elevated in cultured cor-
tical neurons subjected to ischemic-like conditions in vitro,
consisting of 3 to 6 h of oxygen and glucose deprivation
(Arumugam et al., 2006). !-Secretase-mediated Notch-1 sig-
naling endangered neuronal survival in ischemic stroke by
modulating pathways that increase their vulnerability to
apoptosis and by activating microglial cells and stimulating
the infiltration of proinflammatory leukocytes (Arumugam et
al., 2006). These effects on cell death were reduced by
intravenous treatment with !-secretase inhibitors, N-[N-(3,
5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
(DAPT) or ((S,S)-2-[2-(3,5-difluorophenyl) acetylamino]-N-(5-
methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7yl) propi-
onamide) (DBZ), resulting in reduced brain damage and im-
proved functional outcome in vivo (Arumugam et al., 2006).
There is much evidence to suggest that !-secretase is in-
volved in the regulation of cellular Ca2! homeostasis (Leis-
sring et al., 2002; Smith et al., 2005; Tu et al., 2006). We have
examined the effect of !-secretase inhibitors on Ca2!-trig-
gered cell death in B103 rat neuroblastoma cells (Choi et al.,
2010). However, a role for the Notch pathway in Ca2!-medi-
ated neuronal death after ischemic stroke remains to be
established.
Several studies have provided evidence for the activation of
NF-"B in neurons, glial, and endothelial cells during isch-
emic stroke (Gabriel et al., 1999; Stephenson et al., 2000;
Nurmi et al., 2004; Tang et al., 2007). !-Secretase-mediated
Notch-1 signaling is required to sustain NF-"B activity and
cytokine production in peripheral T cells because pharmaco-
logical inhibition of Notch attenuates the nuclear distribu-
tion of NF-"B, resulting in reduced transcriptional activity
(Shin et al., 2006). !-Secretase-mediated Notch signaling can
also enhance NF-"B activation by increasing the expression
of components of the active NF-"B signaling complex (Os-
wald et al., 1998). Whether Notch induced by cerebral isch-
emia results in a protracted activation of NF-"B, and atten-
dant transcriptional activity is not known. In the present
study, we provide evidence that Notch activation induced by
ischemia promotes neuronal cell death and brain injury by a
Ca2!-dependent mechanism that can be blocked by inhibi-
tion of the Janus kinase (JAK) and NF-"B-Bim pathway.
Materials and Methods
Cell Culture and Transfection. SH-SY5Y (human neuroblas-
toma) cells were cultured in Dulbecco’s modified Eagle’s medium
including 10% fetal bovine serum supplemented with 1% penicillin
and streptomycin. These cells were maintained at 37°C with 5% CO2.
For transfections, cells were plated at a density of 2 " 105/well in
six-well plates 1 day before transfection. Cells were transfected using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s protocol, and then incubated with complete medium for
24 h. Notch-1 siRNA was purchased from Santa Cruz (Santa Cruz
Biotechnology, Santa Cruz, CA). NICD, NICD-NES, and NICD-NLS
constructs were kindly provided by Dr. B. A. Osborne (University of
Massachusetts, Amherst, MA) (Shin et al., 2006).
Cortical Neuron Primary Cultures.Dissociated cell cultures of
neocortical fragments were established from 18-day Sprague-Dawley
rat or 16-day C57B/6 mouse embryos as described previously (Okun
et al., 2007). Cells were plated in 35- or 60-mm diameter plastic
dishes and maintained at 37°C in neurobasal medium containing 25
mM glucose and B-27 supplements (Invitrogen), 2 mM L-glutamine,
0.001% gentamicin sulfate, and 1 mM HEPES, pH 7.2. Approxi-
mately 95% of the cells in such cultures were neurons, and the
remaining cells were astrocytes. Sodium cyanide was purchased
from Sigma-Aldrich (St. Louis, MO) and was prepared as a 100"
stock in culture medium.
Cytosol and Nuclear Extract Preparation.Mouse brain tissue
pellets were suspended in 1.5 ml of buffer A (10 mM Hepes, pH 7.9,
1.5 mM MgCl2, 10 mM KCl, and 1 mM EDTA) supplemented with 1
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 0.5 #g/ml
leupeptin, 1 #M pepstatin, and 0.05% Nonidet P-40, and left on ice
for 10 min. The nuclei were separated from the cytosol fraction by
centrifugation at 4°C at 3000 rpm for 10 min. Supernatants were
collected as cytosolic protein extracts. To prepare nuclear extracts,
the pellets were resuspended in 1.2 ml of buffer B (20 mMHepes, pH
7.9, 1.5 mM MgCl2, 420 mM KCl, 25% glycerol, and 0.2 mM EDTA)
supplemented with 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, 0.5 #g/ml leupeptin, and 1 #M pepstatin, homogenized and
left on ice for 30 min. Samples were centrifuged at 14,000 rpm for 20
min at 4°C. The supernatant, containing nuclear proteins, was trans-
ferred to a microcentrifuge tube. The supernatant (10 #l) was used
for a Bradford assay and the remainder was stored at #80°C.
Luciferase Assay. SH-SY5Y cells were plated at a density of 2 "
105/well in 12-well dishes and transiently transfected with 50 ng of
pRL-TK, 200 ng of NF-"B-Luc, 400 ng of Myc NICD, and control
pcDNA3.0 using linear polyethylenimine (Polysciences Inc., War-
rington, PA). pRL-TK transfection was used for normalization of
transfection efficiency. Transfected cells were treated with
BAPTA/AM (Calbiochem, San Diego, CA) or $-cyano-(3,4-dihy-
droxy)-N-benzylcinnamide (AG490) (A.G. Scientific, Inc., San
Diego, CA) for 12 h or kept as control. Twenty-four hours after
transfection, cells were harvested in passive lysis buffer. NF-"B
luciferase assay performed using dual-luciferase reporter assay
system (Promega, Madison, WI). Luciferase activity was mea-
sured in a FB12 luminometer (Berthold detection systems;
Berthold Technologies, Bad Wildbad, Germany).
Glucose Deprivation. For glucose deprivation (GD), glucose-free
Locke’s buffer containing 154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2,
1 mM MgCl2, 3.6 mM NaHCO3, and 5 mM HEPES, pH 7.2, supple-
mented with gentamicin (5 mg/l) was used. For glucose-deprived
experiments, the cultured neurons were incubated with glucose-free
Locke’s buffer for 3, 12, 18, or 24 h. We have selected the GD model
rather than oxygen and glucose deprivation to induce slow cell death
through apoptotic mechanisms.
Western Blot Analysis. Protein samples were subjected to 10%
SDS-polyacrylamide gel electrophoresis using a Tris-glycine running
buffer. Gels were then electroblotted using a semidry transfer appa-
ratus (Bio-Rad Laboratories, Hercules, CA) in transfer buffer con-
taining 0.025 M Tris base, 0.15 M glycine, and 10% (v/v) methanol for
1.5 h at 15 V onto a nitrocellulose membrane (Bio-Rad Laboratories).
The membranes were then incubated in blocking buffer (5% nonfat
milk in 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, and 0.2% Tween 20)
for 1 h at 23°C. The membrane was then incubated overnight at 4°C
with a primary antibody. After washing three times (5 min per wash)
with Tris-buffered saline-T (20 mM Tris-HCl, pH 7.5, 137 mM NaCl,
24 Arumugam et al.
 at UQ Library on July 12, 2011
m
olpharm
.aspetjournals.org
Downloaded from
 
and 0.2% Tween 20), the membrane was incubated with a horserad-
ish peroxidase-conjugated secondary antibody. After washing five
times (5 min per wash) with Tris-buffered saline, the membrane was
incubated with chemiluminescent substrate for enhanced chemilu-
minescence (Pierce Endogen, Rockford, IL) for 5 min, and chemilu-
minescent signals were visualized by exposing the membrane to
X-ray film (Kodak X-ray film; InterScience, Markham, ON, Canada).
Cell Viability Assay. Cell viability was determined by the trypan
blue exclusion assay. For the transfected cells, cell viability was
determined based on the morphology of GFP-positive cells under a
fluorescence microscope.
Middle Cerebral Artery Occlusion and Reperfusion. Three-
month-old C57BL/6 male mice were used for in vivo experiments.
The focal cerebral ischemia/reperfusion model was similar to that
described previously (Arumugam et al., 2004). In brief, the mice were
anesthetized with isoflurane, a midline incision was made in the
neck, and the left external carotid and pterygopalatine arteries were
isolated and ligated with 5–0 silk thread. The internal carotid artery
(ICA) was occluded at the peripheral site of the bifurcation of the ICA
and the pterygopalatine artery with a small clip, and the common
carotid artery was ligated with 5–0 silk thread. The external carotid
artery (ECA) was cut, and a 6–0 nylon monofilament with a tip that
was blunted (0.2–0.22 mm) using a coagulator was inserted into the
ECA. After the clip at the ICA was removed, the nylon thread was
advanced into the middle cerebral artery until light resistance was
felt. The nylon thread and the common carotid artery ligature were
removed after 1 h of occlusion to initiate reperfusion. In the sham
group, these arteries were visualized but not disturbed. Mice were
administered either 1 mg/kg compound E or vehicle (dimethyl sul-
foxide) by infusion into the femoral vein (20 !l) 15 min before the
start of surgery, which was approximately 30 min before the onset of
ischemia or immediately after the ischemic period. Cerebral blood
flow was measured by placing the animal’s head in a fixed frame
after it had been anesthetized and prepared for surgery. A craniot-
omy was performed to access the left middle cerebral artery and was
extended to allow positioning of a 0.5-mm Doppler probe (Moor LAB;
Moor Instruments, Wilmington, DE) over the underlying parietal
cortex approximately 1 mm posterior to bregma and 1 mm lateral to
the midline. Laser-Doppler recordings are expressed as percentages
of the preischemic baseline and were averaged over 30-min periods
during 1 h of ischemia and 0, 30, 90, 120, and 180 and min of
postischemic reperfusion. The University of Queensland Animal
Care and Use Committee approved these procedures.
Neurological Assessment. The functional consequences of focal
cerebral ischemia and reperfusion injury were evaluated using a
five-point neurological deficit score (0, no deficit; 1, failure to extend
right paw; 2, circling to the right; 3, falling to the right; and 4, unable
to walk spontaneously) and were assessed in a blinded fashion, as
described previously (Bederson et al., 1986).
Quantification of Cerebral Infarction. At 72 h of reperfusion,
the mice were euthanized with a lethal dose of isoflurane. The brains
were immediately removed and placed into phosphate-buffered sa-
line (4°C) for 15 min, and 2-mm coronal sections were cut with a
tissue cutter. The brain sections were stained with 2% 2,3,5-triphe-
nyltetrazolium chloride in phosphate buffer at 37°C for 15 min.
The stained sections were photographed, and the digitized images
were used for analysis. The borders of the infarct in each brain
slice were outlined and the area quantified using NIH Image 6.1
software (http://rsb.info.nih.gov/nih-image/). To correct for brain
swelling, the infarct area was determined by subtracting the area
of undamaged tissue in the left hemisphere from that of the intact
contralateral hemisphere. Infarct volume was calculated by inte-
gration of infarct areas for all slices of each brain in a blinded
manner, and was expressed as a percentage of the ipsilateral
hemisphere.
Data Analysis. All of the results are reported as the means !
S.D. The overall significance of the data was examined by one-way
analysis of variance. The differences between the groups were con-
sidered significant at P " 0.05 with the appropriate Bonferroni
correction made for multiple comparisons. Neurological behavior
scores were analyzed by using a nonparametric Kruskal-Wallis test
and Dunn’s multiple comparison test.
Results
Modulation of CalciumOverload-TriggeredCell Death
by Notch. Calcium overload in response to ischemic injury is
known to trigger cell death by activating various proteases
including caspases and calpains and by triggering other cata-
bolic processes mediated by lipases and nucleases. To evaluate
the role of Notch in calcium overload-triggered cell death, we
used RNA interference to specifically knockdown endogenous
Notch-1 (Fig. 1A) and gene transfection approaches to overex-
press the NICD (Fig. 1B) in human neuroblastoma cells (SH-
SY5Y). To induce calcium overload, the calcium ionophore, cal-
cimycin (A23187), was added after 12 h to cells transfected with
either Notch-1 siRNA or control siRNA. A23187-induced SH-
SY5Y cell death was significantly reduced in cells transfected
with Notch-1 siRNA compared with control siRNA (Fig. 1C).
Next, we examined whether the Notch pathway contributes to
GD or sodium cyanide (NaCN)-induced cell death, which is
known to involve calcium overload as the result of cellular
energy depletion. Both GD and NaCN-induced cell death were
significantly reduced in cultures transfected with Notch-1
siRNA compared with the control siRNA group (Fig. 1D). On
the other hand, ectopic NICD expression, which was sufficient
to induce cell death (Fig. 1E), further enhanced A23187-trig-
gered cell death (Fig. 1F).
Modulation of Cell Death by NICD Overexpression
and Its Localization. NICD migrates into the nucleus and
associates with a transcription factor, RBP-Jk, which in turn
up-regulates the expression of various Notch effector target
genes. To test whether Notch-mediated cell death is corre-
lated with nuclear translocation of NICD, we used two mod-
ified GFP-NICD constructs (Fig. 2A). Specifically, GFP-
NICD was modified by inclusion of either an additional
nuclear export signal to increase cytosol levels (NICD-NES)
or an additional nuclear localization signal to increase its
nuclear retention (NICD-NLS) (Shin et al., 2006). SH-SY5Y
cells were transfected with either NICD-NLS or NICD-NES,
and fluorescence imaging was used to confirm their subcel-
lular localization (Fig. 2B). We observed that transfection
with either NICD, NICD-NLS, or NICD-NES resulted in
significantly increased cell death compared with vector
transfected group (Fig. 2C). Cell death was substantially
potentiated in the NICD-NES transfected group compared
with the NICD and NICD-NLS groups (Fig. 2C). These re-
sults demonstrate that cytosol-localized NICD can trigger
cell death cascades that may be independent of the expres-
sion of Notch effector target genes.
Effects of a Calcium Chelator, Pan Caspase Inhibi-
tor, and JAK Inhibitor on NICD-Mediated Cell Death.
Because Notch modulation can influence calcium overload-
triggered cell death, we next investigated the relationship
between calcium signaling and caspase activation in NICD
overexpression-induced cell death. SH-SY5Y cells were
transfected with NICD, NICD-NLS, or NICD-NES and then
treated with 10 !M BAPTA/AM (a cell-permeable calcium
chelator) or 10 !M Z-VAD (a pan caspase inhibitor) 2 h after
transfection (Fig. 3, A and B). As demonstrated previously
Proapoptotic Role for Notch in Ischemic Stroke 25
 at UQ Library on July 12, 2011
m
olpharm
.aspetjournals.org
Downloaded from
 
(Fig. 2C), cell death was enhanced by overexpression of
NICD, NICD-NLS, or NICD-NES 24 h after transfection.
Treatments with BAPTA/AM (Fig. 3C) or Z-VAD signifi-
cantly ameliorated cell death induced by NICD. Key players
in the intracellular response to ischemic stroke are kinase
pathways that induce alterations in the pattern of gene tran-
scription (Planas et al., 2006). To examine the contribution of
kinases to Notch-induced cell death, we tested the effects of
several kinase inhibitors (data not shown). Among them, the
JAK inhibitor (AG490) was effective against NICD-induced
cell death. Two hours after transfection of NICD, NICD-NLS,
or NICD-NES, SH-SY5Y cells were treated with 10 !M
AG490, and cell death was assessed 24 h later. NICD-in-
duced cell death was significantly reduced by AG490 treat-
ment in NICD and NICD-NLS transfected groups, but inter-
estingly it had no effect in the NICD-NES transfected group,
in which cytosolic NICD retention was enhanced (Fig. 3D).
This may suggest that JAK signaling is essential for cell
death potentiation by NICD in the nucleus but not in the
cytosol. Furthermore, we have performed NF-"B luciferase
reporter assay to test whether NICD-induced NF-"B activity
was blocked by the calcium chelator BAPTA/AM (5 !M) and
the JAK2 inhibitor AG490 (5 !M). Our data indicate that
both BAPTA/AM and AG490 significantly reduced the NICD-
induced NF-"B activity (Fig. 3E).
Involvement of !-Secretase in Cell Death Induced by
Ischemia-Like Conditions.We next investigated the effect
of a #-secretase inhibitor against ischemic stroke-like cell
Fig. 1. Modulation of cell death by Notch-1. Knockdown of endogenous Notch-1 using Notch-1 siRNA (A), and overexpression of NICD in human
neuroblastoma cells (SH-SY5Y) (B). C, A23187, a calcium ionophore, induced SH-SY5Y cell death and was significantly reduced in cells transfected
with Notch-1 siRNA compared with control siRNA. !!, P ! 0.01 compared with the control siRNA group; #, P ! 0.05 compared with the control siRNA
group. D, GD or NaCN-induced cell death was significantly reduced in cultures transfected with Notch-1 siRNA compared with the control siRNA
group. !!, P ! 0.001 compared with the control siRNA group; ###, P ! 0.05 compared with the control siRNA group. E, NICD transfection itself
significantly increased cell death after 24 h compared with vector-transfected cells. !!, P ! 0.01 compared with the vector group. F, A23187-induced
calcium-mediated cell death was significantly increased when NICD was overexpressed in human neuroblastoma cells. !!!, P ! 0.001 compared with
the vector group.
Fig. 2. Modulation of cell death by NICD
localization. A, schematic diagram shows
that GFP-NICD was modified by inclu-
sion of either an additional nuclear export
signal to increase cytosol levels (NICD-
NES) or an additional nuclear localization
signal to increase its nuclear retention
(NICD-NLS). B, representative immuno-
fluorescence shows that the GFP-NICD,
NICD-NLS, or NICD-NES expression vec-
tors were transfected into SH-SY5Y cells.
C, transfection with NICD, NICD-NLS, or
NICD-NES resulted in significantly in-
creased cell death compared with vector-
transfected group. !!, P ! 0.001 compared
with the vector group.
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death in vitro using both SH-SY5Y and primary neuronal
cells. We subjected SH-SH5Y cells to GD in the presence of a
!-secretase inhibitor, either DAPT or compound E. GD-in-
duced cell death was significantly reduced by either DAPT or
compound E (Fig. 4A). Because we showed previously that
DAPT reduced GD-induced primary neuronal cell death, here
we only show the effect of compound E (Arumugam et al.,
2006). Similar to SH-SY5Y cells, compound E also signifi-
cantly reduced GD-induced cell death in primary cortical
neurons (Fig. 4B). Next, we have performed immunocyto-
chemistry analysis of NICD in primary neuronal cells after
GD. NICD translocation into cytoplasm and nucleus was
observed after GD in primary neurons (Fig. 4C). Further-
more, we investigated how the !-secretase inhibitor protects
against neuronal cell death under GD conditions. GD re-
sulted in increased levels of an apoptotic protease cleaved
caspase-3, NF"B (phospho-p65 and phospho-p50), and a pro-
death BH3-only protein, Bim (Fig. 4D). Treatment with the
!-secretase inhibitor reduced levels of cleaved caspase-3,
p-p65, p-p50, and Bim (Fig. 4, D–F). Furthermore, to test
whether NF-"B activation is directly linked to GD-mediated
apoptosis via Bim, we treated neurons with an NF-"B inhib-
itor (7-methoxy-5,11,12-trihydroxycoumestan, 1 #M; Sigma-
Aldrich). The NF-"B inhibitor reduced expression levels of
both cleaved caspase-3 and Bim after 12 and 24 h of GD. In
addition, we observed that at 24 h, the level of apoptosis-
inducing factor induced by GD was attenuated by the NF-"B
inhibitor (Fig. 4G).
!-Secretase Inhibitor Treatment In Vivo Protects
against Neurological Deficit and Infarct Development
after Ischemic Stroke.We have shown previously that the
!-secretase inhibitors DAPT and DBZ reduce brain damage
and neurological deficits measured 3 days after cerebral isch-
emia reperfusion. The cerebral blood flow measurements ob-
tained immediately before and after middle cerebral artery
occlusion showed !90% reduction in blood flow to the middle
cerebral artery occlusion infarct region, which did not differ
between groups. To test whether a !-secretase inhibitor
might protect against stroke-induced brain injury by similar
mechanisms as those observed in vitro (see Fig. 4), we used
the !-secretase inhibitor compound E, which has not been
tested previously in a model of stroke. Treatment with
compound E by intravenous infusion 30 min before or
immediately after ischemia resulted in reduced brain dam-
age (Fig. 5A) and improved functional outcome (Fig. 5B).
Nonparametric Kruskal-Wallis test and Dunn’s multiple
comparison test show that the group treated with com-
pound E was not significantly different from the sham
group before or after treatment. However, only the vehicle-
treated group showed a significant increase in neurological
deficit score compared with sham animals. Our data
clearly show that the compound E-treated groups had a
reduced neurological deficit score. Next, we analyzed the
protein levels of NICD and Bim in the ipsilateral brain
region after 1, 3, or 24 h of reperfusion (Fig. 5C). As
expected, we found that both NICD and Bim were elevated
in the brain after ischemic stroke (Fig. 5C). Next, we
measured the levels of NICD, p-p65 and Bim to assess
whether compound E might protect against ischemic
stroke-induced brain injury by affecting these proteins
(Fig. 5D). Our data confirmed that levels of NICD, p-p65
and Bim were all significantly reduced in the compound
E-treated group compared with the vehicle-treated group
(Fig. 5, D–G).
Fig. 3. Effect of a calcium chelator,
caspase inhibitor, and kinase inhibitor
against NICD-mediated cell death. A and
B, NICD, NICD-NLS, or NICD-NES-
transfected SH-SY5Y cells treated with
BAPTA/AM or Z-VAD. C, NICD, NICD-
NLS, or NICD-NES-induced cell death
was significantly reduced by treatment of
BAPTA/AM or Z-VAD. !!, P " 0.001 com-
pared with the vector group; ##, P "
0.05 compared with the NICD vehicle
group; ##, P " 0.05 compared with the
NICD-NLS vehicle group; $$, P " 0.01
compared with the NICD-NES vehicle
group. D, JAK inhibitor (AG490) was sig-
nificantly reduced NICD- or NICD-NLS-
induced cell death. Increased activity of
NF-"B by NICD was decreased by
BAPTA/AM and AG490. !, P " 0.01 com-
pared with the vector group; !!, P" 0.001
compared with the vector group; ##, P "
0.01 compared with the NICD vehicle
group; ##, P " 0.01 compared with the
NICD-NLS vehicle group. E, NF-"B lu-
ciferase reporter (200 ng) plasmid and
pRL-TK (50 ng) plasmid of an internal
control were transiently transfected with
NICD (400 ng) or empty control (400 ng)
into SH-SY5Y cells. Transfected cells
were treated with the calcium chelator,
BAPTA/AM (5 #M) and JAK2 inhibitor
AG490 (5 #M) for 12 h. Cells were har-
vested for dual luciferase assay after 12 h
exposure to BAPTA/AM, AG490, or the
vehicle (dimethyl sulfoxide). !!!, P "
0.0001 compared with the control value.
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Discussion
A major finding of this study is that Notch signaling en-
dangers neurons after ischemic stroke by modulating the
NF-!B, pro-death protein Bim, calcium signaling, and
caspase pathways, and that this neuronal damage can be
inhibited in vitro and in vivo by treatment with a "-secretase
inhibitor. We have shown previously that activity of "-secre-
tase and subsequent Notch activation are elevated after isch-
emic stroke (Arumugam et al., 2006). Furthermore, "-secre-
tase activity was elevated in cultured cortical neurons after
ischemic conditions, and "-secretase-mediated Notch signal-
ing endangers neurons in ischemic stroke by increasing their
vulnerability to apoptosis and by activating microglial cells
and stimulating the infiltration of proinflammatory leuko-
cytes (Arumugam et al., 2006). Thus, intravenous treatment
with "-secretase inhibitors DAPT or DBZ improved func-
tional outcome and reduced brain damage (Arumugam et al.,
2006). Thus, here we have further investigated the mecha-
nisms by which Notch mediates cell death after ischemic
stroke.
Ca2! is a major intracellular messenger that mediates
many physiological responses in neurons (Foster, 2007).
Studies of animal and cell culture models have clearly dem-
onstrated that neuronal Ca2! overload is pivotal to the death
of neurons after ischemic stroke (Broughton et al., 2009).
Ca2! induces oxidative stress through several different
mechanisms. These include activation of oxygenases, pertur-
bation of mitochondrial Ca2! and energy metabolism, and
induction of membrane-associated oxidative stress. Ca2!
overload also triggers apoptosis, a form of programmed cell
death (Mattson et al., 2001; Berna-Erro et al., 2009;
Broughton et al., 2009). This might occur by Ca2!-media-
ted activation of proapoptotic proteins such as Bax, Par-4,
and p53, leading to mitochondrial membrane-permeability
changes, release of cytochrome c, and caspase activation
(Mattson et al., 2000). There is much evidence to suggest that
"-secretase is also involved in the regulation of cellular Ca2!
homeostasis. Mutations in the "-secretase subunit presenilin
perturb endoplasmic reticulum Ca2! homeostasis such that
greater amounts of Ca2! are released upon stimulation, pos-
sibly as a result of alterations in inositol 1,4,5-trisphosphate,
Fig. 4. "-Secretase inhibitor protects against ischemic neuronal cell death. A, GD-induced SH-SY5Y cell death was significantly reduced by either
DAPT or compound E. !!, P " 0.01 compared with the GD group. B, compound E significantly reduced GD-induced cell death in primary cortical
neurons. !!, P " 0.01 compared with the GD group. C, NICD translocation into cytoplasm and nucleus following GD in primary neurons. D, E, and
F, treatment with the "-secretase inhibitor significantly reduced levels of cleaved caspase-3, p-p65, p-p50, and Bim in primary neurons after 12 h GD
condition. !!!, P " 0.05 compared with the GD group; n # 6 in each group. G, the NF-!B inhibitor, 7-methoxy-5,11,12-trihydroxycoumestan, reduced
expression levels of both cleaved caspase-3 and Bim after 12 and 24 h of GD. The level of apoptosis-inducing factor was also attenuated by the NF-!B
inhibitor at 24 h after GD.
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ryanodine receptor channels, calcium-ATPases, and the en-
doplasmic reticulum stress protein Herp (LaFerla, 2002;
Smith et al., 2005; Tu et al., 2006).
These observations implicate the involvement of !-secre-
tase-mediated Notch signaling in neuronal cell death under
the conditions of overloaded intracellular Ca2! after isch-
emia. To directly determine whether !-secretase-mediated
Notch signaling is involved in Ca2!-induced cell death, we
have examined the effect of !-secretase inhibitors on Ca2!-
triggered cell death in B103 rat neuroblastoma cells (Choi et
al., 2010). However, the role of Notch signaling in Ca2!-
mediated neuronal cell death after ischemic stroke is still
poorly understood. Using siRNA to target Notch-1, and NICD
transfection to increase Notch signaling, here we found evi-
dence for an effect of Notch in Ca2!-triggered cell death of
cultured human neuroblastoma cells. Furthermore, we
showed that cell death induced by ischemic stroke-like con-
ditions (i.e., chemical hypoxia and GD) is significantly re-
duced in Notch-1-depleted cells. These conclusions regarding
the role of Notch in Ca2!-triggered cell death were strength-
ened by the observation of reduced death of NICD-trans-
fected cells in the presence of BAPTA/AM.
To investigate the mechanisms by which NICD induces cell
death, we next studied whether NICD localization in the
cytosol or its translocation to the nucleus was related to
NICD-induced cell death. Both cytosol and nucleus localiza-
tion of NICD caused significant cell death, but NICD local-
ized in cytosol further potentiated the cell death. Cell death
induced by NICD transfection was significantly reduced by
either the pan caspase inhibitor Z-VAD or the selective che-
lator of intracellular Ca2! stores BAPTA/AM. These results
suggest that NICD overexpression leads to calcium-induced
cell caspase-mediated apoptosis. However, treatment with a
JAK inhibitor only blocked NICD-induced cell death in nu-
clear NICD overexpressed cells, whereas it had no effect in
the cytosol-transfected NICD group. This result suggests
that cytosolic NICD-induced cell death occurs independently
of JAK transcription.
Several studies have provided evidence for the activation of
NF-"B in neurons, glial, and endothelial cells during isch-
emic stroke (Gabriel et al., 1999; Stephenson et al., 2000;
Nurmi et al., 2004; Tang et al., 2007). The activation of
NF-"B is mainly controlled at the post-transcriptional level
by complex formation with the inhibitory subunit I"B in the
cytoplasm. Activating stimuli (e.g., tumor necrosis factor)
activate the I"B kinase leading to phosphorylation of the
inhibitory subunit, which is then ubiquitinylated and de-
graded by the proteasome (Wallach et al., 2002). This trig-
Fig. 5. !-Secretase inhibitor treatment in vivo. Treatment
with compound E by intravenous infusion 30 min before
the onset of ischemia or immediately after ischemia re-
sulted in reduced brain damage (A) and reduced neurolog-
ical deficit (B). !!!, P " 0.05 compared with the vehicle
treated group; n # 6 to 14 in each group. Nonparametric
Kruskal-Wallis test and Dunn’s multiple comparison test
shows that the group treated with compound E was not
significantly different from the sham group before or after
treatment. Neurological data are shown as grouped with
mean only values. C, the protein levels of NICD and Bim in
the ipsilateral brain region were increased after 3 or 24 h of
reperfusion. D, E, F, and G, the protein levels of NICD and
Bim were significantly reduced in the compound E-treated
group compared with the vehicle-treated group. !!, P " 0.05
compared with the vehicle-treated group; !!!, P " 0.01 com-
pared with the vehicle treated group; n# 6 to 8 in each group.
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gers liberation and translocation of the NF-!B complex into
the nucleus, in which it initiates transcription by binding to
regulatory DNA sequences. "-Secretase-mediated Notch sig-
naling is required to sustain NF-!B activity and cytokine
production in peripheral T cells because inhibition of Notch
by "-secretase inhibitors attenuates the translocation of
NF-!B to the nucleus and down-regulates its activity (Shin et
al., 2006). "-Secretase-mediated Notch signaling can also
enhance NF-!B activation by increasing the expression of
components of the active NF-!B signaling complex (Oswald
et al., 1998). Notch signaling may also increase NF-!B activ-
ity by binding to and enhancing the nuclear distribution of
the active NF-!B signaling complex (Shin et al., 2006). We
have found that Notch is activated in cultured neurons sub-
jected to ischemia-like conditions, as demonstrated by an
increase in levels of NICD—the active component of Notch
signaling, during GD.
Furthermore, our studies have found that "-secretase inhib-
itor treatment reduces GD-induced NF-!B-p65 and NF-!B-p50
levels in neurons. To date, only a few NF-!B-regulated genes
have been identified to be involved in neuronal cell death.
NF-!B has been shown to have a significant association with
the pro-death BH3-only protein, Bim, in mediating apoptosis
after ischemic stroke (Okuno et al., 2004). Recent evidence
implies that Bim is essential for proapoptotic Bax and Bak
activation (Okuno et al., 2004). Bim targets the BH3 domain of
Bax, causing its conformational change, which leads to its oli-
gomerization and integration into the outer mitochondrial
membrane, and the formation of channels for release of cyto-
chrome c and othermitochondrial apoptogenic factors (Donovan
and Cotter, 2002), which in turn lead to apoptosis. Our data
show that a "-secretase inhibitor not only reduces p65 and p50,
but also Bim, in vitro and in vivo after conditions of ischemic
stroke. We have further confirmed that inhibition of NF-!B
activity in ischemic conditions in neurons reduces the level of
Bim, which further supports the conclusion that "-secretase-
mediated Notch signaling induces neuronal cell death via NF-
!B-Bim pathway.
We have shown previously that after 3 days, the degree of
brain damage and neurological deficit resulting from cerebral
ischemia-reperfusion is reduced in mice transgenic for anti-
sense Notch compared with nontransgenic mice (Arumugam
et al., 2006). Here, we report similar results obtained using
another potent "-secretase inhibitor, compound E. Notably,
compound E was effective in reducing infarct volume and
improving functional outcome when administered 30 min
before the onset of ischemia or immediately after the isch-
emic period. It was shown previously that compound E
crosses the blood-brain barrier and inhibits cortical "-secre-
tase activity, determined ex vivo using the recombinant sub-
strate (Grimwood et al., 2005). Our in vivo data also confirm
the neuroprotective mechanisms of compound E observed in
vitro in that levels of NICD, p65, and Bim were reduced in
compound E-treated animals compared with vehicle-treated
control animals. Our findings suggest that agents that target
"-secretase and Notch signaling pathway may prove effective
in reducing neuronal cell death and brain injury after isch-
emic stroke.
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Recent findings suggest that Notch-1 signaling contributes to neuronal death in ischemic stroke, but the
underlying mechanisms are unknown. Hypoxia inducible factor-1α (HIF-1α), a global regulator of cellular
responses to hypoxia, can interact with Notch and modulate its signaling during hypoxic stress. Here we show
that Notch signaling interacts with the HIF-1α pathway in the process of ischemic neuronal death. We found
that a chemical inhibitor of the Notch-activating enzyme, γ-secretase, and a HIF-1α inhibitor, protect cultured
cortical neurons against ischemic stress, and combined inhibition of Notch-1 and HIF-1α further decreased
neuronal death. HIF-1α and Notch intracellular domain (NICD) are co-expressed in the neuronal nucleus, and
co-immunoprecipitated in cultured neurons and in brain tissue from mice subjected to focal ischemic stroke.
Overexpression of NICD and HIF-1α in cultured human neural cells enhanced cell death under ischemia-like
conditions, and a HIF-1α inhibitor rescued the cells. RNA interference-mediated depletion of endogenous
NICD and HIF-1α also decreased cell death under ischemia-like conditions. Finally, mice treated with inhibitors
of γ-secretase and HIF-1α exhibited improved outcome after focal ischemic stroke, with combined treatment
being superior to individual treatments. Additional findings suggest that the NICD and HIF-1α collaborate to
engage pro-inflammatory and apoptotic signaling pathways in stroke.
© 2013 Elsevier Inc. All rights reserved.
Introduction
Aging is a major risk factor for stroke, a leading cause of morbidity
and death worldwide (Mukherjee and Patil, 2011). The cellular and
molecular mechanisms responsible for the degeneration and death of
neurons affected in stroke are poorly understood, but involve oxidative
stress, a neuronal energy deficit, inflammation and a form of pro-
grammed cell death called apoptosis (Broughton et al., 2009; Hou and
MacManus, 2002; Sims and Muyderman, 2010 for review). Notch-1
(Notch) signaling plays a crucial role in all phases of brain development;
it regulates the proliferation and differentiation of neural stem cells, and
influences cell survival and synaptic plasticity. In addition, there is
increasing evidence that Notch pathways are important in neuro-
pathological events including inflammatory central nervous system
(CNS) disease, brain and spinal cord trauma, and ischemic stroke
(Arumugam et al., 2006, 2011; Dias et al., 2012; Park et al., 2013; Wei
et al., 2011; Yuan and Yu, 2010). We previously reported that activity
of γ-secretase, and resulting Notch activation, is elevated in cultured
primary cortical neurons subjected to ischemia-like conditions
consisting of 3–6 h of oxygen and glucose deprivation (OGD)
(Arumugam et al., 2006). We also found that γ-secretase activity is
elevated in ischemic brain tissue in a mouse model of focal ischemic
stroke (Arumugam et al., 2006). It was also shown that Notch signaling
may interact with hypoxia inducible factor-1 (HIF-1) to contribute to
injury outcome following hypoxic conditions (Zheng et al., 2008).
Hypoxia inducible factor-1 (HIF-1) is a transcription factor re-
sponsible for cellular and tissue adaptation to low oxygen tension.
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HIF-1 is a heterodimer consisting of a constitutively expressedβ subunit
and an oxygen-regulated α subunit, which primarily determines HIF-1
activation, and regulates a series of genes that participate in angio-
genesis, iron and glucose metabolism and cell proliferation and survival
(Shi, 2009; Singh et al., 2012). HIF-1 responds to reduced oxygen levels
in the brain after cerebral ischemia. Systemic hypoxia rapidly increases
the nuclear content of HIF-1α in mouse brains (Bernaudin et al., 2002;
Stroka et al., 2001). Furthermore, HIF-1α expression is induced in the
brain following focal ischemia (Bergeron et al., 1999), with HIF-1α
levels diminishing gradually from the ischemic core to more distant
regions (Demougeot et al., 2004). Both neuroprotective and detrimental
effects of HIF-1 have been reported in experimental models of ischemic
stroke (Baranova et al., 2007; Chen et al., 2007; Helton et al., 2005; Shi,
2009; Xin et al., 2011), including in neuron-specific HIF-1α deficient
mice. One study reported that neuron-specific knockdown of HIF-1α
resulted in increased tissue damage and reduced survival rate following
middle cerebral artery occlusion (MCAO), suggesting a neuroprotective
effect of HIF-1α (Baranova et al., 2007). In contrast, in other studies
inhibition or deletion of HIF-1α resulted in reduced damage following
ischemic stroke or hypoxic conditions, indicating a detrimental effect
of HIF-1α (Chen et al., 2009; Helton et al., 2005). Other studies have
shown HIF-1α to play a role in hypoxic preconditioning, a process in
which mild stress prior to a stroke is neuroprotective (Liu et al., 2005).
Taken together, these observations might suggest the possibility that
HIF-1α can induce cell death in severe and protracted ischemia, but
promote cell survival when activated prior to stroke and during mild
ischemic stress. Another recent study provided a mechanistic paradigm
for HIF-1α and Notch interaction in Drosophila that may also be present
in mammals, involving a ligand-independent mechanism for hemocyte
survival during both normal development andhypoxic stress (Mukherjee
et al., 2011). Furthermore, recent evidence showed that HIF-1α-induced
activation of the Notch pathway is essential for hypoxia-mediated
maintenance of glioblastoma stem cells (Qiang et al., 2012). Whether
the interaction between Notch and HIF-1α by ischemia leads to
neuronal cell death or survival and attendant transcriptional
activity is unknown. In the present study we provide evidence
that Notch and HIF-1α collaborate in the activation of apoptotic,
pro-inflammatory, and neurodegenerative pathways during brain
injury following ischemia–reperfusion.
Material and methods
Primary cortical neuronal cultures
Dissociated cell cultures of mouse cortex were established from day
16 C57BL/6Jmouse embryos, as previously described (Okun et al., 2007).
Cells were plated in 35, 60 or 100-mm diameter polyethylenimine-
coated plastic dishes and maintained at 37 °C in Neurobasal medium
containing 25mM of glucose and B-27 supplement (Invitrogen), 2mM
L-glutamine, 0.001% gentamycin sulfate and 1 mM HEPES (pH 7.2).
Approximately 95% of the cells in such cultures were neurons and the
remaining cells were astrocytes.
Pharmaceuticals
γ-Secretase inhibitor XXI (Compound E)was purchased fromMerck
Calbiochem (565790), HIF-1α inhibitor 2ME2 was purchased from
Sigma-Aldrich (M6383), and HIF-1α stabilizer (DMOG) was purchased
from Sigma-Aldrich (D3695). Primary neuronal cultureswere subjected
to glucose deprivation or oxygen and glucose deprivation at 7days after
plating, together with pharmaceutical treatment at the stated
concentrations. For NICD and/or HIF-1α-transfected SY5Y cultures,
OGD experiments were conducted 24h after transfection, accompanied
by the treatment with 2ME2.
Glucose deprivation and oxygen glucose deprivation
For glucose deprivation (GD), glucose-free Locke's buffer containing
(in mmol/L) 154 NaCl, 5.6 KCl, 2.3 CaCl2, 1 MgCl2, 3.6 NaHCO3, 5 HEPES
(pH 7.2) and 5 mg/L gentamycin was used. For GD, cultured neurons
were incubated with glucose-free Locke's buffer for 6, 12 or 24 h. For
combined oxygen and glucose deprivation, neurons were incubated in
GD medium in an oxygen-free chamber for 1, 3 and 8h.
Western blot analysis
Protein samples were subjected to sodium dodecyl sulfate-poly-
acrylamide (10%) gel electrophoresis using a Tris-glycine running
buffer. Gels were then electro-blotted using a transfer apparatus
(Bio-Rad) in transfer buffer containing 0.025 mol/L Tris base,
0.15mol/L glycine, and 10% (v/v) methanol for 1.5 h at 15 V onto a
nitrocellulose membrane (Bio-Rad). The membrane was then
incubated in blocking buffer (5% non-fat milk in 20 mmol/L Tris–
HCl, pH 7.5, 137mmol/L NaCl, 0.2% Tween-20) for 1 h at 23 °C. The
membrane was then incubated overnight at 4 °C with primary anti-
bodies including those that selectively bind cleaved caspase-3 (Cell
Signaling), NICD (Abcam), HIF-1α (Novus Biologicals), phosphorylated
p65 (Ser536; Cell Signaling), Notch-1 (Santa Cruz), phospho JNK (Cell
Signaling), total JNK (Cell Signaling), and actin (Sigma). After washing
three times (5 min per wash) with Tris-buffered saline-T (20 mmol/L
Tris–HCl, pH 7.5, 137 mmol/L NaCl, 0.2% Tween-20), the membrane
was incubated with a horse radish peroxidase-conjugated secondary
antibody. After washing five times (5min per wash) with Tris-buffered
saline, the membrane was incubated with chemiluminescent substrate
for enhanced chemiluminescence (Pierce Endogen) for 5 min, and
chemiluminescent signals were visualized by exposing the membrane
to an X-ray film (Kodak X-ray film; InterScience).
Immunocytochemistry and immunohistochemistry
Coverslips containing cortical neurons subjected either to normal
Neurobasal medium or GD medium were fixed in 4% buffered
paraformaldehyde in phosphate-buffered saline (PBS; Sigma-Aldrich).
Fixed cells were permeabilized and incubated in blocking solution
(1% BSA and 0.1% Triton-X in PBS) at room temperature for 1 h before
overnight incubation at 4 °C with microtubule-associated protein 2
antibody (MAP2, mouse monoclonal, Millipore) along with either HIF-
1α (rabbit polyclonal, Santa Cruz), NICD (rabbit polyclonal, Abcam), or
p-p65 (Ser536; Cell signaling) diluted in blocking solution. Following
incubation in the primary antibody, the cells were incubated in the
appropriate Alexa Fluor-conjugated secondary antibodies (Invitrogen)
for 1h at room temperature. Following secondary antibody incubation,
coverslips were sealed with Vectashield mounting solution (Vector) on
glass slides. For immunohistochemistry, frozen cryostat brain sections
were obtained from sham surgery and stroke mice, following trans-
cardiac perfusion with 4% paraformaldehyde and were immunostained
with antibodies against HIF-1α (mousemonoclonal, Novus Biologicals),
NICD (rabbit polyclonal, Abcam) and MAP2 (chicken monoclonal,
Abcam). Imaging was performed using confocal microscopy (LSM700,
Carl Zeiss, Göttingen, Germany) with a 100× oil immersion objective.
Single confocal images were converted to 512 × 512 pixel 12 bit TIFF
images.
Overexpression and siRNA experiments
SH-SY5Y (human neuroblastoma) cells were cultured in Dulbecco's
modified Eagle's medium including 10% fetal bovine serum sup-
plemented with 1% penicillin and streptomycin. These cells were
maintained at 37 °C in a 5% CO2 atmosphere. For transfections, cells
were plated at a density of 2 × 105/well in six-well plates 1 day
before transfection. Cells were transfected using Lipofectamine 2000
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(Invitrogen) according to the manufacturer's protocol, and then incu-
bated with complete medium for 24 h. NICD construct was kindly
provided by Dr. B. A. Osborne (University of Massachusetts; Shin et al.,
2006) and the FLAG-tagged full-length HIF-1α was constructed by
inserting a PCR-amplified full-length HIF-1α fragment into the KpnI/
BamHI site of p3XFLAG-7.1 (Sigma). For siRNA experiments, 5days old
primary cortical neurons were used and both Notch-1 siRNA and HIF-
1α siRNA were purchased from Santa Cruz.
Cell viability assays
Cell viabilitywas determined by the Trypan blue exclusion assay. For
the transfected SH-SY5Y cells, cell viability was determined based on
the morphology of GFP-positive cells under a fluorescence microscope.
Middle cerebral artery occlusion and reperfusion
Three-month-old C57BL/6J male mice were used for in vivo
experiments. The focal cerebral ischemia/reperfusionmodelwas similar
to that described previously (Arumugam et al., 2004). Briefly, the mice
were anesthetized with isoflurane, a midline incision was made in the
neck, and the left external carotid and pterygopalatine arteries were
isolated and ligated with 5–0 silk thread. The internal carotid artery
(ICA) was occluded at the peripheral site of the bifurcation of the ICA
and the pterygopalatine artery with a small clip, and the common
carotid artery (CCA) was ligated with 6–0 silk thread. The external
carotid artery (ECA) was cut, and a 6–0 nylon monofilament with a tip
that was blunted (0.2–0.22mm) using a coagulator was inserted into
the ECA. After the clip at the ICA was removed, the nylon thread was
advanced into the middle cerebral artery (MCA) until light resistance
was felt. The nylon thread and the CCA ligature were removed after
1 h of occlusion to initiate reperfusion. In the sham group, these
arteries were visualized but not disturbed. Mice were administered
either 1mg/kg compound E (Merck), 20mg/kg 2ME2 (Sigma-Aldrich)
or vehicle (DMSO) by infusion into the femoral vein (20 μL) im-
mediately after the ischemic period. Cerebral blood flowwas measured
by placing the animal's head in a fixed frame after it had been
anesthetized and prepared for surgery. A craniotomy was performed
to access the left middle cerebral artery and was extended to allow
positioning of a 0.5-mm Doppler probe (Moor LAB, Moor Instruments)
over the underlying parietal cortex approximately 1 mm posterior to
bregma and 1mm lateral to the midline. The University of Queensland
Animal Care and Use Committee approved these procedures.
Neurological assessment
The functional consequences of focal cerebral ischemia and reper-
fusion (I/R) injury were evaluated using a 5-point neurological deficit
score (0, no deficit; 1, failure to extend right paw; 2, circling to the
right; 3, falling to the right; and 4, unable to walk spontaneously) and
were assessed in a blinded fashion.
Quantification of cerebral infarction
Following 72 h of reperfusion, the mice were euthanized with a
lethal dose of isoflurane. The brains were immediately removed
and placed into PBS (4 °C) for 15 min, and 2-mm coronal sections
were cut with a tissue cutter. The brain sections were stained with 2%
2,3,5-triphenyltetrazolium chloride (TTC) in phosphate buffer at 37 °C
for 15min. The stained sections were photographed, and the digitized
images were used for analysis. The borders of the infarct in each brain
slice were outlined and the area quantified using NIH image 6.1
software (National Institutes of Health, USA). To correct for brain
swelling, the infarct area was determined by subtracting the area of
undamaged tissue in the left hemisphere from that of the intact
contralateral hemisphere. Infarct volume was calculated by integration
of infarct areas for all slices of each brain in a blinded manner, and
was expressed as a % of the ipsilateral hemisphere.
Data analysis
All the results are reported as the means ± S.E.M. The overall
significance of the data was examined by one-way analysis of variance
(ANOVA). The differences between the groups were considered signif-
icant at Pb0.05with the appropriate Bonferroni correctionmade formul-
tiple comparisons. Neurological behavior scoreswere analyzed by using a
nonparametric Kruskal–Wallis test andDunn'sMultiple Comparison Test.
Results
Inhibition of HIF-1α/and γ-secretase reduces neuronal death during
ischemia-like conditions
We first investigated the effects of the cell-permeable HIF-1α
inhibitor 2-methoxyestradiol (2ME2) which is a competitive in-
hibitor of HIF-1α prolyl hydroxylase (HIF-PH) (Chen et al., 2008),
and the HIF-1α inducer DMOG (Zhou et al., 2006), against ischemic
stroke-like cell death in mouse primary cortical neurons. We
subjected 7–10 days old cortical neurons to glucose deprivation
(GD) in the presence of 2ME2 or DMOG. GD-induced cell death
was attenuated by 2ME2 (5 μM) and increased by DMOG
(500 μM) (Fig. 1A). We previously showed that the γ-secretase inhib-
itors N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester (DAPT) and (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-
methyl-2-oxo-5-phenyl-2,3-dihydro-1H benzo[e][1,4]diazepin-3-yl)-
propionamide (Compound E; CE), decreased primary neuronal cell
death during GD, or combined oxygen and glucose deprivation (OGD)
(Arumugam et al., 2006, 2011). Here, CE (1 μM) also decreased death
of primary cortical neurons under both GD and OGD conditions
(Figs. 1B, C). Moreover, combined HIF-1α and γ-secretase inhibition
with 2ME2 and CE, respectively, provided enhanced protection against
cell death compared to either CE or 2ME2 alone following GD (Fig. 1B).
We next analyzed levels of cleaved caspase-3, the active form of an
apoptotic protease, following GD or OGD. Treatment with either 2ME2
or CE reduced cleaved caspase-3 levels compared to vehicle treatment
under either GD or OGD conditions (Figs. 1D, E, F, G). Furthermore,
combined 2ME2/CE treatment was more effective than either single
treatment in reducing cleaved caspase-3 during GD and OGD (Figs. 1D,
E, F, G). Both NICD and HIF-1α were elevated following OGD condition
and reduced by treatment with CE and 2ME2 (Fig. 1H).
HIF-1α and Notch-1 co-localize in the nucleus of neurons in response to
ischemia-like conditions
In order to investigate whether Notch-1 and HIF-1α cooperate in
promoting neuronal death in stroke, we first analyzed the expression
profiles of NICD and HIF-1α in primary cortical neurons under
ischemia-like conditions. Levels of both NICD and HIF-1α increased
after 6–24 h of GD and 1–8 h of OGD (Figs. 2A, B). NICD is believed to
migrate into the nucleus and associate with a transcription factor,
RBP-Jk, which up-regulates the expression of various Notch effector
target genes (Guruharsha et al., 2012). Confocal imaging confirmed
NICD accumulation in the nucleus following OGD (Fig. 2C). In normoxic
conditions, hydroxylation of two proline residues and acetylation of a
lysine residue at the oxygen-dependent degradation domain (ODDD)
of HIF-1α trigger its association with the pVHL E3 ligase complex,
leading to HIF-1α degradation via the ubiquitin–proteasome pathway
(Ke and Costa, 2006). Under hypoxic conditions, HIF-1α becomes stable
and translocates from the cytoplasm to the nucleus, where it dimerizes
with HIF-1β forming a HIF-1 complex that becomes transcriptionally
active and regulates the expression of target genes (Ke and Costa,
2006). Our confocal imaging analysis of cortical neurons immunostained
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with HIF-1α antibody confirmed increased levels of HIF-1α in the
nucleus in response to OGD (Fig. 2D). Using confocal imaging, we next
established that NICD and HIF-1α both accumulate in and around the
nucleus during ischemia-like conditions (Fig. 3A).
We next examined whether Notch and HIF-1α are expressed after
stroke in vivo. In the cerebral cortex of sham-operated control mice,
little immunoreactivity with HIF-1α antibodies was observed and
NICD appeared restricted to the neuronal cytoplasm (Fig. 3B). At 24 h
after I/R, neurons in the ischemic cortex exhibited robust NICD immuno-
reactivity in both nucleus and cytoplasm,while the expression of HIF-1α
around the nucleus was increased (Fig. 3B). Immunoblots of tissue
samples taken from the ischemic cortex further demonstrated increased
levels of NICD and HIF-1α proteins within 1–24h of ischemia (Fig. 3C).
Immunoprecipitation analysis of cortical neurons following OGD and of
brain samples from the ischemic hemisphere showed that NICD and
HIF-1α do indeed interact in cortical neurons. Co-immunoprecipitation
data further supported the notion that Notch and HIF-1α bind directly
to each other and/or are part of a multi-protein complex (Fig. 3D).
Over-expression of NICD and HIF-1α exacerbate neuronal death during
ischemia-like conditions
In order to confirm that Notch and HIF-1α collaboration promotes
cell death under ischemic conditions, SH-SY5Y human neuroblastoma
cells were transfected with either NICD or HIF-1α. Our present data
show that transfection with either NICD, HIF-1α, or both, increased ex-
pression of both the phosphorylated (p-p65) and non-phosphorylated
(p65) forms of the 65kDa subunit of NFκB under normal (Fig. 4A) and
OGD conditions (Fig. 4B). Furthermore, 2ME2 treatment of cells
transfected with NICD or HIF-1α alone, or both resulted in decreased
levels of total and phosphorylated p65 under both normal and OGD
conditions (Figs. 4A, B). Overexpression of HIF-1α and NICD had no
significant effects on cell death under normoxic conditions (Fig. 4C).
Cell death was substantially potentiated in NICD- or HIF-1α-transfected
cells compared with the control pcDNA group under OGD conditions
(Fig. 4D). Furthermore, cell death was increased in cells overexpressing
NICD and HIF-1α compared with cells overexpressing either NICD or
HIF-1α alone (Fig. 4D). In addition, treatment with 2ME2 reduced cell
death induced by either HIF-1α or both NICD plus HIF-1α (Fig. 4D).
These results demonstrate that NICD and HIF-1α can potentiate cell
death under ischemic conditions and that ischemic cell death is
exacerbated by combined elevation of NICD and HIF-1α levels. Immuno-
cytochemical analyses of NICD and HIF-1α-transfected cells indicate
nuclear translocation of p-p65 under OGD conditions (Fig. 4E). To
evaluate the roles of endogenous Notch and HIF-1α in neuronal cell
death under ischemic conditions, we used RNA interference to specifical-
ly knockdown endogenous Notch andHIF-1α (Figs. 4F, G, H, I). Cell death
was reduced in both GD- and OGD-induced cultures transfected with
Fig. 1. Inhibition of NICD and HIF-1α protects cultured cortical neurons against death under ischemia-like conditions. (A) Treatment with 2ME2 significantly reduced cell death, and
treatment with DMOG increased cell death, under GD condition. n = 6, ***p b 0.005 compared with the vehicle-treated group under normal culture conditions; +++, ###p b 0.005
compared with the vehicle treated group under GD condition. (B) Compound E and 2ME2 each significantly reduced GD-induced cell death, and combined treatment further reduced
cell death during GD. n= 6, ***p b 0.005 compared with the untreated group under normal conditions; +++p b 0.005 compared with the vehicle treated group under GD conditions;
**p b 0.01 2ME2 compared with compound E+2ME2 treated group; *pb 0.05 compound E compared with compound E+2ME2 treated groups. (C) Neuronal cell death was quantified
in cultures that had been subjected toOGD. n=6, ***pb0.005 comparedwith theuntreated groupunder normal condition;+++pb0.005 comparedwith the vehicle treatedgroup under
OGD condition. (D–G) Treatment with either compound E or 2ME2 reduced the level of cleaved caspase-3, and combined treatment further reduced cleaved caspase-3 levels under GD
(D, E) and OGD (F, G) conditions. (H) NICD andHIF-1α expression in 2ME2 and CE treated cultures. n=4 cultures in each group, *pb0.05 comparedwith vehicle-treated group; **pb0.01
compared with vehicle-treated group.
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Notch siRNA and HIF-1α siRNA compared with the control siRNA group
(Figs. 4J, K). However, combined Notch and HIF-1α siRNA treatment
did not achieve any further reduction in cell death. These results suggest
that Notch and HIF-1α act via the same pathway during hypoxia/
ischemia-induced cell death (Figs. 4F, G, H, I).
Inhibition of HIF-1α and γ-secretase protects against ischemic stroke-
induced brain injury
To determine whether blockade of both γ-secretase-mediated
Notch activation and HIF-1α protect against stroke-induced brain
injury by reducing the interaction between NICD and HIF1-α, we used
the γ-secretase inhibitor CE and the HIF1-α inhibitor 2ME2. Treatment
with either CE or 2ME2 by intravenous infusion immediately after
ischemia resulted in reduced brain damage (Figs. 5A, B, C). In addition,
combined CE and 2ME2 treatment further reduced brain damage
(Figs. 5B, C). Next, we analyzed protein levels of NICD and HIF-1α in
the ischemic hemisphere after 24 h of reperfusion (Fig. 5D). We found
that both NICD and HIF-1α were elevated in the brain after ischemic
stroke and reduced by treatment with CE and 2ME2 respectively
(Fig. 5D). Next, we measured the levels of NF-κB phospho-p65 and
JNK levels to assess whether inhibition of Notch and HIF-1α might
protect against ischemic stroke-induced brain injury by affecting these
proteins. Our data showed no significant difference in total and
phospho-p65 and total and phospho-JNK levels between treatment
groups (CE, 2ME2, or combination treatment) and the vehicle-
treatment group after 6 h of reperfusion (n = 5 in each group)
(Fig. 5E). However, the levels of cleaved caspase-3 (Figs. 5F, G), NF-κB
phospho-p65 (Figs. 5F, H), phospho-JNK1, 2/3 (Figs. 5F, I, J) and total
JNK1, 2/3 (Figs. 5F, K, L) were all significantly reduced in the CE, 2ME2
and combined treatment groups compared with the vehicle-treatment
group at 24 h reperfusion. Furthermore, combined CE and 2ME2
treatment further reduced cleaved caspase-3 and JNK levels (total
JNK1 and phospho-JNK1) compared to either CE or 2ME2 treatments
alone.
Discussion
A major finding of this study is the compromising effect that Notch
and HIF-1α signaling exert on neuronal viability after ischemic stroke,
and that this neuronal damage can be inhibited under in vitro and
in vivo conditions by treatment with inhibitors of γ-secretase and HIF-
1α. Furthermore, blockade of both Notch and HIF-1α using a com-
bination of γ-secretase and HIF-1α inhibitors resulted in enhanced
neuroprotection. Notch and HIF-1α have been shown to be important
under both physiological and pathological conditions. HIF-1α interacts
Fig. 2. NICD and HIF-1α levels in primary cortical neurons under normal, GD and OGD conditions. (A–B) Immunoblots showing NICD and HIF-1α protein levels at different time points
during GD (A) and OGD (B) conditions. NICD levels were increased with GD and OGD treatment. HIF-1α levels increased from 6 h to 12 h of GD and from 1 h to 3 h of OGD, and then
decreased at later time points. (C, D) Immunofluorescence images showing staining of NICD (C, green), HIF-1α (D, green), the neuronal marker MAP2 (red) and the nuclear marker
4′,6-diamidino-2-phenylindol (DAPI) (blue). Both NICD and HIF-1α staining showed a slight increase at 8 h of OGD. Scale bar: 10 μm.
290 Y.-L. Cheng et al. / Neurobiology of Disease 62 (2014) 286–295
with NICD in order to maintain neural stem cells in an undifferentiated
state under low oxygen conditions (Gustafsson et al., 2005). Hypoxia
directly enhances Notch signaling by increasing and stabilizing NICD
and recruiting HIF-1α to NICD and the Notch-responsive promoter,
and consequently upregulates expression of downstream genes such as
Hes1 and Herp1 (Gustafsson et al., 2005). In addition, NICD modulates
HIF-1α post-transcriptionally by increasing the recruitment of HIF-1α
to hypoxia response elements and the transcription of its target genes
(Zheng et al., 2008). We previously showed that the γ-secretase
inhibitors DAPT and CE reduce brain damage and neurological deficits
when assessed 3days after cerebral ischemia/reperfusion; neither 2ME2
or CE affected cerebral blood flow immediately before or after MCAO
(90–95% reduction in blood flow in the infarct region) (Arumugam
et al., 2006). It was previously shown that the HIF-1α inhibitor
2ME2 worsens outcome after global ischemia in rats (Zhou et al.,
2008) but is neuroprotective in focal ischemia by preserving
blood brain barrier (BBB) integrity, and reducing brain edema and
neuronal apoptosis (Chen et al., 2007, 2008). A recent study
suggested a key role for Notch as a mediator in the crosstalk between
HIF-1α and aspartyl-(asparaginyl)-β-hydroxylase (AAH) for the
regulation of neuronal migration in primitive neuroectodermal
tumor cells (Lawton et al., 2010). Further, the interaction of HIF-1α
and Notch was found to be important in the regulation of medullo-
blastoma precursor cell proliferation and survival (Pistollato et al.,
2010). Our data further supports the existence of a Notch-HIF-1α
collaboration as NICD inhibition affects HIF-1α levels and, likewise,
HIF-1α inhibition affects NICD levels under in vitro and in vivo
ischemic conditions. However, further research is needed to unravel
the precise molecular mechanisms of how Notch inhibition affects
HIF-1α levels, and how HIF-1α inhibition affects NICD levels under
cerebral ischemic conditions. These lines of evidence are consistent
with the possibility that HIF-1α and Notch interact and additively
contribute to neuronal injury under conditions of severe metabolic
stress such as that which occurs in ischemic stroke.
Fig. 3.NICD and HIF-1α interaction in cortical neurons and mouse brain under ischemic conditions. (A) Immunofluorescence staining of NICD and HIF-1α in mouse cortical neurons and
neurons under GD conditions. NICD (red), HIF-1α (green) and DAPI (blue) staining showing translocation of NICD andHIF-1α from cytoplasm to the nucleus at 24h GD. Scale bar: 20μm.
(B) Immunofluorescence staining of NICD and HIF-1α in the ipsilateral peri-infarct tissue section showing NICD (red), HIF-1α (green), MAP2 (magenta) and DAPI (blue) staining. The
immunoreactivity of NICD and HIF-1α was more robust at 24 h after ischemia/reperfusion (I/R) compared to the sham control. Scale bar: 40 μm. (C) The expression level of NICD and
HIF-1α was increased in the ipsilateral hemisphere after 1 h, 12 h and 24 h of I/R compared to sham. (D) Co-immunoprecipitation of NICD and HIF-1α in neurons under OGD 8 h and
in brain tissue from the ipsilateral cerebral cortex following 1 h ischemia and 24 h reperfusion showing increased binding of NICD and HIF-1α compared to controls.
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Fig. 4. Effect of over-expression and inhibition of NICD andHIF-1α in neurons under ischemia-like conditions. NICD andHIF-1αwere transfected to SH-SY5Y cells to induce NICD andHIF-1α expression;Notch-1 andHIF-1α siRNAwere transfected to
primary cortical neurons to inhibit endogenousNICD andHIF-1α expression. (A) Cells overexpressingNICD or HIF-1α showed an increased level of NF-κB p65/p-p65when compared to cells transfectedwith control plasmid cDNA (pcDNA). The level
of NF-κB p65/p-p65 was further increased when both NICD and HIF-1α were overexpressed. The NF-κB p65/p-p65 levels were reduced by treatment with 2ME2 under normal conditions (A) and 6 h of OGD (B). (C) Cell death in SH-SY5Y cells
overexpressing NICD and HIF-1α. (D) Cell death in SH-SY5Y neurons was increased when NICD and HIF-1α were over-expressed, and was significantly reduced at 6 h OGD when treated with 2ME2. (E) Immunofluorescence staining of
phosphorylated p65 in SH-SY5Y cells overexpressing NICD and HIF1-α under OGD (9 h) condition. Scale bar: 10 μm. (F, G) Knockdown of endogenous Notch-1 using Notch-1 siRNA. (H, I) Knockdown of endogenous HIF-1α using HIF-1α siRNA.
(J) Cell death in neurons transfected with Notch-1 and HIF-1α siRNA was significantly reduced at 9 h GD (K) and 8 h OGD (J). n= 3 cultures. *p b 0.05, **p b 0.01, ***p b 0.005 compared with the vehicle treated group.
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Elevated NF-κB activation has also been demonstrated in various
animal models of stroke, suggesting that this could contribute to the
inflammatory reaction and apoptotic cell death in post-stroke brain
injury. γ-Secretase-mediated Notch signaling is required to sustain
NF-κB activity, and NICD may increase NF-κB activity by binding to
and enhancing the nuclear distribution of the active NF-κB signaling
complex (Shin et al., 2006). The phosphorylation at serine 536 of p65
by IκB kinases has been shown to increase transcriptional activity
(Sakurai et al., 1999). It has also been shown that phosphorylation of
p65 at serine 536 contributes to various proinflammatory responses
and neuronal vulnerability in ischemic stroke (Crack et al., 2006; Ryu
et al., 2011; Shen et al., 2003; Yang et al., 2003). We found that
treatment with a γ-secretase inhibitor reduces ischemia-induced
levels of NF-κB-p65 in neurons, and that overexpression of NICD and
HIF-1α increases expression of total and serine 536-phosphorylated
NF-κB-p65 under normal and ischemic conditions. Furthermore,
2ME2 treatment resulted in decreased levels of total and serine 536-
phosphorylated NF-κB-p65under both normal and ischemic conditions,
suggesting that NF-κB expression and activation are Notch-mediated
and may also require HIF-1α. Moreover, cell death was further
increased with combined NICD and HIF-1α overexpression compared
with overexpression of either protein alone. In addition, 2ME2 treat-
ment reduced cell death induced by either HIF-1α alone or both NICD
and HIF-1α. These results provide further support for collaborative
detrimental roles for NICD and HIF-1α signaling under ischemic con-
ditions. Confocal imaging data revealed that serine 536-phosphorylated
NF-κB-p65 translocates into the nucleus of NICD and HIF-1α-expressing
cells under ischemia-like conditions, but not under normal conditions.
This result can help explain the accelerated cell death during OGD
conditions, while p65 and p-p65 were upregulated in both normoxia
and OGD conditions. Therefore, this observation indicates that Notch
and HIF-1α-mediated activation of NF-kB is a cellular signaling pathway
that was specific to OGD conditions. Immunoprecipitation analysis of
cortical neurons following OGD, and of brain samples from the ischemic
hemisphere, revealed that an interaction between NICD and HIF-1α
occurs under these conditions providing further evidence that NICD
and HIF-1α interact following ischemia. Our data suggesting that NICD
and HIF-1α interact in neuronal cells is consistent with a previous
report that NICD and HIF-1α interact in muscle cells (Gustafsson
et al., 2005).
Fig. 5. Inhibition of NICD and HIF-1α reduces focal ischemic brain injury in vivo. (A and B)Mice underwent 1h MCAO and 24–72h reperfusion. Mice treated with CE (n=11) and 2ME2
(n=10), alone or in combination (n=13), exhibited improved neurological function and reduced brain injury after stroke, compared to vehicle-treated (n=11)mice. Neurological score
was measured at 24, 48, and 72 h following reperfusion; infarct volume was measured at 72 h following reperfusion. Mice treated with both 2ME2 and CE treated showed significant
reduction in infarct size compared to mice treated with either CE or 2ME2 alone. Data are represented as mean± SEM. (C) Representative images of brains from each treatment group
following 1 h MCAO and 72 h reperfusion. (D) NICD and HIF-1α expression in 2ME2 and CE treated mouse brains after MCAO and 24 h of reperfusion. n= 5 in each group. (E) NF-κB
p65/p-p65, total JNK/p-JNK expression in the ipsilateral brain hemisphere at 6 h I/R from mice treated with either 2ME2, CE, or both 2ME2 and CE. (F) Cleaved caspase-3, NF-κB p65/p-p65,
total JNK/p-JNK expression in the ipsilateral brain hemisphere at 24 h I/R from mice treated with 2ME2, CE, and both 2ME2 and CE. (G, H, I, J, K, L) Quantification of cleaved caspase 3, p-p65
and total JNK/p-JNK expression. n=5 in each group, *p b 0.05, **p b 0.01, ***p b 0.005 compared with the vehicle treated group.
293Y.-L. Cheng et al. / Neurobiology of Disease 62 (2014) 286–295
It was recently shown that selective inhibition of early but not late
expressed HIF-1α is neuroprotective in rats after focal ischemia (Yeh
et al., 2011). Treating neurons with 2ME2 0.5 h after ischemic stress or
pre-silencing HIF-1α with siRNA decreased brain injury, edema and
apoptotic cell death (Yeh et al., 2011). Conversely, applying 2ME2 to
neurons 8 h after ischemic stress, or silencing HIF-1α with siRNA 12 h
after OGD, increased neuronal damage (Yeh et al., 2011). Another
study showed that 2ME2 and D609 powerfully protect the brain
from ischemic injury by inhibiting HIF-1α expression, attenuating
expression of vascular endothelial growth factor to avoid blood–brain
barrier disruption, and suppressing ceramide generation and neuronal
apoptosis via the BCL2/adenovirus E1B 19 kDa interacting protein 3
(BNIP3) pathway (Chen et al., 2007; Yu et al., 2000). The latter results
demonstrate that HIF-1α induced early after ischemia leads to cellular
apoptosis, whereas later induction of HIF-1α promotes survival.
Coapplication of Notch siRNA and HIF-1α siRNA following ischemic
conditions in vitro did not have an additive effect when compared to
individual siRNA treatment, consistent with these two proteins acting
via the same pathway during hypoxia/ischemia-induced cell death.
However, our current investigation following in vivo ischemia and
reperfusion found that early inhibition of HIF-1α protects neurons
in vitro and reduces neurological deficits and brain infarct volume
in vivo; additional protection is obtained with combined inhibition of
γ-secretase and HIF-1α.
In order to investigate the mechanism of enhanced protection by
combined γ-secretase and HIF-1α inhibition, we analyzed the levels of
NF-κB phospho-p65, JNK and cleaved caspase-3. Our data show that
the levels of NF-κB phospho-p65, JNK and cleaved caspase-3 were all
reduced by γ-secretase and HIF-1α inhibition alone or in combination
when compared with vehicle control. Interestingly, JNK and caspase-3
levels were further reduced by combined γ-secretase and HIF-1α
inhibition. This indicates that combined early intervention may lead to
protection following stroke by targeting cell death pathways mediated
by JNK activation. NICD has been shown to physically associate with
the JNK binding domain of JNK-interacting protein 1 (JIP), thereby
interfering with the binding of JIP1 and JNK and inhibiting JNK
activation during GD (Kim et al., 2005). Another study showed that
loss of Notch in Drosophila embryos resulted in high levels of JNK
activity, indicating that Notch represses JNK signaling in development
(Zecchini et al., 1999). However, our data show that treatment with a
γ-secretase inhibitor leads to a reduction in ischemic stroke-induced
phosphorylation of JNK. Furthermore, it was shown that treatment
with D-JNKI1, a JNK-inhibiting peptide, rescues adult hypoxic neurons
from death and contributes to HIF-1α upregulation, probably via
a direct interaction with the HIF-1α protein (Antoniou et al., 2009).
AP-1 is a transcription factor belonging to the leucine zipper family,
and it has been demonstrated that ischemic or hypoxic conditions
lead to an increase in JNK-AP-1 activity (Michiels et al., 2001; Tang
et al., 2007). HIF-1α and AP-1 have been shown to cooperate to increase
transcription (Michiels et al., 2001). Our findings suggest that ischemic
stroke-induced elevation of total JNK levels was reduced by combined
inhibition of Notch and HIF-1α. This may suggest roles for Notch and
HIF-1α signaling in JNK expression following stroke. However, the
exact molecular mechanisms by which the NICD-HIF-1α association
affects JNK expression and augments neuronal damage in cerebral
ischemia remain unknown and further research is needed to answer
this question. In conclusion, our present findings suggest that agents
that target the γ-secretase-Notch pathway and HIF-1α pathway may
prove effective in reducing neuronal cell death and brain injury after
ischemic stroke.
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Notch signaling is a highly conserved pathway that regulates cell fate decisions during
embryonic development. We have recently identified that in ischemic stroke, activity of
γ-secretase and the resulting Notch activation may endanger neurons by modulating NF-κB
and HIF-1α pathways. Notch signaling can also modulate MAPK-related pathways. How-
ever, the role of γ-secretase-mediated Notch signaling in activating MAPK following
ischemic stroke has not been investigated. We used control and NICD1-overexpressing
HEK and SH-SY5Y cell lines, and inhibitors of γ-secretase and JNK, to explore novel roles of
Notch in modulating cell death following ischemic stress in vitro. Our findings indicate that
expression of NICD1, JNK/cJun, p38-MAPK and the pro-apoptotic marker, cleaved caspase-
3, increased during ischemic conditions. γ-Secretase inhibitors reduced ischemia-induced
increase in NICD1 and JNK/p-cJun. Furthermore, NICD overexpression augmented JNK/cJun
levels and cell death under these conditions. These results suggest that Notch signaling
contributes to the pathogenesis of ischemic stroke, in part by promoting JNK/cJun
signaling. These results provide further support for the potential use of γ-secretase
inhibitors as therapy for ischemic stroke.
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1. Introduction
Notch signaling is a highly conserved pathway that regulates
cell fate decisions during embryonic development, and influ-
ences cell survival and synaptic plasticity in the adult brain
(Lathia et al., 2008). Besides the role of Notch in all phases of
brain development, and in physiological events in the adult,
there is growing evidence that Notch also plays an important
role in pathological events. We and others recently reported
that activity of γ-secretase, and the resulting Notch activa-
tion, may endanger neurons in ischemic stroke by modulat-
ing pathways to increase vulnerability to apoptosis, and by
activating microglial cells and stimulating the infiltration of
pro-inflammatory leukocytes (Arumugam et al., 2006; Li et al.,
2012; Wang et al., 2012). Furthermore, we have shown that
Notch signaling endangers neurons after ischemic stroke by
modulating the nuclear factor-κB (NF-κB), pro-death protein
Bim, hypoxia inducible factor-1α (HIF-1α) and caspase path-
ways (Arumugam et al., 2011; Wei et al., 2011; Cheng et al.,
2014).
Notch signaling is known to also modulate mitogen-
activated protein kinase (MAPK) pathways and to regulate
cell proliferation and inflammation (Gentle et al., 2012; Pallavi
et al., 2012). The stress-activated MAPKs has been linked to
inflammatory cytokine production and cell death following
ischemic stroke (Maddahi and Edvinsson, 2010). These MAPKs
play important roles in transducing stress-related signals by
phosphorylating intracellular enzymes, transcription factors
and cytosolic proteins involved in apoptosis and pro-
inflammatory cytokine production. Sustained activation of
c-Jun N-terminal kinases (JNK) and p38 MAPK have been
shown to be associated with neuronal death/apoptosis
following ischemic stroke, and selective inhibitors of JNK
and p38 can promote the survival of neurons (Tang et al.,
2008). We have reported that JNK activates the transcription
factor, activator protein-1 (AP-1), to contribute to neuronal
cell death (Tang et al., 2007). Recent studies have also shown
that γ-secretase is involved in MAPK activation (Shin et al.,
1999; Mizugaki et al., 2012). However, the role of γ-secretase-
mediated Notch signaling in activating MAPK following
ischemic stroke is not known. Here we demonstrate that
neuronal Notch signaling promotes JNK/c-Jun activation and
cell death under ischemic conditions.
2. Results
2.1. Expression of NICD1 and pro-apoptotic cleaved
caspase-3 during ischemic conditions
We first assessed the levels of Notch1 signaling (NICD1) and a
pro-apoptotic marker, cleaved caspase-3, expressed in an
in vitro model of ischemic neuronal injury using human
SH-SY5Y cells. Oxygen- and glucose-deprived (OGD) condi-
tions increased both NICD1 (Fig. 1A and B) and cleaved
caspase-3 (Fig. 1C and D) over a time-course of 0.5–6 h,
consistent with previous findings in mouse primary neuronal
cultures (Arumugam et al., 2006; Arumugam et al., 2011,
Cheng et al., 2014).
2.2. Expression of MAPKs during ischemic conditions
In order to investigate if Notch signaling may be involved in
modulating MAPK activity under ischemic conditions, we next
measured the ratio of phosphorylated and total- JNK, c-Jun, p38
Fig. 1 – Notch Intracellular Domain (NICD) and pro-apoptotic cleaved caspase-3 in SH-SY5Y cells subjected to oxygen–glucose
deprivation (OGD). (A and B) NICD1 expression was significantly increased over 0.5–6 h OGD. (C and D) Expression of cleaved
caspase-3 was also significantly increased at 3 h OGD treatment. *po0.05, **po0.01 Compared with normal; n¼4 different
cultures.
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Fig. 2 – MAPKs in SH-SY5Y cells subjected to OGD treatment. (A) Representative immunoblots showing phosphorylated and
total JNK1 and JNK 2/3 under normal and OGD conditions. (B) Levels of phosphorylated JNK1 and JNK 2/3 were significantly
increased following OGD compared to normal cultures. (C) Representative immunoblots showing phosphorylated and total
c-Jun under normal and OGD conditions. (D) Levels of phosphorylated and total c-Jun were significantly increased following
OGD compared to normal cultures. (E) Representative immunoblots showing phosphorylated and total p38 under normal and
OGD conditions. (F) Levels of phosphorylated p38 were significantly increased following OGD compared to normal cultures.
(G) Representative immunoblots showing phosphorylated ERK42 and ERK44 under normal and OGD conditions. (H) Levels of
phosphorylated ERK42 and ERK44 were significantly decreased following OGD compared to normal cultures. *po0.05,
**po0.01, ***po0.001 Compared with normal group; n¼4 different cultures.
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and ERK during OGD conditions. Expression of phosphorylated-
JNK (p-JNK) 1 and p-JNK2/3 significantly increased within 0.5–6 h
OGD conditions, with a peak level of expression occurring at 3 h
(Fig. 2A and B). However, total expression of JNK remained
constant, consistent with phosphorylation and not synthesis of
JNK contributing to SH-SY5Y cell death under OGD conditions
(Fig. 2A and B). By contrast, levels of both phosphorylated- and
total cJun were increased after 3–6 h of OGD (Fig. 2C and D).
Whereas similar to JNK, phosphorylated p38 was increased while
total p38 remained during OGD treatment (Fig. 2E and F),
consistent with a role for p38-MAPK in OGD-induced cell death.
ERK, on the other hand, exhibited an opposite trend in response
to OGD treatment. Phosphorylated-ERK-42 expression was
reduced in cells subjected to OGD, whilst the total ERK-42 level
was unchanged (Fig. 2G and H).
2.3. Effects of a γ-secretase inhibitor on expression of
NICD1 and p-cJun during ischemic conditions
In order to determine whether Notch signaling may directly
affect activity of MAP kinases during ischemic conditions, we
next assessed the expression and cellular localization of NICD
and phosphorylated-cJun using immunofluorescence. Confocal
images confirmed that accumulation of NICD occurred in the
nucleus following OGD, and that it is inhibited by the
γ-secretase inhibitor, compound E (1 μM, CE). Similar to NICD,
the level of phosphorylated-cJun was also increased by OGD,
and was reduced with CE treatment. Interestingly, NICD and
phosphorylated-cJun appeared to co-localise (as seen in yellow).
The robust expression of both NICD and phosphorylated-cJun
was reduced with CE treatment (Fig. 3). Next we determined the
Fig. 3 – NICD and p-cJun found to be co-expressed in SH-SY5Y cells under ischemic conditions. Immunofluorescence staining
of NICD1 (red), p-cJun (green) and DAPI (blue) in SY5Y cells under normal and OGD conditions. The immunofluorescence
images show that levels of both NICD and p-cJun robustly increased in the nucleus following OGD. Addition of the γ-secretase
inhibitor, compound E (CE), decreased the expression of NICD and p-cJun. Scale bar: 10 μm.
Fig. 4 – Treatment with a γ-secretase inhibitor downregulates expression of JNK/c-Jun in SH-SY5Y cells subjected to OGD
treatment. (A) NICD1 levels in SH-SY5Y cells under normal conditions and OGD with or without two concentrations of
γ-secretase inhibitors, CE and DAPT. Selected concentrations for subsequent experiments were 1 μM of CE and 20 μM of DAPT.
(B) Representative immunoblots showing phosphorylated and total JNK1 and JNK 2/3 under normal and OGD conditions.
(C) γ-Secretase inhibitors CE and DAPT significantly reduced the levels of phosphorylated JNK1 and JNK 2/3 following OGD
compared to vehicle-treated cells. *po0.05; n¼5 Different cultures. (D) Representative immunoblots showing phosphorylated
and total c-Jun under normal and OGD conditions. (E) γ-Secretase inhibitors, CE and DAPT, significantly reduced the levels of
phosphorylated c-Jun following OGD compared to vehicle-treated cells. **po0.01, ***po0.001; n¼5 Different cultures. (F and G)
Immunoblots showing the levels of phosphorylated/total p38 and ERK were not changed following γ-secretase inhibitor
treatments.
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concentrations of two γ-secretase inhibitors, compound E (CE)
and DAPT, that was required to inhibit Notch activation
(Fig. 4A). Based on these data, 1 μM of CE and 20 μM of DAPT
were chosen to inhibit γ-secretase activity and thus Notch
signaling. We subjected SH-SY5Y cells to OGD conditions with
or without the addition of CE and DAPT, and expressions of
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MAPKs were quantified. Levels of phosphorylated-JNK were
higher in OGD-treated cells when compared with cells under
normal conditions (Fig. 4B and C), expression of phosphorylated-
JNK was lower in cells treated with either CE or DAPT compared
to vehicle-treated cells (Fig. 4B and C). Similarly, levels of
phosphorylated-cJun were reduced in cells treated with CE or
DAPT compared to vehicle treatment (Fig. 4D and E), consistent
with an involvement of cJun, a downstream effector of the JNK
pathway, in Notch-mediated cell death during ischemic condi-
tions. By contrast, neither phosphorylated or total expression
levels of p38 and ERK were affected by the treatment of γ-
secretase inhibitors (Fig. 4F and G).
2.4. NICD overexpression potentiate expression levels of
JNK/cJun and cell death following ischemic condition
To further investigate Notch-mediated JNK/cJun activation
under ischemic conditions, we next employed c-Myc-tagged
NICD1 protein-overexpressing HEK cells. Immunoblot analysis
of c-Myc confirmed overexpression of NICD1 (Fig. 5A). Immu-
noblot analysis indicated that under normal conditions there
tended to be an increased basal level of phosphorylation of
JNK 1 and 2/3 in NICD1-overexpressing cells compared to wild
type cells. Unlike SHSY5Y cells wild type HEK cells did not
show significantly increased level of JNK levels following OGD.
This may be due to the cell type used in this experiment (HEK
cells) and shorter time point of OGD. However, under OGD
conditions, phosphorylation of both JNK 1 and 2/3 was sig-
nificantly increased in NICD1-overexpressed cells compared to
wild type cells (Fig. 5B and C). Similarly, phosphorylated-cJun
levels were significantly higher in NICD1 overexpressed cells
compared to wild type cells under both basal and OGD
conditions (Fig. 5D and E). Immunocytochemical analysis
further confirmed increased expression of phosphorylated-
cJun in NICD-overexpressing cells during OGD conditions
(Fig. 6A). Finally, we analyzed cell death by LDH release in
wild type and NICD1-overexpressing cells. The experiments
confirmed that NICD1-overexpressing cells were more suscep-
tible to OGD than wild type cells, and that cell death was
reduced in cells treated with the JNK inhibitor, SP600125
(Fig. 6B).
3. Discussion
A major finding of this study is that Notch signaling endan-
gers neurons under conditions that simulate ischemic stroke
by modulating the JNK/c-Jun pathways, and that this
neuronal damage can be inhibited in vitro by treatment
with a γ-secretase inhibitor. We have shown previously that
γ-secretase activity and subsequent Notch signaling are
elevated in the brain after ischemic stroke in vivo
(Arumugam et al., 2006). Furthermore, γ-secretase activity
was elevated in cultured primary neurons after ischemic
conditions, and γ-secretase-mediated Notch signaling contri-
butes to neuronal death in ischemic stroke by modulating the
NF-κB, pro-death protein Bim, calcium signaling, HIF1α, and
caspase pathways (Arumugam et al., 2011; Cheng et al., 2014).
Recent evidence indicates that Notch may mediate several
of its physiological responses through MAPK pathways
(Stockhausen et al., 2005; Kondoh et al., 2007; Yamashita
et al., 2013). Therefore, here we have tested the hypothesis
that Notch mediates cell death after an ischemic condition by
modulating MAPK signaling.
In agreement with our previous studies, increased expres-
sion of NICD1 and cleaved caspase-3 following OGD in SH-
SY5Y cells indicate a detrimental role of Notch activation in
ischemic cell death. An increased phosphorylation level of
both JNK and p38 pathways, indicative of activation, was also
observed under OGD conditions in SH-SY5Y cells. In addition,
both phosphorylated and total expression levels of c-Jun were
observed, suggesting that activation might occur through both
phosphorylation and translation of c-Jun protein. To explore
whether Notch1 signaling plays a role in the activation of
MAPKs during ischemic stroke-like conditions, γ-secretase
inhibitors were administered to SH-SY5Y cells during OGD
conditions. Our data show that inhibition of γ-secretase results
in decreased levels of phosphorylated JNK and c-Jun, consis-
tent with Notch signaling modulating JNK and c-Jun activation
during ischemia. Furthermore, to further test this possibility,
we studied HEK cells that overexpressed NICD1. Our data
indicate higher levels of phosphorylated JNK and c-Jun were
present in NICD1-overexpressing cells under both normal and
OGD conditions compared to wild type controls. Moreover, the
NICD1-overexpressing cells were more susceptible to OGD-
induced cell death, and inhibition of JNK was able to salvage
the cells. These results indicate that Notch signaling may
activate the JNK-c-Jun pathway to promote ischemic cell
death. However, it is not known how end product of Notch-
MAPK axis mediates neuronal cell death following ischemic
condition. Further research is needed to answer this question.
It was previously shown that both Notch and JNK-c-Jun
signaling can regulate interact under different physiological
circumstances. It was found that JNK signaling can mediate
expression of Hes-1, immediately downstream of Notch sig-
naling (Curry et al., 2006). Another recent study found that
moderate Notch activation led to increased AP-1 transcription
and DNA binding activity, which contributed to increased
viability and anchorage-independent growth in HPV-infected
cervical cancer cells (Henken et al., 2012). MAPK pathways are
known to contribute to ischemic stroke injury by promoting
the transcription of pro-inflammatory mediators (Wang et al.,
2004; Sawe et al., 2008). JNK-MAPK signaling has also been
implicated in stress-induced neuronal apoptosis (Pirianov
et al., 2007; Coffey, 2014). Activation of JNK may result in the
phosphorylation of many transcription factors, including com-
ponents of the AP-1 family, c-Jun, and activating transcription
factor 2 (ATF2) (Coffey, 2014). Recent studies have indicated
that JNK/c-Jun pathway plays a critical role during the injury
responses in association with stroke (Simi et al., 2000; Dong
et al., 2009). Furthermore, Notch-MAPK pathway interactions
have been reported to occur in the context of macrophage
polarization (Xu et al., 2012). Here, we have shown for the first
time that Notch signaling modulates the JNK-c-Jun pathway
under ischemic conditions.
Our study also shows that the p38-MAPK pathway is
activated under these conditions, consistent reports that
phosphorylated p38-MAPK increases following ischemic
stroke in neurons (Irving et al., 2000). While it has been
demonstrated that Notch signaling may regulate the p38
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Fig. 5 – NICD overexpression promotes JNK/c-Jun signaling under OGD conditions. (A) Immunoblot analysis shows stable
overexpression of c-Myc-NICD1 protein in transfected cells. (B) Representative immunoblots showing phosphorylated and
total JNK expression in wild type and NICD overexpressed cells under normal and OGD conditions. (C) Levels of
phosphorylated JNK1 and JNK 2/3 were increased in NICD1 overexpressed cells following OGD condition compared to wild
type cultures. (D) Representative immunoblots showing phosphorylated and total c-Jun expression in wild type and NICD
overexpressing cells under normal and OGD conditions. (E) Levels of phosphorylated c-Jun were significantly increased in
NICD1 overexpressing cells under normal and OGD conditions compared to wild type cells. *po0.01; n¼6 Different cultures.
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pathway in various cell types (Song et al., 2002; Xu et al.,
2012), our data indicate that Notch activation may not be
involved in the regulation of p38 pathway following ischemic
condition. While current literature postulates that ERK has
dual roles in ischemic stroke (Szydlowska et al., 2010;
Gladbach et al., 2014), this study found that ERK activity
was actually reduced under ischemic stress in SH-SY5Y cells.
There was also no clear evidence for Notch signaling in the
regulation of ERK signaling under ischemic conditions in
this study.
The present study supports the conclusion that JNK path-
way is activated and contributes to ischemic-induced injury,
and provides further evidence that Notch signaling activates
the JNK-c-Jun pathway following ischemic stroke. As it has
been shown that Notch signaling induces neuronal death
following ischemic stroke via NF-κB and HIF-1α pathways,
our results further support the use of γ-secretase inhibitors
as potential ischemic stroke therapy via inhibition of Notch-
JNK signaling.
4. Experimental procedures
4.1. Human neuroblastoma cell culture
SH-SY5Y cells (ATCC, USA) were cultured in complete growth
medium composed of Dulbecco's modified Eagle's medium-
F12 (DMEM/F12) (Invitrogen, USA) supplemented with 10%
fetal bovine serum and 1% penicillin and 1% streptomycin
(Gibco, USA) in a 37 1C humidified incubator with 5% CO2. To
differentiate neuroblast-like cells towards a neuronal-like
phenotype, cells were cultured in complete growth medium
with the addition of 10 μM all-trans retinoic acid (RA, Sigma,
USA) for 1 week. The culture medium was replaced every
3–4 days.
4.2. NICD1-overexpressing HEK cell culture
Human embryonic kidney (HEK) 293T cells and Myc-tagged
NICD1 stably-overexpressing HEK 293T cells were cultured in
a complete growth medium composed of Dulbecco's modified
Eagle's medium (DMEM) (Invitrogen, USA) supplemented with
10% fetal bovine serum and 1% penicillin and 1% streptomy-
cin (Gibco, USA) in a 37 1C humidified incubator with 5% CO2.
To generate stable NICD1-overexpressing cell lines, HEK 293T
cells were co-transfected with myc-tagged NICD1 and pBABE-
puro using Lipofectamine 2000 (Invitrogen, USA). Cells exp-
ressing transgenes were selected with 1 μg/ml of puromycin
(Calbiochem, USA).
4.3. Pharmaceuticals
The γ-secretase inhibitors IX (DAPT) and XXI (compound E)
were purchased from Merck Calbiochem (Germany). DAPT
was administered into SY5Y cultures in a final concentration
of 20 μM and the final concentration of compound E was 1 μM.
The JNK inhibitor SP600125 was purchased from Cayman
Chemical (USA). SP600125 was dissolved in DMSO and a final
concentration of 20 μM was used.
4.4. Oxygen–glucose deprivation (OGD)
To induce oxygen–glucose deprivation (OGD), the complete
growth medium was replaced with glucose-free Locke's
buffer containing 154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2,
1 mM MgCl2, 3.6 mM NaHCO3, 5 mM HEPES and 5 mg/L gen-
tamycin, and pH 7.2. The plates were then incubated in an
airtight hypoxia chamber by replacing the air with 95% N2/5%
CO2 for different time points.
Fig. 6 – Phosphorylated c-Jun expression and LDH release
under OGD conditions in NICD-overexpressing cells.
Immunofluorescence images show phosphorylated c-Jun
increased under OGD, with more intense staining in NICD1-
overexpressing cells. Scale bar: 10 μm. (B) LDH release data
shows that cell death was significantly higher in NICD1-
overexpressing cells compared to wild type cells under OGD
conditions. NICD1-overexpressing cells treated with a JNK
inhibitor display a significant decrease of LDH release
compared to vehicle-treated cells. ***po0.001; n¼5 Different
cultures.
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4.5. Lactate dehydrogenase (LDH) assay
A cytotoxicity detection kit was purchased from Roche
(Germany) and used to detect cell death based on measuring
the activity of lactate dehydrogenase (LDH) which is released
from the cytosol of damaged cells into the supernatant. The
assay was performed according to the kit instructions with
some modifications. In brief, the medium of treated cells
were collected and cells were lysed with 500 μl PBSþ0.1%
Triton X-100. Samples were mixed with reaction solution and
incubated for 10 min at room temperature before stopping
the reaction in 1 N hydrochloric acid. Absorbance of the
samples was measured at 490 nm with a reference wave-
length at 700 nm.
4.6. Immunoblot analysis
To obtain protein lysate for immunoblot analysis, cells were
lysed by RIPA buffer (Thermo Scientific, USA) containing 1%
of protease inhibitors and phosphatase inhibitors. The super-
natants were collected after sonication and centrifugation at
13,000 rpm at 4 1C for 10 min as protein lysate. Protein lysates
were subjected to sodium dodecyl sulphate-poly-acrylamide
gel (10%) electrophoresis using a Tris–glycine–SDS running
buffer and then transferred onto a nitrocellulose membrane
(Bio-Rad, USA). The membrane was blocked with 5% bovine
serum albumin (BSA) in Tris-Buffered Saline and Tween 20
(TBST) for 1 h at room temperature. The membrane was then
incubated overnight at 4 1C with primary antibodies including
those that selectively bind to cleaved caspase-3 (Cell Signal-
ing, USA), activated Notch1 (Abcam, UK), phosphorylated JNK
(Cell Signaling, USA), phosphorylated c-Jun (Cell Signaling,
USA), phosphorylated p38 (Cell Signaling, USA), phosphory-
lated ERK (Cell Signaling, USA), total JNK (Cell Signaling, USA),
total c-Jun (Cell Signaling, USA), total p38 (Cell Signaling,
USA), total ERK (Cell Signaling, USA), c-Myc (Roche, Germany),
and Actin (Sigma, USA). The membrane was then washed
with TBST and incubated with a horseradish peroxidase-
conjugated secondary antibody for 1 h at room temperature.
After washing, the membrane was incubated in chemilumi-
nescent substrate for enhanced chemiluminescence (BioRad,
USA). Chemiluminescent signals of protein bands were
visualized using a ChemiDoc imaging system (BioRad, USA).
4.7. Immunofluorescence
Coverslips containing SY5Y neuroblastoma cells subjected
either to normal medium or OGD medium were fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS, Sigma,
USA). Fixed cells were blocked and permeabilized with
blocking buffer (0.2% BSA, 1% Fetal Bovine Serum (FBS), and
0.1% Triton-X in PBS) at room temperature for 1 h before 2 h
incubation with NICD (rabbit polyclonal, Abcam, USA) and
p-c-Jun (mouse monoclonal, Santa cruz, USA) antibodies
diluted in blocking buffer. Cells were then incubated with
Alexa Fluor-conjugated secondary antibodies (Invitrogen,
USA) diluted in blocking buffer for 45 min at room tempera-
ture. Following secondary antibody incubation, the nuclei of
all cells were stained with DAPI (BioRad, USA) for 10 min at
room temperature and coverslips were sealed with
Vectashield mounting solution (vECTOR, USA) on microscope
slides. The slides were observed under a confocal microscope
(Olympus LV1000, Japan).
4.8. Data analysis
All results are reported as mean7standard deviation (SD).
Overall significance of the data was examined by analysis of
variance (ANOVA). Differences between groups were consid-
ered significant at po0.05 with the appropriate Bonferroni
correction made for multiple comparisons.
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Abstract 
 
Gamma-secretase is a fairly distinct proteolytic complex required for the activation of many 
transmembrane proteins. The cleavage of gamma-secretase to its substrates plays diverse biological 
roles in producing essential products for the organism. More than 90 transmembrane proteins have 
been reported as substrates of gamma-secretase. Two of the most widely known and studied 
substrates of gamma-secretase are the amyloid precursor protein (APP) and the Notch receptor, 
which results from the generation of amyloid-beta (Aβ) and the Notch intracellular domain (NICD), 
respectively. The wide spectrum of gamma-secretase substrates has made analyses of the pathology 
of gamma-secretase-related diseases and underlying mechanisms more challenging. Inflammation is 
an important part of disease pathology and progression and thus requires a more in-depth analysis. 
Gamma-secretase contributes to disease progression or development by directly increases the 
production of pro-inflammatory cytokines and by regulating the production of pro-inflammatory 
cytokines. This review summarizes recent evidences of gamma-secretase’s role in inflammatory 
diseases, namely its involvement in inflammatory pathways, and discusses the potential use of 
gamma-secretase inhibitors as an effective treatment option. 
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ABSTRACT  
 
   Acute ischemic stroke (AIS) causes a high rate of deaths and permanent neurological deficits 
in survivors. Current interventional treatment, in the form of enzymatic thrombolysis, benefits 
only a small percentage of patients. Brain ischemia triggers mobilization of innate immunity, 
specifically the complement system and Toll-like receptors (TLRs), ultimately leading to an 
exaggerated inflammatory response.  Here we demonstrate that intravenous immunoglobulin 
(IVIG), a scavenger of potentially harmful complement fragments, and C1-esterase inhibitor 
(C1-INH), an inhibitor of complement activation, exert a beneficial effect on the outcome of 
experimental brain ischemia (I) and reperfusion (R) injury induced by transient occlusion of 
middle cerebral artery in mice. Both IVIG and C1-INH significantly and in a dose-responsive 
manner reduced brain infarction size, neurological deficit and mortality when administered to 
young, old and female mice 30 min before ischemia or up to 6 h after the onset of reperfusion. 
When combined, suboptimal doses of   IVIG and C1-INH potentiated each other’s 
neuroprotective therapeutic effects. Complement C3 and TLR2 signals were co-localized and 
significantly greater in brain cells adjacent to infarcted brain lesions when compared to the 
corresponding regions of the contralateral hemisphere and to control (sham) mice.   Treatment 
with IVIG and C1-INH effectively reduced deposition of C3b and downregulated excessive 
TLR2 and p-JNK1 expression at the site of I/R injury. Taken together, these results provide a 
rationale for potential use of IVIG and C1-INH, alone or in combination, to target 
inappropriately activated components of the innate immune system. 
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Abstract 
Objective: Stroke is a leading cause of mortality and disability. The peptidyl-prolyl 
cis/trans isomerase Pin1 regulates factors involved in cell growth. Recent evidence 
has shown that Pin1 plays a major role in apoptosis. However the role of Pin1 in 
ischemic stroke remains to be investigated.  
Methods: We used Pin1 overexpression and knockdown to manipulate Pin1 
expression and explore the effects of Pin1 in cell death on ischemic stress in vitro and 
in a mouse stroke model. We also used Pin 1 inhibitor, γ-secretase inhibitor, NICD1 
domain-deleted mutant cells and Pin1 mutant cells to investigate the underlying 
mechanisms of Pin1-NICD1 mediated cell death. 
Results: Our findings indicate that Pin1 facilitates NICD1 stability and its pro-
apoptotic function following ischemic stroke. Thus, overexpression of Pin1 increased 
NICD1 levels and enhanced its pot ntiation of neuronal death in simulated ischemia. 
By contrast, depletion or knockout of Pin1 reduced the NICD1 level, which in turn 
desensitized neurons to ischemic conditions. Pin1 interacted with NICD1 and 
increased its stability by inhibiting FBW7-induced poly-ubiquitination. We also 
demonstrate that Pin1 and NICD1 levels increase following stroke. Pin1 heterozygote 
(+/-) and knockout (-/-) mice, and also wild-type mice treated with an inhibitor of 
Pin1, each showed reduced brain damage and improved functional outcomes in a 
model of focal ischemic stroke. 
Interpretation: These results suggest that Pin1 contributes to the pathogenesis of 
ischemic stroke by promoting Notch signaling, and that inhibition of Pin1 is a novel 
approach for treating ischemic stroke.  
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Recent findings have revealed a novel inflammatory mechanism that contributes to tissue injury in cerebral
ischemia mediated by multi-protein complexes termed inflammasomes. Intermittent fasting (IF) can decrease
the levels of pro-inflammatory cytokines in the periphery and brain. Here we investigated the impact of IF (16
h of food deprivation daily) for 4 months onNLRP1 andNLRP3 inflammasome activities following cerebral ische-
mia. Ischemic stroke was induced in C57BL/6J mice by middle cerebral artery occlusion, followed by reperfusion
(I/R). IF decreased the activation of NF-κB and MAPK signaling pathways, the expression of NLRP1 and NLRP3
inflammasome proteins, and both IL-1β and IL-18 in the ischemic brain tissue. These findings demonstrate
that IF can attenuate the inflammatory response and tissue damage following ischemic stroke by a mechanism
involving suppression of NLRP1 and NLRP3 inflammasome activity.
© 2014 Elsevier Inc. All rights reserved.
Introduction
Ischemic stroke is the secondmajor cause ofmorbidity andmortality
worldwide (Donnan et al., 2008). The mechanisms responsible for is-
chemic stroke-induced neuronal cell death involve bioenergetic failure,
excitotoxicity, metabolic and oxidative stress, apoptosis, and inflamma-
tory processes, including activation of resident glial cells and infiltrating
leukocytes (Arumugam et al., 2005; Broughton et al., 2009; Dirnagl,
2012). Inflammasomes are involved in a newly discovered multi-
protein complex signaling pathway that contributes to inflammation
and cell death in various pathological conditions. Nucleotide-binding
oligomerization domain (NOD)-like receptor (NLR) pyrin domain-
containing (NLRP) inflammasomes play a role in the inflammatory
response during ischemic stroke (Fann et al., 2013a,b). The NLRP
inflammasomes are cytosolic macromolecular complexes composed of
the NLRP receptor, ASC (apoptosis-associated speck-like protein con-
taining a caspase recruitment domain), precursor caspase-1, precursor
caspase-11 and/or XIAP (X-linked inhibitor of apoptosis) (Martinon
et al., 2002). Activation and homo-oligomerization of NLRP receptors
induce formation of the NLRP inflammasome, which converts precursor
caspase-1 into cleaved caspase-1 via proximity-induced auto-activation
(Martinon et al., 2002; Schroder and Tschopp, 2010). Cleaved caspase-1
converts precursors interleukin (IL)-1β and IL-18 into biologically active
mature pro-inflammatory cytokines that are released into the extracel-
lular environment (Schroder and Tschopp, 2010). In addition, cleaved
caspase-1 can initiate cell death directly via pyroptosis, or indirectly
via apoptosis (Aachoui et al., 2013; Lamkanfi and Dixit, 2012). Further-
more, we have recently demonstrated that ischemia-like conditions in-
creased the levels of NLRP inflammasome proteins, and both IL-1β and
IL-18, in primary cortical neurons (Fann et al., 2013a). An increase in ex-
pression of NLRP1 and NLRP3 inflammasome proteins and both IL-1β
and IL-18 precursor proteins in brain cells under ischemic conditions
may be induced by the activation of NF-κB and MAPK signaling path-
ways via a process called ‘priming’ (Gross et al., 2011; He et al., 2012).
Dietary energy restriction, by daily calorie reduction (CR) or inter-
mittent fasting (IF), extends lifespan and decreases the development
of age-related diseases, including diabetes, cardiovascular disease and
neurodegenerative diseases (Mattson, 2000). CR and IF can reduce cir-
culatingmarkers of oxidative stress and inflammation, and can improve
cardiovascular disease risks (Harvie et al., 2011; Johnson et al., 2007;
Mager et al., 2006; Mattison et al., 2012; Weiss and Fontana, 2011).
Several studies suggest dietary restriction may promote neuronal sur-
vival and plasticity in ischemic stroke, by inducing neuroprotective fac-
tors and suppressing inflammatory pathways (Arumugam et al., 2010;
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Manzanero et al., 2011; Yu and Mattson, 1999). Major pro-
inflammatory cytokines implicated in ischemic brain injury are tumor
necrosis factor (TNF), IL-1β and IL-6 (Arumugam et al., 2010;
Lambertsen et al., 2012). IF enhances the ability of brain cells to protect
neurons against ischemic injury by a mechanism involving the coordi-
nate upregulation of multiple neuroprotective proteins (neurotrophic
factors, protein chaperones, and antioxidant enzymes) and downregu-
lation of proinflammatory cytokines such as TNF, IL-6 and IL-1β
(Arumugam et al., 2010). Furthermore, we recently reported that levels
of NLRP inflammasome proteins, IL-1β and IL-18 were elevated in ipsi-
lateral brain tissues of cerebral I/R mice and stroke patients, and that
caspase-1 inhibitor treatment protected cultured cortical neurons and
brain cells in vivo in experimental stroke models (Fann et al., 2013a).
Since IF is neuroprotective and reduces pro-inflammatory cytokines in
stroke, and inflammasomes are involved in the production of pro-
inflammatory cytokines such as IL-1β, we tested the hypothesis whether
IF impairs stroke-induced inflammasome expression and activation. Here
we demonstrate for the first time that the neuroprotective effect of IF in
experimental stroke involves suppression of inflammasome activity.
Methods
Animals and diets
Male C57BL6/J mice were obtained from the Animal Resources
Centre in Canning Vale, Australia, and group housed upon arrival at
The University of Queensland Animal Facility. At ten weeks of age,
mice were randomly assigned to either the ad libitum (AL) or intermit-
tent fasting (IF) diet conditions. Mice in the IF conditionwere fed for 8 h
out of every 24-hour period, with food available between 07:00 and
15:00 (lights on at 06:00, lights off at 18:00) for fourmonths. The Animal
Care and Use Committee of The University of Queensland approved all
procedures.
Focal cerebral ischemia/reperfusion (I/R) stroke model
Three-month-old C57BL/6J male mice were subjected to transient
middle cerebral artery ischemia and reperfusion (I/R) injury, as de-
scribed previously (Arumugam et al., 2004). Briefly, aftermaking amid-
line incision in the neck, the left external carotid and pterygopalatine
arteries were isolated and ligated with 6–0 silk thread. The internal
carotid artery (ICA) was occluded at the peripheral site of the bifurca-
tion with a small clip and the common carotid artery (CCA) was ligated
with 5–0 silk thread. The external carotid artery (ECA)was cut, and a 6–
0 nylonmonofilamentwith a tip thatwas blunted (0.20–0.22mm)with
a coagulator was inserted into the ECA. After the clip at the ICA was
removed, the nylon thread was advanced to the origin of the middle
cerebral artery (MCA) until light resistance was evident. The nylon
thread and the CCA ligature were removed after 1 h to initiate reperfu-
sion. In the Sham group, surgery was performed until the arteries were
visualized. In a separate set of experiments, anesthetized animals from
all groups (5–6 mice per group) underwent cerebral blood flow (CBF)
measurements using a Laser Doppler Perfusion Monitor (Moor Lab,
UK). The University of Queensland Animal Care and Use Committee
approved all in vivo experimental procedures.
Immunoblot analysis
Protein samples from the cerebral cortex were subjected to sodium
dodecyl sulfate-polyacrylamide (10%) gel electrophoresis using a Tris-
glycine running buffer. Gels were then electro-blotted using a transfer
apparatus (Bio-Rad) in transfer buffer containing 0.025 mol/L Tris
base, 0.15 mol/L glycine, and 10% (v/v) methanol for 1.5 h at 15 V
onto a nitrocellulosemembrane (Bio-Rad). Themembranewas then in-
cubated in blocking buffer (5% non-fat milk in 20 mM Tris–HCl, pH 7.5,
137mMNaCl, 0.2% Tween-20) for 1 h at 23 °C. Themembranewas then
incubated overnight at 4 °C with primary antibodies including those
that selectively bind p-P65 (Cell Signaling), P65 (Cell Signaling), p-P38
(Cell Signaling), P38 (Cell Signaling), p-JNK (Cell Signaling), JNK (Cell
Signaling), p-ERK (Cell Signaling), ERK (Cell Signaling), p–c-Jun
(Cell Signaling), c-Jun (Cell Signaling), NLRP1 (Novus Biologicals),
NLRP3 (Novus Biologicals), ASC (Abcam), caspase-1 (Abcam), caspase-
11 (Abcam), IL-1β (Abcam), IL-18 (Abcam), caspase-3 (Cell Signaling),
Cleaved caspase-3 (Cell Signaling), Bcl-2 (Cell Signaling), Bcl-xL (Cell
Signaling) and β-actin (Sigma). After washing three times (10 min per
wash) with Tris-buffered saline-T (20 mM Tris–HCL, pH 7.5, 137 mM
NaCl, 0.2% Tween-20), the membrane was incubated with secondary
antibodies against the primary antibody and β-actin for 1 h at room
temperature. The membrane was washed with Tris-buffered saline-T
and scanned using the Odyssey® Infrared Imaging System (LI-COR
Biosciences). Quantification of protein levels was achieved by densi-
tometry analysis using Image J software. In detail, the densitometry of
the NF-κB and MAPK signaling proteins was determined and divided
by the densitometry of its corresponding “total protein” indicating
activation. The densitometry of the inflammasome proteins, IL-1β and
IL-18, and caspase-3, Bcl-2 and Bcl-xL was determined and divided by
the densitometry of its corresponding β-actin, which was used as a
loading control.
Results
In addition to our previously published studies (Arumugam et al.,
2010), recently, we have tested the functional consequences of focal
stroke in the IF mice that were fed for 8 h out of every 24-hour period.
Similar to 24-hour IF mice (Arumugam et al., 2010), these mice also ex-
hibited smaller infarcts three days after ischemia and reperfusion injury,
relative to mice on the ad libitum diet (Manzanero et al., 2014). In this
study, we subsequently investigated the effect of IF on the activation
of intracellularNF-κB andMAPK signalingpathways, and the expression
of NLRP1 and NLRP3 inflammasome proteins and both IL-1β and IL-18
in ipsilateral brain tissue (cerebral cortex) following 24 h of I/R. IF signif-
icantly attenuated the ischemia-induced increase in levels of
phosphorylated-P65-NF-κB and phosphorylated MAPKs such as p-P38,
p-JNK, p-ERK and p–c-Jun compared to the AL group in ipsilateral
brain tissue following 24 h of I/R (Figs. 1A and B). However, no
difference was observed in these proteins under Sham conditions
between AL and IF groups. Furthermore, levels of total NF-κB and
MAPKs were similar in AL and IF groups under both Sham and I/R con-
ditions (Fig. 1A). Next, we analyzed the levels of NLRP1 and NLRP3
inflammasome components such as NLRP1, NLRP3, ASC, precursor
caspase-1 and 11, as well as the precursors of IL-1β and IL-18 in ipsilat-
eral brain tissue 24 h after I/R. Similar to both total NF-κB and MAPKs
levels, no differences in inflammasome proteins and precursors of IL-
1β and IL-18 were observed under Sham conditions between AL and
IF groups. However, ischemia-induced increases in inflammasome pro-
teins and precursors of IL-1β and IL-18were significantly reduced in the
IF group compared to the AL group in ipsilateral brain tissue following
24 h of I/R (Figs. 1C and D). We further investigated the effect of IF on
inflammasome activation by measuring the levels of cleaved caspases
1 and 11, andmature forms of IL-1β and IL-18, in ipsilateral brain tissue
at 24 h of I/R. IF significantly decreased the levels of both cleaved
caspase-1 and 11, and both mature IL-1β and IL-18 in the ischemic cor-
tex (Figs. 2A and B). In addition, the data indicated that inflammasome
activity in the contra-lateral brain hemispherewas lower in comparison
to the ipsilateral brain hemisphere in ad libitum ischemic mice. How-
ever, no change was evident between the contra-lateral and ipsi-
lateral brain hemispheres in IF ischemic mice (Figs. 2A and B). Further-
more, levels of pro-apoptotic cleaved caspase-3 was significantly lower
and anti-apoptotic protein Bcl-xL was significantly higher in the IF
group in comparison to AL controls in the ischemic cortical brain tissue
at 24 h after I/R. However, no significant difference was observed in the
levels of precursor caspase-3 and Bcl-2 in the IF group in comparison to
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AL controls in the ischemic cortical brain tissue at 24 h following I/R
(Figs. 2C and D).
Discussion
Amacromolecular complex, termed the inflammasome, in particular
the NLRP1 and NLRP3 inflammasomes, regulate the maturation of pro-
inflammatory cytokines such as IL-1β and IL-18. Several lines of evi-
dence suggest that activation of inflammasomes may contribute to cell
death via apoptosis or pyroptosis (Aachoui et al., 2013). Pyroptosis
and apoptosis are both programmed cell death mechanisms, with
pyroptosis being highly inflammatory and involving cytoplasmic swell-
ing and early plasma membrane rupture (Lamkanfi and Dixit, 2012).
We have recently shown that the NLRP1 and NLRP3 inflammasomes
Fig. 1. Intermittent fasting reduces NF-κB, MAPKs and inflammasome expression in a mouse model of focal ischemic stroke. (A & B) Representative immunoblots and quantification
illustrating increases in the activation levels of NF-κB (p-P65) and MAPKs such as p-P38, p-JNK and p-ERK and p–c-Jun in ipsilateral brain tissues of C57BL/6J mice following middle
cerebral artery occlusion (1 h) and reperfusion (24 h). Intermittent fasting (IF) significantly reduced the activation levels of NF-κB (p-P65) and MAPKs such as p-P38, p-JNK and p-ERK
and p–c-Jun. Data are represented asmean± SD. n= 5–6 animals in each group. *p b 0.05 in comparison to AL I/R(Ips); **p b 0.01 in comparison to AL I/R(Ips); ***p b 0.001 in comparison
to AL I/R(Ips) group. (C & D) Representative immunoblots and quantification illustrating increases in the levels of inflammasome proteins such as NLRP1, NLRP3, ASC, pre-caspase-1, pre-
caspase-11 and pre-IL-1β and pre-IL-18 in ipsilateral brain tissues of C57BL/6J mice following middle cerebral artery occlusion (1 h) and reperfusion (24 h). Intermittent fasting (IF) sig-
nificantly reduced the levels of all inflammasome proteins aswell as pre-IL-1β and pre-IL-18. Data are represented as mean± SD. n= 5–6 animals in each group. *p b 0.05 in comparison
to AL I/R(Ips) **p b 0.01 in comparison to AL I/R(Ips); ***p b 0.001 in comparison to AL I/R(Ips) group. β-actin was used as a loading control.
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play a major role in neuronal cell death and sensorimotor impairment
following stroke (Fann et al., 2013a). The present results demonstrate
for the first time that dietary restriction in the form of intermittent
fasting can attenuate ischemic stroke-induced expression levels of
NLRP1 and NLRP3 inflammasome proteins, together with a correspond-
ing down-regulation of pro-inflammatory cytokines such as IL-1β and
IL-18 and pro-apoptotic protein cleaved caspase-3.
An increase in expression of NLRP1 and NLRP3 inflammasome pro-
teins and precursors of IL-1β and IL-18 in the brain following ischemic
strokemay be induced by the activationof pattern recognition receptors
(PRRs) present on neurons, glial and microvascular endothelial cells,
which detect damage associated molecular patterns (DAMPs) released
from necrotic tissue within the infarct core (Caso et al., 2007; Tang
et al., 2007, 2013). DAMPs activate PRRs such as toll-like receptors
(TLRs), the receptor for advanced glycation end products (RAGE), and
the IL-1 receptor 1 (IL-1R1) which activate intracellular NF-κB and
MAPK signaling pathways through a process known as ‘priming’ (Fann
et al., 2013b; Gross et al., 2011; He et al., 2012). Several studies have
provided evidence that activation of NF-κB and MAPK pathways occur
in neurons and glial cells during ischemic stroke (Arumugam et al.,
2011; Legos et al., 2001; Tang et al., 2007). Our current data shows
that I/R-induced activation of bothNF-κB andMAPK signaling pathways
was significantly down regulated by IF. This was supported by studies
that alternate-day fasting is neuro-protective and cardio-protective
against age-induced inflammation by inhibiting NF-κB and MAPK acti-
vation and oxidative damage via inhibition of the DNA binding activity
of NF-κB and activator protein 1 (AP-1) (Castello et al., 2010; Jung
et al., 2009; Tajes et al., 2010). Consequently, the NF-κB and MAPK
signaling pathways may induce the expression of NLRP1 and NLRP3
inflammasome proteins and the precursors of IL-1β and IL-18 under
ischemic conditions (Bauernfeind et al., 2009; He et al., 2012; Kang
et al., 2000; Liu et al., 2004; Zhao et al., 2013). Our previous findings
indicate that cerebral ischemia increased the expression of NLRP1 and
NLRP3 inflammasome proteins and precursors of IL-1β and IL-18, and
increased inflammasome activation demonstrated by an accumulation
of cleaved caspases 1 and 11, and mature IL-1β and IL-18 (Fann et al.,
2013a). Our findings suggest that the neuroprotective effects of IF are
associated with a significant reduction in the levels of NLRP1 and
NLRP3 inflammasome proteins as well as precursors of IL-1β and IL-
18 in a mouse model of focal ischemic stroke.
Our data indicate that IF significantly attenuated ischemia-induced
activation of caspase-3, which is associatedwith a decreased production
of cleaved caspase-1 and 11 and both mature pro-inflammatory cyto-
kines, IL-1β and IL-18. Cleaved caspase-1 has been shown to induce
apoptotic cell death by cleaving and activating the executioner caspases
3 and 7, and Bid (BH3 interacting death domain agonist) (Guégan et al.,
2002; Zhang et al., 2003). Furthermore, cleaved caspase 11 can activate
caspase-3 and cause apoptosis in neurons and glial cells under ischemic
conditions (Kang et al., 2000, 2003; Kayagaki et al., 2011). In addition,
it was shown that cleaved caspase 1 might require the presence of
cleaved caspase 11 for the maturation of precursors IL-1β and IL-18
(Kang et al., 2000, 2002). While the mechanism(s) by which IF reduces
inflammasome activation in ischemic stroke remains to be fully deter-
mined, the present data fit a model in which IF inhibits inflammasome
priming by decreasing the activity of both intracellular NF-κB and
MAPK signaling pathways. This effect would be expected to attenuate
Fig. 2. Intermittent fasting reduces inflammasome activity and cell death in a mouse model of focal ischemic stroke. (A & B) Representative immunoblots and quantification illustrating
increases in the levels of activated inflammasome proteins such as Cl.caspase-1 and Cl-caspase-11 andmaturation of IL-1β and IL-18 in ipsilateral brain tissues of C57BL/6Jmice following
middle cerebral artery occlusion (1 h) and reperfusion (24 h). Intermittent fasting (IF) significantly reduced the levels of Cl.caspase-1 and Cl-caspase-11 andmaturation of IL-1β and IL-18.
Data are represented asmean± SD. n= 5–6 animals in each group. **p b 0.01 in comparison to AL I/R(Ips); ***p b 0.001 in comparison to AL I/R(Ips) group. (C & D) Representative immu-
noblots and quantification illustrating increased levels of pro-apoptotic protein Cl.caspase-3 and reduced levels of anti-apoptotic protein Bcl-xL in ipsilateral brain tissues of C57BL/6Jmice
followingmiddle cerebral artery occlusion (1 h) and reperfusion (24 h). Intermittent fasting (IF) significantly reduced the levels of Cl.caspase-3 and increased the levels of Bcl-xL. Data are
represented as mean ± SD. n = 5–6 animals in each group. **p b 0.01 in comparison to AL I/R(Ips) group. β-actin was used as a loading control.
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the production of NLRP1 and NLRP3 inflammasome proteins and the
precursors of IL-1β and IL-18, thereby decreasing the production of
both cleaved caspases 1 and 11 and maturation of precursors IL-1β
and IL-18. We therefore speculate that IF would attenuate cleaved
caspase-1-dependent pyroptosis and apoptosis.
Dietary restriction was shown to substantially increase levels of the
anti-apoptotic protein Bcl-2 and Bcl-xL in heart cells (Niemann et al.,
2010; Peart et al., 2012). Studies have demonstrated that Bcl-2 can di-
rectly bind and inhibit the NLRP1 and NLRP3 receptors in macrophages
by specifically preventing ATP from binding onto the nucleotide-
binding domain (NBD) of both receptors (Bruey et al., 2007; Fann
et al., 2013a; Faustin et al., 2009; Shimada et al., 2012). Therefore,
inhibiting the oligomerization of the NLRP1 and NLRP3 receptor is
expected to reduce caspase 1 activation and maturation of IL-1β and
IL-18 (Bruey et al., 2007; Fann et al., 2013b; Faustin et al., 2009;
Shimada et al., 2012). Accordingly, it appears that Bcl-2 and Bcl-xL are
both tight regulators of NLRP1 receptor activation and Bcl-2 inhibits
NLRP3 receptor activation; however, whether Bcl-xL regulates NLRP3
receptor activation, and how IF increases Bcl-2 and Bcl-xL levels,
remains to be determined (Bruey et al., 2007; Faustin et al., 2009;
Shimada et al., 2012).
Conclusion
The presentfindings show that IF can suppress ischemia-induced ac-
tivation of the inflammasome in the cerebral cortex in amousemodel of
focal ischemic stroke. IF suppressed the activation of NF-κB and MAPK
signaling pathways which likely contributes to reduced expression of
NLRP1 and NLRP3 inflammasome proteins and the precursors of IL-1β
and IL-18, and reduced activation of caspases 1 and 11. These findings
suggest that therapeutic interventions that target inflammasome ex-
pression, assembly or activity during ischemiamay provide new oppor-
tunities in the treatment of ischemic stroke.
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Intravenous immunoglobulin suppresses NLRP1 and
NLRP3 inflammasome-mediated neuronal death in
ischemic stroke
D Yang-Wei Fann1, S-Y Lee1, S Manzanero1, S-C Tang2, M Gelderblom3, P Chunduri1, C Bernreuther4, M Glatzel4, Y-L Cheng1,
J Thundyil1, A Widiapradja1, K-Z Lok1, SL Foo1, Y-C Wang2, Y-I Li2, GR Drummond5, M Basta6, T Magnus3, D-G Jo7, MP Mattson8,
CG Sobey*,5 and TV Arumugam*,1,7,9
Multi-protein complexes called inflammasomes have recently been identified and shown to contribute to cell death in tissue
injury. Intravenous immunoglobulin (IVIg) is an FDA-approved therapeutic modality used for various inflammatory diseases. The
objective of this study is to investigate dynamic responses of the NLRP1 and NLRP3 inflammasomes in stroke and to determine
whether the NLRP1 and NLRP3 inflammasomes can be targeted with IVIg for therapeutic intervention. Primary cortical neurons
were subjected to glucose deprivation (GD), oxygen–glucose deprivation (OGD) or simulated ischemia-reperfusion (I/R).
Ischemic stroke was induced in C57BL/6J mice by middle cerebral artery occlusion, followed by reperfusion. Neurological
assessment was performed, brain tissue damage was quantified, and NLRP1 and NLRP3 inflammasome protein levels were
evaluated. NLRP1 and NLRP3 inflammasome components were also analyzed in postmortem brain tissue samples from stroke
patients. Ischemia-like conditions increased the levels of NLRP1 and NLRP3 inflammasome proteins, and IL-1b and IL-18, in
primary cortical neurons. Similarly, levels of NLRP1 and NLRP3 inflammasome proteins, IL-1b and IL-18 were elevated in
ipsilateral brain tissues of cerebral I/R mice and stroke patients. Caspase-1 inhibitor treatment protected cultured cortical
neurons and brain cells in vivo in experimental stroke models. IVIg treatment protected neurons in experimental stroke models
by a mechanism involving suppression of NLRP1 and NLRP3 inflammasome activity. Our findings provide evidence that the
NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke. We also identified
NLRP1 and NLRP3 inflammasome inhibition as a novel mechanism by which IVIg can protect brain cells against ischemic
damage, suggesting a potential clinical benefit of therapeutic interventions that target inflammasome assembly and activity.
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Stroke is the second leading cause of death worldwide and a
major cause of permanent disability. The molecular and
cellular mechanisms responsible for the degeneration of
neurons affected by stroke are complex and poorly under-
stood, but involve bioenergetic failure, acidosis, excitotoxicity,
oxidative stress and inflammation, resulting in necrotic or
apoptotic cell death.1–3 Post-stroke inflammation is a complex
process involving activation of innate local immune responses
in glial cells and recruitment of circulating leukocytes into the
affected brain tissue.4,5 Activated glia and leukocytes produce
multiple pro-inflammatory mediators including complement
anaphylatoxins, cytokines, chemokines and prostaglan-
dins.4,5 Recent findings have provided insight into a newly
discovered inflammatory mechanism that contributes to
neuronal and glial cell death in cerebral ischemia mediated
by multi-protein complexes called inflammasomes. Studies of
the inflammasome complex in peripheral tissues have
shown that it amplifies the production and secretion of pro-
inflammatory cytokines, and apoptotic and pyroptotic cell
death.6 It was recently reported that the nucleotide-binding
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oligomerization domain (NOD)-like receptor (NLR) pyrin
domain-containing (NLRP) inflammasomes has a role in the
inflammatory response during ischemic stroke.7
The NLRP1 and NLRP3 inflammasomes are cytosolic
macromolecular complexes composed of the NLRP1/3
receptor, ASC (apoptosis-associated speck-like protein con-
taining a caspase recruitment domain), precursor caspase-1,
precursor caspase-11 (homologous to precursor caspase-4 or 5
in humans) and/or XIAP (X-linked inhibitor of apoptosis).8–10
Activation and homo-oligomerization of NLRP1 and NLRP3
receptors induces formation of the NLRP1 and NLRP3
inflammasomes, respectively, which convert precursor cas-
pase-1 into cleaved caspase-1 via proximity-induced auto-
activation.6,10 Cleaved caspase-1 converts precursors of both
IL-1b and IL-18 into biologically active mature pro-inflamma-
tory cytokines that are then released into the extracellular
environment.7,11,12 Moreover, increased cleaved caspase-1
can initiate cell death directly via pyroptosis, or indirectly via
apoptosis.13,14 In stroke-related studies, reduced brain
expression of mature IL-1b and IL-18 was shown in mice
following cerebral ischemia, using an anti-NLRP1 antibody.7
Moreover, in caspase-1 knockout mice there was a reduction
in mature IL-1b and IL-18 levels in association with a smaller
infarct.15 Furthermore, administration of an IL-1b-neutralizing
antibody or IL-1 receptor antagonist reduced subarachnoid
hemorrhagic injury.16 However, the specific pathophysiological
role of the NLRP1 and NLRP3 inflammasome in neuronal
cell death following ischemic stroke remains to be established.
Intravenous immunoglobulin (IVIg) is an FDA-approved
therapeutic modality used for various inflammatory and
autoimmune diseases such as Kawasaki’s disease, immune
thrombocytopenia and humoral immunodeficiency.17,18 Thus,
IVIg has potential for diminishing inappropriate inflammatory
and immune activation and neuroprotection.19,20 IVIg can
inhibit complement activation and infiltration of leukocytes,
modulate the cytokine network and inhibit neuronal apoptosis
by cleaved caspase-3 in mouse models of ischemic stroke.21
The pleiotropic effects of IVIg in inhibiting multiple compo-
nents of inflammation in different cell types make it an
attractive candidate for use in stroke therapy.21–24 Potential
effects and underlying mechanisms of IVIg on inflammasome
activation in ischemic stroke-induced neuronal cell death have
not been reported. In the present study, we performed a
comprehensive investigation of the dynamic expression
patterns of the NLRP1 and NLRP3 inflammasome in primary
cortical neurons subjected to simulated ischemia, in a mouse
model of focal ischemic stroke, and in brain tissue samples
from stroke patients. We demonstrate expression and a
functional role for the NLRP1 and NLRP3 inflammasome in
neuronal cell death, and show that the neuroprotective effect
of IVIg in experimental stroke involves suppression of
inflammasome activity. Collectively, our findings reveal IVIg
as a potential therapeutic modality for targeting ischemic
stroke-induced inflammasome assembly and activity.
Results
Ischemia induces increased expression of inflammasome
proteins, and IL-1b and IL-18, in primary cortical neurons
in simulated ischemia. To determine whether ischemia-like
conditions activate the inflammasome in neurons, we
evaluated the temporal expression of all NLRP1 and NLRP3
inflammasome components in neurons subjected to simu-
lated ischemia-reperfusion (I/R). The levels of all major
inflammasome components and effectors were increased in
primary cortical neurons in response to glucose deprivation
(GD), oxygen–glucose deprivation (OGD) and simulated I/R
conditions including NLRP1, NLRP3, ASC, XIAP, and
precursor caspases 1 and 11 (Figures 1a–f; Supplementary
Figures 1–3). Levels of the latter proteins increased within 1 h
of exposure to simulated ischemia and remained elevated for
12–24h. Activation and oligomerization of the NLRP1 and
NLRP3 receptors individually induces the formation of the
NLRP1 and NLRP3 inflammasome, respectively, which then
activates both precursor caspase-1 and -11 into biologically
active cleaved caspase-1 and 11.10 Following activation,
caspase-1 cleaves both precursors IL-1b and IL-18 into
biologically active mature pro-inflammatory cytokines, which
are released into the extracellular environment.25 Consistent
with the notion that ischemic conditions increase NLRP1 and
NLRP3 inflammasome activation, we observed significantly
increased levels of both cleaved caspase-1 and ! 11 and
both mature IL-1b and IL-18 in primary cortical neurons
following GD, OGD or simulated I/R conditions over 24 h in
comparison with control (Figures 1a–f; Supplementary
Figures 1–3).
I/R induces increased expression of NLRP1 and NLRP3
inflammasome proteins and also IL-1b and IL-18 in
ipsilateral brain tissues of cerebral I/R mice and stroke
patients. The role of the NLRP1 and NLRP3 inflamma-
somes in ischemic stroke was further investigated by
measuring the expression levels of NLRP1 and NLRP3
inflammasome proteins in ipsilateral (i.e., ischemic) brain
tissues of cerebral I/R injury mice. It was shown that I/R
significantly increased the expression of NLRP1 and
NLRP3 inflammasome proteins, including NLRP1, NLRP3,
ASC, XIAP, precursor caspases 1 and 11 in ipsilateral brain
tissue as early as 1 h, and it remained higher at 12, 24, and
72 h following I/R in comparison with sham controls
(Figures 2a–c; Supplementary Figures 4 and 5). An
indication of NLRP1 and NLRP3 inflammasome activation
was demonstrated by increased levels of cleaved caspases
1 and 11, and both mature IL-1b and IL-18, at all time points
following I/R in comparison with sham controls (Figures 2a
and b). Furthermore, to determine whether increased
NLRP1 and NLRP3 inflammasome protein expression
might occur in the human brain following ischemic stroke,
we analyzed brain tissues obtained from stroke patients
at the University Medical Center Hamburg-Eppendorf
(Figures 3a and b) and National Taiwan University Hospital
(Supplementary Figures 6a and b). We found evidence that
ischemic stroke increased NLRP1 and NLRP3 inflamma-
some proteins and both IL-1b and IL-18 in comparison
with control patients (Figures 3a and b; Supplementary
Figures 6a and b). In addition, immunohistochemical
analysis in ipsilateral brain tissues from stroke patients
confirmed a higher level of cleaved caspase-1 in comparison
with control patients, suggesting increased inflammasome
activity (Supplementary Figure 6a).
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Caspase-1 inhibitor treatment protects cultured cortical
neurons and brain cells in vivo in experimental stroke
models. In light of the increased expression of NLRP1 and
NLRP3 inflammasome proteins and both IL-1b and IL-18 in
primary cortical neurons, we next determined the functional
role of inflammasomes in the degeneration of neurons
subjected to ischemia-like conditions. We tested the efficacy
of a caspase-1 inhibitor in primary cortical neurons under
ischemic conditions. Increasing concentrations of a caspase-
1 inhibitor Ac-YVAD-CMK (1–100 mM) were applied and
neurons were then analyzed for cleaved caspase-1, an
indicator of inflammasome activation. Caspase-1 inhibitor
Ac-YVAD-CMK concentrations above 30mM were effective in
reducing levels of cleaved caspase-1, as well as of cleaved
caspase-3, a marker of apoptosis (Figures 4a and b). Mouse
primary cortical neurons treated with a caspase-1 inhibitor
(30 and 100 mM) were less vulnerable to apoptotic cell death
under GD and OGD conditions (Figures 4a and b; Figures 4d
and e). The results of a cell viability assay showed that
caspase-1 inhibitor (30–100 mM) treatment reduced neuronal
cell death under GD conditions (Figures 4a and c). In
addition, we investigated the effect of caspase-1 inhibitor
Ac-YVAD-CMK (30 and 100mM) on the expression levels of
NLRP1 and NLRP3 inflammasome proteins and both precursor
and mature forms of IL-1b and IL-18 during a 6-h period of
OGD. Caspase-1 inhibition had no effect on levels of NLRP1,
NLRP3, ASC, XIAP, cleaved XIAP, precursor caspase-1,
caspase-11, and IL-1b and IL-18 precursors in comparison
Figure 1 Simulated ischemia increases the levels of multiple inflammasome proteins in primary cortical neurons. (a and b) Representative immunoblots and quantification
of inflammasome proteins, and IL-1b and IL-18, in lysates of cortical neurons at the indicated time points during GD. (c and d) Representative immunoblots and quantification
of inflammasome proteins, IL-1b and IL-18 in lysates of cortical neurons at the indicated time points during OGD. (e and f) Representative immunoblots and quantification of
inflammasome proteins, IL-1b and IL-18 in lysates of cortical neurons after simulated I/R. b-actin was used as a loading control. Data are represented as mean±S.E.M. n¼ 5
cultures. ***Po0.001 compared with control
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Figure 2 Evidence that focal ischemic stroke activates the inflammasome in cerebral cortical cells. (a and b) Representative immunoblots and quantification of
inflammasome proteins, IL-1b and IL-18 in ipsilateral brain lysates at the indicated post-stroke time points. Data are represented as mean±S.E.M. n¼ 3–6. *Po0.05;
**Po0.01; ***Po0.001 compared with SHAM (control). (c) Immunohistochemical analysis on caspase-1 and IL-1b show localization within the cytoplasm of cortical neurons.
The levels of inflammasome proteins, IL-1b and IL-18 are upregulated in I/R in comparison with SHAM (control). Magnification, " 1000. Scale bar, 10mm. Images were taken
under identical conditions and exposures
Figure 3 Evidence for inflammasome activation in brain tissue affected by stroke in human patients. (a and b) Immunohistochemical analysis of NLRP1, NLRP3, ASC,
IL-1b, IL-18 show localization within the cytoplasm of cortical neurons. The levels of inflammasome proteins and both IL-1b and IL-18 are elevated in brain tissues of stroke
patients in comparison with neurologically normal control subjects. H&E stain was used to distinguish cell types. Images were taken under identical conditions and exposures
Figure 4 Inhibition of caspase-1 reduces inflammasome activation and cell death in primary cortical neurons subjected to ischemia-like conditions. (a and b)
Representative immunoblots and quantification illustrating the effect of increasing concentrations (mM) of Ac-YVAD.CMK on levels of cleaved caspase-1 and caspase-3
proteins in primary cortical neurons subjected to GD. (c) The effect of Ac-YVAD.CMK treatment on cell death (%) in primary cortical neurons subjected to GD. (d and e)
Representative immunoblots and quantification illustrating the effect of 30 mM and 100mM Ac-YVAD.CMK treatment on inflammasome proteins, IL-1b, IL-18, and cleaved
caspase-3 in primary cortical neurons subjected to OGD. b-actin was used as a loading control. Data are represented as mean±S.E.M. n¼ 5–6 cultures. ***Po0.001
compared with control
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with vehicle controls under OGD conditions (Figure 4d).
However, caspase-1 inhibitor (30 and 100mM) treatment
reduced the levels of cleaved caspase-1 and both mature
IL-1b and IL-18 (Figures 4d and e). Furthermore, the levels of
cleaved caspase-3 were lower in caspase-1 inhibitor (30 and
100mM)-treated neurons in comparison with vehicle controls
under OGD conditions (Figure 4e).
We next evaluated the potential therapeutic efficacy of a
caspase-1 inhibitor in amousemodel of focal ischemic stroke.
A dose–response experiment was performed to identify the
efficacy of a caspase-1 inhibitor on brain infarct size. It was
found that whereas intravenous administration of the two
lower doses of the caspase-1 inhibitor (1 and 6mg/kg) at 3 h
after reperfusion had no effect on brain infarct size in
comparison with I/R vehicle controls (data not shown), both
10 and 20mg/kg reduced brain infarct size (Po0.0001) and
improved functional outcome in comparison with I/R vehicle
controls (Figures 5a and b). Cerebral blood flow measure-
ments obtained immediately before and after middle cerebral
artery occlusion (MCAO), and at 60, 120, and 180min after
reperfusion, showed a B90–95% reduction in blood flow in
the cerebral cortex supplied by the middle cerebral artery
during ischemia, and flow was not significantly different
between groups at up to 180min of reperfusion (data not
shown). In addition, we investigated the effect of a caspase-1
inhibitor (10mg/kg) on levels of the NLRP1 and NLRP3
inflammasome proteins and IL-1b and IL-18 precursor
proteins in ipsilateral brain tissues 24 h after I/R. Caspase-1
inhibition had no effect on expression of NLRP1, NLRP3,
ASC, XIAP, cleaved XIAP, caspase-1 precursor, caspase-11,
and IL-1b and IL-18 precursors in comparison with vehicle
controls (Figure 5c). However, the caspase-1 inhibitor at
10mg/kg significantly reduced the levels of cleaved caspase-1
and both mature IL-1b and IL-18 at 24 h following I/R
(Figures 5c and d). Furthermore, levels of cleaved caspase-3
were lower in caspase-1 inhibitor (10mg/kg)-treated groups in
comparison with vehicle controls (Figures 5c and d).
IVIg treatment protects primary cortical neurons and
brain tissue by decreasing inflammasome activity under
in vitro and in vivo ischemic conditions. We recently
identified IVIg as a potent stroke therapy.21,24 Specifically,
we reported that administration of IVIg to mice subjected to
experimental stroke significantly reduced brain infarct size
and nearly eliminated mortality. Moreover, there was a
reduced volume of infarct, but within the ischemic region
neurons were spared and only occasional cell loss was
observed. Recently, it was demonstrated that IVIg could
decrease the activity of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) and mitogen-activated
protein kinases (MAPK) signaling pathways in neurons under
ischemic conditions through an unknown mechanism.24 We
therefore investigated the effect of IVIg (5mg/ml) on levels of
the NLRP1 and NLRP3 inflammasome proteins and IL-1b
and IL-18 in primary cortical neurons under GD conditions
over 6, 12 or 24 h. Indeed, we found that IVIg treatment
significantly decreases levels of NLRP1, NLRP3, ASC, XIAP,
caspase-1, caspase-11, IL-1b and IL-18 in comparison with
vehicle-treated neurons during GD (Figures 6a and b;
Supplementary Figure 7). Furthermore, levels of cleaved
caspase-3 were significantly lower in IVIg (5mg/ml)–treated,
compared with vehicle-treated neurons during GD
(Figures 6a and b). In addition, immunocytochemical analysis
indicated that levels of inflammasome proteins and both IL-1b
and IL-18 were lower in IVIg-treated neurons compared with
vehicle-treated neurons after 12h of GD (Figure 6c).
We also investigated the effect of IVIg (5mg/ml) on levels of
NLRP1 and NLRP3 inflammasome proteins and both IL-1b
and IL-18 in primary cortical neurons subjected to transient
OGD (simulated I/R) conditions. We found that IVIg treatment
inhibited the simulated I/R-induced elevation of NLRP1,
NLRP3, IL-1b and IL-18 levels (Figures 6d and e;
Supplementary Figure 8). Furthermore, IVIg treatment
significantly attenuated the simulated I/R-induced increase
in levels of NLRP1, NLRP3, ASC, XIAP, cleaved XIAP,
caspase-1, caspase-11, IL-1b, and IL-18 and cleaved
caspase-3 (Figures 6d and e).
We also tested the effect of IVIg treatment on inflamma-
some activity in vivo following experimental stroke.
Intravenous administration of 1 g/kg IVIg at 3 h following
reperfusion was previously reported to reduce brain infarct
size and improve neurological outcome in rodent stroke
Figure 5 A caspase-1 inhibitor improves neurological outcome, reduces infarct size and suppresses the inflammasome in a mouse model of focal ischemic stroke. (a) The
effect of Ac-YVAD.CMK (10mg/kg and 20mg/kg) treatment on neurological scores of C57BL/6J mice following MCAO (1 h) and reperfusion at indicated times. *Po0.05.
(b) The effect of Ac-YVAD.CMK (10mg/kg and 20mg/kg) treatment on ipsilateral infarct area (%) of C57BL/6J mice. n¼ 9–11 in each group. *Po0.05, ***Po0.001.
(c) Representative images of brains from each treatment group. (d) Representative immunoblots and quantification illustrating the effect of Ac-YVAD.CMK (30 and 100mM)
treatment on the expression levels of inflammasome proteins, IL-1b, IL-18, and cleaved caspase-3 following MCAO (1 h) and reperfusion (24 h) in ipsilateral brain tissues of
C57BL/6J mice. (e) Administration of Ac-YVAD.CMK significantly reduces the levels of inflammasome proteins, IL-1b, IL-18, and cleaved caspase-3. Data are represented as
mean±S.E.M. n¼ 5–6 animals. ***Po0.001 compared with I/R
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models.21,24 Here, we investigated the effect of IVIg
(1 g/kg) on levels of NLRP1 and NLRP3 inflammasome
proteins, and IL-1b and IL-18, in ipsilateral brain tissue at
6 and 24 h of I/R. IVIg treatment significantly decreased
levels of NLRP1 and NLRP3 inflammasome proteins, and
IL-1b and IL-18, in comparison with vehicle-treated mice
(Figures 6f and g; Supplementary Figure 9). Furthermore,
levels of cleaved caspase-3 were significantly lower in IVIg
(1 g/kg)-treated groups in comparison with vehicle controls
(Figures 6f and g).
Discussion
Inflammation is a major contributor to the pathogenesis of
ischemic stroke. The deleterious effects of the inflammatory
response following cerebral ischemia are mediated by
Figure 6 IVIg treatment inhibits the inflammasome in cultured cortical neurons subjected to simulated ischemia, and in a mouse model of focal ischemic stroke. (a and b)
Representative immunoblots and quantification illustrating increases in the levels of inflammasome proteins, and both IL-1b and IL-18 in primary cortical neurons at indicated
times during GD. Administration of IVIg (5 mg/ml) significantly reduces the levels of inflammasome proteins and both IL-1b and IL-18. Data are represented as mean±S.E.M.
n¼ 6 cultures. ***Po0.001 in comparison with GD. (c) Immunocytochemical analysis of NLRP1, ASC, caspase-1, IL-1b, and IL-18 show localization within the cytoplasm of
primary cortical neurons. The levels of inflammasome proteins and both IL-1b and IL-18 are elevated in neurons subjected to GD. Treatment with IVIg (5mg/ml) significantly
reduced the levels of inflammasome proteins and both IL-1b and IL-18 in neurons subjected to GD. Magnification " 1000. Scale bar, 10mm. Images were taken under
identical conditions and exposures. (d and e) Representative immunoblots and quantification illustrating increases in the levels of inflammasome proteins and both IL-1b and
IL-18 in primary cortical neurons subjected to simulated I/R. Administration of IVIg (5 mg/ml) significantly reduces the levels of inflammasome proteins and both IL-1b and
IL-18. Data are represented as mean±S.E.M. n¼ 6 cultures. *Po0.05; **Po0.01; ***Po0.001 in comparison with cultures not treated with IVIg. (f and g) Representative
immunoblots and quantification illustrating increase in the levels of inflammasome proteins and both IL-1b and IL-18 in ipsilateral brain tissues of C57BL/6J mice following
MCAO (1 h) and reperfusion (6 and 24 h). b-actin was used as a loading control. Administration of IVIg (1 g/kg) significantly reduces the levels of inflammasome proteins and
both IL-1b and IL-18. Data are represented as mean±S.E.M. n¼ 5–6 animals in each group. ***Po0.001 in comparison with I/R (6 and 24 h)
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neurons, glial cells, endothelial cells, and infiltrating leuko-
cytes in the brain, which secrete numerous cytokines and
chemokines at the site of injury. Studies have shown that
pro-inflammatory cytokines such as IL-1b and IL-18 have a
significant role in cerebral ischemic damage.7,9,26,27
A macromolecular complex, termed the inflammasome, in
particular the NLRP1 and NLRP3 inflammasomes, regulate
the maturation of these pro-inflammatory cytokines. The
present study provides strong evidence that the NLRP1 and
NLRP3 inflammasomes have a major role in neuronal cell
death and behavioral outcome following stroke. The second
part of the study investigated the effect of IVIg treatment on
ischemic stroke-induced NLRP1 and NLRP3 inflammasome
activity. A high concentration of IVIg has been reported to
exert protective effects in neurons during ischemic
conditions.21,23,24 The present results demonstrate for the first
time that IVIg modulates ischemic stroke-induced NLRP1 and
NLRP3 inflammasome levels, with a corresponding down-
regulation of the pro-inflammatory cytokines IL-1b and IL-18.
An increase in expression of NLRP1 and NLRP3 inflamma-
some proteins and IL-1b and IL-18 precursor proteins in
neurons under ischemic conditions may be induced by the
activation of pattern recognition receptors (PRRs), such as
toll-like receptors (TLRs), the receptor for advanced glycation
end products (RAGE), and the IL-1 receptor 1 (IL-1R1)
present on neurons and glial cells, which detect damage-
associated molecular patterns (DAMPs) released from
necrotic tissue within the infarct core.28–31 TLR and pro-
inflammatory cytokine signaling activate intracellular NF-kB
and MAPK signaling pathways resulting in increased produc-
tion of NLRP1 and NLRP3 inflammasome proteins and IL-1b
and IL-18 precursors, a process called ‘priming’.32–35 The
activation and oligomerization of the NLRP1 and NLRP3
receptors in response to DAMPs, or irregularities within the
cellular microenvironment under ischemic conditions, results
in the formation of the NLRP1 and NLRP3 inflammasome,
which then activates precursor caspase-1 into cleaved
caspase-1 through proximity-induced auto-activation facilitat-
ing the cleavage of IL-1b and IL-18 precursors to generate
their biologically active mature forms.7,9 Although previous
studies have shown that priming is required for the expression
of NLRP1 and NLRP3 inflammasome proteins and IL-1b and
IL-18 precursor proteins in immune cells,25,36 it is not known
whether inflammasome priming occurs similarly in neurons
during ischemic conditions.
We found that when cultured cortical neurons were
subjected to ischemia-like conditions (GD or OGD), NLRP1
and NLRP3 proteins were increased, and this was accom-
panied by elevated levels of cleaved caspase-1 and cleaved
caspase-11, and maturation of IL-1b and IL-18 precursor
proteins. Furthermore, immunofluorescence data showed
expression and localization of these proteins in the cytoplasm
of neurons following ischemia. These findings suggest that
the NLRP1 and NLRP3 inflammasome complex is formed in
neurons following cerebral ischemic damage. In relation to
ischemic stroke, no DAMPs have yet been identified that can
directly activate the NLRP1 and NLRP3 receptors in neurons.
However, evidence suggests that ATP, released from necrotic
neurons in culture, and in the ischemic core in vivo, binds to
P2X7 receptors on the plasma membrane of neighboring
neurons and glial cells to cause the opening of ligand-gated
ion channels and increased efflux of Kþ .37,38 A decreased
intracellular Kþ ion concentration in neurons and glial cells
may induce activation of the NLRP1 and NLRP3 receptors,
either directly or indirectly through an unknown mechanism.39
Recent studies have suggested that stimulation of astrocytes
with ATP results in activation of the NLRP2 inflammasome,
and that ATP-induced activation of the NLRP2 inflammasome
was inhibited by a pannexin 1 inhibitor and a P2X7 receptor
antagonist.40,41 The ATP-dependent oligomerization of
NLRPs will then promote cleavage of precursor caspase-1
into cleaved caspase-1, which in turn will cleave IL-1b and
IL-18 into their mature forms.39,40,41
The current data show an increase in levels of the NLRP1
and NLRP3 receptors and in the products of inflammasome
activation in cultured neurons subjected to simulated ische-
mia. However, whether activation of the NLRP1 and NLRP3
inflammasome in neurons under ischemia-like conditions is a
result of ATP release from necrotic neurons remains to be
determined. The increase in levels of both mature IL-1b and
IL-18 under ischemia-like conditions in vitro supports findings
in which both IL-1b and IL-18 were implicated in causing
autocrine and paracrine effects by binding to their respective
receptors on the plasma membrane of neighboring neurons
and glial cells, and activating NF-kB and MAPK signaling
pathways.42 Accordingly, increased priming would be
expected to lead to increased production of NLRP1 and
NLRP3 inflammasome proteins and IL-1b and IL-18 precursor
proteins. In addition, these pro-inflammatory cytokines will
induce secondary injuries by facilitating leukocyte recruit-
ment, which in turn leads to an increased production of
reactive oxygen species and pro-inflammatory cytokines, thus
exacerbating neuronal cell death and tissue damage during
ischemia.7,41,43
Our findings indicate increased levels of not only cleaved
caspase-1 but also cleaved caspase-11, in neurons under
ischemia-like conditions. Recent evidence suggests that
cleaved caspase-1 may require the presence of cleaved
caspase-11 for the maturation of IL-1b and IL-18
precursors.44 Cleaved caspase-11 can activate caspase-3
and cause apoptosis in neurons and glial cells under ischemic
conditions.45 Another role of cleaved caspase-1 is to induce
apoptotic cell death by cleaving Bid (BH3 Interacting Domain
Death Agonist) into its truncated form and activating both
executioner caspases-3 and -7, respectively.46,47 Our data
further support the role of the NLRP1 and NLRP3 inflamma-
some in mediating apoptotic cell death in neurons under
ischemic conditions.
It was previously reported that intracerebroventricular
administration of the caspase-1 inhibitor Ac-YVAD.CMK
reduced brain damage in a rat permanent MCAO stroke
model.47 We found that IVIg and Ac-YVAD.CMK inhibited
activation of caspase-3. This link between the inflammasome
and apoptotic cascades supports the idea that increased
expression levels of cleaved caspase-1 may mediate a
number of pleiotropic effects.13,46,47,48 Besides apoptosis,
pyroptosis is another form of cell death directly linked to the
inflammasome. Studies suggest that pyroptosis is exclusively
regulated by cleaved caspase-1, which induces pore forma-
tion in the plasma membrane of cells, thereby allowing an
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osmotic influx of water molecules to cause cell lysis and
release of pro-inflammatory contents.13,49 However, whether
neurons undergo pyroptosis during cerebral ischemia
remains to be determined.
We previously reported that treatment of cultured neurons
with IVIg reduced ischemic neuronal cell death, in part, by
inhibiting the complement cascade.21 The present results
demonstrate neuroprotective effects of IVIg on ischemia-
induced NLRP1 and NLRP3 inflammasome activity in primary
cortical neurons. We found evidence that the neuroprotective
effects of IVIg are associated with a significant reduction in the
levels of NLRP1 and NLRP3 inflammasome proteins as well
as precursors of both IL-1b and IL-18 during simulated
ischemia in vitro and in a mouse model of focal ischemic
stroke. IVIg was previously shown to reduce activation of
caspase-3 and to protect neurons from undergoing apoptosis
under ischemic conditions.21,24
Although the molecular basis of the neuroprotective action
of IVIg in ischemic stroke-induced NLRP1 and NLRP3
inflammasome activity remains to be established, the present
data fit a model in which IVIg inhibits inflammasome priming
by decreasing the activity of both intracellular NF-kB and
apoptotic MAPK signaling pathways, a possibility consistent
with the recent report that IVIg protects neurons from cell
death under ischemic conditions by inhibiting the phosphory-
lation levels of NF-kB, p38, and JNK.24 This effect would be
expected to attenuate the production of NLRP1 and
NLRP3 inflammasome proteins and IL-1b and IL-18 pre-
cursors, thereby decreasing the production of both cleaved
caspase-1 and caspase-11 and hence mature IL-1b and
IL-18. Indeed, we found that both IVIg and the caspase-1
inhibitor blockedmaturation of IL-1b and IL-18 precursors.We
therefore speculate that cleaved caspase-1-dependent pyr-
optosis and apoptosis would be reduced by IVIg treatment.
Consistent with the latter possibility, IVIg can increase the
expression of the anti-apoptotic protein Bcl-2 in cultured
cortical neurons and in an animal model of stroke24
(Supplementary Figure 10). Studies have demonstrated that
Bcl-2 and Bcl-xL, both anti-apoptotic proteins, directly bind
and inhibit the NLRP1 receptor in macrophages by specifically
preventing ATP from binding onto the nucleotide-binding
domain (NBD) in the NLRP1 receptor.50,51 Therefore,
inhibiting the oligomerization of the NLRP1 receptor is likely
to reduce caspase-1 activation and maturation of both IL-1b
and IL-18.50,51 Accordingly, it appears that both Bcl-2 and
Bcl-xL are tight regulators of NLRP1 receptor activation;
however, whether Bcl-2 and Bcl-xL regulate NLRP3 receptor
activation, and how IVIg increases Bcl-2 levels, remain to be
determined.
Previous reports have suggested IVIg to be a promising
therapeutic modality for targeting a number of injury mechan-
isms in multiple cell types under ischemic conditions.19,21,24
The present study has identified a novel mechanism by which
IVIg can protect neurons and brain tissue from ischemic
damage. These findings suggest that therapeutic interven-
tions targeting inflammasome assembly and activity during
ischemia may offer substantial promise. Hence, continued
investigation into the mechanisms underlying NLRP1 and
NLRP3 inflammasome activity in settings of brain tissue injury
and neurodegeneration is warranted.
Materials and Methods
Focal cerebral I/R stroke model. Three-month-old C57BL/6J male mice
were subjected to transient middle cerebral artery I/R injury, as described
previously.52 Briefly, after making a midline incision in the neck, the left external
carotid and pterygopalatine arteries were isolated and ligated with 6-0 silk thread.
The internal carotid artery (ICA) was occluded at the peripheral site of the
bifurcation with a small clip and the common carotid artery (CCA) was ligated with
5-0 silk thread. The external carotid artery (ECA) was cut, and a 6-0 nylon
monofilament with a tip that was blunted (0.20–0.22mm) with a coagulator was
inserted into the ECA. After the clip at the ICA was removed, the nylon thread was
advanced to the origin of the middle cerebral artery until light resistance was
evident. The nylon thread and the CCA ligature were removed after 1 h to initiate
reperfusion. In the sham group, surgery was performed until the arteries were
visualized. Mice were administered with either 10 or 20mg/kg of a caspase-1
inhibitor (20ml; Ac-YVAD-CMK, Cayman Chemical, Ann Arbor, MI, USA), 1 g/kg of
IVIg (250ml; Privigen, CSL Behring, King of Prussia, PA, USA, CSL) or vehicle by
infusion into the femoral vein 3 h after the start of reperfusion. In a separate set of
experiments, anesthetized animals from all groups (5–6 mice per group)
underwent cerebral blood flow measurements using a laser Doppler perfusion
monitor (Moor Lab, Moor Instruments, Axminster, UK).
The functional consequences of I/R injury were evaluated using a five-point
neurological deficit score (0, no deficit; 1, failure to extend right paw; 2, circling to the
right; 3, falling to the right; and 4, unable to walk spontaneously) and were assessed
in a blinded fashion. At 72 h of reperfusion, the mice were euthanized with a lethal
dose of isoflurane. Brains were immediately removed and placed into phosphate-
buffered saline (PBS; Sigma-Aldrich, Castle Hill, NSW, Australia) at 4 1C for 15min,
and four 2-mm coronal sections were made from the olfactory bulb to the
cerebellum. The brain sections were stained with 2% 2,3,5-triphenyltetrazolium
chloride in PBS at 37 1C for 15min. The stained sections were photographed and
the digitized images used for analysis. Borders of the infarct in the image of each
brain slice were outlined and the area quantified (NIH Image J software). To correct
for brain swelling, the infarct area was determined by subtracting the area of
undamaged tissue in the left hemisphere from that of the intact contralateral
hemisphere. The infarct volume was determined by calculating the percentage of
infarcted area in each brain slice, and then integrating the infarct areas for all slices
of each brain. All in vivo experimental procedures were approved by The University
of Queensland Animal Care and Use Committee.
Primary cortical neuronal cultures. Dissociated neuron-enriched cell
cultures of cerebral cortex were established from day 16 C57BL/6J mouse
embryos, as described.53 Experiments were performed in 7–9 day-old cultures.
Approximately 95% of the cells in such cultures were neurons, and the remaining
cells were astrocytes. For glucose-deprivation studies, glucose-free Locke’s buffer
containing: 154mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 1 mM MgCl2, 3.6 mM
NaHCO3, 5mM HEPES, pH 7.2, supplemented with gentamicin (5mg/l) was used.
The cultured neurons were incubated in glucose-free Locke’s buffer for 1–24 h.
Controls were incubated in Locke’s buffer containing 10mM glucose. For OGD,
neurons were incubated in glucose-free Locke’s buffer in an oxygen-free chamber
for 3, 6, or 12 h. For simulated I/R experiments, neurons were incubated in
glucose-free Locke’s medium in an oxygen-free chamber for 3 h and then the
mediumreplaced with glucose-containing Neurobasal medium for 3, 6, 12, or 24 h.
To observe the effect of a caspase-1 inhibitor (Ac-YVAD-CMK) or IVIg, either drug
were added to cultures during and after GD, OGD or simulated I/R. Control
conditions included exposure to vehicle or a negative control protein (bovine
serum albumin (BSA)) (Sigma-Aldrich).
Cell viability. Neuronal cell viability was determined by trypan blue exclusion
assay. The assay is based on the principle that live cells possess intact cell
membranes, which will exclude the dye trypan blue, while the membrane of injured
or dead cells is permeable to trypan blue. Hence, injured or dead cells are stained
blue whereas live cells will show no staining. Following incubation with trypan blue,
the plates were emptied and the cells fixed with 4% paraformaldehyde for 20min
at room temperature. The cells were then washed with PBS three times and
stored in PBS for latter observation under a light microscope to quantify the
percentage of cells that were trypan blue-positive in each culture.
Western blot analysis. Protein samples were subjected to sodium dodecyl
sulfate–polyacrylamide (10%) gel electrophoresis using a Tris-glycine running
buffer. Gels were then electro-blotted using a transfer apparatus (Bio-Rad
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Laboratories, Inc., Hercules, CA, USA) in transfer buffer containing 0.025mol/l Tris
base, 0.15mol/l glycine, and 10% (v/v) methanol for 1.5 h at 15 V onto a
nitrocellulose membrane (Bio-Rad Laboratories, Inc.). The membrane was then
incubated in blocking buffer (5% non-fat milk in 20mM Tris-HCl, pH 7.5, 137mM
NaCl, 0.2% Tween-20) for 1 h at 23 1C. The membrane was then incubated
overnight at 4 1C with primary antibodies including those that selectively
bind NLRP1 (Novus Biologicals, Littleton, CO, USA), NLRP3 (Novus Biologicals),
ASC (Abcam, Cambridge, UK), caspase-1 (Abcam), caspase-11 (Abcam), XIAP
(Novus Biologicals), IL-1b (Abcam), IL-18 (Abcam), Bcl-2 (Cell Signaling
Technology, Danvers, MA, USA), cleaved caspase-3 (Cell Signaling Technology)
and b-actin (Sigma-Aldrich). After washing three times (10min per wash) with
Tris-buffered saline-T (20mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.2% Tween-20),
the membrane was incubated with secondary antibodies against the primary
antibody and b-actin for 1 h at room temperature. The membrane was washed
with Tris-Buffered saline-T and scanned using the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA). Quantification of protein levels
was achieved by densitometry analysis using Image J software.
Immunocytochemistry and immunohistochemistry. Coverslips
containing cortical neurons subjected to either control Neurobasal medium or
GD medium were fixed in 4% buffered paraformaldehyde in PBS. Fixed cells were
permeabilized and incubated in blocking solution (1% BSA and 0.1% Triton-X in
PBS) at room temperature for 1 h before overnight incubation at 4 1C with
microtubule-associated protein 2 antibody (MAP2, mouse monoclonal, Millipore,
Temecula, CA, USA) along with primary antibodies that selectively bind NLRP1
(Novus Biologicals), ASC (Abcam), caspase-1 (Abcam), caspase-11 (Abcam),
IL-1b (Abcam) or IL-18 (Abcam) diluted in blocking solution. Following incubation
with primary antibodies, the cells were incubated with the appropriate Alexa Fluor-
conjugated secondary antibodies (Invitrogen) for 1 h at room temperature. The nuclei
were counterstained with DAPI (AbD Serotec, Oxford, UK) for 10min at room
temperature. Following secondary antibody incubation, coverslips were sealed with
Vectashield Fluorescent Mounting Medium (Vector Laboratories, Burlingame, CA,
USA) on glass slides. For immunohistochemistry, frozen cryostat brain sections were
obtained from sham and focal ischemic stroke mice following trans-cardiac perfusion
with 4% paraformaldehyde and immunostained with primary antibodies against
NLRP1 (Novus Biologicals), ASC (Abcam), caspase-1 (Abcam), caspase-11
(Abcam), IL-1b (Abcam) or MAP2 (Abcam). Images were acquired using an
Olympus BX61 confocal laser-scanning microscope (Olympus, Tokyo, Japan) with a
! 100 oil immersion objective. Single confocal images were converted to 512! 512
pixel 12-bit TIFF images.
Patient brain tissue samples. Human brain tissues were obtained from
anonymized autopsy patients from files of the Institute of Neuropathology at the
University Medical Center Hamburg-Eppendorf and National Taiwan University
Hospital, as approved by the National Taiwan University Hospital ethics
committee. Brain specimens had been fixed in 4% buffered formalin for at least
3 weeks before paraffin embedding. Brain sections (3mm) were stained according
to standard immunohistochemistry procedures with primary antibodies against
NLRP1 (Novus Biologicals), NLRP3 (Abcam), ASC (Abcam), caspase-1 (Abcam),
IL-1b (Abcam) or IL-18 (Novus Biologicals).
Statistical analysis. Numerical values are expressed as mean±S.E.M.
Statistical analysis of all data except the behavioral score data were performed
using one-way ANOVA followed by a Bonferroni post hoc analysis to determine
between-group differences. Statistical difference was taken as Po0.05.
Neurological behavior scores were analyzed using a non-parametric Kruskal–
Wallis test and Dunn’s Multiple Comparison test. Statistical analyses were
performed using GraphPad Prism 5.02 software.
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Abstract
Calsenilin is a calcium sensor protein that interacts with presenilin and increases calcium-
triggered neuronal apoptosis, and g-secretase activity. Notch is a cell surface receptor that
regulates cell-fate decisions and synaptic plasticity in brain. The aim of the present study
was to characterize the role of calsenilin as a regulator of the g-secretase cleavage of Notch
in ischemic stroke. Here, we determined the modulation of expression level and cellular
distribution of calsenilin in neurons subjected to ischemic-like conditions. The levels of
calsenilin and presenilin were increased in primary neurons after oxygen and glucose
deprivation. Furthermore, calsenilin was found to enhance the g-secretase cleavage of
Notch and to contribute to cell death under ischemia-like conditions. The inhibition
of g-secretase activity and a presenilin deficiency were both found to protect against
calsenilin-mediated ischemic neuronal death. The expression of calsenilin was found to be
increased in brain following experimental ischemic stroke. These findings establish a
specific molecular mechanism by which the induction of calsenilin enhances Notch acti-
vation in ischemic stroke, and identify calsenilin as an upstream of the g-secretase cleavage
of Notch.
INTRODUCTION
g-Secretase is an intramembrane multi-protein complex that
cleaves many type-I proteins. Some of these proteins are relevant
in the brain, such as the N- and E-cadherins, that participate in
neuronal development and synapse formation (21). Furthermore,
the cleavage of amyloid precursor protein (APP) by g-secretase
contributes to the generation of amyloid-b peptide in Alzheimer’s
disease (10, 12, 15). Moreover, Notch-1 is cleaved by g-secretase
to form Notch intracellular domain (NICD), a transcription factor
responsible for cell-fate determination in the developing nervous
system (23). g-Secretase is composed of four integral membrane
proteins, including presenilin (PS) as a catalytic subunit. PS has
two isoforms, PS-1 and PS-2, that have equivalent catalytic activi-
ties within g-secretase complex (27), and both isoforms are located
in the plasma membrane and in the membranes of the endoplasmic
reticulum (ER) and Golgi (4, 13).
Calsenilin is a neuronal Ca2+-binding protein and a member
of the recoverin family, and is distinguished from other family
members by the presence of a long N-terminal domain (29).
Calsenilin has been independently described as a binding partner
for PS (5), as a gene transcription repressor termed “downstream
regulatory element antagonist modulator” (6), and as a potassium
channel modulator (1). Although not necessary for g-secretase
activity, calsenilin binds PS-C-terminal fragments (CTF), but
its modulation of PS activity seems to be substrate-dependent.
Calsenilin was shown to increase g-secretase cleavage of APP
in the presence of Ca2+ (16), and this effect of calsenilin was
completely abrogated by a g-secretase inhibitor. We previously
reported that aberrant Notch signaling induced by cerebral
ischemia worsens brain damage and functional outcome. In these
previous studies, we found that brain damage and post-ischemic
inflammation were significantly attenuated in Notch antisense
mice and in normal mice treated with g-secretase (2, 26).
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However, the role of calsenilin as a regulator of g-secretase cleav-
age of Notch in ischemic stroke has not been determined.
Here we show that calsenilin contributes to g-secretase-
mediated Notch signaling and to the activations of downstream
apoptotic proteins under ischemic stroke conditions. In addition,
we found that focal ischemia increases calsenilin levels in the
brain, and that these increases are correlated with cell death.
Finally, we examined the effect of g-secretase inhibition on the
activation of apoptotic proteins and on the over-expression of
calsenilin.
MATERIALS AND METHODS
Middle cerebral artery occlusion (MCAO)
Three-month-old C57BL/6 male mice were used for in vivo
experiments. The focal cerebral ischemia/reperfusion was induced
by MCAO as described previously (2). MCAO was induced by the
intraluminal filament technique. In brief, a 6-0 nylon filament was
inserted through the external carotid artery stump and advanced
into the right internal carotid artery until it blocked the origin of
the middle cerebral artery. After 60 min of MCAO, the filament
was withdrawn to restore blood flow. Sham-operated mice under-
went the same surgical procedure without filament insertion.
Rectal temperature was monitored throughout the entire duration
of the surgical procedure and maintained at 37.5°C with a
feedback-controlled heating pad. These procedures were approved
by the University of QueenslandAnimal Care and Use Committee.
Transient global cerebral ischemia in rats
Animal experiments were performed in accordance with the
Guide of Ulsan University College of Medicine for Care and Use
of Laboratory Animals. Under halothane anaesthesia, common
carotid arteries of male Sprague–Dawley rats weighing 300–350 g
were bilaterally occluded with vascular clamps and mean arterial
blood pressure was lowered to 50! 5 mmHg by withdrawing
blood from the femoral artery. After 12 min, the blood perfusion
was recovered by removing clips and reinfusion of blood. During
and for 2 h after the ischemic surgery, body and brain temperatures
were maintained at 37.5°C using a heating blanket and lamp.
Sample processing for brain sections
Brains were fixed by transcardial perfusion with saline followed
by perfusion and immersion in 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) and immersed into a sucrose
gradient from 10 to 30% for cryopreservation. Serial coronal sec-
tions (10-mm thickness) were cut with a freezing microtome (Leica
1900, Wetzlar, Germany) and collected on slides.
Tissue preparation and cresyl violet stain
At 24, 48 and 72 h after ischemia, brains were removed and
quickly frozen in liquid nitrogen. Coronal brain sections contain-
ing hippocampus were prepared with cryostat (10-mm thickness)
and put onto the slide glass pre-coated with poly-L-lysine. To
identify neuronal death, the brain sections were stained with 0.5%
cresyl violet.
Immunohistochemistry
To verify immunocytochemically the expression of calsenilin in
brain, sections were exposed to an anti-calsenilin (Upstate, Lake
Placid, NY, USA) antibody. Briefly, after incubating in 0.2% H2O2
for 10 min, brain sections were blocked with 3% goat serum con-
taining 0.3%Triton X-100 and incubated overnight with anti-rabbit
calsenilin polyclonal antibody diluted at 1:100. After reaction with
biotinylated secondary antibody (goat anti-rabbit immunoglobulin
G;Vector Labs, Burlingame, CA, USA), sections were treated with
avidin-horseradish peroxide solution and developed by a nickel-
enriched reaction with diaminobenzidine and hydrogen peroxide.
Anti-calsenilin immunopositive cells in the hippocampus were
examined under a light microscope (Olympus, Tokyo, Japan) and
photographed with a digital camera (Camedia C2000; Olympus).
Calsenilin co-localization with astrocytes, microglia and endo-
thelium in the mouse stroke brain was performed in 10-mm cryo-
sections using the following antibodies: rabbit anti-calsenilin
(Abcam), mouse anti-glial fibrillary acidic protein (GFAP) (Sigma,
St. Louis, MO, USA), goat anti-Iba1 (Abcam, Cambridge, UK) and
sheep anti-VonWillebrand Factor (Abcam). Images were examined
under a confocal BX-61 Olympus microscope.
Hippocampal and cortical neuron
primary cultures
Dissociated cell cultures of neocortical fragments and hippocampi
were prepared from 16-day C57BL/6 mouse embryos as described
previously (22). Cells were plated in 35- and 60-mm diameter
plastic dishes or 96-well plates and maintained at 37°C in neuro-
basal medium containing 25 mM glucose and B-27 supplements
(Invitrogen, Carlsbad, CA, USA), 2 mM L-glutamine, 0.001%
gentamicin sulfate, and 1 mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) at pH 7.2. Approximately, 95%
of the cells in such cultures were neurons and the remaining
cells were astrocytes. Caspase inhibitors, 20 mM Z-Val-Ala-Asp
(VAD)-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone; Enzyme System Products, Livermore, CA,
USA) and 10 mM Asp-Glu-Val-Asp (DEVD)-Asp-Glu- Val-Asp
(CHO) (Calbiochem, Billerica, MA, USA) was added into culture
medium 2 h before hypoxia.
Plasmid DNA and siRNA
To construct plasmid expressing calsenilin (calsenilin-pcDNA3.1)
or calsenilin-enhanced green fluorescence protein fusion construct
(calsenilin-pEGFP), the entire coding region of calsenilin was sub-
cloned into pcDNA3.1 (Invitrogen) or pEGFP-N1 (ClontechMoun-
tain View, CA, USA) (18). Plasmid DNA was extracted using the
Hybrid-Q plasmid (GeneAll, Seoul, KOREA). Calsenilin siRNA
was purchased from Santa Cruz (sc-42399; Santa Cruz, CA, USA).
Cell culture and transfection
HT-22 (mouse hippocampal) and mouse embryonic fibroblast
(MEF) (15) cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum supplemented with
1% penicillin and streptomycin. Cells were maintained at 37°C in
a 5% CO2 atmosphere. For transfections into HT-22 and MEF
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cells, cells were plated in 35-mm dish or 96-well plate and plasmid
DNA and siRNA were transfected using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol and then
incubated with complete medium for 24 h.
For transfection into primary cortical neurons, cells were plated
in 96-well pates and plasmid DNA was transfected using Neuro-
FECT (Genlantis, San Diego, CA, USA) according to the manu-
facturer’s protocol and then incubated with neurobasal medium for
24 h.
Oxygen glucose deprivation (OGD)
OGD was performed using glucose-free Locke’s medium consist-
ing of (in mM): 154 NaCl, 5.6 KCl, 2.3 CaCl2, 1 MgCl2, 3.6
NaHCO3 and5 HEPES at pH 7.2 and culture plates were placed in
a hypoxic chamber (Stemcell, San Diego, CA, USA). The chamber
was flushed with 95% N2 and 5% CO2 for 10 min, sealed and
placed in a 37°C incubator for the appropriate duration.
Cytoplasmic and nuclear extraction
Cytoplasmic and nuclear extracts were obtained according to
NE-PER nuclear and cytoplasmic extraction reagents kit
(Thermo, Walteham, MA, USA). Briefly, the isolation of nuclear
and cytoplasmic fractions using the NE-PER kit maintains the
integrity of the two cellular compartments before extraction. The
nuclear extracts were separated from the cytoplasmic extracts by
centrifugation at 4°C at 12 000 rpm for 10 min. Supernatants were
collected as cytoplasmic extracts. The protein was calculated
according to the bicinchoninic acid (BCA) protein assay kit
(Thermo).
Immunoblotting
Protein concentrations were determined using the BCA protein
assay (Thermo); 20 mg of total protein was separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE)
and transferred onto polyvinylidene difluoride membranes (PVD)
(Millipore, Billerica, MA, USA). Blots were incubated in blocking
buffer (5% non-fat milk) for 1 h at a room temperature. Then the
blots were incubated with primary antibodies to NICD (Abcam),
calsenilin (Upstate), PS 1 (Chemicon, Temecule, CA, USA), p65
(Cell Signaling, Danvers, MA, USA), p-p65 (Cell Signaling),
Bax (Cell Signaling), Bim (Santa Cruz), cleaved caspase (Cell
Signaling), procaspase-3 (Cell Signaling), Poly [ADP-ribose]
polymerase-1 (PARP-1, cell Signaling) a-tubulin (Epitomics,
Burlingame, CA, USA) and b-actin (Sigma) overnight at 4°C.
Protein bands were detected using a secondary antibody conju-
gated with horseradish peroxidase (Jackson Immunoresearch,
Baltimore, PA, USA) and a chemiluminescence detection system
(Pierce, Pockford, IL, USA).
Immunofluorescence
Neuronal cells seeded on cover slips were fixed in 4% PFA for
10 min, permeabilized with 0.1% Triton X-100 in PBS for 5 min.
Blocking was performed by incubation in 5% normal serum for
1 h, which the cells were incubated with primary antibodies to
NICD (Abcam), mouse calsenilin (Upstate) and microtubule
associated protein 2 (MAP-2; Abcam) overnight at 4°C and then
with Alexa 488-conjugated or Alexa 568-conjugated secondary
antibodies (Molecular Probes, Karlsruhe, Germany) for 1 h at
room temperature. Nuclei of immunolabeled specimens were
visualized with 4’,6-diamidino-2-phenylindol (DAPI) (Molecular
Probes). Images were examined under conforcal microscope
(LSM510, Carl Zeiss, Göttingen, Germany).
Cell viability assay
To perform quantification of cell viability in neuronal cells, the
CellTiter-Glo luminescent cell viability assay (Promega, Madison,
WI, USA) was used following the manufacturer’s instructions.
Neuronal cells were seeded in 96-well plates for luminescence
measurements (Berthold Detection Systems, Huntsvile, AL,
USA).
pEGFP or Calsenilin-pEGFP transfected HT-22 cells were
stained with propidium iodide (PI) to differentiate apoptotic and
normal cells. The transfected HT-22 cells were rinsed with PBS
and fixed with 4% PFA. The fixed cells were stained for 5 min in
500 nM of PI (Sigma) at room temperature.
Statistical analysis
Statistical analysis was performed using one-way analysis of vari-
ance followed by Newman–Keuls post hoc test using GraphPad
Prism, version 5.0 (San Diego, CA, USA). Statistical significance
was accepted at the 95% confidence level (P < 0.05).
RESULTS
Calsenilin is expressed predominantly in
the adult, but not embryonic, mouse brain
To verify results reported by Zaidi et al (29), expression levels of
calsenilin were compared in mouse tissues at different stages
of development using an antibody that recognizes the non-
phosphorylated form of this protein around the phosphorylation
site at serine 63 (Figure 1A). Absence of calsenilin in the embry-
onic brain and increased expressions of multiple isoforms at post-
natal day 3 confirmed previous results (29).We observed calsenilin
expression in embryonic and postnatal hearts and lungs, but in
adults, although calsenilin remained strongly expressed in brain,
no traces were found in any other tissues studied. Furthermore,
when regional localization within the brain was assessed, calseni-
lin was found to be most highly expressed in the cortex, hippoc-
ampus and cerebellum, which is compatible with its functional
relevance in these tissues.
Neuronal levels of calsenilin were up-regulated
by OGD, and its cleavage during OGD was
mediated by caspase-3
Calsenilin is a pro-apoptotic protein expressed in neurons, and has
been reported to exert its effects under conditions of high Ca2+
concentrations (7) or serum deprivation (20). In the present study,
calsenilin levels were up-regulated in primary hippocampal
neurons after only 3 h of OGD, and its cleaved form was apparent
(Figure 1B). The active (p20) form of caspase-3, which is able to
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cleave calsenilin (8), was also up-regulated after 3 h of OGD. To
verify that calsenilin was cleaved by caspase-3, cells were sub-
jected to OGD and treated with the caspase inhibitors, z-VAD or
DEVD (Figure 1C). The inhibition of caspase-3 cleavage, as
evidenced by stable levels of procaspase-3 in treated cells, did
not affect levels of full-length calsenilin protein, but it prevented
the appearance of the cleaved, smaller protein product. The
up-regulation of calsenilin in cultured primary cortical neurons
Figure 1. Calsenilin expression was increased by a combination of
hypoxia and oxygen glucose deprivation (OGD). A. At embryonic day 15
(E15) calsenilin was present in heart and lung, but not in brain, but at
only 3 days after birth (P3) calsenilin was expressed predominantly in
the mouse brain (left panel). Only the mouse adult brain expressed
calsenilin (middle panel), which was present in all brain regions, but
particularly in cortex, hippocampus and cerebellum (right panel). B.
Immunoblot of primary hippocampal neuron lysates subjected to OGD
in vitro. A strong increase in total and cleaved calsenilin levels was seen
3-h post-OGD and at the same time, cleaved caspase-3 was observed.
Quantification of calsenilin levels normalized to a-tubulin levels as a
loading control. Values are the mean with standard error of measure-
ment (SEM). ***P < 0.001 vs. control. C. OGD-induced cleavage of
calsenilin was prevented in the presence of the caspase inhibitors z-VAD
or DEVD. Whereas levels of calsenilin increased under OGD conditions,
the cleaved form of calsenilin was absent when caspase inhibitors were
present. In addition, levels of procaspase-3, which reduce due to cleav-
age after OGD, were maintained in the presence of inhibitors. Quanti-
fication of casenilin and presenilin levels normalized to a-tubulin
levels as a loading control. Values are the mean with SEM. *P < 0.05,
**P < 0.01, ***P < 0.001 vs. control. D. Immunoblot of primary cortical
neuron lysates subjected to OGD. Quantification of casenilin and prese-
nilin levels normalized to b-action levels as a loading control. Values are
the mean with SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.
Calsenilin and Notch in Ischemic Stroke Park et al
4 Brain Pathology •• (2012) ••–••
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology
during OGD conditions, another in vitromodel of ischemic stroke,
was confirmed by immunoblotting (Figure 1D). Furthermore, level
of PS induced by OGD conditions in cultured primary hippocam-
pal and cortical neurons (Figure 1C,D).
To study the distribution of calsenilin in primary cortical
neurons subjected to ischemia-like conditions, cultures were
subjected to GD for up to 24 h and neurons were stained with
MAP-2 (neuronal marker, red) and calsenilin (green) antibodies
(Figure 2A). Calsenilin signals in control cells and in the early
stages of GD appeared dispersed throughout the cell. However,
after 24 h of GD, when most cells are undergoing apoptosis,
signals accumulated around the nuclear region of the cells.
To determine whether calsenilin and PS-1 co-localized in situ,
primary cortical neurons subjected to GD were labeled with calse-
nilin (green) and PS-1 (red) antibodies (Figure 2B). No obvious
co-localization was found during the early stages of GD, but at
24 h strong, the perinuclear calsenilin and PS-1 staining was
observed in many cells. These results suggest the up-regulated
clasenilin under ischemic condition increase g-secretase activity
through interaction with PS-1.
Calsenilin overexpression enhanced Notch-1
cleavage and signals downstream of Notch-1
We previously reported that g-secretase-mediated Notch signaling
induces neuronal cell death in ischemic stroke (2, 3). To test the
hypothesis that calsenilin enhances the g-secretase cleavage of
Notch-1, HT-22 cells were transfected with calsenilin and then
assessed by immunofluorescence and immunoblotting for NICD
levels. Figure 3A shows that overexpression of calsenilin increased
the NICD signal (red) after immunostaining with a specific
antibody for NICD that does not bind to full length Notch-1.
When these cells were subjected to OGD for 6 h, NICD staining
increased even more dramatically, whereas transfection with
vector only did not increase the NICD signal in OGD condition
(Figure 3A). These results were confirmed by immunoblotting,
where overexpression of calsenilin (verified in the top panel)
increased the levels of NICD, and this increase was even more
dramatic after 6 h of OGD (Figure 3B,C). NICD has been shown
to increase levels of the NF-kB activated subunit, phospho-p65,
in neurons in response to ischemia-like conditions (26), and
consistently, the overexpression of calsenilin contributes to an
increase in phospho-p65 under both normal and OGD conditions
(Figure 3B,C).
Calsenilin-regulated apoptotic neuronal death
under ischemia-like conditions
Calsenilin is a pro-apoptotic protein, and has been shown to
increase cell death in response to the toxic Alzheimer’s disease-
related by-product, amyloid-b (18). We found that calsenilin
also increases cell death under ischemia-like conditions, in that
calsenilin-transfected primary cortical neurons and HT-22
cells subjected to OGD showed a 40% higher cell death rate than
control cells (Figure 4A,B). Furthermore, treatment with N-[N-
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
Figure 2. The distribution of calsenilin and presenilin (PS) 1 in primary
cortical neurons subjected to ischemia-like conditions. A. Calsenilin
immunofluorescence in mouse primary cortical neurons, showing
calsenilin (green), the neuronal marker MAP2 (red) and 4’,6-diamidino-
2-phenylindol (DAPI) (blue). Calsenilin staining showed a small, non-
significant increase after 3 h of glucose deprivation (GD). At 24 h,
calsenilin congregated at nuclear peripheries. Staining was prominent
around apoptotic bodies (asterisk). B. Calsenilin (green) and PS1 (red)
immunofluorescence in mouse primary cortical neurons, both showing
a small increase with GD. Calsenilin, but not PS1, congregated around
apoptotic bodies (GD for 3 h, asterisk). At 24 h, calsenilin and PS1
signals co-localized around nucleus. Scale bar: 10 mm.
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(DAPT) significantly decreased cell death, indicating that
g-secretase, at least in part, mediates this effect of calsenilin. These
results were also confirmed by PI staining. Cell death was assessed
by PI staining in the GFP-positive cells. Calsenlin-GFP positive
HT-22 cells showed significantlymore PI staining byOGD,whereas
treatment with DAPT reduced co-localization of PI and calsenilin-
GFP (Figure 4C). Immunoblotting with specific antibodies showed
that the pathways activated by calsenilin under OGD conditions
involve the up-regulations of the pro-apoptotic proteins Bim, Bcl-
2–associated X protein (Bax) and the cleavage of caspase-3
(Figure 4D,E). None of these pathways appeared to be affected by
g-secretase inhibition by DAPT, indicating the complexity of the
interaction between calsenilin, g-secretase and cell death pathways
(Figure 4D,E).
Next, we evaluated the neuroprotective effect of calsenilin
knockdown in neuronal cell death following OGD. Calsenilin
Figure 3. Calsenilin affected Notch cleavage in HT-22 cells subjected to
oxygen glucose deprivation (OGD). A. The overexpression of calsenilin
in standard conditions (left panels) increased Notch intracellular domain
(NICD) (red) levels. Under OGD (right panels), calsenilin overexpression
dramatically increased NICD (red) levels. Original magnification: 1000¥.
Scale bar: 50 mm. B. The overexpression of calsenilin potentiated OGD-
induced cell death. HT-22 cells were transfected with either vector or
calsenilin constructs. Calsenilin overexpression increased NICD, and the
phosphorylation of p65 (p-p65) in cultured cells. After 6 h of OGD, NICD
and phospho-p65 levels increased further. C. Quantification of NICD,
p-p65 and p65 levels normalized to b-actin levels as a loading control.
Values are the mean with standard error of measurement. *P < 0.05,
***P < 0.001 vs. vector, #P < 0.05 vs. vector + OGD 6 h.
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siRNA, but not control scrambled siRNA, attenuated cell death
in OGD-induced HT-22 cells (Figure 4F). We also performed
Western blotting with antibody against calsenilin to establish the
down-regulation of calsenilin expression. Treatment of calsenilin-
siRNA reduced the protein level to less than 50% of control
(Figure 4G).
PS mediated the apoptotic effects of calsenilin
To further understand the interplay between calsenilin and PS
in cells subjected to ischemia-like conditions, PS-1, 2 double
knockout (PSKO) MEFs were subjected to OGD for 6 h after
transfection with calsenilin or vector only. The results (Figure 5A)
obtained showed that absence of PS significantly decreased the
rate of cell death caused by the overexpression of calsenilin during
OGD. The localization of calsenilin to different cellular organelles
has been shown to affect its activity as a partner of PS and as a
transcriptional regulator (28). To determine whether the absence of
PS affects the cellular distribution of calsenilin, PSKO MEFs
subjected to 6 h of OGD were immunostained for calsenilin
(Figure 5B).A dramatic increase in non-nuclear calsenilin staining
was seen in cells in response to OGD in wild-type MEFs. In
addition, the levels of calsenilin in the cytoplasmic fraction
increased compared with control in OGD-induced WT MEF
(Figure 5C,D). Calsenilin in the nucleus also increased compared
with WT MEFs in PSKO MEFs (Figure 5B–D). These results
Figure 4. Calsenilin regulated oxygen glucose deprivation (OGD)-
induced neuronal cell death and the levels of associated signaling pro-
teins. A. Primary cortical neurons were transfected with either vector or
calsenilin constructs. Transfected primary cortical neurons pretreated
with 5 mM DAPT for 12 h. Primary cortical neurons were exposed to 2 h
of OGD. The overexpression of calsenilin increased OGD-induced cell
death as determined by luminescent cell viability assay. Values are the
mean with standard error of measurement (SEM). (n = 3). *P < 0.05 vs.
vector + OGD 2 h, #P < 0.05 vs. calsenilin + OGD 2 h. B. Overexpressed
HT-22 cells were exposed to 6 h of OGD. The overexpression of
calsenilin significantly increased cell death caused by OGD, but the
g-secretase inhibitor DAPT reduced this cell death. Values are the
mean with SEM. (n = 3). *P < 0.05 vs. vector + OGD 6 h, #P < 0.05 vs.
calsenilin + OGD 6 h. C. Only green fluorescence protein (GFP)-positive
dead cells were counted and cell death measured by propidium iodide
(PI) staining. Values are the mean with SEM. (n = 4). ***P < 0.001 vs.
GFP, #P < 0.05 calsenilin-GFP. D. Immunoblot showing the levels of
proteins involved in OGD-induced neuronal death. The top panel con-
firms calsenilin overexpression. The pro-apoptotic proteins Bim, Bax,
and cleaved caspase-3, whose levels were increased by OGD, were
further increased by calsenilin overexpression. Whereas, these changes
were independent of g-secretase inhibition by DAPT. E.Quantification of
D normalized to b-actin levels as a loading control. Values are the mean
with SEM. *P < 0.05, ***P < 0.001 vs. calsenilin + OGD6 h. F. Silencing
of calsenilin enhanced cell viability in OGD-induced HT-22 cells as
detected by luminescent cell viability assay. Values the mean with
SEM. (n = 3). ***P < 0.001 vs. control-siRNA + control. ##P < 0.01 vs.
control-siRNA + OGD 6 h. G. Down-regulation of calsenilin protein was
confirmed by performing ummunoblot analyses. For quantification
calsenilin levels were normalized to b-actin levels as a loading control.
Values are the mean with SEM. **P < 0.01 vs. control-siRNA.
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indicate that calsenilin accumulates in the nucleus of PSKOMEFs,
which would thereby prevent it from reaching the ER and Golgi
where it exerts its pro-apoptotic function.
Calsenilin levels increased in vivo in response
to focal ischemia and correlated with
increased cell death and with the
up-regulations of apoptosis-related proteins
Given that calsenilin levels increase in ischemia-like conditions in
vitro in parallel with the levels of the apoptosis-related protein,
Bim and the phosphorylated form of NF-kB p65, we investigated
calsenilin and NICD levels in the brains of animals following
ischemic stroke. In mouse brain, an increase in calsenilin levels
was observed across all time points post-focal ischemia, but
peaking at 24 h. Furthermore, this correlated with the sustained
activation of p65 and increased levels of NICD, particularly at
12 h post-reperfusion, indicating that calsenilin protein expres-
sion is similarly enhanced following cerebral ischemia in vivo
(Figure 6A,B). This was further confirmed by immunohistochem-
istry of calsenilin in a rat global ischemic model. Figure 6C (top
row of panels) shows a small increase in calsenilin, particularly in
the dentate gyrus, 24 h post-reperfusion and a dramatic increase
throughout the hippocampus 72-h post-reperfusion. The expres-
sion pattern of calsenilin in the dentate gyrus was similar to that
in CA1-3 regions. We also investigated also calsenilin levels in
non-neuronal cells (astrocytes, microglia, endothelia) of ischemic
stroke tissues. Astrocytes marginally showed expression of calse-
nilin, but calsenilin were not found in microglial and endothelial
cells (Figure 6D).
Figure 5. Calsenilin over-expression in PS-1, 2 double knockout (PSKO)
cells reduces OGD-induced cell death. A. No significant cell death rate
difference was observed between WT and PSKO mouse embryonic
fibroblast (MEFs) subjected to OGD. However, after cells had been
transfected with calsenilin, PSKO MEFs showed significantly lower
death rates than WT MEFs. Cell viability determined by luminescent cell
viability assay. Values are the mean with standard error of measurement
(SEM). (n = 4). *P < 0.05, ***P < 0.001 vs. vector + control, #P < 0.05
MEF WT calsenilin + OGD6h. B. PSKO MEFs, exposed to OGD for 6 h
and then immunostained with anti-calsenilin, showed a cell-wide calse-
nilin distribution whereas in WT MEFs, calsenilin was restricted to
the nucleus. Original magnification, 1000¥. Scale bar: 50 mm. C. Repre-
sentative immunoblot of cytoplasmic and nuclear fractions of WT and
PSKO MEF cells showed that nuclear localization of calsenilin was
significantly increased in PSKOMEF cells compared with WTMEF cells,
however nuclear calsenilin of PSKO MEF cells decreased significantly
after OGD. D. Quantification of calsenilin levels normalized to a loading
control (b-actin for cytoplasmic fraction; Poly [ADP-ribose] polymerase-1
(PARP-1) for nuclear fraction). Values are the mean with SEM. (n = 3)
*P < 0.01, ***P < 0.001 vs. MEF WT + control.
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Figure 6. Role of calsenilin in vivo. A and B. Immunoblots (A) and
quantitative densitometric analysis (B) showing significant increases
in calsenilin, Notch intracellular domain, p-p65 and Bim levels of whole
brain after cerebral ischemia/reperfusion: from sham (no ischemia) to
after 1 h ischemia and 1, 12 and 24 h of reperfusion. Values are the
meanwith standard error of measurement (n = 5mice/group). *P < 0.05,
**P < 0.01, ***P < 0.001 vs. sham. C. Calsenilin immunohistochemistry
in the hippocampus of rats subjected to a sham-operation or transient
global ischemia after 24 or 72 h of reperfusion. Top panels: magnification
100¥, hippocampus, middle panels: magnification 200¥, close-up of CA1
pyramidal neurons, and inset: magnification, 200¥. Scale bar, 200 mm;
arrows show calsenilin. Bottom: cresyl violet staining of hippocampal
CA1 neurons from sham-operated and ischemic rats after 24 or 72 h of
reperfusion. Scale bar, 100 mm. D. Confocal images of ipsilateral peri-
infarct tissue sections showing green fluorescent signals for calsenilin
and red fluorescent signals for astrocyte (left), microglia (middle) and
endothelial cells (right). Only astrocytes showed very weak calsenilin
signals. Original magnification: 200¥. Scale bar: 20 mm.
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DISCUSSION
The results of this study provide evidence that calsenilin is an
important protein constitutively present primarily in the adult
brain, and that its expression is up-regulated under ischemic con-
ditions in mouse and rat models. Calsenilin is known to be a
pro-apoptotic factor, and the present study demonstrates this
action in several in vitro models of stroke, including a glucose
deprivation model and a model of combined hypoxia and glucose
deprivation (i.e. OGD). Furthermore, calsenilin is known to inter-
act with PS, the catalytic subunit of the multi-protein enzyme
g-secretase, and in the present study, it was found that it increases
cell death by increasing the activity of g-secretase, and that this is
primarily driven by other PS-dependent mechanisms.
Calsenilin was previously shown to be pro-apoptotic in an in
vitro model of Alzheimer’s Disease (18), in which it not only
increased the rate of apoptotic cell death, but also up-regulated
the generation of Ab42, the form of Ab responsible for neuronal
damage in Alzheimer’s disease. In addition, both of these effects
of calsenilin were found to be mediated by g-secretase. Further-
more, the overexpression of calsenilin was found to enhance
g-secretase activity, including the cleavage that leads to Ab42, and
this effect was blocked by g-secretase inhibitors (17). The impor-
tance of g-secretase and its substrate Notch-1, which is cleaved to
form the transcription factor NICD (19), has been established in
the contexts of neuronal damage and cell death in stroke (2). The
present study also shows that calsenilin overexpression increases
the production of NICD, and of downstream proteins related to
cell damage and neuronal death. However, to our surprise, only
a fraction of these effects can be accounted for by the actions
of g-secretase, because in the presence of g-secretase inhibitors,
calsenilin-mediated cell death was only partially diminished.
These results suggest that g-secretase-independent pathways
mediate much of the calsenilin-dependent effect on OGD-induced
neuronal death.
We also observed that calsenilin and PS co-localize at the peri-
nuclear region of primary cortical neurons subjected to 24 h of
glucose deprivation in vitro. PS is not only localized on the plasma
membrane, where it acts as part of g-secretase, but it also resides to
a great extent on the ER membrane, where it regulates intracellular
Ca2+ signaling (24), and calsenilin has been reported to participate
in both of these processes (11, 16). Furthermore, these two roles of
PS are not independent, as g-secretase activity was found to be
up-regulated in response to increases in cytosolic Ca2+ (9). In
addition, it has been demonstrated that modulation by PS of Ca2+
release from the ER is independent of g-secretase (25). It is there-
fore plausible that the increased cell death caused by the overex-
pression of calsenilin observed in this study occurred via the
activation of PS by calsenilin to modulate Ca2+ release from the
ER. To examine this mechanism further, calsenilin-overexpressing
PSKO MEFs were subjected to OGD, and it was found that the
pro-apoptotic effects of calsenilin were mediated by PS more so
than by g-secretase. This finding can be explained by the effects of
calsenilin on g-secretase–independent, but PS-dependent actions,
such as Ca2+ release from the ER (25). In this regard, it is known
that calsenilin increases the ability of PS-2 to reduce ER Ca2+
concentrations (11), but on the other hand, it has been observed
that PSs affect calsenilin trafficking because in cells overexpress-
ing PS-2, calsenilin accumulates in the perinuclear regions of the
ER and Golgi (28). Consistent with this, we found that calsenilin
accumulates in the nucleus of PSKO MEFs, which would thereby
prevent it from reaching the ER and Golgi where it exerts its
pro-apoptotic function. This study also shows that in primary
cortical neurons subjected to ischemia-like conditions for 24 h,
calsenilin and PS-1 co-localize in perinuclear regions, possibly in
the ER and Golgi. Interestingly, apoptotic bodies in this region
display calsenilin, but not PS. It is evident that the role of calse-
nilin in neuronal injury is complex, for example calsenilin has also
been reported to exert PS-independent functions such as transcrip-
tional repression in the nucleus (6).
Our finding that calsenilin is cleaved by caspase-3 concurs with
previous reports, and it has been proposed that this process may
have a regulatory function (8, 14). Full-length calsenilin localizes
to membrane fractions where it can interact with PS and exert its
Ca2+-modulatory and g-secretase activating roles, but cleaved
calsenilin remains in the cytosol where it loses these activities.
Therefore, the activity of g-secretase appears to be regulated by
calsenilin’s subcellular localization.
Considering its roles in apoptosis and Ca2+ modulation in
response to stress stimuli, such as OGD, we propose that calsenilin
participates in stroke-induced neuronal damage. Such a role is
supported by our finding that calsenilin is up-regulated in vivo in
focal ischemia and that this up-regulation is correlated with the
activation of other ischemia-induced factors, such as phosphor-
ylated p65 and Bim.
The role played by calsenilin in ischemia-induced neuronal
injury is complex, as are its mechanisms of action, which include
transcriptional repression, PS regulation, and the modulation
of potassium channels. Calsenilin also modulates the catalytic
subunit of g-secretase and intracellular Ca2+ signaling, which are
both involved in stroke-induced injury. Here, we provide novel
evidence regarding the relevance of calsenilin in ischemic injury,
its up-regulation in animal models of focal ischemia, and its
activation of cell death mediated by apoptotic factors. The pro-
apoptotic effects of calsenilin seem to be partly mediated by the
g-secretase activity of PS and by other roles of PS, such as its
modulation of Ca2+ ER levels. Furthermore, the mediation of
calsenilin-activated cell death by PS seems to involve changes in
the intracellular distribution of calsenilin. We hope that these find-
ings open new avenues to the effective clinical treatment of stroke.
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Abstract
Intravenous immunoglobulin (IVIg) preparations obtained by
fractionating blood plasma, are increasingly being used
increasingly as an effective therapeutic agent in treatment of
several inflammatory diseases. Its use as a potential thera-
peutic agent for treatment of stroke and Alzheimer’s disease
has beenproposed, but little is knownabout the neuroprotective
mechanisms of IVIg. In this study, we investigated the effect of
IVIg on downstream signaling pathways that are involved in
neuronal cell death in experimental models of stroke and
Alzheimer’s disease. Treatment of cultured neurons with IVIg
reduced simulated ischemia- and amyloid bpeptide (Ab)-
induced caspase 3 cleavage, and phosphorylation of the cell
death-associated kinases p38MAPK, c-Jun NH2-terminal
kinase and p65, in vitro. Additionally, Ab-induced accumulation
of the lipid peroxidation product 4-hydroxynonenal was atten-
uated in neurons treated with IVIg. IVIg treatment also up-reg-
ulated the anti-apoptotic protein, Bcl2 in cortical neurons under
ischemia-like conditions and exposure to Ab. Treatment ofmice
with IVIg reduced neuronal cell loss, apoptosis and infarct size,
and improved functional outcome in a model of focal ischemic
stroke. Together, these results indicate that IVIg acts directly on
neurons to protect them against ischemic stroke and Ab-
induced neuronal apoptosis by inhibiting cell death pathways
and by elevating levels of the anti-apoptotic protein Bcl2.
Keywords: Ab, Alzheimer’s disease, apoptosis, IVIg,
neurons, stroke.
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Intravenous immunoglobulin (IVIg) preparations are ob-
tained by fractionating blood plasma from a pool of healthy
donors. IVIg is used as a replacement therapy for patient with
primary immune deficiencies. In addition, due to its immu-
nomodulatory effects, IVIg has become a treatment of choice
for a variety of immune disorders, including those that that
affect the nervous system (Kotlan et al. 2009; Baerenwaldt
et al. 2010). IVIg is also being used increasingly to treat
autoimmune disorders, including those that that affect the
nervous system (Baerenwaldt et al. 2010). Numerous mech-
anisms have been proposed to explain the clinical effects of
IVIg preparations. IVIg can block the function of Fc receptors
on phagocytes by saturating, altering or down-regulating the
affinity of the Fc receptors (Aschermann et al. 2010; Anthony
et al. 2011). IVIg can also impair leukocyte adhesion to
endothelial cells, attenuate complement-mediated damage,
modulate cytokine production by various cell types and
inhibit apoptosis (Arumugam et al. 2007; Arumugam et al.
2008; Arumugam et al. 2009) and attenuate complement-
mediated damage (Basta et al. 1989a,b, Basta et al. 2003).
Recently, we demonstrated that IVIg treatment significantly
reduced brain infarct volume and mortality in a mouse model
of stroke (Arumugam et al. 2007). We have also shown that
human IgG levels were higher in samples obtained from the
infarcted area as compared with the corresponding region in
the contralateral non-injured brain hemisphere. We confirmed
this by immunohistochemistry, which showed more intense
and extensive staining for human IgG at the site of injury as
compared with the contralateral side of the brain (Arumugam
et al. 2007). Furthermore, dual staining for human IgG and
blood vessels (collagen IV) allowed us to visualize the
leakage of the blood brain barrier (BBB) and the crossing of
IgG into the parenchyma.
IVIg selectively neutralized complement component C3b
and decreased the expression levels of endothelial and
leukocyte adhesion molecules, neutrophil infiltration and
microglial activation (Arumugam et al. 2007). However, it is
not known whether the neuroprotective actions of IVIg in
vivo are due only to effects on inflammatory cells, or might
also involve direct actions on neurons.
The potential therapeutic efficacy of IVIG has recently
been tested in Alzheimer’s disease (AD) patients (Dodel
et al. 2002; Relkin et al. 2009). Human clinical studies
showed stabilization and even a mild improvement in
cognitive function in the patients treated with IVIg (Dodel
et al. 2004; Relkin et al. 2009). Furthermore, a recent study
demonstrated the protective effects of IVIg against Ab
toxicity in primary mouse hippocampal neuronal cultures
(Magga et al. 2010). However, the exact mechanisms by
which IVIg elicits its neuroprotective effects are unknown.
Hence, the main objective of our study was to explore the
direct mechanisms involved in IVIg-induced neuroprotection
in models of stroke and Ab toxicity. We observed that IVIg
promotes neuronal survival by inhibiting the activation of
several stress-induced signaling pathways and up-regulating
the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2).
Materials and methods
Primary cortical neuronal cultures
All animal experimental procedures performed were reviewed and
approved by the University of Queensland Animal Care and Use
Committee. The primary cortical neurons culture were obtained from
16-day C57B/6 mouse embryos as described previously (Okun et al.
2007). Cells were cultured on 35- 60- or 100-mm diameter petri
dishes containing Neurobasal medium containing 25 mM glucose
and B-27 supplements (Invitrogen, Mount Waverly, VIC, Australia),
2 mM L-glutamine, 0.001% gentamycin sulfate and 1 mM HEPES
(pH 7.2) and maintained in 37!C incubator. The neuronal purity of
the cultures was approximately 95%, determined by immnunostain-
ing using neuronal specific marker (MAP2) antibody and astrocyte-
specific marker glial fibrillary acidic protein (GFAP) antibody.
Glucose, oxygen–glucose deprivation and cell viability analysis
To induce glucose deprived (GD) condition, neuronal cultures were
incubated in glucose-free Locke’s medium containing (in mmol/L)
154 NaCl, 5.6 KCl, 2.3 CaCl2, 1 MgCl2 3.6 NaHCO3, 5 HEPES, pH
7.2, supplemented with gentamycin (5 mg/L; Invitrogen) for 12 or
24 h. For oxygen and glucose deprivation (OGD), hypoxia was
induced by saturating the Locke’s buffer with 95% N2/5% CO2, pH
7.4 gas mixture for 10 min before incubating the cultures in an
oxygen-free chamber with 95% N2/5% CO2 atmosphere for 12 h.
Cell viability was determined by the trypan blue exclusion assay
(Woodruff et al. 2011). To observe the effect of IVIg on GD- or
OGD-induced cell death, the cultures were treated with different
concentrations of IVIg (Sandoglobulin; CLS Biotherapy, Broad-
meadows, VIC, Australia). Controls such as a vehicle- and a
negative control (bovine serum albumin (BSA) (Sigma Aldrich,
Castle Hill, NSW, Australia) were also included in the experiment.
Ab toxicity experiments
Ab1-42 (American Peptide, Sunnyvale, CA, USA) was prepared
according to the 1,1,1,3,3,3-hexafluro-2-propanol-based protocol, as
described previously (Stine et al. 2003). Vehicle control was made by
adding the same volume of dimethyl sulfoxide with 1· PBS as used to
prepare the peptide solutions. The concentration of Ab1-42
(10.0 lM) that was able to induce !90% of neuronal cell death in
vitrowas used. To examine the effect of IVIg onAb-induced neuronal
cell death, primary neurons were co-treated with 10.0 lM of
oligomerized Ab1-42 and different concentrations of IVIg (Sando-
globulin; CLS Biotherapy) for 24 h at 37!C. A vehicle control and a
negative control were also included in the experiment: dimethyl
sulfoxide, and 10 mg/mL of BSA (Sigma Aldrich), respectively.
Western blot analysis
20lg of protein samples were loaded into 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and run in a Tris-glycine
running buffer (Bio-Rad, Hercules, CA, USA) at 80 V until the
protein ladder (Lonza, Rockland, ME, USA) was spread optimally.
The proteins were then transferred into nitrocellulose membranes
(Bio-Rad) using semi-dry transfer apparatus (Bio-Rad) in transfer
buffer (BioRad) for 1.5 h at 350 mA. The membranes were then
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incubated in blocking buffer (5% BSA ; Sigma Aldrich) in Tris-
buffered saline-T for 1 h at 24!C. The membranes were then
incubated overnight at 4!C with primary antibodies against cleaved
caspase 3, phospho-SAPK/c-Jun NH2-terminal kinase (JNK),
phospho-p38, phospho-p65 nuclear factor kappa B (NFjB), Bcl-2
(Cell Signaling Technology, Beverly, MA, USA), 4-hydroxynon-
enal (4-HNE) (Abcam, Cambridge, UK) and actin (Sigma Aldrich).
The membranes were washed with Tris-buffered saline-T before
they were incubated with a horseradish peroxidase-conjugated
secondary antibody for 2 h. The membranes were then washed
again with Tris-buffered saline-T and incubated with chemilumi-
nescent substrate for enhanced chemiluminescence (Pierce Endo-
gen, USA) for 2 min. The signals were visualized using X-ray films
(Fujifilm Corporation, Tokyo, Japan).
Middle cerebral artery occlusion and reperfusion
Three-month-old C57BL/6 male mice were used for in vivo
experiments. The focal cerebral ischemia/reperfusion (I/R) model
was similar to that described previously (Arumugam et al. 2004).
In the sham group, these arteries were visualized but not
disturbed. Mice were either administered with 2 g/kg IVIg or
vehicle by direct infusion into the femoral vein (200 lL) either
30 min before the onset of ischemia or 3 h after the ischemic
period. Cerebral blood flow was measured by placing the animal’s
head in a fixed frame after it had been anesthetized and prepared
for surgery. A craniotomy was performed to access the left middle
cerebral artery and was extended to allow positioning of a 0.5-mm
Doppler probe (Moor LAB, Moor Instruments, Axminster, UK)
over the underlying parietal cortex approximately 1 mm posterior
to bregma and 1 mm lateral to the midline. The functional
consequences of focal cerebral I/R injury were evaluated using a
5-point neurological deficit score and were assessed in a blinded
fashion (Bederson et al. 1986).
Immunocytochemistry and Immunohistochemistry
The cortical neurons were cultured in 6- well plates containing
microscope coverslips, treated with glucose free Locke’s buffer and
IVIg and then were fixed in 4% paraformaldehyde. The cells were
then incubated for 1 h with primary cleaved caspase 3 (Cell
signaling) and MAP2 (Millipore, Temecula, CA, USA) antibody
followed by 2 h incubation with Alexa fluor 488 (Invitrogen)
conjugated secondary antibody and Alexa fluor 568 (Invitrogen)
conjugated secondary antibody at 24!C respectively. Frozen brain
sections were incubated for 1 h with primary MAP2 (Millipore),
glial fibrillary acidid protein (GFAP) (Sigma Aldrich) and Iba1
(Abcam) antibodies followed by 2 h incubation with Alexa fluor
488 (Invitrogen) conjugated secondary antibody at 24!C. Both cells
and frozen sections were stained with nuclear stain DAPI for 15 min
before mounted with VectaShield (Vector Laboratories, Burlingame,
CA, USA). Images were acquired using fluorescence microscope
(Olympus, Tokyo, Japan).
TUNEL assay
The tissue slides were dried at 24!C for 24 h and washed in 1· PBS
for 15 min. The TUNEL assay was done according to the
manufacturer’s instruction (Roche, Basle, Switzerland). Once the
assay procedure was completed, and the coverslip was mounted on a
slide. The slides were viewed under the fluorescence microscope
and TUNEL-positive cells were counted.
In vivo magnetic resonance imaging method
In vivo mouse brain data were acquired on a Bruker 16.4T
(700 MHz) small animal MRI scanner, connected to an AVANCE
spectrometer running ParaVision 5.1. Multiple echo time T2-
weighted and multiple b-value diffusion-weighted images were
acquired for the study. Two-dimensional contiguous slices were
obtained with an in-plane field-of-view of 15 mm; the number of
slices was 9 with a slice thickness of 0.9 mm and without
acceleration. The standard T2 relaxometry sequence was used with
the following parameters: matrix size = 256, TE = 14, 28, 42, 56,
70, and 84 ms, TR = 2000 ms, number of averages = 1, and
bandwidth = 50 000 Hz. The standard diffusion sequence was used
with the following parameters: matrix size = 128, TE = 20 ms,
T2 = 1500 ms, number of averages = 1, bandwidth = 50 000 Hz
and b-value = 151, 705, 1169, 1618 ms. Individual mouse brains
were segmented based on a combination of T2-weighted images,
and using our in-house developed region growing MATLAB
(version 7.10.0 R2010a) program.
T2-map and apparent diffusion coefficient computation
T2 values were calculated by masking individual brain slices and
performing a fit in a voxel-by-voxel manner across all TE images of
the T2-weighted acquisition. The standard model was used to obtain
the T2 map: S ¼ S0e"TE=T2 þ k where S is the measured image
voxel signal, S0 is the TE = 0 ms signal (unknown), TE (in ms) is
the echo time used to acquire the image and k (unknown) is the
offset applied to improve the quality of fit. T2 values calculated at
each voxel in the brain were used to form the T2 map. Similarly, the
apparent diffusion coefficient was computed using the following
standard model: logðSÞ ¼ logðS0Þ " b& ADC, where b is the
b-value, and apparent diffusion coefficient (ADC) is the apparent
diffusion coefficient (unknown). A brain volume corresponding to
the region affected by stroke was calculated by thresholding T2 and
ADC values and by counting the number of voxels that were larger
than the set value. This count was multiplied by voxel volume to
obtained infarct volume for both the T2 and diffusion-based
analyses.
Data analysis
All the results are reported as the means ± SD. The overall
significance of the data was examined by one-way analysis of
variance (ANOVA). The differences between the groups were
considered significant at p < 0.05 with the appropriate Bonferroni
correction made for multiple comparisons. Neurological behavior
scores were analyzed by using a non-parametric Kruskal–Wallis test
and Dunn’s Multiple Comparison test.
Results
Modulation of in vitro ischemic stroke-induced neuronal
cell death by IVIg
We first evaluated the effect of different concentrations of
IVIg in a cell culture model of ischemic neuronal injury in
which primary mouse cortical neurons were subjected to
conditions mimicking in vivo occlusion of a cerebral artery,
including glucose deprivation (GD), and combined OGD.
Treatment with low concentrations of IVIg (0.1 and 0.3 mg/
" 2012 The Authors
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mL) significantly increased GD-induced neuronal cell death
whereas high concentrations of IVIg (3, 5, and 10 mg/mL)
significantly decreased GD-induced neuronal cell death
(Fig. 1a). Treatment with high concentration of IVIg (5 and
10 mg/mL) also significantly decreased OGD-induced neu-
ronal cell death (Fig. 1b). We next analyzed levels of cleaved
caspase 3, an apoptotic protease, following GD and OGD
conditions. Treatment with a low concentration of IVIg
(0.1 mg/mL) increased the levels of cleaved caspase 3
(Fig. 1c and d) whereas, higher concentrations of IVIg (2.5
and 5 mg/mL) significantly reduced the level of cleaved
caspase 3 (Fig. 1d) in primary neuronal cells subjected to GD
for 12 h. Similarly, in cultured neurons subjected to OGD
conditions for 12 h, the level of cleaved caspase 3 increased
in response to a low concentration of IVIg treatment (0.1 mg/
mL) and significantly decreased in response to higher
concentrations of IVIg treatment (2.5 and 5 mg/mL) (Fig. 1e
and f).
Fig. 1 IVIg protects cultured neurons against simulated ischemia. (a)
Treatment with low concentrations of IVIg (0.1 and 0.3 mg/ml) signifi-
cantly increased GD-induced neuronal cell death, whereas high
concentrations of IVIg (3, 5, and 10 mg/mL) significantly decreasedGD-
induced neuronal cell death. ***p < 0.05 compared with the vehicle +
GD group; +++p < 0.05 compared with the GD group. (b) Treatment with
high concentrations of IVIg (5 and 10 mg/mL) also decreased OGD-
induced neuronal cell death. ***p < 0.05 compared with the normal
group; +++p < 0.05 compared with the vehicle + OGD group. Treatment
with a low concentration of IVIg (0.1 mg/mL) increased the expression
level of cleaved caspase 3 (c, d), whereas high concentrations of IVIg
(2.5 and 5 mg/mL) significantly reduced the expression level of cleaved
caspase 3 (d) in primary neuronal cells subjected to GD conditions for
12 h. *p < 0.05 compared with GD + vehicle group; ++p < 0.01 com-
pared with GD + vehicle. (e, f) Similarly, the level of cleaved caspase 3
increased with low concentrations of IVIg (0.1 mg/mL) and decreased
with high concentrations of IVIg treatment (2.5 and 5 mg/mL) in primary
neuronal cells subjected to OGD conditions for 12 h. n = 3 or more
biologically different cultures in each group. *p < 0.05 compared with
GD + vehicle group; ++p < 0.01 compared with GD + vehicle.
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Modulation of Ab-induced neuronal death by IVIg
To evaluate the effect of IVIg on Ab-induced neuronal cell
death in vitro, a dose titration of Ab was first performed to
identify a toxic concentration of oligomerized Ab to be used
in subsequent experiments. Various concentrations of Ab
ranging from 0.1 to 10 lM significantly increased the
percentage of neuronal cell death compared with vehicle-
treated neurons. It was observed that the most toxic dose of
oligomerized Ab on primary neuron cultures was 10 lM
(Fig. 2a). Furthermore, the addition of IVIg treatment to Ab-
treated neurons significantly reduced cell death (Fig. 2b).
This protective effect was concentration-dependent, with
10 mg/mL IVIg having the maximum protection, reducing
cell death to 30% (Fig. 2b). As cleavage of caspase 3 is
implicated in Ab-induced neuronal cell death (Mattson et al.
1998), we further looked at the levels of the apoptotic
protease cleaved caspase 3 in primary cortical neurons
subjected to Ab for 24 h. The elevated level of cleaved
caspase 3 observed in neurons treated with Ab was
significantly reduced following IVIg treatment (Fig. 2c and
d). Immunocytochemistry was also performed to visualize
the expression levels of cleaved caspase 3. Consistent with
the immunoblot results, the level of cleaved caspase 3 was
significantly reduced in IVIg-treated (10 mg/mL) neurons
exposed to Ab compared with neurons exposed to Ab alone
(Figure S1).
Effect of IVIg on GD- or Ab-induced stress-sensitive
kinases and a marker of oxidative stress
Because the activation of p38-MAPK, JNK and NFjB
pathways are implicated in ischemia-induced cellular stress
responses and neuronal death, (Thundyil et al. 2010;
Arumugam et al. 2011), we next measured levels of p38-
MAPK, JNK and NFjB-p65 following GD in IVIg-treated
neurons compared with vehicle-treated neurons. IVIg treat-
ment significantly reduced p-JNK and NFjB-p65 (Fig. 3a, c
and d) following GD condition as compared with vehicle-
treated neurons. A similar trend was also observed in p38-
MAPK levels in the IVIg-treated neuron groups as compared
with the vehicle groups (Fig. 3a and b). JNK and p38MAPK
has also been shown to be activated by Ab (Yang et al. 2010;
Ramin et al. 2011) and their activation leads to the
phosphorylation and activation of several transcription
factors, involved in Ab-induced cell death (Vukic et al.
2009). Similar to these findings, we found that exposure of
primary neurons to Ab significantly increased levels of
Fig. 2 Treatment with IVIg reduces cell death in Ab-treated neuro-
nal cultures in a concentration-dependent manner. (a) Treatment
with Ab42 in primary neuronal cultures for 24 h increased the level
cell death significantly in a concentration-dependent manner.
***p < 0.05 compared with vehicle. (b) Treatment with 10 lM Ab42
significantly increased neuronal cell death whereas the co-treatment
with IVIg (1–10 mg/mL) significantly decreased Ab42-induced neu-
ronal cell death in a concentration-dependent manner. *p < 0.05
compared with vehicle; ***p < 0.01 compared with Ab42-treated
group. (c, d) Similarly the treatment of primary neuronal cells with
Ab42 significantly increased cleaved caspase 3 levels, and co-
treatment with IVIg significantly decreased cleaved caspase 3 levels
in a concentration-manner. *p < 0.05 compared with vehicle;
+p < 0.05 compared with Ab42 treated group;
++p < 0.01 compared
with Ab42-treated group. n = 3 or more biologically different cultures
in each group.
! 2012 The Authors
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p38MAPK (Fig. 4a and b) and p-JNK (Fig. 4a and c) and
IVIg treatment significantly reduced these levels (Fig. 4a–c).
To further explore the mechanism underlying the protective
effect of IVIg against Ab-induced cell death, the production
of 4-HNE was examined. It has previously been shown that
the lipid peroxidation product 4-HNE, generated in response
to membrane-associated stress, is involved in Ab-induced
neuronal damage (Mark et al. 1997; Tang et al. 2008). Ab-
induced protein modification by 4-HNE was significantly
reduced by IVIg treatment (Fig. 4a and d).
IVIg treatment elevates Bcl-2 levels in neurons subjected
to GD or exposed to Ab
A well-established anti-death protein, Bcl-2, has been shown
to be down-regulated in neurons under stress conditions,
such as in ischemic stroke and Ab toxicity (Prehn et al.
1994; Alves da Costa et al. 2003). We therefore evaluated
Bcl-2 protein levels in primary neurons treated with IVIg or
vehicle and then subjected to GD or exposure to Ab. IVIg
treatment significantly increased the level of Bcl-2 in GD
conditions (Fig. 5a and b). Furthermore, neurons treated with
IVIg and then exposed to Ab exhibited Bcl-2 levels that were
significantly greater than vehicle-treated neurons exposed to
Ab (Fig. 5c and d).
IVIg treatment improves neuronal survival, reduces infarct
size and improves functional outcome following ischemic
stroke in vivo
We previously reported that IVIg treatment can reduce brain
damage and neurological deficits measured 3 days after
cerebral I/R in mice (Arumugam et al. 2007). Cerebral blood
flow measurements obtained immediately before and after
middle cerebral artery occlusion showed !90% reduction in
blood flow to the middle cerebral artery occlusion infarct
region, which did not differ between groups. To test whether
IVIg was able to enter brain tissue, we first performed
immunohistochemistry to locate human IgG in control and
IVIg-treated mice. Immunohistochemistry analysis showed
more intense and extensive staining for human IgG at the site
of injury (Fig. 6a). To investigate whether IVIg was able to
protect neurons in core and/or penumbra regions of ischemic
cerebral cortex, we evaluated levels of the neuronal marker
microtubule-associated protein 2 (MAP2). We found that the
extent of MAP2 positive cell loss was significantly reduced
by both pre- and post-stroke IVIg treatment as compared
with vehicle-treated mice (Fig. 6b, d and e). We next
investigated the amount of TUNEL positive cells in the
penumbra regions of ischemic stroke. Both pre- and post-
treatment of IVIg significantly reduced I/R induced apoptosis
Fig. 3 Treatment with high concentrations
of IVIg reduces the level of pro-apoptotic
proteins during GD-induced neuronal cell
death. (a–c) Low concentration of IVIg
(0.1 mg/mL) increased the expression level
of P-p38, P-JNK and P-p65 whereas high
concentrations (2.5 and 5 mg/mL) of IVIg
decreased the expression level of P-p38
(b), P-JNK (c) and NFjB P-p65 (c) signifi-
cantly after 12 h in GD-exposed primary
neuronal cells. ns, non-significant reduction
compared with vehicle; **p < 0.05 com-
pared with vehicle; n = 3 or more biologi-
cally different cultures in each group.
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Fig. 4 IVIg treatment reduces the level of
pro-apoptotic proteins and the generation of
lipid peroxidation product 4-HNE in Ab42-
induced neuronal cell death. (a–c) Treat-
ments with different concentrations of IVIg
(0.1, 2.5, and 5 mg/mL) against Ab42-in-
duced neuronal cell significantly decreased
the expression level of P-p38 (b), P-JNK (c)
and the production of 4-HNE (d). *p < 0.05
compared with vehicle; **p < 0.01 com-
pared with vehicle; n = 3 or more biologi-
cally different cultures in each group.
Fig. 5 IVIg treatment increases the level of
the anti-apoptotic protein Bcl2 in cultured
neurons. Increasing concentrations of IVIg
significantly increased the level of Bcl2
during GD-induced neuronal cell death (a,
b). Ab42 treatment decreased the expres-
sion level of Bcl2; however, treatment with
increasing concentrations of IVIg increased
Bcl2 expression level in Ab42-treated cul-
tures (c, d). **p < 0.05 compared with
vehicle; ***p < 0.001 compared with vehi-
cle; +p < 0.05 compared with Ab42-treated
group; +++p < 0.001 compared with Ab42-
treated group; n = 3 or more biologically
different cultures in each group.
! 2012 The Authors
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compared with vehicle treated group (Fig. 6c) and most of
TUNEL positive cells in the penumbra regions were found to
be primarily neurons (Figure S2). To further confirm the
protective effect of IVIg against stroke-induced infarct
development, we used in vivo magnetic resonance imaging
methods. In vivo results obtained using T2 (Fig. 7a) and
diffusion-based (Fig. 7b) analysis showed that both pre- and
post-stroke IVIg treated mice had a significantly lower brain
damage compared with the vehicle treated group (Fig. 7a–c).
We further evaluated the functional aspect of our stroke
model in vivo by scoring cerebral I/R induced neurological
deficit in a blinded manner. The data show that the IVIg-
treated mice had significantly reduced neurological deficit
score compared with vehicle-treated mice (Fig. 7d).
Discussion
IVIg therapy has been shown to be effective in the treatment
of various autoimmune and inflammatory disorders, and
several mechanisms have been proposed to explain these
beneficial effects. Some of these mechanisms include
inhibiting the activation of complement pathways and release
of inflammatory cytokines, neutralization of T- and B-cell
activation, and their differentiation and effector functions
(Samuelsson et al. 2001; Kaneko et al. 2006; Basta 2008).
IgG can exert both pro- and anti-inflammatory activities,
depending upon its concentration (Durandy et al. 2009). The
proinflammatory activity of low dose IVIg requires comple-
ment activation or binding of the Fc fragment of IgG to IgG-
specific Fc receptors. This results in an increase in intracel-
lular calcium levels and activation of proinflammatory or
death signaling pathways. Our data also showed that low
dose of IVIg significantly increased GD- and Ab- induced
neuronal cell death. In contrast, when administered in high
concentrations, IVIg has anti-inflammatory properties. We
previously provided pre-clinical evidence supporting the
possibility of using high-dose IVIg as a stroke therapy
targeting the complement cascade and inflammatory mech-
anisms (Arumugam et al. 2007). As naturally occurring
autoantibodies against Ab (nAbs-Ab), which can block the
toxic effects of Ab, are found in intravenous immunoglob-
ulin (IVIg), such preparations have been suggested to be
efficacious and safe in the treatment of AD (Dodel et al.
2004). Recent studies have suggested the possibility that
IVIg treatment may reduce the risk of developing AD and
related disorders (Fillit et al. 2009). Furthermore, two open-
label pilot studies have reported that IVIg-treated AD
patients show improved cognition (Dodel et al. 2004; Relkin
et al. 2009). However, little is known about how IVIg
protects neurons in such conditions. Numerous studies have
shown that MAPK signaling pathways such as p38, JNK,
and NFjB-p-p65 are two major signaling cascades involved
in neuronal cell death (Tamatani et al. 2000; Legos et al.
2001; Tang et al. 2007; Arumugam et al. 2011). Further-
more, the role of Bcl-2 in stroke outcome has been studied
extensively. Increased Bcl-2 expression promotes cell
Fig. 6 IVIg treatment reduces neuronal cell death in vivo following
ischemic stroke. (a) Intravenously injected IVIg reached the brain as a
result of blood–brain barrier breakdown (scale bars: 100 lM). (b–d)
MAP2-positive neuronal cells were significantly decreased in number
in infarcted brain area whereas the treatment with IVIg in both pre- and
post-treatment significantly reduced the amount of neuronal loss in
infarcted area. ***p < 0.05 compared with middle cerebral artery
occlusion/reperfusion (MCAO/R) group; n = 3–6 in each group. (e, f)
TUNEL staining showed that both pre- and post-treatment of IVIg
decreased the amount of cell apoptosis in the infarcted region of the
brain. ***p < 0.05 compared with MCAO/R group; n = 3–6 in each
group.
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survival and protects against neuronal apoptosis and cellular
necrosis. In addition, treatments that increase Bcl-2 expres-
sion have proven to be neuroprotective (Linnik et al. 1995;
Paradis et al. 1996; Mattson et al. 2000). In this study. we
found that IVIg directly protects cortical neurons against
ischemic and Ab-induced cell death by preventing the
activation of caspase 3, p38MAPK, JNK and NFjB
signaling pathways, by reducing the production of 4-HNE,
and by elevating Bcl2 protein levels.
Activation of the p38MAPK pathway and its downstream
signaling has been shown to play a role in the post-ischemic
brain damage in animal models of stroke (Legos et al. 2001).
The stress-activated p38MAPK plays important roles in
transducing stress-related signals by phosphorylating intra-
cellular enzymes, transcription factors and cytosolic proteins
involved in apoptosis and inflammatory cytokine production.
Sustained activation of p38MAPK is associated with
neuronal death/apoptosis following ischemic stroke and its
Fig. 7 IVIg treatment reduces brain damage and improves functional
outcome in a mouse stroke model. (a, b) T2-based magnetic reso-
nance imaging analysis and diffusion-based analysis show that both
pre- and post-IVIg treatment significantly reduced cerebral I/R induced
infarct volume compared with the vehicle-treated group. *p < 0.05
compared with middle cerebral artery occlusion/reperfusion (MCAO/R)
group; n = 6 in each group. (c) Corresponding representative images
show rows 1–4 MRI slices. Provided are normalized T2-weighted
images obtained using TE = 14 ms (left panel), calculated T2-map
(ms) (middle panel), and apparent diffusion coefficient (ADC) (right
panel). The images show increased T2-weighted image signal inten-
sity and reduced ADC value used to estimate stroke volume. (d) A five-
point neurological score was applied to the sham (n = 7), vehicle
MCAO/R (n = 10), IVIg (2 g/kg) pre-treated MCAO/R (n = 10) and
IVIg (2 g/kg) post-treated MCAO/R mice; *p < 0.05 compared with
vehicle MCAO/R group.
! 2012 The Authors
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inhibition is neuroprotective (Legos et al. 2001). There is
accumulating evidence that p38MAPK plays a role in AD
pathophysiology (Munoz and Ammit 2010). Furthermore,
recent findings suggest that p38MAPK operates in other
events related to AD, such as excitotoxicity, synaptic
plasticity and tau phosphorylation. Our findings show that
IVIg treatment significantly reduces ischemic or Ab-induced
neuronal p38MAPK levels.
The c-Jun NH2-terminal kinase (JNK) signaling pathway
is frequently induced by cellular stress and is correlated with
neuronal death. Activation of the JNK pathway may trigger
cell death by phosphorylating transcription factors regulating
cell death (Tang et al. 2007). Several studies with JNK
inhibitors such as SP600125 decreased apoptotic neuronal
cell death following ischemic stroke (Guan et al. 2006).
Recent observations have also linked the JNK pathway to
AD, including the ability of JNK to phosphorylate Tau and
amyloid precursor protein, promoting the accumulation of
two neurotoxic species, hyperphosphorylated Tau and Ab42
(Sahara et al. 2008; Tang et al. 2008). Our findings suggest
that IVIg protects neurons by down-regulating the JNK
pathway during both ischemic and Ab42-induced neuronal
cell death.
There is ample evidence that NFjB is activated in
ischemic stroke (Tamatani et al. 2000). Most investigators
have found NFjB to be activated in neurons following stroke
(Arumugam et al. 2011). NFjB activation involves nuclear
translocation of the subunits p65 and p50 where it initiates
transcription by binding to regulatory DNA sequences.
Studies have shown that expression of the pro-apoptotic
Bcl-2-homology domain 3 (BH3)-only genes, Bim and
Noxa, depend on p65 (Inta et al. 2006). NFjB stimulates
Bim and Noxa gene transcription in primary cortical
neurones and binds to the promoter of both genes. As the
ratio of pro- and anti-apoptotic Bcl-2 family members
determines cell fate, Bim and Noxa could be candidates to
mediate the detrimental effects of NFjB activation in
ischemia-induced neuronal cell death. Our data demonstrate
that IVIg treatment significantly reduces levels of NFjB-p65.
There is a growing body of evidence indicating that Ab
damages neurons by inducing lipid peroxidation of brain cell
membranes and this has been shown to be inhibited by
antioxidants. Peroxidation of membrane unsaturated fatty
acids leads to the production of several different aldehydes,
and one of the major products is 4HNE (Mattson 2009).
4HNE is lipid-soluble and may damage proteins by rapidly
conjugating to lysine, histidine and cysteine, and it can be
toxic to neurons via this mechanism (Mark et al. 1997;
Keller and Mattson 1998). Furthermore, Ab is able to induce
the production of 4-HNE in hippocampal neurons and can
inhibit DNA, RNA and protein synthesis as well as alter the
activity of degradative, glycolytic and transport proteins
(Mark et al. 1997). This will then result in the disruption of
calcium homeostasis, reduction in the activity of Na+/K+-
ATPase and impairment of glucose transport, thus increasing
neuronal vulnerability to excitotoxicity, leading to neuronal
cell death (Mark et al. 1997). Consistent with the latter
scenario, our findings demonstrate that Ab led to a significant
increase in the level of 4-HNE in primary cortical neurons.
IVIg treatment ameliorated Ab-induced accumulation of 4-
HNE in cultured neurons. Interestingly, 4-HNE has been
shown to activate both the p38MAPK and JNK signaling
pathways, which can mediate neuronal apoptosis (Tamagno
et al. 2003). Therefore, it is postulated that the ability of IVIg
to reduce the production of 4-HNE induced by Ab leads to
inhibition of both p38MAPK and JNK signaling pathways,
thereby protecting neurons against Ab-induced oxidative
injury.
Members of the Bcl-2 gene family, such as B-cell-
leukemia/lymphoma-2-associated X protein (Bax), Bcl-2 and
B-cell lymphoma-extra large (Bcl-xL), play pivotal roles in
determining whether cells survive or die under stressful
conditions. Bcl-2 is able to prevent ischemia-induced
neuronal death (Mattson et al. 2000). The pro-apoptotic
Bax and anti-apoptotic Bcl-2 have been shown to be
involved in the Ab-induced neurotoxic mechanism (Paradis
et al. 1996). In this study, ischemic conditions and exposure
to Ab decreased Bcl-2 protein levels, consistent with several
studies suggesting that both ischemia and Ab lead to down-
regulation of Bcl-2 protein (Paradis et al. 1996). The results
obtained in this study demonstrated that IVIg is able to
support Bcl-2 protein levels in primary neurons subjected to
ischemic conditions or exposure to Ab. Up-regulation of Bcl-
2 expression suggested that IVIg is able to prevent apoptosis.
We have shown previously that after 3 days, the degree of
brain damage and neurological deficit resulting from cerebral
I/R is reduced in mice treated with IVIg compared with
vehicle-treated controls (Arumugam et al. 2007). Here, we
report similar results obtained using in vivo magnetic
resonance imaging method. Our in vivo data also confirm the
neuroprotective mechanisms of IVIg observed in vitro as IVIg
preserved the numbers of MAP2-positive neuronal cells in
both core and infarct areas compared with vehicle-treatment.
Furthermore, stroke-induced neurological deficit was also
improved with IVIg treatment. Our findings suggest that IVIg
targets multiple cell death pathways in ischemic stroke and Ab
toxicity to protect neurons. These studies further suggest that
IVIg may prove effective in reducing neuronal cell death and
brain injury in ischemic stroke and AD.
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